GOName,GOID,DiseaseName,DiseaseID,InferenceChemicalQty,InferenceChemicalNames,InferenceGeneQty,InferenceGeneSymbols
2-oxoglutarate metabolic process,GO:0006103,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
4-hydroxyproline metabolic process,GO:0019471,Parkinson Disease,MESH:D010300,3,Carbon Tetrachloride|Paraquat|Particulate Matter,0,
4-hydroxyproline metabolic process,GO:0019471,"Parkinson Disease, Secondary",MESH:D010302,3,Doxorubicin|Paraquat|Resveratrol,0,
4-hydroxyproline metabolic process,GO:0019471,Parkinsonian Disorders,MESH:D020734,4,Docosahexaenoic Acids|Paraquat|Particulate Matter|Resveratrol,0,
4-nitrophenol metabolic process,GO:0018960,Parkinson Disease,MESH:D010300,0,,1,CYP2E1
5-methylcytosine metabolic process,GO:0019857,Parkinson Disease,MESH:D010300,2,Particulate Matter|Vehicle Emissions,0,
5-methylcytosine metabolic process,GO:0019857,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
9-cis-retinoic acid biosynthetic process,GO:0042904,Parkinsonian Disorders,MESH:D020734,0,,2,ALDH1A1|ALDH1A2
9-cis-retinoic acid metabolic process,GO:0042905,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A1
abscission,GO:0009838,Parkinson Disease,MESH:D010300,1,Melatonin,0,
abscission,GO:0009838,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
abscission,GO:0009838,Parkinsonian Disorders,MESH:D020734,1,Melatonin,0,
acetaldehyde metabolic process,GO:0006117,Parkinson Disease,MESH:D010300,3,Chlorpyrifos|Diazinon|Maneb,1,ALDH2
acetaldehyde metabolic process,GO:0006117,"Parkinson Disease, Secondary",MESH:D010302,1,Maneb,0,
acetaldehyde metabolic process,GO:0006117,Parkinsonian Disorders,MESH:D020734,2,mancozeb|Maneb,0,
acetate biosynthetic process,GO:0019413,Parkinson Disease,MESH:D010300,1,Endosulfan,0,
acetate metabolic process,GO:0006083,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|Ziram,0,
acetate metabolic process,GO:0006083,"Parkinson Disease, Secondary",MESH:D010302,3,Amiodarone|geraniol|Ziram,0,
acetate metabolic process,GO:0006083,Parkinsonian Disorders,MESH:D020734,2,Amiodarone|geraniol,0,
acetate metabolic process,GO:0006083,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
acetoacetic acid metabolic process,GO:0043438,"Parkinson Disease, Secondary",MESH:D010302,1,Amiodarone,0,
acetoacetic acid metabolic process,GO:0043438,Parkinsonian Disorders,MESH:D020734,1,Amiodarone,0,
acetoacetic acid metabolic process,GO:0043438,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
acetylcholine biosynthetic process,GO:0008292,Parkinson Disease,MESH:D010300,3,Diazinon|Paraquat|Polychlorinated Biphenyls,0,
acetylcholine biosynthetic process,GO:0008292,"Parkinson Disease, Secondary",MESH:D010302,1,Paraquat,0,
acetylcholine biosynthetic process,GO:0008292,Parkinsonian Disorders,MESH:D020734,3,Donepezil|ginsenoside Re|Paraquat,0,
acetylcholine catabolic process,GO:0006581,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
acetylcholine catabolic process,GO:0006581,"Parkinson Disease, Secondary",MESH:D010302,0,,1,BCHE
acetylcholine catabolic process,GO:0006581,Parkinsonian Disorders,MESH:D020734,1,Donepezil,0,
acetylcholine-mediated vasodilation involved in regulation of systemic arterial blood pressure,GO:0003069,Parkinson Disease,MESH:D010300,0,,1,SOD2
acetylcholine metabolic process,GO:0008291,Parkinson Disease,MESH:D010300,4,Chlorpyrifos|Lipopolysaccharides|Methomyl|Zinc,0,
acetylcholine metabolic process,GO:0008291,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
acetylcholine receptor signaling pathway,GO:0095500,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
acetylcholine secretion,GO:0061526,Parkinson Disease,MESH:D010300,1,Manganese,0,
acetylcholine secretion,GO:0061526,"Parkinson Disease, Secondary",MESH:D010302,1,Manganese,0,
acetylcholine secretion,GO:0061526,Parkinsonian Disorders,MESH:D020734,2,Manganese|manganese chloride,0,
acidic amino acid transport,GO:0015800,Parkinson Disease,MESH:D010300,0,,1,SLC38A2
acid secretion,GO:0046717,Parkinson Disease,MESH:D010300,0,,1,DRD2
acid secretion,GO:0046717,Parkinsonian Disorders,MESH:D020734,0,,1,DRD2
acrosome assembly,GO:0001675,Parkinson Disease,MESH:D010300,0,,1,NECTIN2
acrosome assembly,GO:0001675,"Parkinson Disease, Secondary",MESH:D010302,1,Paroxetine,0,
acrosome assembly,GO:0001675,Parkinsonian Disorders,MESH:D020734,1,Paroxetine,0,
acrosome reaction,GO:0007340,"Parkinson Disease, Secondary",MESH:D010302,1,Chlorpromazine,0,
acrosome reaction,GO:0007340,Parkinsonian Disorders,MESH:D020734,3,Chlorpromazine|coenzyme Q10|cypermethrin,0,
actin crosslink formation,GO:0051764,Parkinson Disease,MESH:D010300,0,,1,AIF1
actin crosslink formation,GO:0051764,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
actin cytoskeleton organization,GO:0030036,Parkinson Disease,MESH:D010300,4,Endosulfan|Estradiol|Smoke|Tea,2,KST|MLP60A
actin cytoskeleton organization,GO:0030036,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ATXN3
actin cytoskeleton organization,GO:0030036,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
actin cytoskeleton organization,GO:0030036,Parkinsonian Disorders,MESH:D020734,1,Plant Extracts,0,
actin filament bundle assembly,GO:0051017,Parkinson Disease,MESH:D010300,1,Trichloroethylene,2,AIF1|KST
actin filament bundle assembly,GO:0051017,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
actin filament bundle assembly,GO:0051017,"Parkinson Disease, Secondary",MESH:D010302,1,Trichloroethylene,0,
actin filament organization,GO:0007015,Parkinson Disease,MESH:D010300,1,Melatonin,0,
actin filament organization,GO:0007015,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
actin filament organization,GO:0007015,Parkinsonian Disorders,MESH:D020734,1,Melatonin,0,
actin filament polymerization,GO:0030041,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,1,AIF1
actin filament polymerization,GO:0030041,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
actin filament polymerization,GO:0030041,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Resveratrol,0,
actin filament reorganization,GO:0090527,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
actin filament reorganization,GO:0090527,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
action potential,GO:0001508,Parkinson Disease,MESH:D010300,2,Minocycline|Particulate Matter,0,
action potential,GO:0001508,"Parkinson Disease, Secondary",MESH:D010302,3,Minocycline|Nicotine|Nifedipine,0,
action potential,GO:0001508,Parkinsonian Disorders,MESH:D020734,2,Particulate Matter|Rimonabant,0,
action potential initiation,GO:0099610,Parkinson Disease,MESH:D010300,1,Paraquat,2,CNTNAP2|SOD1
action potential initiation,GO:0099610,"Parkinson Disease, Secondary",MESH:D010302,5,Carbamazepine|Fluoxetine|Lamotrigine|Paraquat|Valproic Acid,0,
action potential initiation,GO:0099610,Parkinsonian Disorders,MESH:D020734,2,Paraquat|Valproic Acid,0,
action potential initiation,GO:0099610,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Flecainide,0,
activation of adenylate cyclase activity,GO:0007190,Parkinson Disease,MESH:D010300,4,Dopamine|Ketoconazole|Lithium Carbonate|Manganese,1,DRD1
activation of adenylate cyclase activity,GO:0007190,"Parkinson Disease, Secondary",MESH:D010302,2,Lithium Carbonate|Manganese,0,
activation of adenylate cyclase activity,GO:0007190,Parkinsonian Disorders,MESH:D020734,4,Dopamine|Ketoconazole|Manganese|manganese chloride,0,
activation of adenylate cyclase activity,GO:0007190,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
activation of cysteine-type endopeptidase activity,GO:0097202,Parkinson Disease,MESH:D010300,7,1-Methyl-4-phenylpyridinium|Estradiol|Homocysteine|Manganese|Paraquat|Particulate Matter|Reactive Oxygen Species,0,
activation of cysteine-type endopeptidase activity,GO:0097202,"Parkinson Disease, Secondary",MESH:D010302,7,3-methyladenine|Dichlorvos|Manganese|Paraquat|Resveratrol|thymoquinone|Verapamil,0,
activation of cysteine-type endopeptidase activity,GO:0097202,Parkinsonian Disorders,MESH:D020734,9,1-Methyl-4-phenylpyridinium|cypermethrin|Indomethacin|Manganese|manganese chloride|Paraquat|Particulate Matter|Resveratrol|Verapamil,0,
activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006919,Parkinson Disease,MESH:D010300,6,Chlorpyrifos|Lead|Manganese|mangiferin|Methamphetamine|Nitric Oxide,0,
activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006919,"Parkinson Disease, Secondary",MESH:D010302,8,3-methyladenine|Benzo(a)pyrene|Doxorubicin|Manganese|Methamphetamine|Methotrexate|Resveratrol|Sertraline,0,
activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006919,Parkinsonian Disorders,MESH:D020734,8,annonacin|Cadmium|Docosahexaenoic Acids|Indomethacin|Manganese|manganese chloride|Resveratrol|Sertraline,0,
activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c,GO:0008635,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|Manganese,0,
activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c,GO:0008635,"Parkinson Disease, Secondary",MESH:D010302,1,Manganese,0,
activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c,GO:0008635,Parkinsonian Disorders,MESH:D020734,2,Manganese|manganese chloride,0,
activation of immune response,GO:0002253,Parkinson Disease,MESH:D010300,1,Paraquat,0,
activation of immune response,GO:0002253,"Parkinson Disease, Secondary",MESH:D010302,1,Paraquat,0,
activation of immune response,GO:0002253,Parkinsonian Disorders,MESH:D020734,1,Paraquat,0,
activation of innate immune response,GO:0002218,Parkinson Disease,MESH:D010300,1,"Water Pollutants, Chemical",0,
activation of protein kinase A activity,GO:0034199,Parkinson Disease,MESH:D010300,3,Endosulfan|Ketoconazole|Lead,0,
activation of protein kinase A activity,GO:0034199,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
activation of protein kinase A activity,GO:0034199,Parkinsonian Disorders,MESH:D020734,2,Ketoconazole|Resveratrol,0,
activation of protein kinase activity,GO:0032147,Parkinson Disease,MESH:D010300,3,Aspirin|Lipopolysaccharides|Permethrin,2,DRD2|INSR
activation of protein kinase activity,GO:0032147,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Permethrin,2,DRD2|PRKCD
activation of protein kinase B activity,GO:0032148,Parkinson Disease,MESH:D010300,19,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Atrazine|Carbon Disulfide|Carbon Tetrachloride|Chlorpyrifos|Copper|Dieldrin|Estradiol|Lipopolysaccharides|Melatonin|Oxidopamine|Paraquat|Particulate Matter|Permethrin|Reactive Oxygen Species|Sirolimus|Tea|Testosterone",2,INS|INSR
activation of protein kinase B activity,GO:0032148,"Parkinson Disease, Secondary",MESH:D010302,16,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|3-methyladenine|Atrazine|Benzo(a)pyrene|Dieldrin|Doxorubicin|Ethosuximide|Famotidine|geraniol|Melatonin|Nicotine|Oxidopamine|Paraquat|Resveratrol|sodium bisulfide|Sulpiride",0,
activation of protein kinase B activity,GO:0032148,Parkinsonian Disorders,MESH:D020734,16,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Carbon Disulfide|Clonidine|Curcumin|Docosahexaenoic Acids|geraniol|Lipopolysaccharides|Melatonin|Oxidopamine|Paraquat|Particulate Matter|Permethrin|Plant Extracts|Quinpirole|Resveratrol",0,
activation of protein kinase C activity,GO:1990051,Parkinson Disease,MESH:D010300,4,Lead|Mirtazapine|Paclitaxel|Reactive Oxygen Species,0,
activation of protein kinase C activity,GO:1990051,"Parkinson Disease, Secondary",MESH:D010302,2,geraniol|Vincristine,0,
activation of protein kinase C activity,GO:1990051,Parkinsonian Disorders,MESH:D020734,1,geraniol,0,
actomyosin structure organization,GO:0031032,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
acute inflammatory response,GO:0002526,Parkinson Disease,MESH:D010300,2,Lipopolysaccharides|Ozone,0,
acute inflammatory response,GO:0002526,Parkinsonian Disorders,MESH:D020734,2,Curcumin|Lipopolysaccharides,0,
acute inflammatory response to antigenic stimulus,GO:0002438,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
acute inflammatory response to antigenic stimulus,GO:0002438,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
acute-phase response,GO:0006953,Parkinson Disease,MESH:D010300,0,,3,HFE|IL6|INS
acute-phase response,GO:0006953,"Parkinson Disease, Secondary",MESH:D010302,1,geraniol,0,
acute-phase response,GO:0006953,Parkinsonian Disorders,MESH:D020734,1,geraniol,0,
acylglycerol homeostasis,GO:0055090,Parkinson Disease,MESH:D010300,1,Paraquat,0,
acylglycerol homeostasis,GO:0055090,"Parkinson Disease, Secondary",MESH:D010302,1,Paraquat,0,
acylglycerol homeostasis,GO:0055090,Parkinsonian Disorders,MESH:D020734,2,cypermethrin|Paraquat,0,
adaptive immune response,GO:0002250,Parkinson Disease,MESH:D010300,1,4-phenylbutyric acid,3,FGB|HLA-DRA|HLA-DRB5
adaptive thermogenesis,GO:1990845,Parkinson Disease,MESH:D010300,2,Caffeine|Propranolol,1,PPARGC1A
adaptive thermogenesis,GO:1990845,"Parkinson Disease, Secondary",MESH:D010302,1,Cimetidine,0,
adaptive thermogenesis,GO:1990845,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Propranolol,0,
adenine biosynthetic process,GO:0046084,Parkinson Disease,MESH:D010300,1,1-Methyl-4-phenylpyridinium,0,
adenine biosynthetic process,GO:0046084,Parkinsonian Disorders,MESH:D020734,1,1-Methyl-4-phenylpyridinium,0,
adenine metabolic process,GO:0046083,"Parkinson Disease, Secondary",MESH:D010302,1,3-methyladenine,0,
adenine metabolic process,GO:0046083,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
adenohypophysis development,GO:0021984,Parkinson Disease,MESH:D010300,0,,2,DRD2|SLC6A3
adenohypophysis development,GO:0021984,Parkinsonian Disorders,MESH:D020734,0,,1,DRD2
adenohypophysis development,GO:0021984,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
adenosine metabolic process,GO:0046085,"Parkinson Disease, Secondary",MESH:D010302,1,Amiodarone,0,
adenosine metabolic process,GO:0046085,Parkinsonian Disorders,MESH:D020734,2,Amiodarone|Indomethacin,0,
adenosine metabolic process,GO:0046085,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
adenosine to inosine editing,GO:0006382,Parkinson Disease,MESH:D010300,0,,1,ADARB2
adenosine to inosine editing,GO:0006382,"Parkinson Disease, Secondary",MESH:D010302,1,Methotrexate,0,
adenylate cyclase-activating adrenergic receptor signaling pathway,GO:0071880,Parkinson Disease,MESH:D010300,0,,2,DRD1|DRD2
adenylate cyclase-activating adrenergic receptor signaling pathway,GO:0071880,Parkinsonian Disorders,MESH:D020734,0,,2,DOP1R2|DRD2
adenylate cyclase-activating adrenergic receptor signaling pathway,GO:0071880,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
adenylate cyclase-activating dopamine receptor signaling pathway,GO:0007191,Parkinson Disease,MESH:D010300,0,,1,DRD1
adenylate cyclase-activating dopamine receptor signaling pathway,GO:0007191,Parkinsonian Disorders,MESH:D020734,0,,1,DOP1R2
adenylate cyclase-activating G protein-coupled receptor signaling pathway,GO:0007189,Parkinson Disease,MESH:D010300,0,,1,DRD1
adenylate cyclase-activating G protein-coupled receptor signaling pathway,GO:0007189,"Parkinson Disease, Secondary",MESH:D010302,0,,1,CNR2
adenylate cyclase-activating G protein-coupled receptor signaling pathway,GO:0007189,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
adenylate cyclase-inhibiting dopamine receptor signaling pathway,GO:0007195,Parkinson Disease,MESH:D010300,0,,1,DRD2
adenylate cyclase-inhibiting dopamine receptor signaling pathway,GO:0007195,Parkinsonian Disorders,MESH:D020734,0,,1,DRD2
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway,GO:0007197,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway,GO:0007193,Parkinson Disease,MESH:D010300,0,,1,EDN1
adenylate cyclase-modulating G protein-coupled receptor signaling pathway,GO:0007188,Parkinson Disease,MESH:D010300,0,,1,DRD2
adenylate cyclase-modulating G protein-coupled receptor signaling pathway,GO:0007188,Parkinsonian Disorders,MESH:D020734,0,,1,DRD2
adhesion of symbiont to host,GO:0044406,Parkinson Disease,MESH:D010300,0,,1,NECTIN2
adiponectin secretion,GO:0070162,Parkinsonian Disorders,MESH:D020734,1,Plant Preparations,0,
adipose tissue development,GO:0060612,Parkinson Disease,MESH:D010300,8,Air Pollutants|Clozapine|Melatonin|Particulate Matter|Pesticides|Pioglitazone|Sirolimus|Testosterone,1,PPARGC1A
adipose tissue development,GO:0060612,"Parkinson Disease, Secondary",MESH:D010302,10,Amiodarone|Benzo(a)pyrene|Cimetidine|Melatonin|Nicotine|Olanzapine|Pesticides|Resveratrol|Risperidone|Ritonavir,0,
adipose tissue development,GO:0060612,Parkinsonian Disorders,MESH:D020734,13,Amiodarone|Cadmium|Clozapine|Indomethacin|Lopinavir|Melatonin|Olanzapine|Particulate Matter|Plant Extracts|Resveratrol|Risperidone|Ritonavir|Zidovudine,0,
adipose tissue development,GO:0060612,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
ADP biosynthetic process,GO:0006172,Parkinson Disease,MESH:D010300,2,1-Methyl-4-phenylpyridinium|Polychlorinated Biphenyls,0,
ADP biosynthetic process,GO:0006172,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
ADP biosynthetic process,GO:0006172,Parkinsonian Disorders,MESH:D020734,1,1-Methyl-4-phenylpyridinium,0,
ADP catabolic process,GO:0046032,Parkinson Disease,MESH:D010300,1,Homocysteine,0,
ADP metabolic process,GO:0046031,Parkinson Disease,MESH:D010300,1,Trichloroethylene,0,
ADP metabolic process,GO:0046031,"Parkinson Disease, Secondary",MESH:D010302,1,Trichloroethylene,0,
adrenal gland development,GO:0030325,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
adult behavior,GO:0030534,Parkinson Disease,MESH:D010300,1,Atrazine,2,CNTNAP2|DRD2
adult behavior,GO:0030534,"Parkinson Disease, Secondary",MESH:D010302,1,Atrazine,0,
adult behavior,GO:0030534,Parkinsonian Disorders,MESH:D020734,2,cypermethrin|Rimonabant,1,DRD2
adult chitin-containing cuticle pigmentation,GO:0048085,Parkinson Disease,MESH:D010300,0,,1,DDC
adult chitin-containing cuticle pigmentation,GO:0048085,Parkinsonian Disorders,MESH:D020734,0,,1,DDC
adult feeding behavior,GO:0008343,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|Sirolimus,0,
adult feeding behavior,GO:0008343,"Parkinson Disease, Secondary",MESH:D010302,1,Fluoxetine,0,
adult feeding behavior,GO:0008343,Parkinsonian Disorders,MESH:D020734,3,Creatine|cypermethrin|Rimonabant,0,
adult locomotory behavior,GO:0008344,Parkinson Disease,MESH:D010300,9,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Air Pollutants|Apomorphine|Chlorpyrifos|istradefylline|Paraquat|Particulate Matter|Pesticides|tetrachloroisophthalonitrile",5,GDNF|NGF|PARK7|PRKN|SNCA
adult locomotory behavior,GO:0008344,Parkinson Disease 11,MESH:C564345,0,,1,GIGYF2
adult locomotory behavior,GO:0008344,Parkinson Disease 13,MESH:C565204,0,,1,HTRA2
adult locomotory behavior,GO:0008344,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
adult locomotory behavior,GO:0008344,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
adult locomotory behavior,GO:0008344,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
adult locomotory behavior,GO:0008344,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
adult locomotory behavior,GO:0008344,"Parkinson Disease, Secondary",MESH:D010302,11,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Apomorphine|Benzo(a)pyrene|Dichlorvos|Doxorubicin|Fluoxetine|Nicotine|Paraquat|Paroxetine|Pesticides|Valproic Acid",3,GDNF|PRKN|SNCA
adult locomotory behavior,GO:0008344,Parkinsonian Disorders,MESH:D020734,10,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Apomorphine|istradefylline|manganese chloride|Paraquat|Paroxetine|Particulate Matter|Raclopride|Rimonabant|Valproic Acid",8,ATP1A3|DJ-1BETA|GDNF|HTRA2|NGF|PARK7|PRKN|SNCA
adult walking behavior,GO:0007628,Parkinson Disease,MESH:D010300,4,Copper|Lead|Melatonin|Rotenone,3,DRD1|DRD2|MAPT
adult walking behavior,GO:0007628,Parkinson Disease 13,MESH:C565204,0,,1,HTRA2
adult walking behavior,GO:0007628,"PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:613643,0,,1,UCHL1
adult walking behavior,GO:0007628,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
adult walking behavior,GO:0007628,"Parkinson Disease, Secondary",MESH:D010302,2,Melatonin|Rotenone,0,
adult walking behavior,GO:0007628,Parkinsonian Disorders,MESH:D020734,3,Melatonin|oleuropein|Rotenone,3,DRD2|HTRA2|MAPT
aerobic electron transport chain,GO:0019646,Parkinson Disease,MESH:D010300,2,Eicosapentaenoic Acid|Rotenone,1,PPARGC1A
aerobic electron transport chain,GO:0019646,"Parkinson Disease, Secondary",MESH:D010302,3,geraniol|Methotrexate|Rotenone,0,
aerobic electron transport chain,GO:0019646,Parkinsonian Disorders,MESH:D020734,4,Curcumin|Docosahexaenoic Acids|geraniol|Rotenone,0,
aerobic respiration,GO:0009060,Parkinson Disease,MESH:D010300,13,Air Pollutants|Chlorpyrifos|Dopamine|Lead|Lipopolysaccharides|Maneb|Methamphetamine|Paraquat|Particulate Matter|Rotenone|Testosterone|Vehicle Emissions|Zinc,0,
aerobic respiration,GO:0009060,"Parkinson Disease, Secondary",MESH:D010302,10,Amiodarone|Benzo(a)pyrene|Doxorubicin|Maneb|Methamphetamine|Paraquat|Resveratrol|Rotenone|Trifluoperazine|Valproic Acid,0,
aerobic respiration,GO:0009060,Parkinsonian Disorders,MESH:D020734,14,Amiodarone|annonacin|Cadmium|Curcumin|Dopamine|Lipopolysaccharides|Maneb|manganese chloride|Paraquat|Particulate Matter|Resveratrol|Rotenone|Trifluoperazine|Valproic Acid,0,
aerobic respiration,GO:0009060,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
aggresome assembly,GO:0070842,Parkinson Disease,MESH:D010300,3,1-Methyl-4-phenylpyridinium|Dopamine|Paraquat,1,PRKN
aggresome assembly,GO:0070842,"Parkinson Disease, Secondary",MESH:D010302,1,Paraquat,1,PRKN
aggresome assembly,GO:0070842,Parkinsonian Disorders,MESH:D020734,3,1-Methyl-4-phenylpyridinium|Dopamine|Paraquat,1,PRKN
aggressive behavior,GO:0002118,Parkinson Disease,MESH:D010300,1,Lead,0,
aggressive behavior,GO:0002118,Parkinsonian Disorders,MESH:D020734,1,Docosahexaenoic Acids,0,
alanine biosynthetic process,GO:0006523,Parkinson Disease,MESH:D010300,1,Carbon Tetrachloride,0,
alanine metabolic process,GO:0006522,Parkinson Disease,MESH:D010300,1,Endosulfan,0,
alanine metabolic process,GO:0006522,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
alanine transport,GO:0032328,Parkinson Disease,MESH:D010300,0,,1,SLC38A2
alanyl-tRNA aminoacylation,GO:0006419,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
alanyl-tRNA aminoacylation,GO:0006419,Parkinson Disease,MESH:D010300,1,beta-N-methylamino-L-alanine,0,
alcohol metabolic process,GO:0006066,Parkinson Disease,MESH:D010300,1,Melatonin,1,ALDH2
alcohol metabolic process,GO:0006066,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
alcohol metabolic process,GO:0006066,Parkinsonian Disorders,MESH:D020734,1,Melatonin,0,
aldehyde catabolic process,GO:0046185,Parkinson Disease,MESH:D010300,0,,1,ALDH2
aldosterone biosynthetic process,GO:0032342,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
aldosterone biosynthetic process,GO:0032342,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
aldosterone secretion,GO:0035932,Parkinson Disease,MESH:D010300,1,4-phenylbutyric acid,0,
alkaloid catabolic process,GO:0009822,Parkinson Disease,MESH:D010300,0,,1,CYP2D6
alkaloid metabolic process,GO:0009820,Parkinson Disease,MESH:D010300,1,Atrazine,1,CYP2D6
alkaloid metabolic process,GO:0009820,"Parkinson Disease, Secondary",MESH:D010302,2,Atrazine|Doxorubicin,0,
allantois development,GO:1905069,Parkinson Disease,MESH:D010300,1,Caffeine,0,
alpha-beta T cell activation,GO:0046631,Parkinson Disease,MESH:D010300,0,,1,INS
alpha-beta T cell differentiation,GO:0046632,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
alpha-tubulin acetylation,GO:0071929,Parkinson Disease,MESH:D010300,4,Benomyl|Lipopolysaccharides|Methamphetamine|Paclitaxel,0,
alpha-tubulin acetylation,GO:0071929,"Parkinson Disease, Secondary",MESH:D010302,2,Methamphetamine|Resveratrol,1,SHH
alpha-tubulin acetylation,GO:0071929,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Resveratrol,0,
aluminum ion homeostasis,GO:0055079,Parkinson Disease,MESH:D010300,1,Aluminum,0,
amide metabolic process,GO:0043603,Parkinson Disease,MESH:D010300,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
amide metabolic process,GO:0043603,"Parkinson Disease, Secondary",MESH:D010302,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
amide metabolic process,GO:0043603,Parkinsonian Disorders,MESH:D020734,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
amine metabolic process,GO:0009308,Parkinson Disease,MESH:D010300,3,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Lead|Levodopa",0,
amine metabolic process,GO:0009308,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
amine metabolic process,GO:0009308,"Parkinson Disease, Secondary",MESH:D010302,4,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Levodopa|Methotrexate|Ribavirin",0,
amine metabolic process,GO:0009308,Parkinsonian Disorders,MESH:D020734,3,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Indomethacin|Levodopa",0,
aminergic neurotransmitter loading into synaptic vesicle,GO:0015842,Parkinson Disease,MESH:D010300,0,,3,DDC|SLC18A2|TH
aminergic neurotransmitter loading into synaptic vesicle,GO:0015842,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SLC18A2
aminergic neurotransmitter loading into synaptic vesicle,GO:0015842,Parkinsonian Disorders,MESH:D020734,0,,3,DDC|SLC18A2|TH
amino-acid betaine biosynthetic process,GO:0006578,Parkinson Disease,MESH:D010300,1,Polychlorinated Biphenyls,0,
amino-acid betaine metabolic process,GO:0006577,Parkinson Disease,MESH:D010300,1,Endosulfan,0,
amino-acid betaine metabolic process,GO:0006577,"Parkinson Disease, Secondary",MESH:D010302,1,Amiodarone,0,
amino-acid betaine metabolic process,GO:0006577,Parkinsonian Disorders,MESH:D020734,1,Amiodarone,0,
amino-acid betaine metabolic process,GO:0006577,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
amino acid biosynthetic process,GO:0008652,Parkinson Disease,MESH:D010300,5,Chlorpyrifos|Endosulfan|Homocysteine|Ozone|Rotenone,0,
amino acid biosynthetic process,GO:0008652,"Parkinson Disease, Secondary",MESH:D010302,2,Rotenone|Valproic Acid,0,
amino acid biosynthetic process,GO:0008652,Parkinsonian Disorders,MESH:D020734,4,Cadmium|Creatine|Rotenone|Valproic Acid,0,
amino acid import,GO:0043090,Parkinson Disease,MESH:D010300,1,Vehicle Emissions,1,SLC38A2
amino acid import,GO:0043090,Parkinsonian Disorders,MESH:D020734,1,Curcumin,0,
amino acid metabolic process,GO:0006520,Parkinson Disease,MESH:D010300,11,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Air Pollutants|Glutathione Disulfide|Homocysteine|Melatonin|Paraquat|Particulate Matter|Polychlorinated Biphenyls|Probenecid|Vehicle Emissions|Zinc",1,DDC
amino acid metabolic process,GO:0006520,"Parkinson Disease, Secondary",MESH:D010302,9,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Amiodarone|Benzo(a)pyrene|Doxorubicin|Melatonin|Methotrexate|Paraquat|Resveratrol|Ribavirin",0,
amino acid metabolic process,GO:0006520,Parkinsonian Disorders,MESH:D020734,10,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Amiodarone|Cadmium|Creatine|Indomethacin|Melatonin|Paraquat|Particulate Matter|Probenecid|Resveratrol",1,DDC
amino acid metabolic process,GO:0006520,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
amino acid transmembrane transport,GO:0003333,Parkinson Disease,MESH:D010300,0,,1,SLC38A2
amino acid transport,GO:0006865,Parkinson Disease,MESH:D010300,0,,1,SLC38A2
AMPA selective glutamate receptor signaling pathway,GO:0098990,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
AMPA selective glutamate receptor signaling pathway,GO:0098990,Parkinson Disease,MESH:D010300,2,beta-N-methylamino-L-alanine|Oxidopamine,0,
AMPA selective glutamate receptor signaling pathway,GO:0098990,"Parkinson Disease, Secondary",MESH:D010302,1,Oxidopamine,0,
AMPA selective glutamate receptor signaling pathway,GO:0098990,Parkinsonian Disorders,MESH:D020734,1,Oxidopamine,0,
AMP biosynthetic process,GO:0006167,Parkinson Disease,MESH:D010300,1,1-Methyl-4-phenylpyridinium,0,
AMP biosynthetic process,GO:0006167,Parkinsonian Disorders,MESH:D020734,1,1-Methyl-4-phenylpyridinium,0,
AMP catabolic process,GO:0006196,Parkinson Disease,MESH:D010300,2,Caffeine|Homocysteine,0,
AMP catabolic process,GO:0006196,"Parkinson Disease, Secondary",MESH:D010302,1,Haloperidol,0,
AMP catabolic process,GO:0006196,Parkinsonian Disorders,MESH:D020734,1,Haloperidol,0,
amphibian larval development,GO:0002117,Parkinson Disease,MESH:D010300,1,tetrachloroisophthalonitrile,0,
amyloid-beta clearance,GO:0097242,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
amyloid-beta metabolic process,GO:0050435,Parkinson Disease,MESH:D010300,2,Particulate Matter|Vehicle Emissions,0,
amyloid-beta metabolic process,GO:0050435,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
amyloid fibril formation,GO:1990000,Parkinson Disease,MESH:D010300,4,Eicosapentaenoic Acid|Paraquat|Particulate Matter|Vehicle Emissions,3,MAPT|PRKN|SNCA
amyloid fibril formation,GO:1990000,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
amyloid fibril formation,GO:1990000,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
amyloid fibril formation,GO:1990000,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
amyloid fibril formation,GO:1990000,"Parkinson Disease, Secondary",MESH:D010302,2,Paraquat|thymoquinone,2,PRKN|SNCA
amyloid fibril formation,GO:1990000,Parkinsonian Disorders,MESH:D020734,3,Docosahexaenoic Acids|Paraquat|Particulate Matter,3,MAPT|PRKN|SNCA
anatomical structure arrangement,GO:0048532,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
anatomical structure development,GO:0048856,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,1,SHH
anatomical structure development,GO:0048856,Parkinsonian Disorders,MESH:D020734,1,Valproic Acid,0,
anatomical structure formation involved in morphogenesis,GO:0048646,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
anatomical structure morphogenesis,GO:0009653,Parkinson Disease,MESH:D010300,0,,1,TH
anatomical structure morphogenesis,GO:0009653,"Parkinson Disease, Secondary",MESH:D010302,1,Cytarabine,0,
anatomical structure morphogenesis,GO:0009653,Parkinsonian Disorders,MESH:D020734,0,,1,TH
anatomical structure regression,GO:0060033,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
anatomical structure regression,GO:0060033,Parkinsonian Disorders,MESH:D020734,2,Curcumin|Particulate Matter,0,
androgen biosynthetic process,GO:0006702,Parkinson Disease,MESH:D010300,2,Atrazine|Testosterone,0,
androgen biosynthetic process,GO:0006702,"Parkinson Disease, Secondary",MESH:D010302,3,Atrazine|Flurbiprofen|Nicotine,0,
androgen catabolic process,GO:0006710,Parkinson Disease,MESH:D010300,2,Ketoconazole|Testosterone,0,
androgen catabolic process,GO:0006710,Parkinsonian Disorders,MESH:D020734,1,Ketoconazole,0,
androgen metabolic process,GO:0008209,Parkinson Disease,MESH:D010300,4,Estradiol|Ketoconazole|Orphenadrine|Testosterone,1,PPARGC1A
androgen metabolic process,GO:0008209,"Parkinson Disease, Secondary",MESH:D010302,4,Nifedipine|Orphenadrine|Phenytoin|Verapamil,1,SHH
androgen metabolic process,GO:0008209,Parkinsonian Disorders,MESH:D020734,2,Ketoconazole|Verapamil,0,
androgen receptor signaling pathway,GO:0030521,Parkinson Disease,MESH:D010300,4,"Atrazine|Testosterone|Trifluralin|Water Pollutants, Chemical",1,PARK7
androgen receptor signaling pathway,GO:0030521,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
androgen receptor signaling pathway,GO:0030521,"Parkinson Disease, Secondary",MESH:D010302,2,Atrazine|Resveratrol,0,
androgen receptor signaling pathway,GO:0030521,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,1,PARK7
"androst-4-ene-3,17-dione biosynthetic process",GO:1903449,Parkinson Disease,MESH:D010300,1,Clozapine,0,
"androst-4-ene-3,17-dione biosynthetic process",GO:1903449,"Parkinson Disease, Secondary",MESH:D010302,3,Chlorpromazine|Haloperidol|Risperidone,0,
"androst-4-ene-3,17-dione biosynthetic process",GO:1903449,Parkinsonian Disorders,MESH:D020734,4,Chlorpromazine|Clozapine|Haloperidol|Risperidone,0,
anesthesia-resistant memory,GO:0007615,Parkinson Disease,MESH:D010300,0,,1,DDC
anesthesia-resistant memory,GO:0007615,Parkinsonian Disorders,MESH:D020734,0,,1,DDC
angiogenesis,GO:0001525,Parkinson Disease,MESH:D010300,6,Aluminum|Caffeine|Carbon Tetrachloride|Chlorpyrifos|Copper|Particulate Matter,2,COL19A1|HMOX1
angiogenesis,GO:0001525,"Parkinson Disease, Secondary",MESH:D010302,3,Amiodarone|Doxorubicin|Nicotine,1,SHH
angiogenesis,GO:0001525,Parkinsonian Disorders,MESH:D020734,6,Amiodarone|annonacin|Cadmium|Curcumin|cypermethrin|Particulate Matter,0,
angiogenesis,GO:0001525,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
angiotensin maturation,GO:0002003,"PARKINSONISM WITH SPASTICITY, X-LINKED",OMIM:300911,0,,1,ATP6AP2
animal organ development,GO:0048513,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
animal organ formation,GO:0048645,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
animal organ morphogenesis,GO:0009887,Parkinson Disease,MESH:D010300,0,,5,IGF1R|IGF2|INSR|TH|TNF
animal organ morphogenesis,GO:0009887,Parkinsonian Disorders,MESH:D020734,0,,1,TH
animal organ regeneration,GO:0031100,Parkinson Disease,MESH:D010300,0,,2,GSTP1|IGF2R
animal organ regeneration,GO:0031100,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ADH1C
anoikis,GO:0043276,Parkinson Disease,MESH:D010300,1,Nitric Oxide,0,
anoikis,GO:0043276,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
antennal morphogenesis,GO:0048800,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|tetrachloroisophthalonitrile,0,
anterior commissure morphogenesis,GO:0021960,Parkinson Disease,MESH:D010300,0,,1,DRAXIN
anterior lateral line development,GO:0048899,Parkinson Disease,MESH:D010300,0,,1,EDN1
anterior lateral line neuromast development,GO:0048901,Parkinson Disease,MESH:D010300,0,,1,EDN1
anterior/posterior pattern specification,GO:0009952,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
anterior/posterior pattern specification,GO:0009952,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A2
anterograde axonal transport,GO:0008089,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
anterograde axonal transport,GO:0008089,Parkinson Disease,MESH:D010300,1,beta-N-methylamino-L-alanine,1,SOD1
antibacterial humoral response,GO:0019731,Parkinson Disease,MESH:D010300,0,,1,DEFA4
antibacterial humoral response,GO:0019731,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
antifungal humoral response,GO:0019732,Parkinson Disease,MESH:D010300,0,,1,DEFA4
antigen processing and presentation,GO:0019882,Parkinson Disease,MESH:D010300,0,,2,GBA1|RAB32
antigen processing and presentation,GO:0019882,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
antigen processing and presentation,GO:0019882,Parkinsonian Disorders,MESH:D020734,0,,1,GBA1
antigen processing and presentation of endogenous peptide antigen via MHC class Ib,GO:0002476,Parkinson Disease,MESH:D010300,0,,1,HFE
antigen processing and presentation of endogenous peptide antigen via MHC class II,GO:0002491,Parkinson Disease,MESH:D010300,0,,1,HLA-DRA
"antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent",GO:0002486,Parkinson Disease,MESH:D010300,0,,1,HFE
antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0019886,Parkinson Disease,MESH:D010300,0,,1,HLA-DRA
antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0002504,Parkinson Disease,MESH:D010300,0,,1,HLA-DRA
antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0061844,Parkinson Disease,MESH:D010300,0,,1,DEFA4
antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0061844,Parkinsonian Disorders,MESH:D020734,0,,1,GAPDH
antimicrobial humoral response,GO:0019730,Parkinson Disease,MESH:D010300,0,,1,DEFA4
antiviral innate immune response,GO:0140374,Parkinson Disease,MESH:D010300,0,,1,TNF
antiviral innate immune response,GO:0140374,Parkinsonian Disorders,MESH:D020734,0,,1,PRKRA
antral ovarian follicle growth,GO:0001547,Parkinson Disease,MESH:D010300,1,"Fungicides, Industrial",0,
antral ovarian follicle growth,GO:0001547,"Parkinson Disease, Secondary",MESH:D010302,2,Doxorubicin|Resveratrol,0,
antral ovarian follicle growth,GO:0001547,Parkinsonian Disorders,MESH:D020734,2,Curcumin|Resveratrol,0,
aorta morphogenesis,GO:0035909,Parkinson Disease,MESH:D010300,1,Zinc,0,
apical dendrite arborization,GO:0150023,"Parkinson Disease, Secondary",MESH:D010302,1,Methotrexate,0,
apical dendrite morphogenesis,GO:0150021,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
apical dendrite morphogenesis,GO:0150021,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
apical protein localization,GO:0045176,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,0,
apical protein localization,GO:0045176,Parkinsonian Disorders,MESH:D020734,1,Valproic Acid,0,
apical protein localization,GO:0045176,"PARKINSONISM WITH SPASTICITY, X-LINKED",OMIM:300911,0,,1,ATP6AP2
apoptotic cell clearance,GO:0043277,Parkinson Disease,MESH:D010300,3,Aspirin|Organophosphorus Compounds|Propranolol,0,
apoptotic cell clearance,GO:0043277,"Parkinson Disease, Secondary",MESH:D010302,2,Doxorubicin|Organophosphorus Compounds,0,
apoptotic cell clearance,GO:0043277,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Propranolol,0,
apoptotic chromosome condensation,GO:0030263,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
apoptotic chromosome condensation,GO:0030263,Parkinson Disease,MESH:D010300,23,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Air Pollutants|Aluminum|Atrazine|beta-N-methylamino-L-alanine|Carbidopa|Chlorpyrifos|Diazinon|Herbicides|Lead|Lipopolysaccharides|Lithium|Lithium Carbonate|Maneb|Melatonin|Nitrogen Dioxide|Paraquat|Particulate Matter|pendimethalin|Rivastigmine|Rotenone|Zinc",0,
apoptotic chromosome condensation,GO:0030263,"Parkinson Disease, Secondary",MESH:D010302,18,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Amiodarone|Atrazine|Carbidopa|Carbon Monoxide|Doxorubicin|Lithium|Lithium Carbonate|Maneb|Melatonin|Methotrexate|Paraquat|Resveratrol|Rotenone|thymoquinone|Valproic Acid|Verapamil|Vincristine",0,
apoptotic chromosome condensation,GO:0030263,Parkinsonian Disorders,MESH:D020734,20,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Amiodarone|Cadmium|Carbidopa|coenzyme Q10|Curcumin|Donepezil|Lipopolysaccharides|Maneb|Melatonin|Paraquat|Particulate Matter|Plant Extracts|Resveratrol|Rimonabant|Rivastigmine|Rotenone|Valproic Acid|Verapamil",0,
apoptotic chromosome condensation,GO:0030263,Wolff-Parkinson-White Syndrome,MESH:D014927,3,Amiodarone|Isoproterenol|Lithium,0,
apoptotic DNA fragmentation,GO:0006309,Parkinson Disease,MESH:D010300,29,1-Methyl-4-phenylpyridinium|Apomorphine|Aspirin|Caffeine|Carbon Tetrachloride|Estradiol|Homocysteine|Levodopa|Lipopolysaccharides|Lithium|mangiferin|Melatonin|Minocycline|Nitric Oxide|Oxidopamine|Paclitaxel|Paraquat|Particulate Matter|Pentoxifylline|Propranolol|Reactive Oxygen Species|Rotenone|Sirolimus|Smoke|Tea|Testosterone|Tranylcypromine|Vehicle Emissions|Zinc,0,
apoptotic DNA fragmentation,GO:0006309,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
apoptotic DNA fragmentation,GO:0006309,"Parkinson Disease, Secondary",MESH:D010302,21,3-methyladenine|Amiodarone|Apomorphine|Cytarabine|Doxorubicin|Fluoxetine|Haloperidol|Levodopa|Lithium|Melatonin|Minocycline|Nicotine|Nifedipine|Oxidopamine|Paraquat|Resveratrol|Rotenone|Tacrine|Valproic Acid|Verapamil|Vincristine,0,
apoptotic DNA fragmentation,GO:0006309,Parkinsonian Disorders,MESH:D020734,28,1-Methyl-4-phenylpyridinium|Amiodarone|Amitriptyline|Apomorphine|Cadmium|Citalopram|Clonidine|crocin|Curcumin|Diazoxide|Disulfiram|Docosahexaenoic Acids|Donepezil|Haloperidol|Indomethacin|Levodopa|linsidomine|Lipopolysaccharides|Melatonin|Oxidopamine|Paraquat|Particulate Matter|Plant Extracts|Resveratrol|Rotenone|sesamin|Valproic Acid|Verapamil,0,
apoptotic DNA fragmentation,GO:0006309,Wolff-Parkinson-White Syndrome,MESH:D014927,4,Amiodarone|Isoproterenol|Lithium|Propranolol,0,
apoptotic mitochondrial changes,GO:0008637,Parkinson Disease,MESH:D010300,0,,2,ALDH2|SOD2
apoptotic mitochondrial changes,GO:0008637,"Parkinson Disease, Mitochondrial",MESH:C564015,0,,1,FMC1
apoptotic mitochondrial changes,GO:0008637,"Parkinson Disease, Secondary",MESH:D010302,0,,1,FMC1
apoptotic mitochondrial changes,GO:0008637,Parkinsonian Disorders,MESH:D020734,1,Curcumin,0,
apoptotic nuclear changes,GO:0030262,Parkinson Disease,MESH:D010300,7,Chlorpyrifos|Maneb|Melatonin|Paclitaxel|Paraquat|Rotenone|Testosterone,0,
apoptotic nuclear changes,GO:0030262,"Parkinson Disease, Secondary",MESH:D010302,6,Cisapride|Doxorubicin|Maneb|Melatonin|Paraquat|Rotenone,0,
apoptotic nuclear changes,GO:0030262,Parkinsonian Disorders,MESH:D020734,5,Maneb|Melatonin|Paraquat|Plant Extracts|Rotenone,0,
apoptotic process,GO:0006915,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
apoptotic process,GO:0006915,Parkinson Disease,MESH:D010300,82,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|4-phenylbutyric acid|6,7-dihydroxyflavone|Acrolein|Air Pollutants|Aluminum|Amphetamine|Apomorphine|Aprepitant|Aspirin|Astemizole|Atrazine|Benomyl|beta-N-methylamino-L-alanine|Bromocriptine|Caffeine|Carbidopa|Carbon Disulfide|Carbon Tetrachloride|Chlorpyrifos|Clozapine|Copper|Desipramine|Diazepam|Diazinon|Ditiocarb|Dopamine|Eicosapentaenoic Acid|Endosulfan|Estradiol|Eugenol|Fatty Acids|Hexachlorocyclohexane|Homocysteine|Iron|Ketoconazole|Lead|Levodopa|Lipopolysaccharides|Lithium|Maneb|Manganese|mangiferin|Melatonin|Methamphetamine|Metoclopramide|Minocycline|Naproxen|Nitric Oxide|Nitrites|Nitrogen Dioxide|Oxidopamine|Ozone|Paclitaxel|Paraquat|Particulate Matter|pendimethalin|Pentoxifylline|Pergolide|Permethrin|Pioglitazone|Polychlorinated Biphenyls|Probenecid|Propranolol|Quetiapine Fumarate|Reactive Oxygen Species|Reserpine|Roflumilast|ropinirole|Rotenone|Sirolimus|Smoke|Soot|Tea|Testosterone|tetrachloroisophthalonitrile|Trichloroethylene|Vehicle Emissions|Water Pollutants, Chemical|Zinc|Ziram",3,CEACAM6|DDIT4|SOD1
apoptotic process,GO:0006915,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
apoptotic process,GO:0006915,"Parkinson Disease, Secondary",MESH:D010302,64,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|3-methyladenine|Amiodarone|Amlodipine|Apomorphine|Atrazine|Benzo(a)pyrene|Buspirone|Carbidopa|Carbon Monoxide|Chlorpromazine|Cimetidine|Cytarabine|Diazepam|Dichlorvos|Diltiazem|Diphenhydramine|Ditiocarb|Doxorubicin|Exenatide|Flunarizine|Fluoxetine|Haloperidol|Indinavir|Levodopa|Lithium|Maneb|Manganese|Melatonin|Methamphetamine|Methotrexate|Metoclopramide|Minocycline|Nicotine|Nifedipine|Nortriptyline|Octreotide|Olanzapine|Oxcarbazepine|Oxidopamine|Paraquat|Pargyline|Paroxetine|Phenytoin|Poly I-C|PQQ Cofactor|Pyridostigmine Bromide|Reserpine|Resveratrol|Ribavirin|Ritonavir|Rotenone|Sertraline|Silymarin|sodium bisulfide|Tacrine|thymoquinone|Trichloroethylene|Trifluoperazine|Valproic Acid|Venlafaxine Hydrochloride|Verapamil|Vincristine|Ziram",0,
apoptotic process,GO:0006915,Parkinsonian Disorders,MESH:D020734,76,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside|4-hydroxy-2-nonenal|6-methyl-2-(phenylethynyl)pyridine|Amiodarone|Amitriptyline|Amlodipine|Apomorphine|Arecoline|Aripiprazole|baicalin|Bromocriptine|Budesonide|Buspirone|Cadmium|Carbidopa|Carbon Disulfide|Chlorpromazine|Citalopram|Clozapine|coenzyme Q10|Creatine|crocin|Curcumin|cypermethrin|Diazoxide|Disulfiram|Docosahexaenoic Acids|Donepezil|Dopamine|echinacoside|Flunarizine|genkwanin|ginsenoside Re|Haloperidol|Indomethacin|Ketoconazole|Levodopa|linsidomine|Lipopolysaccharides|Malondialdehyde|mancozeb|Maneb|Manganese|manganese chloride|Melatonin|Muscimol|Olanzapine|Oxidopamine|Paraquat|Paroxetine|Particulate Matter|Pergolide|Permethrin|Phenol|Pimozide|Plant Extracts|Plant Preparations|Probenecid|Procaine|Quetiapine Fumarate|Reserpine|Resveratrol|Rimonabant|Ritonavir|ropinirole|Rotenone|SCH 23390|Sertraline|sesamin|Silymarin|Trifluoperazine|Valproic Acid|Verapamil|Zidovudine",4,ALDH1A1|GAPDH|PARP1|PRKCD
apoptotic process,GO:0006915,Wolff-Parkinson-White Syndrome,MESH:D014927,6,Amiodarone|Diltiazem|Isoproterenol|Lithium|Propranolol|Quinidine,0,
apoptotic signaling pathway,GO:0097190,Parkinson Disease,MESH:D010300,0,,2,MAP3K5|TNF
apoptotic signaling pathway,GO:0097190,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
arachidonic acid metabolic process,GO:0019369,Parkinson Disease,MESH:D010300,3,Acrolein|Chlorpyrifos|Eicosapentaenoic Acid,1,CYP2D6
arachidonic acid metabolic process,GO:0019369,"Parkinson Disease, Secondary",MESH:D010302,2,Resveratrol|Ribavirin,0,
arachidonic acid metabolic process,GO:0019369,Parkinsonian Disorders,MESH:D020734,2,Docosahexaenoic Acids|Resveratrol,0,
arachidonic acid secretion,GO:0050482,Parkinson Disease,MESH:D010300,0,,1,DRD2
arachidonic acid secretion,GO:0050482,Parkinsonian Disorders,MESH:D020734,0,,1,DRD2
arginine biosynthetic process,GO:0006526,Parkinson Disease,MESH:D010300,2,1-Methyl-4-phenylpyridinium|Carbon Tetrachloride,0,
arginine biosynthetic process,GO:0006526,Parkinsonian Disorders,MESH:D020734,1,1-Methyl-4-phenylpyridinium,0,
arginine catabolic process,GO:0006527,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,1,NOS1
arginine catabolic process,GO:0006527,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
arginine catabolic process,GO:0006527,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
arginine metabolic process,GO:0006525,Parkinson Disease,MESH:D010300,5,Air Pollutants|Endosulfan|Nitrogen Dioxide|Particulate Matter|Trichloroethylene,0,
arginine metabolic process,GO:0006525,"Parkinson Disease, Secondary",MESH:D010302,2,Resveratrol|Trichloroethylene,0,
arginine metabolic process,GO:0006525,Parkinsonian Disorders,MESH:D020734,2,Particulate Matter|Resveratrol,0,
aromatic amino acid metabolic process,GO:0009072,Parkinson Disease,MESH:D010300,0,,1,TH
aromatic amino acid metabolic process,GO:0009072,Parkinsonian Disorders,MESH:D020734,0,,2,CAT-2|TH
artery development,GO:0060840,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,1,SHH
artery smooth muscle contraction,GO:0014824,Parkinson Disease,MESH:D010300,1,Particulate Matter,1,EDN1
artery smooth muscle contraction,GO:0014824,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
artery smooth muscle contraction,GO:0014824,Parkinsonian Disorders,MESH:D020734,3,Particulate Matter|Plant Preparations|Resveratrol,0,
artery vasodilation involved in baroreceptor response to increased systemic arterial blood pressure,GO:0001984,Parkinson Disease,MESH:D010300,2,Air Pollutants|Particulate Matter,0,
artery vasodilation involved in baroreceptor response to increased systemic arterial blood pressure,GO:0001984,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
asparagine biosynthetic process,GO:0006529,Parkinson Disease,MESH:D010300,3,Carbon Tetrachloride|Permethrin|Polychlorinated Biphenyls,0,
asparagine biosynthetic process,GO:0006529,Parkinsonian Disorders,MESH:D020734,1,Permethrin,0,
asparagine metabolic process,GO:0006528,Parkinson Disease,MESH:D010300,2,Endosulfan|Particulate Matter,0,
asparagine metabolic process,GO:0006528,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
aspartate biosynthetic process,GO:0006532,Parkinson Disease,MESH:D010300,2,Carbon Tetrachloride|Permethrin,0,
aspartate biosynthetic process,GO:0006532,Parkinsonian Disorders,MESH:D020734,1,Permethrin,0,
aspartate catabolic process,GO:0006533,Parkinson Disease,MESH:D010300,1,Carbon Tetrachloride,0,
aspartate catabolic process,GO:0006533,Parkinsonian Disorders,MESH:D020734,1,Plant Extracts,0,
aspartate metabolic process,GO:0006531,Parkinson Disease,MESH:D010300,5,Air Pollutants|Endosulfan|Nitrogen Dioxide|Ozone|Particulate Matter,0,
aspartate metabolic process,GO:0006531,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
aspartate metabolic process,GO:0006531,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
associative learning,GO:0008306,Parkinson Disease,MESH:D010300,1,Aspirin,3,CNTNAP2|DRD1|DRD2
associative learning,GO:0008306,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
associative learning,GO:0008306,Parkinsonian Disorders,MESH:D020734,2,cypermethrin|Rimonabant,1,DRD2
astrocyte activation,GO:0048143,Parkinson Disease,MESH:D010300,11,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Air Pollutants|Lead|Lipopolysaccharides|Methamphetamine|Paraquat|Particulate Matter|Permethrin|Reactive Oxygen Species|Rotenone",2,MAPT|TNF
astrocyte activation,GO:0048143,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
astrocyte activation,GO:0048143,"Parkinson Disease, Secondary",MESH:D010302,7,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Methamphetamine|N-(1-methylethyl)-1,1,2-trimethylpropylamine|Paraquat|Pyridostigmine Bromide|Resveratrol|Rotenone",0,
astrocyte activation,GO:0048143,Parkinsonian Disorders,MESH:D020734,10,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Diazoxide|Lipopolysaccharides|N-(1-methylethyl)-1,1,2-trimethylpropylamine|Paraquat|Particulate Matter|Permethrin|Resveratrol|Rotenone",1,MAPT
astrocyte cell migration,GO:0043615,Parkinson Disease,MESH:D010300,2,Air Pollutants|Particulate Matter,0,
astrocyte cell migration,GO:0043615,Parkinsonian Disorders,MESH:D020734,2,Particulate Matter|taxifolin,0,
astrocyte development,GO:0014002,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|Lead,2,DRD1|GFAP
astrocyte development,GO:0014002,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Plant Extracts,0,
astrocyte differentiation,GO:0048708,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
astrocyte differentiation,GO:0048708,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
astrocyte fate commitment,GO:0060018,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
ATP biosynthetic process,GO:0006754,Parkinson Disease,MESH:D010300,19,1-Methyl-4-phenylpyridinium|4-phenylbutyric acid|Air Pollutants|Caffeine|Carbon Tetrachloride|Clozapine|Copper|Dopamine|Ketoconazole|Lead|Lipopolysaccharides|Lithium Carbonate|Melatonin|Paraquat|Particulate Matter|Polychlorinated Biphenyls|Rotenone|Vehicle Emissions|Zinc,0,
ATP biosynthetic process,GO:0006754,"Parkinson Disease, Secondary",MESH:D010302,16,Benzo(a)pyrene|Carbon Monoxide|Chlorpromazine|Dichlorvos|Doxorubicin|Haloperidol|Lithium Carbonate|Melatonin|Paraquat|Resveratrol|Risperidone|Rotenone|Thioridazine|Trifluoperazine|Valproic Acid|Verapamil,0,
ATP biosynthetic process,GO:0006754,Parkinsonian Disorders,MESH:D020734,23,1-Methyl-4-phenylpyridinium|annonacin|Bupropion|Cadmium|Chlorpromazine|Clozapine|coenzyme Q10|Curcumin|Dopamine|Haloperidol|Ketoconazole|Lipopolysaccharides|Melatonin|Paraquat|Particulate Matter|Plant Extracts|Resveratrol|Risperidone|Rotenone|Thioridazine|Trifluoperazine|Valproic Acid|Verapamil,0,
ATP biosynthetic process,GO:0006754,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,1,PRKAG2
ATP generation from ADP,GO:0006757,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
ATP generation from ADP,GO:0006757,Parkinsonian Disorders,MESH:D020734,2,Creatine|Lipopolysaccharides,0,
ATP generation from poly-ADP-D-ribose,GO:1990966,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
ATP metabolic process,GO:0046034,Parkinson Disease,MESH:D010300,31,"1-Methyl-4-phenylpyridinium|4-phenylbutyric acid|Acrolein|Air Pollutants|Carbidopa|carbidopa, levodopa drug combination|Carbon Tetrachloride|Chlorpyrifos|Dieldrin|Estradiol|Hexachlorocyclohexane|Homocysteine|Lead|Lipopolysaccharides|Manganese|Melatonin|Methamphetamine|Nitrogen Dioxide|Oxidopamine|Ozone|Paclitaxel|Paraquat|Particulate Matter|Permethrin|Pramipexole|Rotenone|Sirolimus|Soot|Trichloroethylene|Vehicle Emissions|Zinc",1,HSPA1A
ATP metabolic process,GO:0046034,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Pramipexole,0,
ATP metabolic process,GO:0046034,"Parkinson Disease, Secondary",MESH:D010302,24,"Amiodarone|Amlodipine|Benzo(a)pyrene|Carbidopa|carbidopa, levodopa drug combination|Chlorpromazine|Dieldrin|Doxorubicin|geraniol|Manganese|Melatonin|Methamphetamine|Methotrexate|Nifedipine|Oxidopamine|Paraquat|perhexiline maleate|PQQ Cofactor|Resveratrol|Rotenone|Sertraline|Silymarin|Trichloroethylene|Valproic Acid",0,
ATP metabolic process,GO:0046034,Parkinsonian Disorders,MESH:D020734,28,"1-Methyl-4-phenylpyridinium|4-hydroxy-2-nonenal|Amiodarone|Amlodipine|Cadmium|Carbidopa|carbidopa, levodopa drug combination|Chlorpromazine|coenzyme Q10|Curcumin|Disulfiram|geraniol|Indomethacin|Lipopolysaccharides|Manganese|manganese chloride|Melatonin|Oxidopamine|Paraquat|Particulate Matter|Permethrin|Plant Extracts|Pramipexole|Resveratrol|Rotenone|Sertraline|Silymarin|Valproic Acid",0,
ATP metabolic process,GO:0046034,Wolff-Parkinson-White Syndrome,MESH:D014927,3,Amiodarone|Isoproterenol|Quinidine,0,
attachment of mitotic spindle microtubules to kinetochore,GO:0051315,Parkinson Disease,MESH:D010300,1,Paclitaxel,0,
attachment of spindle microtubules to kinetochore,GO:0008608,Parkinson Disease,MESH:D010300,1,Melatonin,0,
attachment of spindle microtubules to kinetochore,GO:0008608,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
attachment of spindle microtubules to kinetochore,GO:0008608,Parkinsonian Disorders,MESH:D020734,1,Melatonin,0,
attachment of spindle microtubules to kinetochore involved in meiotic chromosome segregation,GO:0051316,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
auditory behavior,GO:0031223,Parkinson Disease,MESH:D010300,0,,1,DRD2
auditory behavior,GO:0031223,Parkinsonian Disorders,MESH:D020734,1,Cadmium,1,DRD2
auditory receptor cell stereocilium organization,GO:0060088,Parkinson Disease,MESH:D010300,0,,1,SOD1
autophagic cell death,GO:0048102,Parkinson Disease,MESH:D010300,3,Lipopolysaccharides|Paclitaxel|Sirolimus,0,
autophagic cell death,GO:0048102,"Parkinson Disease, Secondary",MESH:D010302,2,3-methyladenine|Resveratrol,0,
autophagic cell death,GO:0048102,Parkinsonian Disorders,MESH:D020734,4,Cadmium|ginsenoside Re|Lipopolysaccharides|Resveratrol,0,
autophagosome assembly,GO:0000045,Parkinson Disease,MESH:D010300,12,1-Methyl-4-phenylpyridinium|4-phenylbutyric acid|Acrolein|Atrazine|Caffeine|Lipopolysaccharides|Melatonin|Oxidopamine|Paraquat|Rotenone|Sirolimus|Soot,0,
autophagosome assembly,GO:0000045,"Parkinson Disease, Secondary",MESH:D010302,10,3-methyladenine|Amiodarone|Atrazine|Benzo(a)pyrene|Doxorubicin|Melatonin|Oxidopamine|Paraquat|Resveratrol|Rotenone,0,
autophagosome assembly,GO:0000045,Parkinsonian Disorders,MESH:D020734,12,1-Methyl-4-phenylpyridinium|4-hydroxy-2-nonenal|Amiodarone|Cadmium|Docosahexaenoic Acids|Lipopolysaccharides|manganese chloride|Melatonin|Oxidopamine|Paraquat|Resveratrol|Rotenone,0,
autophagosome assembly,GO:0000045,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
autophagosome-endosome fusion,GO:0061910,Parkinson Disease,MESH:D010300,1,Methamphetamine,0,
autophagosome-endosome fusion,GO:0061910,"Parkinson Disease, Secondary",MESH:D010302,1,Methamphetamine,0,
autophagosome-lysosome fusion,GO:0061909,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
autophagosome-lysosome fusion,GO:0061909,Parkinson Disease,MESH:D010300,4,1-Methyl-4-phenylpyridinium|beta-N-methylamino-L-alanine|Methamphetamine|Sirolimus,1,ATP13A2
autophagosome-lysosome fusion,GO:0061909,"Parkinson Disease, Secondary",MESH:D010302,2,Doxorubicin|Methamphetamine,1,ATP13A2
autophagosome-lysosome fusion,GO:0061909,Parkinsonian Disorders,MESH:D020734,3,1-Methyl-4-phenylpyridinium|Cadmium|Curcumin,1,ATP13A2
autophagosome maturation,GO:0097352,"Parkinson Disease, Secondary",MESH:D010302,1,3-methyladenine,0,
autophagosome organization,GO:1905037,Parkinson Disease,MESH:D010300,4,Carbon Tetrachloride|Lead|Paraquat|Sirolimus,2,ATP13A2|GBA1
autophagosome organization,GO:1905037,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
autophagosome organization,GO:1905037,"Parkinson Disease, Secondary",MESH:D010302,4,3-methyladenine|Doxorubicin|Paraquat|Resveratrol,1,ATP13A2
autophagosome organization,GO:1905037,Parkinsonian Disorders,MESH:D020734,3,Cadmium|Paraquat|Resveratrol,2,ATP13A2|GBA1
autophagy,GO:0006914,Parkinson Disease,MESH:D010300,22,1-Methyl-4-phenylpyridinium|4-phenylbutyric acid|Acrolein|Atrazine|Caffeine|Copper|Iron|Lipopolysaccharides|Lithium|Manganese|Melatonin|Methamphetamine|Minocycline|Ozone|Paclitaxel|Paraquat|Particulate Matter|Pentoxifylline|Reactive Oxygen Species|Rotenone|Sirolimus|Vehicle Emissions,6,ATP13A2|DRD2|GBA1|LRRK2|PARK7|PRKN
autophagy,GO:0006914,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
autophagy,GO:0006914,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
autophagy,GO:0006914,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
autophagy,GO:0006914,"Parkinson Disease, Secondary",MESH:D010302,16,3-methyladenine|Atrazine|Benzo(a)pyrene|Doxorubicin|Exenatide|Fluoxetine|Lithium|Manganese|Melatonin|Methamphetamine|Minocycline|Paraquat|Resveratrol|Rotenone|Sertraline|thymoquinone,2,ATP13A2|PRKN
autophagy,GO:0006914,Parkinsonian Disorders,MESH:D020734,17,1-Methyl-4-phenylpyridinium|Cadmium|Clonidine|crocin|Curcumin|Disulfiram|Indomethacin|Lipopolysaccharides|Manganese|manganese chloride|Melatonin|Paraquat|Particulate Matter|Resveratrol|Rimonabant|Rotenone|Sertraline,6,ATP13A2|DRD2|GBA1|LRRK2|PARK7|PRKN
autophagy,GO:0006914,"Parkinsonism, early onset with mental retardation",MESH:C537179,0,,1,RAB39B
autophagy,GO:0006914,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Lithium,0,
autophagy of mitochondrion,GO:0000422,Parkinson Disease,MESH:D010300,5,1-Methyl-4-phenylpyridinium|Aluminum|Atrazine|Oxidopamine|Rotenone,3,PINK1|PPARGC1A|PRKN
autophagy of mitochondrion,GO:0000422,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
autophagy of mitochondrion,GO:0000422,"Parkinson Disease, Secondary",MESH:D010302,4,Atrazine|Doxorubicin|Oxidopamine|Rotenone,1,PRKN
autophagy of mitochondrion,GO:0000422,Parkinsonian Disorders,MESH:D020734,5,1-Methyl-4-phenylpyridinium|Cadmium|manganese chloride|Oxidopamine|Rotenone,2,PINK1|PRKN
axial mesoderm development,GO:0048318,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A2
axo-dendritic transport,GO:0008088,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,1,MAPT
axo-dendritic transport,GO:0008088,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
axo-dendritic transport,GO:0008088,Parkinsonian Disorders,MESH:D020734,1,Clonidine,1,MAPT
axonal transport,GO:0098930,Parkinson Disease,MESH:D010300,0,,2,MAPT|TMEM230
axonal transport,GO:0098930,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
axonal transport,GO:0098930,"Parkinson Disease, Secondary",MESH:D010302,1,Vincristine,0,
axonal transport,GO:0098930,Parkinsonian Disorders,MESH:D020734,0,,1,MAPT
axonal transport,GO:0098930,"PARKINSONISM WITH SPASTICITY, X-LINKED",OMIM:300911,0,,1,ATP6AP2
axonal transport of mitochondrion,GO:0019896,Parkinson Disease,MESH:D010300,0,,1,MAPT
axonal transport of mitochondrion,GO:0019896,"PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:613643,0,,1,UCHL1
axonal transport of mitochondrion,GO:0019896,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
axonal transport of mitochondrion,GO:0019896,"Parkinson Disease, Secondary",MESH:D010302,1,MDL 201053,0,
axonal transport of mitochondrion,GO:0019896,Parkinsonian Disorders,MESH:D020734,0,,1,MAPT
axon arborization,GO:0140060,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
axon arborization,GO:0140060,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
axon development,GO:0061564,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|Paclitaxel,1,MAPT
axon development,GO:0061564,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
axon development,GO:0061564,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
axon development,GO:0061564,Parkinsonian Disorders,MESH:D020734,0,,1,MAPT
axon extension,GO:0048675,Parkinson Disease,MESH:D010300,4,Chlorpyrifos|Melatonin|Methamphetamine|Paclitaxel,4,BDNF|EDN1|MAPT|NGF
axon extension,GO:0048675,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
axon extension,GO:0048675,"Parkinson Disease, Secondary",MESH:D010302,2,Melatonin|Methamphetamine,0,
axon extension,GO:0048675,Parkinsonian Disorders,MESH:D020734,1,Melatonin,2,MAPT|NGF
axon extension involved in axon guidance,GO:0048846,Parkinson Disease,MESH:D010300,0,,1,COL19A1
axon guidance,GO:0007411,Parkinson Disease,MESH:D010300,1,Copper,3,BDNF|DRAXIN|EDN1
axon guidance,GO:0007411,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,1,SHH
axonogenesis,GO:0007409,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
axonogenesis,GO:0007409,Parkinson Disease,MESH:D010300,5,beta-N-methylamino-L-alanine|Lead|Methamphetamine|Particulate Matter|Vehicle Emissions,6,CNTNAP2|DRD2|FAX|IGF1R|MAP2|MAPT
axonogenesis,GO:0007409,"PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:613643,0,,1,UCHL1
axonogenesis,GO:0007409,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
axonogenesis,GO:0007409,"Parkinson Disease, Secondary",MESH:D010302,1,Methamphetamine,0,
axonogenesis,GO:0007409,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,2,DRD2|MAPT
axonogenesis involved in innervation,GO:0060385,Parkinson Disease,MESH:D010300,0,,1,EDN1
axon regeneration,GO:0031103,Parkinson Disease,MESH:D010300,1,Rotenone,1,MAG
axon regeneration,GO:0031103,"Parkinson Disease, Secondary",MESH:D010302,1,Rotenone,0,
axon regeneration,GO:0031103,Parkinsonian Disorders,MESH:D020734,1,Rotenone,0,
axon target recognition,GO:0007412,Parkinson Disease,MESH:D010300,0,,1,BDNF
axon target recognition,GO:0007412,"PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:613643,0,,1,UCHL1
backward locomotion,GO:0043057,Parkinson Disease,MESH:D010300,1,Methomyl,0,
baroreceptor detection of arterial stretch,GO:0001981,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
basal dendrite arborization,GO:0150020,"Parkinson Disease, Secondary",MESH:D010302,1,Methotrexate,0,
base-excision repair,GO:0006284,Parkinsonian Disorders,MESH:D020734,0,,2,PARP1|POLG
"base-excision repair, gap-filling",GO:0006287,Parkinsonian Disorders,MESH:D020734,0,,1,POLG
B cell antigen processing and presentation,GO:0002450,Parkinson Disease,MESH:D010300,0,,1,FCER2
B cell homeostasis,GO:0001782,Parkinson Disease,MESH:D010300,4,Air Pollutants|Nitrates|Nitrogen Dioxide|Particulate Matter,0,
B cell homeostasis,GO:0001782,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
B cell lineage commitment,GO:0002326,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
B cell proliferation,GO:0042100,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|Lipopolysaccharides,0,
B cell proliferation,GO:0042100,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
B cell proliferation,GO:0042100,Parkinsonian Disorders,MESH:D020734,3,Lipopolysaccharides|Plant Extracts|Resveratrol,1,PRKCD
behavior,GO:0007610,Parkinson Disease,MESH:D010300,11,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Air Pollutants|Chlorpyrifos|Dopamine|Lead|Lipopolysaccharides|Manganese|Particulate Matter|Permethrin|Rotenone|Sirolimus",0,
behavior,GO:0007610,"Parkinson Disease, Secondary",MESH:D010302,4,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Fluoxetine|Manganese|Rotenone",0,
behavior,GO:0007610,Parkinsonian Disorders,MESH:D020734,11,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Cadmium|coenzyme Q10|Dopamine|Lipopolysaccharides|Manganese|manganese chloride|Particulate Matter|Permethrin|Rimonabant|Rotenone",1,ATP1A3
behavioral defense response,GO:0002209,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
behavioral fear response,GO:0001662,Parkinson Disease,MESH:D010300,3,Maneb|Paraquat|Smoke,2,BDNF|DRD1
behavioral fear response,GO:0001662,"PARKINSON DISEASE 18, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:614251,0,,1,EIF4G1
behavioral fear response,GO:0001662,"Parkinson Disease, Secondary",MESH:D010302,3,Maneb|Paraquat|Poly I-C,0,
behavioral fear response,GO:0001662,Parkinsonian Disorders,MESH:D020734,4,Cadmium|Citalopram|Maneb|Paraquat,0,
behavioral response to acetic acid induced pain,GO:0061367,Parkinson Disease,MESH:D010300,1,Rotenone,0,
behavioral response to acetic acid induced pain,GO:0061367,"Parkinson Disease, Secondary",MESH:D010302,3,geraniol|Rotenone|Vincristine,0,
behavioral response to acetic acid induced pain,GO:0061367,Parkinsonian Disorders,MESH:D020734,5,geraniol|Indomethacin|Plant Extracts|Rimonabant|Rotenone,0,
behavioral response to chemical pain,GO:0061366,Parkinson Disease,MESH:D010300,2,Ketoconazole|Zinc,0,
behavioral response to chemical pain,GO:0061366,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
behavioral response to chemical pain,GO:0061366,Parkinsonian Disorders,MESH:D020734,5,Indomethacin|Ketoconazole|Plant Extracts|Resveratrol|Rimonabant,0,
behavioral response to cocaine,GO:0048148,Parkinson Disease,MESH:D010300,0,,5,BDNF|DRD1|DRD2|NOS1|SNCA
behavioral response to cocaine,GO:0048148,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
behavioral response to cocaine,GO:0048148,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
behavioral response to cocaine,GO:0048148,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,1,SNCA
behavioral response to cocaine,GO:0048148,Parkinsonian Disorders,MESH:D020734,1,Rimonabant,3,DRD2|PARP1|SNCA
behavioral response to ethanol,GO:0048149,Parkinson Disease,MESH:D010300,4,Carbon Tetrachloride|Chlorpyrifos|Gabapentin|Oxidopamine,2,ALDH2|DRD2
behavioral response to ethanol,GO:0048149,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ADH1C
behavioral response to ethanol,GO:0048149,"Parkinson Disease, Secondary",MESH:D010302,2,Buspirone|Oxidopamine,0,
behavioral response to ethanol,GO:0048149,Parkinsonian Disorders,MESH:D020734,2,Buspirone|Oxidopamine,1,DRD2
behavioral response to formalin induced pain,GO:0061368,"Parkinson Disease, Secondary",MESH:D010302,3,Flunarizine|geraniol|Silymarin,0,
behavioral response to formalin induced pain,GO:0061368,Parkinsonian Disorders,MESH:D020734,6,Curcumin|Flunarizine|geraniol|Plant Extracts|Rimonabant|Silymarin,0,
behavioral response to nicotine,GO:0035095,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
behavioral response to nicotine,GO:0035095,Parkinsonian Disorders,MESH:D020734,1,Rimonabant,0,
behavioral response to pain,GO:0048266,Parkinson Disease,MESH:D010300,9,Chlorpyrifos|Gabapentin|Ketoconazole|Minocycline|Paclitaxel|Pentoxifylline|Permethrin|Rotenone|Testosterone,1,CNTNAP2
behavioral response to pain,GO:0048266,"Parkinson Disease, Secondary",MESH:D010302,8,Meperidine|Methotrexate|Minocycline|Nicotine|Pyridostigmine Bromide|Rotenone|Valproic Acid|Vincristine,0,
behavioral response to pain,GO:0048266,Parkinsonian Disorders,MESH:D020734,9,Baclofen|Indomethacin|Ketoconazole|Muscimol|Permethrin|Plant Extracts|Rimonabant|Rotenone|Valproic Acid,0,
benzene metabolic process,GO:0018910,Parkinson Disease,MESH:D010300,0,,1,CYP2E1
benzoate transport,GO:0042919,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,0,
benzoate transport,GO:0042919,Parkinsonian Disorders,MESH:D020734,1,Valproic Acid,0,
Bergmann glial cell differentiation,GO:0060020,Parkinson Disease,MESH:D010300,0,,1,GFAP
Bergmann glial cell differentiation,GO:0060020,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
beta-alanine metabolic process,GO:0019482,Parkinson Disease,MESH:D010300,3,Air Pollutants|Nitrogen Dioxide|Particulate Matter,0,
beta-alanine metabolic process,GO:0019482,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
beta-glucoside catabolic process,GO:1901805,Parkinson Disease,MESH:D010300,0,,1,GBA1
beta-glucoside catabolic process,GO:1901805,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
beta-glucoside catabolic process,GO:1901805,Parkinsonian Disorders,MESH:D020734,0,,1,GBA1
bicarbonate transport,GO:0015701,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
bicarbonate transport,GO:0015701,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
bicarbonate transport,GO:0015701,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
bile acid and bile salt transport,GO:0015721,Parkinson Disease,MESH:D010300,1,Probenecid,0,
bile acid and bile salt transport,GO:0015721,"Parkinson Disease, Secondary",MESH:D010302,1,Chlorpromazine,0,
bile acid and bile salt transport,GO:0015721,Parkinsonian Disorders,MESH:D020734,2,Chlorpromazine|Probenecid,0,
bile acid biosynthetic process,GO:0006699,Parkinson Disease,MESH:D010300,1,Melatonin,0,
bile acid biosynthetic process,GO:0006699,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
bile acid biosynthetic process,GO:0006699,Parkinsonian Disorders,MESH:D020734,1,Melatonin,0,
bile acid catabolic process,GO:0030573,Parkinson Disease,MESH:D010300,2,Ketoconazole|Phorate,0,
bile acid catabolic process,GO:0030573,Parkinsonian Disorders,MESH:D020734,1,Ketoconazole,0,
bile acid metabolic process,GO:0008206,Parkinson Disease,MESH:D010300,7,Copper|Estradiol|Ketoconazole|Lead|Lipopolysaccharides|Manganese|Zinc,0,
bile acid metabolic process,GO:0008206,"Parkinson Disease, Secondary",MESH:D010302,3,Benzo(a)pyrene|Manganese|Ribavirin,0,
bile acid metabolic process,GO:0008206,Parkinsonian Disorders,MESH:D020734,6,Amphotericin B|Cadmium|Ketoconazole|Lipopolysaccharides|Lopinavir|Manganese,0,
bile acid secretion,GO:0032782,"Parkinson Disease, Secondary",MESH:D010302,2,Chlorpromazine|Resveratrol,0,
bile acid secretion,GO:0032782,Parkinsonian Disorders,MESH:D020734,3,Chlorpromazine|Lopinavir|Resveratrol,0,
bilirubin transport,GO:0015723,Parkinson Disease,MESH:D010300,3,Carbon Tetrachloride|Homocysteine|Zinc,0,
bilirubin transport,GO:0015723,"Parkinson Disease, Secondary",MESH:D010302,4,geraniol|Methotrexate|Resveratrol|Silymarin,0,
bilirubin transport,GO:0015723,Parkinsonian Disorders,MESH:D020734,4,geraniol|Plant Extracts|Resveratrol|Silymarin,0,
binding of sperm to zona pellucida,GO:0007339,Parkinson Disease,MESH:D010300,1,Melatonin,1,HSPA1A
binding of sperm to zona pellucida,GO:0007339,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
binding of sperm to zona pellucida,GO:0007339,Parkinsonian Disorders,MESH:D020734,1,Melatonin,0,
biogenic amine metabolic process,GO:0006576,Parkinson Disease,MESH:D010300,1,Manganese,1,MAOA
biogenic amine metabolic process,GO:0006576,"Parkinson Disease, Secondary",MESH:D010302,1,Manganese,0,
biogenic amine metabolic process,GO:0006576,Parkinsonian Disorders,MESH:D020734,1,Manganese,0,
biological_process,GO:0008150,Parkinson Disease,MESH:D010300,0,,8,BST1|COL19A1|NECTIN2|RETININ|RPL14|RPL23A|RPS8|VPS35
biological_process,GO:0008150,Parkinson Disease 11,MESH:C564345,0,,1,GIGYF2
biological_process,GO:0008150,PARKINSON DISEASE 17,OMIM:614203,0,,1,VPS35
biological_process,GO:0008150,"PARKINSON DISEASE 19A, JUVENILE-ONSET",OMIM:615528,0,,1,DNAJC6
biological_process,GO:0008150,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ATXN2
biological_process,GO:0008150,Parkinsonian Disorders,MESH:D020734,0,,1,DCTN1
biological_process,GO:0008150,"PARKINSONISM WITH SPASTICITY, X-LINKED",OMIM:300911,0,,1,ATP6AP2
biological process involved in interaction with host,GO:0051701,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
biological process involved in symbiotic interaction,GO:0044403,Parkinson Disease,MESH:D010300,3,Chlorpyrifos|Lipopolysaccharides|Paraquat,0,
biological process involved in symbiotic interaction,GO:0044403,"Parkinson Disease, Secondary",MESH:D010302,3,Doxorubicin|Nicotine|Paraquat,0,
biological process involved in symbiotic interaction,GO:0044403,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Paraquat,0,
biosynthetic process of antibacterial peptides active against Gram-positive bacteria,GO:0002815,Parkinson Disease,MESH:D010300,2,Air Pollutants|Particulate Matter,0,
biosynthetic process of antibacterial peptides active against Gram-positive bacteria,GO:0002815,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
blastocyst formation,GO:0001825,Parkinson Disease,MESH:D010300,4,1-Methyl-4-phenylpyridinium|Chlorpyrifos|Estradiol|Melatonin,0,
blastocyst formation,GO:0001825,"Parkinson Disease, Secondary",MESH:D010302,2,Melatonin|Resveratrol,0,
blastocyst formation,GO:0001825,Parkinsonian Disorders,MESH:D020734,3,1-Methyl-4-phenylpyridinium|Melatonin|Resveratrol,0,
blastocyst hatching,GO:0001835,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
blastocyst hatching,GO:0001835,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
bleb assembly,GO:0032060,"Parkinson Disease, Secondary",MESH:D010302,1,sodium bisulfide,0,
bleb assembly,GO:0032060,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
blood circulation,GO:0008015,Parkinson Disease,MESH:D010300,3,Acrolein|Air Pollutants|Particulate Matter,0,
blood circulation,GO:0008015,"Parkinson Disease, Secondary",MESH:D010302,1,Haloperidol,1,PON1
blood circulation,GO:0008015,Parkinsonian Disorders,MESH:D020734,2,Haloperidol|Particulate Matter,1,ATP1A3
blood coagulation,GO:0007596,Parkinson Disease,MESH:D010300,3,Air Pollutants|Particulate Matter|Probenecid,1,FGB
blood coagulation,GO:0007596,"Parkinson Disease, Secondary",MESH:D010302,1,sodium bisulfide,1,SHH
blood coagulation,GO:0007596,Parkinsonian Disorders,MESH:D020734,3,Particulate Matter|Plant Extracts|Probenecid,0,
"blood coagulation, fibrin clot formation",GO:0072378,Parkinson Disease,MESH:D010300,6,Air Pollutants|Copper|Lipopolysaccharides|Manganese|Particulate Matter|Vehicle Emissions,1,FGB
"blood coagulation, fibrin clot formation",GO:0072378,"Parkinson Disease, Secondary",MESH:D010302,1,Manganese,0,
"blood coagulation, fibrin clot formation",GO:0072378,Parkinsonian Disorders,MESH:D020734,4,Lipopolysaccharides|Manganese|manganese chloride|Particulate Matter,0,
blood vessel development,GO:0001568,Parkinson Disease,MESH:D010300,2,Air Pollutants|Particulate Matter,0,
blood vessel development,GO:0001568,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
blood vessel development,GO:0001568,Parkinsonian Disorders,MESH:D020734,2,Particulate Matter|Resveratrol,1,ALDH1A2
blood vessel diameter maintenance,GO:0097746,Parkinson Disease,MESH:D010300,2,Nitric Oxide|Particulate Matter,1,EDN1
blood vessel diameter maintenance,GO:0097746,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
blood vessel diameter maintenance,GO:0097746,Parkinsonian Disorders,MESH:D020734,3,Cadmium|Particulate Matter|Resveratrol,0,
blood vessel endothelial cell migration,GO:0043534,Parkinson Disease,MESH:D010300,1,Acrolein,0,
blood vessel morphogenesis,GO:0048514,Parkinson Disease,MESH:D010300,0,,1,EDN1
blood vessel remodeling,GO:0001974,Parkinson Disease,MESH:D010300,2,Lipopolysaccharides|Zinc,0,
blood vessel remodeling,GO:0001974,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
blood vessel remodeling,GO:0001974,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
BMP signaling pathway,GO:0030509,Parkinson Disease,MESH:D010300,0,,1,HFE
body fluid secretion,GO:0007589,Parkinson Disease,MESH:D010300,0,,1,EDN1
body morphogenesis,GO:0010171,Parkinson Disease,MESH:D010300,1,Zinc,0,
body morphogenesis,GO:0010171,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
bone development,GO:0060348,Parkinson Disease,MESH:D010300,5,Caffeine|Lead|Nitrogen Dioxide|Particulate Matter|Propranolol,0,
bone development,GO:0060348,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
bone development,GO:0060348,Parkinsonian Disorders,MESH:D020734,3,Cadmium|Curcumin|Particulate Matter,0,
bone development,GO:0060348,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Propranolol,0,
bone growth,GO:0098868,Parkinson Disease,MESH:D010300,4,4-phenylbutyric acid|Air Pollutants|Caffeine|Particulate Matter,0,
bone growth,GO:0098868,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Particulate Matter,0,
bone mineralization,GO:0030282,Parkinson Disease,MESH:D010300,3,Estradiol|Lead|Lipopolysaccharides,0,
bone mineralization,GO:0030282,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
bone mineralization,GO:0030282,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Lipopolysaccharides,0,
bone morphogenesis,GO:0060349,Parkinson Disease,MESH:D010300,0,,1,EDN1
bone remodeling,GO:0046849,Parkinson Disease,MESH:D010300,1,Methamphetamine,1,IL6
bone remodeling,GO:0046849,"Parkinson Disease, Secondary",MESH:D010302,2,Methamphetamine|Nicotine,0,
bone remodeling,GO:0046849,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
bone resorption,GO:0045453,Parkinson Disease,MESH:D010300,2,Iron|Lipopolysaccharides,0,
bone resorption,GO:0045453,Parkinsonian Disorders,MESH:D020734,3,Cadmium|crocin|Lipopolysaccharides,0,
bone trabecula formation,GO:0060346,Parkinson Disease,MESH:D010300,1,Rivastigmine,0,
bone trabecula formation,GO:0060346,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
bone trabecula formation,GO:0060346,Parkinsonian Disorders,MESH:D020734,1,Rivastigmine,0,
bone trabecula morphogenesis,GO:0061430,Parkinson Disease,MESH:D010300,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
bone trabecula morphogenesis,GO:0061430,"Parkinson Disease, Secondary",MESH:D010302,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
bone trabecula morphogenesis,GO:0061430,Parkinsonian Disorders,MESH:D020734,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
brain-derived neurotrophic factor receptor signaling pathway,GO:0031547,Parkinson Disease,MESH:D010300,0,,3,BDNF|IGF1R|INSR
brain-derived neurotrophic factor receptor signaling pathway,GO:0031547,Parkinsonian Disorders,MESH:D020734,1,Plant Extracts,1,ATP1A3
brain development,GO:0007420,Parkinson Disease,MESH:D010300,6,Air Pollutants|Caffeine|Lead|Organophosphates|Particulate Matter|Permethrin,6,BDNF|CNTNAP2|DDC|DDIT4|IGF1R|SLC18A2
brain development,GO:0007420,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
brain development,GO:0007420,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,1,SLC18A2
brain development,GO:0007420,Parkinsonian Disorders,MESH:D020734,4,Cadmium|Curcumin|Particulate Matter|Permethrin,2,DDC|SLC18A2
brain morphogenesis,GO:0048854,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|Pesticides,1,GBA1
brain morphogenesis,GO:0048854,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
brain morphogenesis,GO:0048854,"Parkinson Disease, Secondary",MESH:D010302,1,Pesticides,0,
brain morphogenesis,GO:0048854,Parkinsonian Disorders,MESH:D020734,0,,1,GBA1
branched-chain amino acid metabolic process,GO:0009081,Parkinson Disease,MESH:D010300,1,Ozone,0,
branching involved in blood vessel morphogenesis,GO:0001569,Parkinson Disease,MESH:D010300,0,,1,EDN1
branching involved in blood vessel morphogenesis,GO:0001569,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
branching involved in mammary gland duct morphogenesis,GO:0060444,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
branching involved in prostate gland morphogenesis,GO:0060442,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
branching involved in salivary gland morphogenesis,GO:0060445,Parkinson Disease,MESH:D010300,0,,1,IL6
branching involved in salivary gland morphogenesis,GO:0060445,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
branching involved in ureteric bud morphogenesis,GO:0001658,Parkinson Disease,MESH:D010300,0,,1,GDNF
branching involved in ureteric bud morphogenesis,GO:0001658,"Parkinson Disease, Secondary",MESH:D010302,0,,2,GDNF|SHH
branching involved in ureteric bud morphogenesis,GO:0001658,Parkinsonian Disorders,MESH:D020734,0,,1,GDNF
branching morphogenesis of an epithelial tube,GO:0048754,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
branching morphogenesis of a nerve,GO:0048755,Parkinson Disease,MESH:D010300,0,,1,DRD2
branching morphogenesis of a nerve,GO:0048755,Parkinsonian Disorders,MESH:D020734,0,,1,DRD2
brown fat cell differentiation,GO:0050873,Parkinson Disease,MESH:D010300,0,,1,PPARGC1A
brown fat cell differentiation,GO:0050873,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,1,RGS2
brown fat cell differentiation,GO:0050873,Parkinsonian Disorders,MESH:D020734,2,Indomethacin|Resveratrol,0,
brown fat cell proliferation,GO:0070342,Parkinson Disease,MESH:D010300,2,Air Pollutants|Particulate Matter,0,
brown fat cell proliferation,GO:0070342,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
brush border assembly,GO:1904970,"Parkinson Disease, Secondary",MESH:D010302,1,geraniol,0,
brush border assembly,GO:1904970,Parkinsonian Disorders,MESH:D020734,1,geraniol,0,
bud outgrowth involved in lung branching,GO:0060447,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
butyrate metabolic process,GO:0019605,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
C21-steroid hormone biosynthetic process,GO:0006700,Parkinson Disease,MESH:D010300,1,Caffeine,0,
C21-steroid hormone biosynthetic process,GO:0006700,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
C21-steroid hormone metabolic process,GO:0008207,Parkinson Disease,MESH:D010300,3,Estradiol|Ketoconazole|Testosterone,0,
C21-steroid hormone metabolic process,GO:0008207,Parkinsonian Disorders,MESH:D020734,1,Ketoconazole,0,
C-5 methylation of cytosine,GO:0090116,Parkinson Disease,MESH:D010300,4,Estradiol|Particulate Matter|Permethrin|Pesticides,0,
C-5 methylation of cytosine,GO:0090116,"Parkinson Disease, Secondary",MESH:D010302,5,Benzo(a)pyrene|Doxorubicin|Pesticides|Poly I-C|Resveratrol,0,
C-5 methylation of cytosine,GO:0090116,Parkinsonian Disorders,MESH:D020734,3,Particulate Matter|Permethrin|Resveratrol,0,
cadmium ion homeostasis,GO:0055073,Parkinson Disease,MESH:D010300,1,Zinc,0,
cadmium ion homeostasis,GO:0055073,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
cadmium ion transmembrane transport,GO:0070574,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
cadmium ion transport,GO:0015691,Parkinson Disease,MESH:D010300,1,Zinc,0,
cadmium ion transport,GO:0015691,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
Cajal body organization,GO:0030576,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
calcitriol biosynthetic process from calciol,GO:0036378,Parkinson Disease,MESH:D010300,1,Ketoconazole,0,
calcitriol biosynthetic process from calciol,GO:0036378,Parkinsonian Disorders,MESH:D020734,1,Ketoconazole,0,
calcium-dependent cell-matrix adhesion,GO:0016340,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
calcium import into the mitochondrion,GO:0036444,Parkinson Disease,MESH:D010300,2,Lead|Lithium,1,HSPA9
calcium import into the mitochondrion,GO:0036444,"Parkinson Disease, Secondary",MESH:D010302,2,Lithium|Valproic Acid,0,
calcium import into the mitochondrion,GO:0036444,Parkinsonian Disorders,MESH:D020734,2,ginsenoside Re|Valproic Acid,0,
calcium import into the mitochondrion,GO:0036444,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Isoproterenol|Lithium,0,
calcium ion export,GO:1901660,Parkinson Disease,MESH:D010300,1,Permethrin,0,
calcium ion export,GO:1901660,Parkinsonian Disorders,MESH:D020734,1,Permethrin,0,
calcium ion homeostasis,GO:0055074,Parkinson Disease,MESH:D010300,14,"1-Methyl-4-phenylpyridinium|Atrazine|benserazide, levodopa drug combination|Chlorpyrifos|Endosulfan|Estradiol|Eugenol|Ketoconazole|Lead|Lithium|Oxidopamine|Paraquat|Permethrin|Rotenone",0,
calcium ion homeostasis,GO:0055074,"Parkinson Disease, Secondary",MESH:D010302,15,"Amiodarone|Atrazine|benserazide, levodopa drug combination|Chlorpromazine|Doxorubicin|Lithium|Methotrexate|Nifedipine|Oxidopamine|Paraquat|Resveratrol|Rotenone|Tacrine|Valproic Acid|Verapamil",0,
calcium ion homeostasis,GO:0055074,Parkinsonian Disorders,MESH:D020734,18,"1-Methyl-4-phenylpyridinium|Amiodarone|benserazide, levodopa drug combination|Cadmium|Chlorpromazine|Curcumin|cypermethrin|Docosahexaenoic Acids|Ketoconazole|oleuropein|Oxidopamine|Paraquat|Permethrin|Resveratrol|Rotenone|taxifolin|Valproic Acid|Verapamil",0,
calcium ion homeostasis,GO:0055074,Wolff-Parkinson-White Syndrome,MESH:D014927,3,Amiodarone|Isoproterenol|Lithium,0,
calcium ion import,GO:0070509,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
calcium ion import,GO:0070509,Parkinson Disease,MESH:D010300,8,"beta-N-methylamino-L-alanine|Diazinon|Estradiol|Manganese|Methamphetamine|Paraquat|Vehicle Emissions|Water Pollutants, Chemical",0,
calcium ion import,GO:0070509,"Parkinson Disease, Secondary",MESH:D010302,8,Benzo(a)pyrene|Flunarizine|Manganese|Methamphetamine|Nicotine|Nifedipine|Paraquat|Verapamil,0,
calcium ion import,GO:0070509,Parkinsonian Disorders,MESH:D020734,9,Diazoxide|Flunarizine|linsidomine|Manganese|manganese chloride|Paraquat|Procaine|Rimonabant|Verapamil,0,
calcium ion import across plasma membrane,GO:0098703,Parkinson Disease,MESH:D010300,3,Copper|mangiferin|Pesticides,1,TRPM2
calcium ion import across plasma membrane,GO:0098703,"Parkinson Disease, Secondary",MESH:D010302,1,Pesticides,0,
calcium ion import into cytosol,GO:1902656,Parkinson Disease,MESH:D010300,1,Ziram,0,
calcium ion import into cytosol,GO:1902656,"Parkinson Disease, Secondary",MESH:D010302,1,Ziram,0,
calcium ion regulated lysosome exocytosis,GO:1990927,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
calcium ion regulated lysosome exocytosis,GO:1990927,Parkinson Disease,MESH:D010300,1,beta-N-methylamino-L-alanine,0,
calcium ion transmembrane import into cytosol,GO:0097553,Parkinson Disease,MESH:D010300,0,,1,TRPM2
calcium ion transmembrane transport,GO:0070588,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
calcium ion transmembrane transport,GO:0070588,Parkinson Disease,MESH:D010300,0,,2,EDN1|TRPM2
calcium ion transmembrane transport via high voltage-gated calcium channel,GO:0061577,Parkinson Disease,MESH:D010300,1,Rotenone,0,
calcium ion transmembrane transport via high voltage-gated calcium channel,GO:0061577,"Parkinson Disease, Secondary",MESH:D010302,2,Resveratrol|Rotenone,0,
calcium ion transmembrane transport via high voltage-gated calcium channel,GO:0061577,Parkinsonian Disorders,MESH:D020734,2,Resveratrol|Rotenone,0,
calcium ion transport,GO:0006816,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
calcium ion transport,GO:0006816,Parkinson Disease,MESH:D010300,1,Methamphetamine,3,DNM1L|NOS1|TRPM2
calcium ion transport,GO:0006816,"Parkinson Disease, Secondary",MESH:D010302,2,Methamphetamine|Nicotine,0,
calcium ion transport,GO:0006816,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
calcium-mediated signaling,GO:0019722,Parkinson Disease,MESH:D010300,8,Caffeine|Homocysteine|Melatonin|Particulate Matter|Propranolol|Rotenone|Sirolimus|Testosterone,5,DRD1|EDN1|LRRK2|TNF|TRPM2
calcium-mediated signaling,GO:0019722,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
calcium-mediated signaling,GO:0019722,"Parkinson Disease, Secondary",MESH:D010302,7,Melatonin|Nicotine|Nifedipine|Resveratrol|Risperidone|Rotenone|Verapamil,0,
calcium-mediated signaling,GO:0019722,Parkinsonian Disorders,MESH:D020734,10,Cadmium|Curcumin|Diazoxide|Melatonin|Particulate Matter|Procaine|Resveratrol|Risperidone|Rotenone|Verapamil,2,ATP1A3|LRRK2
calcium-mediated signaling,GO:0019722,Wolff-Parkinson-White Syndrome,MESH:D014927,3,Isoproterenol|Propranolol|Quinidine,0,
camera-type eye development,GO:0043010,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
camera-type eye development,GO:0043010,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A2
camera-type eye morphogenesis,GO:0048593,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A2
CAMKK-AMPK signaling cascade,GO:0061762,Parkinson Disease,MESH:D010300,0,,1,CP
cAMP biosynthetic process,GO:0006171,Parkinson Disease,MESH:D010300,12,Aluminum|Atrazine|Caffeine|Estradiol|Ketoconazole|Lipopolysaccharides|Manganese|Particulate Matter|Propranolol|Roflumilast|SK&F 82958|Vehicle Emissions,0,
cAMP biosynthetic process,GO:0006171,"Parkinson Disease, Secondary",MESH:D010302,4,Atrazine|Manganese|Nicotine|Resveratrol,0,
cAMP biosynthetic process,GO:0006171,Parkinsonian Disorders,MESH:D020734,8,Baclofen|Curcumin|Ketoconazole|Lipopolysaccharides|Manganese|Particulate Matter|Resveratrol|SK&F 82958,0,
cAMP biosynthetic process,GO:0006171,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Isoproterenol|Propranolol,0,
cAMP-mediated signaling,GO:0019933,Parkinsonian Disorders,MESH:D020734,0,,1,GAPDH
cAMP metabolic process,GO:0046058,Parkinson Disease,MESH:D010300,9,Atrazine|Caffeine|Maneb|Paraquat|Particulate Matter|Pentoxifylline|Roflumilast|Rotenone|Vehicle Emissions,0,
cAMP metabolic process,GO:0046058,"Parkinson Disease, Secondary",MESH:D010302,7,Atrazine|Doxorubicin|Maneb|Paraquat|Resveratrol|Rotenone|saxagliptin,0,
cAMP metabolic process,GO:0046058,Parkinsonian Disorders,MESH:D020734,6,Maneb|Paraquat|Particulate Matter|Resveratrol|Rimonabant|Rotenone,0,
cAMP metabolic process,GO:0046058,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
cAMP transport,GO:0070730,Parkinson Disease,MESH:D010300,3,Melatonin|Probenecid|Roflumilast,0,
cAMP transport,GO:0070730,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
cAMP transport,GO:0070730,Parkinsonian Disorders,MESH:D020734,2,Melatonin|Probenecid,0,
cAMP transport,GO:0070730,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
cannabinoid biosynthetic process,GO:1901696,Parkinson Disease,MESH:D010300,1,Rotenone,0,
cannabinoid biosynthetic process,GO:1901696,"Parkinson Disease, Secondary",MESH:D010302,2,Poly I-C|Rotenone,0,
cannabinoid biosynthetic process,GO:1901696,Parkinsonian Disorders,MESH:D020734,1,Rotenone,0,
cannabinoid signaling pathway,GO:0038171,"Parkinson Disease, Secondary",MESH:D010302,0,,1,CNR2
canonical glycolysis,GO:0061621,Parkinson Disease,MESH:D010300,3,Maneb|Oxidopamine|Ozone,1,ENO2
canonical glycolysis,GO:0061621,"Parkinson Disease, Secondary",MESH:D010302,2,Maneb|Oxidopamine,0,
canonical glycolysis,GO:0061621,Parkinsonian Disorders,MESH:D020734,2,Maneb|Oxidopamine,1,GAPDH
canonical Wnt signaling pathway,GO:0060070,Parkinson Disease,MESH:D010300,1,Ziram,2,EDN1|LRRK2
canonical Wnt signaling pathway,GO:0060070,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
canonical Wnt signaling pathway,GO:0060070,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
canonical Wnt signaling pathway,GO:0060070,"Parkinson Disease, Secondary",MESH:D010302,1,Ziram,1,SHH
canonical Wnt signaling pathway,GO:0060070,Parkinsonian Disorders,MESH:D020734,1,Disulfiram,1,LRRK2
canonical Wnt signaling pathway involved in mesenchymal stem cell differentiation,GO:0044338,"Parkinson Disease, Secondary",MESH:D010302,1,Methotrexate,0,
canonical Wnt signaling pathway involved in positive regulation of epithelial to mesenchymal transition,GO:0044334,"Parkinson Disease, Secondary",MESH:D010302,1,thymoquinone,0,
cap-dependent translational initiation,GO:0002191,"PARKINSON DISEASE 18, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:614251,0,,1,EIF4G1
carbohydrate biosynthetic process,GO:0016051,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
carbohydrate derivative metabolic process,GO:1901135,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
carbohydrate export,GO:0033231,Parkinsonian Disorders,MESH:D020734,1,Curcumin,0,
carbohydrate metabolic process,GO:0005975,Parkinson Disease,MESH:D010300,4,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Atrazine|Melatonin|Methomyl",4,ALDH2|FBP1|GPDH1|TALDO1
carbohydrate metabolic process,GO:0005975,"Parkinson Disease, Secondary",MESH:D010302,6,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Atrazine|Benzo(a)pyrene|Doxorubicin|Melatonin|Ribavirin",0,
carbohydrate metabolic process,GO:0005975,Parkinsonian Disorders,MESH:D020734,2,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Melatonin",0,
carbon dioxide transport,GO:0015670,Parkinson Disease,MESH:D010300,0,,1,HBG1
carbon tetrachloride metabolic process,GO:0018885,Parkinson Disease,MESH:D010300,0,,1,CYP2E1
carboxylic acid catabolic process,GO:0046395,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PON1
carboxylic acid metabolic process,GO:0019752,Parkinson Disease,MESH:D010300,5,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Methomyl|Paraquat|Polychlorinated Biphenyls|Zinc",1,DDC
carboxylic acid metabolic process,GO:0019752,"Parkinson Disease, Secondary",MESH:D010302,6,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Benzo(a)pyrene|Homovanillic Acid|Methotrexate|Paraquat|Ribavirin",0,
carboxylic acid metabolic process,GO:0019752,Parkinsonian Disorders,MESH:D020734,5,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Cadmium|Homovanillic Acid|Indomethacin|Paraquat",1,DDC
carboxylic acid transmembrane transport,GO:1905039,Parkinson Disease,MESH:D010300,0,,1,ABCB1
carboxylic acid transmembrane transport,GO:1905039,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ABCB1
carboxylic acid transport,GO:0046942,Parkinsonian Disorders,MESH:D020734,0,,1,ATP1A3
cardiac atrium development,GO:0003230,Parkinson Disease,MESH:D010300,0,,1,IGF1R
cardiac epithelial to mesenchymal transition,GO:0060317,Parkinson Disease,MESH:D010300,1,Zinc,0,
cardiac left ventricle formation,GO:0003218,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
cardiac muscle atrophy,GO:0014899,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
cardiac muscle cell action potential,GO:0086001,"Parkinson Disease, Secondary",MESH:D010302,1,Trazodone,0,
cardiac muscle cell apoptotic process,GO:0010659,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
cardiac muscle cell contraction,GO:0086003,Parkinson Disease,MESH:D010300,4,Caffeine|Paraquat|Propranolol|Sirolimus,0,
cardiac muscle cell contraction,GO:0086003,"Parkinson Disease, Secondary",MESH:D010302,9,3-methyladenine|Diltiazem|Diphenhydramine|Doxorubicin|Haloperidol|Nifedipine|Paraquat|Paroxetine|Verapamil,0,
cardiac muscle cell contraction,GO:0086003,Parkinsonian Disorders,MESH:D020734,6,Amitriptyline|Clonidine|Haloperidol|Paraquat|Paroxetine|Verapamil,0,
cardiac muscle cell contraction,GO:0086003,Wolff-Parkinson-White Syndrome,MESH:D014927,5,Diltiazem|Flecainide|Isoproterenol|Propranolol|Quinidine,0,
cardiac muscle cell development,GO:0055013,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
cardiac muscle cell development,GO:0055013,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
cardiac muscle cell differentiation,GO:0055007,Parkinson Disease,MESH:D010300,1,Ketoconazole,0,
cardiac muscle cell differentiation,GO:0055007,"Parkinson Disease, Secondary",MESH:D010302,2,Nicotine|Valproic Acid,0,
cardiac muscle cell differentiation,GO:0055007,Parkinsonian Disorders,MESH:D020734,3,ginsenoside Re|Ketoconazole|Valproic Acid,0,
cardiac muscle contraction,GO:0060048,Parkinson Disease,MESH:D010300,5,Dopamine|Iron|Particulate Matter|Propranolol|Vehicle Emissions,0,
cardiac muscle contraction,GO:0060048,"Parkinson Disease, Secondary",MESH:D010302,6,Amiodarone|Diltiazem|Doxorubicin|Idazoxan|Nicotine|Nifedipine,0,
cardiac muscle contraction,GO:0060048,Parkinsonian Disorders,MESH:D020734,4,Amiodarone|Dopamine|Idazoxan|Particulate Matter,1,ATP1A3
cardiac muscle contraction,GO:0060048,Wolff-Parkinson-White Syndrome,MESH:D014927,5,Amiodarone|Diltiazem|Isoproterenol|Propranolol|Quinidine,0,
cardiac muscle hypertrophy,GO:0003300,Parkinson Disease,MESH:D010300,2,Lipopolysaccharides|Vehicle Emissions,0,
cardiac muscle hypertrophy,GO:0003300,"Parkinson Disease, Secondary",MESH:D010302,2,Doxorubicin|Resveratrol,0,
cardiac muscle hypertrophy,GO:0003300,Parkinsonian Disorders,MESH:D020734,3,Lipopolysaccharides|Plant Preparations|Resveratrol,0,
cardiac muscle hypertrophy,GO:0003300,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
cardiac muscle tissue development,GO:0048738,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A2
cardiac myofibril assembly,GO:0055003,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
cardiac neural crest cell migration involved in outflow tract morphogenesis,GO:0003253,Parkinson Disease,MESH:D010300,0,,1,EDN1
cardiolipin acyl-chain remodeling,GO:0035965,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
cardiolipin biosynthetic process,GO:0032049,Parkinson Disease,MESH:D010300,1,Atrazine,0,
cardiolipin biosynthetic process,GO:0032049,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
cardiolipin biosynthetic process,GO:0032049,"Parkinson Disease, Secondary",MESH:D010302,1,Atrazine,0,
carnitine biosynthetic process,GO:0045329,"Parkinson Disease, Secondary",MESH:D010302,1,Olanzapine,0,
carnitine biosynthetic process,GO:0045329,Parkinsonian Disorders,MESH:D020734,1,Olanzapine,0,
carnitine metabolic process,GO:0009437,Parkinson Disease,MESH:D010300,2,Probenecid|tetrachloroisophthalonitrile,0,
carnitine metabolic process,GO:0009437,"Parkinson Disease, Secondary",MESH:D010302,3,Amiodarone|Doxorubicin|geraniol,0,
carnitine metabolic process,GO:0009437,Parkinsonian Disorders,MESH:D020734,4,Amiodarone|geraniol|Indomethacin|Probenecid,0,
carnitine metabolic process,GO:0009437,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Amiodarone|Isoproterenol,0,
carnitine transmembrane transport,GO:1902603,Parkinson Disease,MESH:D010300,3,Caffeine|Clozapine|Rotenone,0,
carnitine transmembrane transport,GO:1902603,"Parkinson Disease, Secondary",MESH:D010302,3,Ritonavir|Rotenone|Verapamil,0,
carnitine transmembrane transport,GO:1902603,Parkinsonian Disorders,MESH:D020734,5,Clozapine|Lopinavir|Ritonavir|Rotenone|Verapamil,0,
carnitine transport,GO:0015879,"Parkinson Disease, Secondary",MESH:D010302,1,Olanzapine,0,
carnitine transport,GO:0015879,Parkinsonian Disorders,MESH:D020734,1,Olanzapine,0,
carnosine metabolic process,GO:0035498,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
cartilage development,GO:0051216,Parkinson Disease,MESH:D010300,0,,1,EDN1
cartilage development,GO:0051216,Parkinson Disease 11,MESH:C564345,0,,1,GIGYF2
cartilage development,GO:0051216,"Parkinson Disease, Secondary",MESH:D010302,2,Nicotine|Valproic Acid,0,
cartilage development,GO:0051216,Parkinsonian Disorders,MESH:D020734,1,Valproic Acid,0,
cartilage development involved in endochondral bone morphogenesis,GO:0060351,Parkinson Disease,MESH:D010300,0,,1,EDN1
cartilage homeostasis,GO:1990079,Parkinson Disease,MESH:D010300,1,Lead,0,
cartilage morphogenesis,GO:0060536,Parkinson Disease,MESH:D010300,0,,1,EDN1
catecholamine biosynthetic process,GO:0042423,Parkinson Disease,MESH:D010300,0,,2,DDC|TH
catecholamine biosynthetic process,GO:0042423,Parkinsonian Disorders,MESH:D020734,0,,3,CAT-2|DDC|TH
catecholamine catabolic process,GO:0042424,Parkinson Disease,MESH:D010300,0,,1,MAOA
catecholamine metabolic process,GO:0006584,Parkinson Disease,MESH:D010300,0,,2,DDC|MAOA
catecholamine metabolic process,GO:0006584,Parkinsonian Disorders,MESH:D020734,0,,1,DDC
catecholamine secretion,GO:0050432,Parkinson Disease,MESH:D010300,1,Cinnarizine,1,PINK1
catecholamine secretion,GO:0050432,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
catecholamine secretion,GO:0050432,"Parkinson Disease, Secondary",MESH:D010302,4,Cinnarizine|Flunarizine|Fluspirilene|Nicotine,0,
catecholamine secretion,GO:0050432,Parkinsonian Disorders,MESH:D020734,1,Flunarizine,1,PINK1
catechol-containing compound metabolic process,GO:0009712,Parkinson Disease,MESH:D010300,1,Atrazine,0,
catechol-containing compound metabolic process,GO:0009712,"Parkinson Disease, Secondary",MESH:D010302,1,Atrazine,0,
"CD4-positive, alpha-beta intraepithelial T cell differentiation",GO:0002301,Parkinson Disease,MESH:D010300,1,Lead,0,
"CD4-positive, alpha-beta T cell activation",GO:0035710,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
"CD4-positive, alpha-beta T cell activation",GO:0035710,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
"CD4-positive, alpha-beta T cell cytokine production",GO:0035743,Parkinson Disease,MESH:D010300,1,Trichloroethylene,0,
"CD4-positive, alpha-beta T cell cytokine production",GO:0035743,"Parkinson Disease, Secondary",MESH:D010302,2,Carbamazepine|Trichloroethylene,0,
"CD4-positive, alpha-beta T cell differentiation involved in immune response",GO:0002294,Parkinson Disease,MESH:D010300,1,Pesticides,0,
"CD4-positive, alpha-beta T cell differentiation involved in immune response",GO:0002294,"Parkinson Disease, Secondary",MESH:D010302,1,Pesticides,0,
"CD4-positive or CD8-positive, alpha-beta T cell lineage commitment",GO:0043369,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
"CD4-positive or CD8-positive, alpha-beta T cell lineage commitment",GO:0043369,Parkinsonian Disorders,MESH:D020734,1,cypermethrin,0,
CD80 biosynthetic process,GO:0035780,Parkinsonian Disorders,MESH:D020734,1,Plant Extracts,0,
CD86 biosynthetic process,GO:0035781,Parkinsonian Disorders,MESH:D020734,1,Plant Extracts,0,
"CD8-positive, alpha-beta T cell differentiation",GO:0043374,Parkinson Disease,MESH:D010300,1,Lead,0,
cell-abiotic substrate adhesion,GO:0036164,Parkinson Disease,MESH:D010300,2,Acrolein|Paclitaxel,0,
cell-abiotic substrate adhesion,GO:0036164,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
cell-abiotic substrate adhesion,GO:0036164,Parkinsonian Disorders,MESH:D020734,1,4-hydroxy-2-nonenal,0,
cell activation,GO:0001775,Parkinson Disease,MESH:D010300,5,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Levodopa|Maneb|Minocycline|Paraquat",0,
cell activation,GO:0001775,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
cell activation,GO:0001775,"Parkinson Disease, Secondary",MESH:D010302,6,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Levodopa|Maneb|Minocycline|Paraquat|Resveratrol",0,
cell activation,GO:0001775,Parkinsonian Disorders,MESH:D020734,5,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Levodopa|Maneb|Paraquat|Resveratrol",0,
cell activation involved in immune response,GO:0002263,Parkinson Disease,MESH:D010300,1,Trichloroethylene,0,
cell activation involved in immune response,GO:0002263,"Parkinson Disease, Secondary",MESH:D010302,1,Trichloroethylene,0,
cell adhesion,GO:0007155,Parkinson Disease,MESH:D010300,3,Aluminum|Estradiol|Paraquat,3,CNTNAP2|COL19A1|MAG
cell adhesion,GO:0007155,"Parkinson Disease, Secondary",MESH:D010302,2,Paraquat|Resveratrol,0,
cell adhesion,GO:0007155,Parkinsonian Disorders,MESH:D020734,3,Paraquat|Plant Extracts|Resveratrol,0,
cell aggregation,GO:0098743,Parkinson Disease,MESH:D010300,3,Aluminum|Lipopolysaccharides|Paclitaxel,0,
cell aggregation,GO:0098743,"Parkinson Disease, Secondary",MESH:D010302,6,Benzo(a)pyrene|Chlorpromazine|Doxorubicin|Flurbiprofen|Nicotine|thymoquinone,0,
cell aggregation,GO:0098743,Parkinsonian Disorders,MESH:D020734,5,Chlorpromazine|Indomethacin|Lipopolysaccharides|Plant Extracts|taxifolin,0,
cell-cell adhesion,GO:0098609,Parkinson Disease,MESH:D010300,2,1-Methyl-4-phenylpyridinium|Lipopolysaccharides,2,COL19A1|MAG
cell-cell adhesion,GO:0098609,"Parkinson Disease, Secondary",MESH:D010302,1,3-methyladenine,0,
cell-cell adhesion,GO:0098609,Parkinsonian Disorders,MESH:D020734,3,1-Methyl-4-phenylpyridinium|Lipopolysaccharides|Plant Extracts,0,
cell-cell adhesion in response to extracellular stimulus,GO:0140039,Parkinson Disease,MESH:D010300,1,Melatonin,0,
cell-cell adhesion in response to extracellular stimulus,GO:0140039,"Parkinson Disease, Secondary",MESH:D010302,2,Melatonin|Resveratrol,0,
cell-cell adhesion in response to extracellular stimulus,GO:0140039,Parkinsonian Disorders,MESH:D020734,2,Melatonin|Resveratrol,0,
cell-cell adhesion via plasma-membrane adhesion molecules,GO:0098742,Parkinson Disease,MESH:D010300,1,Particulate Matter,1,MAG
cell-cell adhesion via plasma-membrane adhesion molecules,GO:0098742,Parkinsonian Disorders,MESH:D020734,2,Curcumin|Particulate Matter,0,
cell-cell fusion,GO:0140253,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,0,
cell-cell fusion,GO:0140253,Parkinsonian Disorders,MESH:D020734,1,Valproic Acid,0,
cell-cell junction maintenance,GO:0045217,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
cell-cell junction organization,GO:0045216,Parkinson Disease,MESH:D010300,1,Lead,0,
cell-cell junction organization,GO:0045216,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
cell-cell junction organization,GO:0045216,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
cell-cell signaling,GO:0007267,Parkinson Disease,MESH:D010300,0,,3,EDN1|INS|MAPT
cell-cell signaling,GO:0007267,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
cell-cell signaling,GO:0007267,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,1,SHH
cell-cell signaling,GO:0007267,Parkinsonian Disorders,MESH:D020734,3,Cadmium|ginsenoside Re|Resveratrol,2,DOP1R2|MAPT
cell-cell signaling via exosome,GO:0099156,Parkinson Disease,MESH:D010300,2,Lipopolysaccharides|Methamphetamine,0,
cell-cell signaling via exosome,GO:0099156,"Parkinson Disease, Secondary",MESH:D010302,1,Methamphetamine,0,
cell-cell signaling via exosome,GO:0099156,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
cell chemotaxis,GO:0060326,Parkinson Disease,MESH:D010300,15,Aluminum|Aspirin|Atrazine|Diazepam|Endosulfan|Estradiol|Lipopolysaccharides|mangiferin|Melatonin|Naproxen|Particulate Matter|Pentoxifylline|Propranolol|Trichloroethylene|Vehicle Emissions,1,HGF
cell chemotaxis,GO:0060326,"Parkinson Disease, Secondary",MESH:D010302,12,3-methyladenine|Amiodarone|Atrazine|Benzo(a)pyrene|Diazepam|Doxorubicin|Melatonin|Nicotine|Nifedipine|Resveratrol|Trichloroethylene|Valproic Acid,0,
cell chemotaxis,GO:0060326,Parkinsonian Disorders,MESH:D020734,15,Amiodarone|Amphotericin B|Baclofen|Budesonide|Cadmium|Clonidine|Curcumin|Indomethacin|Lipopolysaccharides|Melatonin|Particulate Matter|Plant Extracts|Resveratrol|Rimonabant|Valproic Acid,1,PRKCD
cell chemotaxis,GO:0060326,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Amiodarone|Propranolol,0,
cell communication,GO:0007154,Parkinson Disease,MESH:D010300,0,,1,LRRK2
cell communication,GO:0007154,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
cell communication,GO:0007154,"Parkinson Disease, Secondary",MESH:D010302,0,,1,CNR2
cell communication,GO:0007154,Parkinsonian Disorders,MESH:D020734,0,,1,LRRK2
cell communication by electrical coupling involved in cardiac conduction,GO:0086064,Parkinsonian Disorders,MESH:D020734,0,,1,ATP1A3
cell cycle,GO:0007049,Parkinson Disease,MESH:D010300,18,Aspirin|Astemizole|Caffeine|Desipramine|Estradiol|Herbicides|Homocysteine|Lithium|Melatonin|Naproxen|Nitric Oxide|Paclitaxel|Pentoxifylline|Pesticides|Propranolol|Reactive Oxygen Species|Rotenone|Sirolimus,0,
cell cycle,GO:0007049,"Parkinson Disease, Secondary",MESH:D010302,16,Amlodipine|Benzo(a)pyrene|Cytarabine|Doxorubicin|Lithium|Melatonin|Methotrexate|Nicotine|Nifedipine|Octreotide|Pesticides|Resveratrol|Ritonavir|Rotenone|Valproic Acid|Vincristine,0,
cell cycle,GO:0007049,Parkinsonian Disorders,MESH:D020734,14,"Amlodipine|Cadmium|Curcumin|Docosahexaenoic Acids|Enkephalin, Leucine-2-Alanine|Indomethacin|Melatonin|Plant Extracts|Resveratrol|Rimonabant|Ritonavir|Rotenone|Valproic Acid|Zidovudine",0,
cell cycle,GO:0007049,Wolff-Parkinson-White Syndrome,MESH:D014927,4,Isoproterenol|Lithium|Propranolol|Quinidine,0,
cell cycle G1/S phase transition,GO:0044843,Parkinson Disease,MESH:D010300,1,Estradiol,0,
cell cycle G1/S phase transition,GO:0044843,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
cell cycle G2/M phase transition,GO:0044839,Parkinson Disease,MESH:D010300,1,Estradiol,0,
cell cycle process,GO:0022402,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
cell death,GO:0008219,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
cell death,GO:0008219,Parkinson Disease,MESH:D010300,72,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine|4-phenylbutyric acid|Acrolein|Air Pollutants|Aluminum|Amantadine|Apomorphine|Aprepitant|Aspirin|benserazide, levodopa drug combination|beta-N-methylamino-L-alanine|Bromocriptine|Caffeine|Carbon Tetrachloride|Chlorpyrifos|Clonazepam|Clozapine|Copper|Desipramine|Diazepam|Dieldrin|Ditiocarb|Dopamine|Eicosapentaenoic Acid|Endosulfan|Estradiol|Eugenol|Hexachlorocyclohexane|Homocysteine|Iron|Ketoconazole|Lead|Levodopa|Lipopolysaccharides|Lithium|Maneb|Manganese|Melatonin|Methamphetamine|Methyldopa|Metoclopramide|Minocycline|Nitric Oxide|Nitrogen Dioxide|Oxidopamine|Ozone|Paclitaxel|Paraquat|Particulate Matter|Pentoxifylline|Pergolide|Permethrin|Probenecid|Propranolol|Pyridoxine|rasagiline|Reactive Oxygen Species|Reserpine|Rivastigmine|Rotenone|salsolinol|Selegiline|Sirolimus|Smoke|Soot|Testosterone|Tranylcypromine|Trichloroethylene|Vehicle Emissions|Zinc",0,
cell death,GO:0008219,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
cell death,GO:0008219,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,SNCAIP
cell death,GO:0008219,"Parkinson Disease, Secondary",MESH:D010302,56,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|3-methyladenine|Amantadine|Amiodarone|Amlodipine|Apomorphine|benserazide, levodopa drug combination|Benzo(a)pyrene|Carbamazepine|Chlorpromazine|Cimetidine|Cytarabine|Diazepam|Dichlorvos|Dieldrin|Diltiazem|Ditiocarb|Doxorubicin|Ethosuximide|Exenatide|Fluoxetine|Haloperidol|Levodopa|Lithium|Maneb|Manganese|Melatonin|Methamphetamine|Methotrexate|Methyldopa|Metoclopramide|Minocycline|Nicotine|Nifedipine|Nortriptyline|Octreotide|Oxidopamine|Paraquat|perhexiline maleate|Phenelzine|Phenytoin|Pyridostigmine Bromide|Pyridoxine|Reserpine|Resveratrol|Ribavirin|Ritonavir|Rotenone|sodium bisulfide|thymoquinone|Trichloroethylene|Trifluoperazine|Valproic Acid|Venlafaxine Hydrochloride|Verapamil|Vincristine",0,
cell death,GO:0008219,Parkinsonian Disorders,MESH:D020734,62,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine|4-hydroxy-2-nonenal|6-methyl-2-(phenylethynyl)pyridine|Amantadine|Amiodarone|Amitriptyline|Amlodipine|Amphotericin B|Apomorphine|benserazide, levodopa drug combination|Bromocriptine|Bupropion|Cadmium|Chlorpromazine|Clonazepam|Clonidine|Clozapine|Creatine|Curcumin|cypermethrin|Diazoxide|Disulfiram|Docosahexaenoic Acids|Dopamine|echinacoside|ginsenoside Re|Haloperidol|Indomethacin|Ketoconazole|Levodopa|linsidomine|Lipopolysaccharides|mancozeb|Maneb|Manganese|manganese chloride|Melatonin|N-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide|oleuropein|Oxidopamine|Paraquat|Particulate Matter|Pergolide|Permethrin|Plant Extracts|Probenecid|Quinpirole|rasagiline|Reserpine|Resveratrol|Rimonabant|Ritonavir|Rivastigmine|Rotenone|Selegiline|taxifolin|Trifluoperazine|Valproic Acid|Verapamil|Zidovudine",0,
cell death,GO:0008219,Wolff-Parkinson-White Syndrome,MESH:D014927,6,Amiodarone|Diltiazem|Isoproterenol|Lithium|Propranolol|Quinidine,0,
cell death in response to hydrogen peroxide,GO:0036474,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
cell death in response to hydrogen peroxide,GO:0036474,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
cell dedifferentiation,GO:0043697,"Parkinson Disease, Secondary",MESH:D010302,1,Nifedipine,0,
cell development,GO:0048468,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
cell differentiation,GO:0030154,Parkinson Disease,MESH:D010300,16,Aspirin|Caffeine|Carbon Tetrachloride|Clozapine|Estradiol|Homocysteine|Lead|Levodopa|Lipopolysaccharides|Lithium|Melatonin|Paclitaxel|Pentoxifylline|Reactive Oxygen Species|Sirolimus|Testosterone,4,COL19A1|IL6|LRRK2|SLC2A14
cell differentiation,GO:0030154,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
cell differentiation,GO:0030154,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
cell differentiation,GO:0030154,"Parkinson Disease, Secondary",MESH:D010302,10,Cytarabine|Indinavir|Levodopa|Lithium|Melatonin|Nicotine|Octreotide|Poly I-C|Resveratrol|Valproic Acid,0,
cell differentiation,GO:0030154,Parkinsonian Disorders,MESH:D020734,10,"Clozapine|Curcumin|Enkephalin, Leucine-2-Alanine|Indomethacin|Levodopa|Lipopolysaccharides|Melatonin|Plant Extracts|Resveratrol|Valproic Acid",1,LRRK2
cell differentiation,GO:0030154,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Lithium|Quinidine,0,
cell division,GO:0051301,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|Paclitaxel,1,NCAPG2
cell division,GO:0051301,"Parkinson Disease, Secondary",MESH:D010302,1,Vincristine,0,
cell division,GO:0051301,Parkinsonian Disorders,MESH:D020734,0,,1,DCTN1
cell fate commitment,GO:0045165,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
cell fate commitment,GO:0045165,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
cell fate specification,GO:0001708,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
cell growth,GO:0016049,Parkinson Disease,MESH:D010300,25,1-Methyl-4-phenylpyridinium|4-phenylbutyric acid|Acrolein|Aprepitant|Caffeine|Carbon Tetrachloride|Chlorpyrifos|Ditiocarb|Dopamine|Endosulfan|Estradiol|Eugenol|Homocysteine|Ketoconazole|Lead|Lipopolysaccharides|Maneb|Melatonin|Oxidopamine|Paclitaxel|Paraquat|Particulate Matter|Propranolol|Rotenone|Sirolimus,0,
cell growth,GO:0016049,"Parkinson Disease, Secondary",MESH:D010302,22,3-methyladenine|Amiodarone|Carbamazepine|Carbon Monoxide|Chlorpromazine|Ditiocarb|Doxorubicin|Exenatide|Fluoxetine|Maneb|Melatonin|Methotrexate|Oxidopamine|Paraquat|Resveratrol|Ribavirin|Rotenone|thymoquinone|Valproic Acid|Venlafaxine Hydrochloride|Verapamil|Vincristine,0,
cell growth,GO:0016049,Parkinsonian Disorders,MESH:D020734,25,1-Methyl-4-phenylpyridinium|4-hydroxy-2-nonenal|Amiodarone|Arecoline|baicalin|Cadmium|Chlorpromazine|crocin|Curcumin|Docosahexaenoic Acids|Dopamine|Ketoconazole|Lipopolysaccharides|Maneb|manganese chloride|Melatonin|Oxidopamine|Paraquat|Particulate Matter|Plant Extracts|Plant Preparations|Resveratrol|Rotenone|Valproic Acid|Verapamil,0,
cell growth,GO:0016049,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Amiodarone|Propranolol,0,
cell killing,GO:0001906,Parkinson Disease,MESH:D010300,2,mangiferin|Oxidopamine,0,
cell killing,GO:0001906,"Parkinson Disease, Secondary",MESH:D010302,2,Doxorubicin|Oxidopamine,0,
cell killing,GO:0001906,Parkinsonian Disorders,MESH:D020734,1,Oxidopamine,0,
cell-matrix adhesion,GO:0007160,Parkinson Disease,MESH:D010300,0,,1,FGB
cell maturation,GO:0048469,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,1,GBA1
cell maturation,GO:0048469,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
cell maturation,GO:0048469,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,1,GBA1
cell migration,GO:0016477,Parkinson Disease,MESH:D010300,16,Acrolein|Aluminum|Carbon Tetrachloride|Clozapine|Copper|Estradiol|Eugenol|Lipopolysaccharides|Paclitaxel|Paraquat|Particulate Matter|Propranolol|Sirolimus|Smoke|Soot|Tea,2,DRD1|DRD2
cell migration,GO:0016477,"Parkinson Disease, Secondary",MESH:D010302,10,3-methyladenine|Benzo(a)pyrene|Carbamazepine|Doxorubicin|Paraquat|Phenytoin|Poly I-C|Resveratrol|thymoquinone|Valproic Acid,1,SHH
cell migration,GO:0016477,Parkinsonian Disorders,MESH:D020734,13,Arecoline|Cadmium|Clozapine|Curcumin|Docosahexaenoic Acids|Indomethacin|Lipopolysaccharides|Paraquat|Particulate Matter|Plant Extracts|Resveratrol|Rimonabant|Valproic Acid,1,DRD2
cell migration,GO:0016477,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Propranolol,0,
cell morphogenesis,GO:0000902,Parkinson Disease,MESH:D010300,2,Lead|Melatonin,3,AIF1|CNTNAP2|HGF
cell morphogenesis,GO:0000902,"Parkinson Disease, Secondary",MESH:D010302,2,Doxorubicin|Melatonin,0,
cell morphogenesis,GO:0000902,Parkinsonian Disorders,MESH:D020734,2,Melatonin|Plant Extracts,0,
cell motility,GO:0048870,Parkinson Disease,MESH:D010300,2,Estradiol|mangiferin,0,
cell motility,GO:0048870,Parkinsonian Disorders,MESH:D020734,1,4-hydroxy-2-nonenal,0,
cell population proliferation,GO:0008283,Parkinson Disease,MESH:D010300,69,"1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline|1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|4-phenylbutyric acid|Acrolein|Air Pollutants|Amphetamine|Aprepitant|Aspirin|Astemizole|Atrazine|Benomyl|Caffeine|Carbon Tetrachloride|Chlorpyrifos|Clonazepam|Clozapine|Copper|Desipramine|Diazepam|Diazinon|Dieldrin|Ditiocarb|Dopamine|Eicosapentaenoic Acid|Endosulfan|Estradiol|Eugenol|Herbicides|Homocysteine|Hydrocarbons, Chlorinated|Iron|Ketoconazole|Lead|Levodopa|Lipopolysaccharides|Lithium|Maneb|Manganese|mangiferin|Melatonin|Methamphetamine|Minocycline|Nitric Oxide|Oxidopamine|Ozone|Paclitaxel|Paraquat|Particulate Matter|Pentoxifylline|Pergolide|Permethrin|Pioglitazone|Polychlorinated Biphenyls|Probenecid|Propranolol|Reactive Oxygen Species|Reserpine|Roflumilast|Rotenone|Sirolimus|Smoke|Soot|Testosterone|Trichloroethylene|Vehicle Emissions|Water Pollutants, Chemical|Zinc|Ziram",3,CNTNAP2|DRD2|NGF
cell population proliferation,GO:0008283,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
cell population proliferation,GO:0008283,"Parkinson Disease, Secondary",MESH:D010302,54,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|3-methyladenine|Amiodarone|Amlodipine|Atrazine|Benzo(a)pyrene|Carbon Monoxide|Chlorpromazine|Cimetidine|Cytarabine|Diazepam|Dichlorvos|Dieldrin|Diltiazem|Diphenhydramine|Ditiocarb|Doxorubicin|Fluoxetine|Flurbiprofen|Hydrocarbons, Chlorinated|Levodopa|Lithium|Maneb|Manganese|Melatonin|Methamphetamine|Methotrexate|Minocycline|N-(1-methylethyl)-1,1,2-trimethylpropylamine|Nicotine|Nifedipine|Octreotide|Olanzapine|Oxidopamine|Paraquat|Paroxetine|Phenytoin|Poly I-C|PQQ Cofactor|Reserpine|Resveratrol|Ribavirin|Ritonavir|Rotenone|Sertraline|Silymarin|sodium bisulfide|thymoquinone|Trichloroethylene|Trifluoperazine|Valproic Acid|Verapamil|Vincristine|Ziram",1,SHH
cell population proliferation,GO:0008283,Parkinsonian Disorders,MESH:D020734,64,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside|3-iodotyrosine|4-hydroxy-2-nonenal|6-methyl-2-(phenylethynyl)pyridine|Amiodarone|Amitriptyline|Amlodipine|Amphotericin B|Arecoline|baicalin|Budesonide|Cadmium|Chlorpromazine|Citalopram|Clonazepam|Clozapine|coenzyme Q10|crocin|Curcumin|cypermethrin|Diazoxide|Disulfiram|Docosahexaenoic Acids|Donepezil|Dopamine|Enkephalin, Leucine-2-Alanine|ginsenoside Re|Indomethacin|Ketoconazole|Levodopa|Lipopolysaccharides|Lopinavir|mancozeb|Maneb|Manganese|manganese chloride|Melatonin|N-(1-methylethyl)-1,1,2-trimethylpropylamine|Olanzapine|Oxidopamine|Paraquat|Paroxetine|Particulate Matter|Pergolide|Permethrin|Phenol|Pimozide|Plant Extracts|Plant Preparations|Probenecid|Reserpine|Resveratrol|Rimonabant|Ritonavir|Rotenone|Sertraline|sesamin|Silymarin|Trifluoperazine|Valproic Acid|Verapamil|Zidovudine",4,ALDH1A2|DRD2|NGF|PRL
cell population proliferation,GO:0008283,Wolff-Parkinson-White Syndrome,MESH:D014927,6,Amiodarone|Diltiazem|Isoproterenol|Lithium|Propranolol|Quinidine,0,
cell projection assembly,GO:0030031,Parkinsonian Disorders,MESH:D020734,1,Plant Extracts,0,
cell projection morphogenesis,GO:0048858,"Parkinson Disease, Secondary",MESH:D010302,1,3-methyladenine,0,
cell projection organization,GO:0030030,Parkinson Disease,MESH:D010300,1,Estradiol,0,
cell proliferation in bone marrow,GO:0071838,Parkinson Disease,MESH:D010300,1,Rivastigmine,0,
cell proliferation in bone marrow,GO:0071838,Parkinsonian Disorders,MESH:D020734,1,Rivastigmine,0,
cell proliferation in external granule layer,GO:0021924,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
cell proliferation in forebrain,GO:0021846,Parkinson Disease,MESH:D010300,1,Methamphetamine,1,NGF
cell proliferation in forebrain,GO:0021846,"Parkinson Disease, Secondary",MESH:D010302,2,Ethosuximide|Methamphetamine,0,
cell proliferation in forebrain,GO:0021846,Parkinsonian Disorders,MESH:D020734,0,,1,NGF
cell proliferation in midbrain,GO:0033278,Parkinson Disease,MESH:D010300,3,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Methamphetamine|Rotenone",0,
cell proliferation in midbrain,GO:0033278,"Parkinson Disease, Secondary",MESH:D010302,4,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Methamphetamine|Rotenone|Trifluoperazine",0,
cell proliferation in midbrain,GO:0033278,Parkinsonian Disorders,MESH:D020734,3,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Rotenone|Trifluoperazine",0,
cell quiescence,GO:0044838,Parkinson Disease,MESH:D010300,2,Aluminum|Lead,0,
cell redox homeostasis,GO:0045454,Parkinson Disease,MESH:D010300,23,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Air Pollutants|Aprepitant|Aspirin|Atrazine|Carbon Tetrachloride|Chlorpyrifos|Copper|Free Radicals|Glutathione Disulfide|Lithium Carbonate|Melatonin|Ozone|Paraquat|Particulate Matter|Pioglitazone|Polychlorinated Biphenyls|Reactive Oxygen Species|Roflumilast|Rotenone|Tea|Testosterone|Zinc",3,IL6|NOS1|NQO1
cell redox homeostasis,GO:0045454,"Parkinson Disease, Secondary",MESH:D010302,12,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Atrazine|Dichlorvos|Doxorubicin|geraniol|Lithium Carbonate|Melatonin|Methotrexate|Paraquat|Resveratrol|Rotenone|sodium bisulfide",1,NOS2
cell redox homeostasis,GO:0045454,Parkinsonian Disorders,MESH:D020734,16,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Cadmium|crocin|Curcumin|geraniol|linsidomine|Malondialdehyde|mancozeb|Melatonin|oleuropein|Paraquat|Particulate Matter|Plant Extracts|Plant Preparations|Resveratrol|Rotenone",1,GSR
cell redox homeostasis,GO:0045454,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
cell-substrate adhesion,GO:0031589,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
cell-substrate adhesion,GO:0031589,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
cell surface receptor signaling pathway,GO:0007166,Parkinson Disease,MESH:D010300,0,,1,EDN1
cellular aldehyde metabolic process,GO:0006081,"Parkinson Disease, Secondary",MESH:D010302,1,Chlorpromazine,0,
cellular aldehyde metabolic process,GO:0006081,Parkinsonian Disorders,MESH:D020734,1,Chlorpromazine,2,ALDH1A1|ALDH1A2
cellular aromatic compound metabolic process,GO:0006725,Parkinson Disease,MESH:D010300,1,"Water Pollutants, Chemical",0,
cellular biogenic amine catabolic process,GO:0042402,Parkinson Disease,MESH:D010300,1,Caffeine,0,
cellular cadmium ion homeostasis,GO:0006876,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
cellular calcium ion homeostasis,GO:0006874,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
cellular calcium ion homeostasis,GO:0006874,Parkinson Disease,MESH:D010300,26,4-phenylbutyric acid|Amantadine|Amphetamine|Benomyl|beta-N-methylamino-L-alanine|Caffeine|Chlorpyrifos|Dopamine|Eicosapentaenoic Acid|Endosulfan|Estradiol|Gabapentin|Insecticides|Ketoconazole|Lead|Lipopolysaccharides|mangiferin|Melatonin|Naproxen|Paclitaxel|Paraquat|Particulate Matter|Propranolol|Trichloroethylene|Vehicle Emissions|Zinc,4,ATP13A2|DRD2|EDN1|UP
cellular calcium ion homeostasis,GO:0006874,"Parkinson Disease, Secondary",MESH:D010302,14,Amantadine|Amiodarone|Benzo(a)pyrene|Chlorpromazine|Diltiazem|Melatonin|Methotrexate|Nicotine|Nifedipine|Paraquat|Resveratrol|Trichloroethylene|Valproic Acid|Verapamil,1,ATP13A2
cellular calcium ion homeostasis,GO:0006874,Parkinsonian Disorders,MESH:D020734,23,Amantadine|Amiodarone|Amitriptyline|Baclofen|Cadmium|Chlorpromazine|cypermethrin|Diazoxide|Docosahexaenoic Acids|Dopamine|ginsenoside Re|Indomethacin|Ketoconazole|Lipopolysaccharides|Melatonin|Paraquat|Particulate Matter|Plant Extracts|Procaine|Resveratrol|Rimonabant|Valproic Acid|Verapamil,2,ATP13A2|DRD2
cellular calcium ion homeostasis,GO:0006874,Wolff-Parkinson-White Syndrome,MESH:D014927,4,Amiodarone|Diltiazem|Isoproterenol|Propranolol,0,
cellular chemical homeostasis,GO:0055082,Parkinsonian Disorders,MESH:D020734,1,Curcumin,0,
cellular component maintenance,GO:0043954,Parkinson Disease,MESH:D010300,2,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Probenecid",0,
cellular component maintenance,GO:0043954,"Parkinson Disease, Secondary",MESH:D010302,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
cellular component maintenance,GO:0043954,Parkinsonian Disorders,MESH:D020734,2,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Probenecid",0,
cellular component morphogenesis,GO:0032989,Parkinson Disease,MESH:D010300,0,,1,NECTIN2
cellular component organization,GO:0016043,Parkinson Disease,MESH:D010300,1,Sirolimus,0,
cellular component organization,GO:0016043,Parkinsonian Disorders,MESH:D020734,3,Docosahexaenoic Acids|Plant Preparations|Quinolines,0,
cellular copper ion homeostasis,GO:0006878,Parkinson Disease,MESH:D010300,2,Copper|Manganese,1,CP
cellular copper ion homeostasis,GO:0006878,"Parkinson Disease, Secondary",MESH:D010302,1,Manganese,0,
cellular copper ion homeostasis,GO:0006878,Parkinsonian Disorders,MESH:D020734,1,Manganese,0,
cellular detoxification of aldehyde,GO:0110095,Parkinson Disease,MESH:D010300,0,,2,ALDH2|PARK7
cellular detoxification of aldehyde,GO:0110095,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
cellular detoxification of aldehyde,GO:0110095,Parkinsonian Disorders,MESH:D020734,1,Felbamate,2,ALDH1A1|PARK7
cellular detoxification of hydrogen peroxide,GO:0061692,Parkinson Disease,MESH:D010300,1,Paraquat,0,
cellular detoxification of hydrogen peroxide,GO:0061692,"Parkinson Disease, Secondary",MESH:D010302,1,Paraquat,0,
cellular detoxification of hydrogen peroxide,GO:0061692,Parkinsonian Disorders,MESH:D020734,2,Curcumin|Paraquat,0,
cellular detoxification of methylglyoxal,GO:0140041,Parkinson Disease,MESH:D010300,0,,1,PARK7
cellular detoxification of methylglyoxal,GO:0140041,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
cellular detoxification of methylglyoxal,GO:0140041,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
cellular detoxification of nitrogen compound,GO:0070458,Parkinson Disease,MESH:D010300,2,mangiferin|Nitric Oxide,1,GSTM1
cellular extravasation,GO:0045123,Parkinson Disease,MESH:D010300,2,Ozone|Paraquat,1,TNF
cellular extravasation,GO:0045123,"Parkinson Disease, Secondary",MESH:D010302,1,Paraquat,0,
cellular extravasation,GO:0045123,Parkinsonian Disorders,MESH:D020734,1,Paraquat,0,
cellular glucose homeostasis,GO:0001678,Parkinson Disease,MESH:D010300,0,,1,PPARGC1A
cellular glucose homeostasis,GO:0001678,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,0,
cellular glucose homeostasis,GO:0001678,Parkinsonian Disorders,MESH:D020734,1,Valproic Acid,0,
cellular glutamate homeostasis,GO:0090461,Parkinsonian Disorders,MESH:D020734,1,Rimonabant,0,
cellular heat acclimation,GO:0070370,Parkinson Disease,MESH:D010300,0,,1,HSPA1A
cellular heat acclimation,GO:0070370,Parkinsonian Disorders,MESH:D020734,1,Disulfiram,0,
cellular hyperosmotic salinity response,GO:0071475,Parkinson Disease,MESH:D010300,0,,1,FBP1
cellular hypotonic salinity response,GO:0071477,Parkinson Disease,MESH:D010300,0,,1,FBP1
cellular iron ion homeostasis,GO:0006879,Parkinson Disease,MESH:D010300,10,1-Methyl-4-phenylpyridinium|4-phenylbutyric acid|Air Pollutants|Carbon Tetrachloride|Copper|Iron|Lead|Paraquat|Particulate Matter|Rotenone,5,ATP13A2|CP|HFE|HMOX1|SOD1
cellular iron ion homeostasis,GO:0006879,"Parkinson Disease, Secondary",MESH:D010302,6,3-methyladenine|Paraquat|Resveratrol|Rotenone|sodium bisulfide|Valproic Acid,1,ATP13A2
cellular iron ion homeostasis,GO:0006879,Parkinsonian Disorders,MESH:D020734,7,1-Methyl-4-phenylpyridinium|Cadmium|Paraquat|Particulate Matter|Resveratrol|Rotenone|Valproic Acid,1,ATP13A2
cellular lipid biosynthetic process,GO:0097384,Parkinson Disease,MESH:D010300,1,Soot,0,
cellular lipid catabolic process,GO:0044242,Parkinson Disease,MESH:D010300,5,Caffeine|Carbon Tetrachloride|Estradiol|Reactive Oxygen Species|Tea,0,
cellular lipid catabolic process,GO:0044242,"Parkinson Disease, Secondary",MESH:D010302,5,Benzo(a)pyrene|Doxorubicin|Methotrexate|Nicotine|Resveratrol,0,
cellular lipid catabolic process,GO:0044242,Parkinsonian Disorders,MESH:D020734,4,Cadmium|Plant Extracts|Plant Preparations|Resveratrol,0,
cellular lipid catabolic process,GO:0044242,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
cellular lipid metabolic process,GO:0044255,Parkinson Disease,MESH:D010300,4,Ozone|Permethrin|Pioglitazone|triflumizol,0,
cellular lipid metabolic process,GO:0044255,"Parkinson Disease, Secondary",MESH:D010302,1,Pyridostigmine Bromide,0,
cellular lipid metabolic process,GO:0044255,Parkinsonian Disorders,MESH:D020734,1,Permethrin,0,
cellular magnesium ion homeostasis,GO:0010961,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
cellular manganese ion homeostasis,GO:0030026,Parkinson Disease,MESH:D010300,0,,1,SLC30A10
cellular manganese ion homeostasis,GO:0030026,Parkinsonian Disorders,MESH:D020734,0,,1,SLC30A10
cellular metabolic process,GO:0044237,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
cellular metabolic process,GO:0044237,Parkinson Disease,MESH:D010300,60,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|4-phenylbutyric acid|6,7-dihydroxyflavone|Acrolein|Air Pollutants|Aluminum|Amantadine|Aspirin|Atrazine|Benomyl|beta-N-methylamino-L-alanine|Caffeine|Carbidopa|Carbon Tetrachloride|Chlorpyrifos|Copper|Dieldrin|Eicosapentaenoic Acid|Endosulfan|Estradiol|Eugenol|Gabapentin|Glutathione Disulfide|Homocysteine|Hydrocarbons, Chlorinated|Iron|Ketoconazole|Lead|Lipopolysaccharides|Lithium|Manganese|mangiferin|Melatonin|Methamphetamine|Minocycline|Mirtazapine|Naproxen|Oxidopamine|Ozone|Paclitaxel|Paraquat|Particulate Matter|Pentoxifylline|Pioglitazone|Probenecid|Propranolol|Pyridoxine|Quetiapine Fumarate|Roflumilast|Rotenone|Sirolimus|Soot|Tea|Testosterone|Trichloroethylene|Vehicle Emissions|Water Pollutants, Chemical|Zinc|Ziram",0,
cellular metabolic process,GO:0044237,"Parkinson Disease, Secondary",MESH:D010302,46,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|3-methyladenine|Amantadine|Amiodarone|Amlodipine|Atrazine|Benzo(a)pyrene|Carbidopa|Chlorpromazine|Cytarabine|Dieldrin|Diltiazem|Doxorubicin|Exenatide|Fluoxetine|Flurbiprofen|Hydrocarbons, Chlorinated|Lithium|Manganese|Melatonin|Methamphetamine|Methotrexate|Minocycline|Nicotine|Nifedipine|Oxcarbazepine|Oxidopamine|Paraquat|Paroxetine|perhexiline maleate|Phenytoin|PQQ Cofactor|Prochlorperazine|Pyridoxine|Resveratrol|Ribavirin|Rotenone|saxagliptin|Silymarin|sodium bisulfide|thymoquinone|Trichloroethylene|Valproic Acid|Verapamil|Vincristine|Ziram",0,
cellular metabolic process,GO:0044237,Parkinsonian Disorders,MESH:D020734,44,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|6-methyl-2-(phenylethynyl)pyridine|Amantadine|Amiodarone|Amitriptyline|Amlodipine|Amphotericin B|baicalin|Cadmium|Carbidopa|Chlorpromazine|Clonidine|coenzyme Q10|Creatine|crocin|Curcumin|cypermethrin|Disulfiram|Docosahexaenoic Acids|Donepezil|genkwanin|Indomethacin|Ketoconazole|linsidomine|Lipopolysaccharides|mancozeb|Manganese|manganese chloride|Melatonin|Oxidopamine|Paraquat|Paroxetine|Particulate Matter|Plant Extracts|Probenecid|Quetiapine Fumarate|Resveratrol|Rimonabant|Rotenone|Silymarin|taxifolin|Valproic Acid|Verapamil",0,
cellular metabolic process,GO:0044237,Wolff-Parkinson-White Syndrome,MESH:D014927,7,Amiodarone|Diltiazem|Isoproterenol|Lithium|Propafenone|Propranolol|Quinidine,0,
cellular metal ion homeostasis,GO:0006875,Parkinson Disease,MESH:D010300,3,Iron|Manganese|Zinc,0,
cellular metal ion homeostasis,GO:0006875,"Parkinson Disease, Secondary",MESH:D010302,1,Manganese,0,
cellular metal ion homeostasis,GO:0006875,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Manganese,0,
cellular monoatomic cation homeostasis,GO:0030003,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
cellular monoatomic cation homeostasis,GO:0030003,Parkinson Disease,MESH:D010300,0,,1,ATP13A2
cellular monoatomic cation homeostasis,GO:0030003,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ATP13A2
cellular monoatomic cation homeostasis,GO:0030003,Parkinsonian Disorders,MESH:D020734,0,,1,ATP13A2
cellular nitric oxide homeostasis,GO:0033484,Parkinson Disease,MESH:D010300,7,Air Pollutants|Atrazine|Lipopolysaccharides|Melatonin|Nitric Oxide|Nitrites|Particulate Matter,0,
cellular nitric oxide homeostasis,GO:0033484,"Parkinson Disease, Secondary",MESH:D010302,2,Atrazine|Melatonin,0,
cellular nitric oxide homeostasis,GO:0033484,Parkinsonian Disorders,MESH:D020734,4,Curcumin|Lipopolysaccharides|Melatonin|Particulate Matter,0,
cellular nitrogen compound biosynthetic process,GO:0044271,Parkinson Disease,MESH:D010300,2,Nitrates|Nitrites,0,
cellular nitrogen compound metabolic process,GO:0034641,Parkinson Disease,MESH:D010300,4,Estradiol|Lipopolysaccharides|Nitrites|Rotenone,0,
cellular nitrogen compound metabolic process,GO:0034641,"Parkinson Disease, Secondary",MESH:D010302,1,Rotenone,0,
cellular nitrogen compound metabolic process,GO:0034641,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Rotenone,0,
cellular oxidant detoxification,GO:0098869,Parkinson Disease,MESH:D010300,2,Free Radicals|Reactive Oxygen Species,3,CP|GSTP1|HBG1
cellular oxidant detoxification,GO:0098869,Parkinsonian Disorders,MESH:D020734,0,,1,GSR
cellular oxygen homeostasis,GO:0032364,Parkinson Disease,MESH:D010300,2,Lipopolysaccharides|Methamphetamine,1,SOD2
cellular oxygen homeostasis,GO:0032364,"Parkinson Disease, Secondary",MESH:D010302,1,Methamphetamine,0,
cellular oxygen homeostasis,GO:0032364,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
cellular pigment accumulation,GO:0043482,Parkinson Disease,MESH:D010300,1,Lipofuscin,0,
cellular pigment accumulation,GO:0043482,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
cellular potassium ion homeostasis,GO:0030007,Parkinson Disease,MESH:D010300,0,,1,DRD2
cellular potassium ion homeostasis,GO:0030007,Parkinsonian Disorders,MESH:D020734,0,,2,ATP1A3|DRD2
cellular respiration,GO:0045333,Parkinson Disease,MESH:D010300,19,1-Methyl-4-phenylpyridinium|Air Pollutants|Caffeine|Chlorpyrifos|Clozapine|Dicamba|Estradiol|Ketoconazole|Lead|Lipopolysaccharides|Manganese|Melatonin|Minocycline|Paraquat|Particulate Matter|Pentoxifylline|Rotenone|Sirolimus|Vehicle Emissions,1,PPARGC1A
cellular respiration,GO:0045333,"Parkinson Disease, Secondary",MESH:D010302,12,3-methyladenine|Doxorubicin|Manganese|Melatonin|Minocycline|Nicotine|Paraquat|Pyridostigmine Bromide|Resveratrol|Rotenone|sodium bisulfide|Valproic Acid,0,
cellular respiration,GO:0045333,Parkinsonian Disorders,MESH:D020734,16,1-Methyl-4-phenylpyridinium|4-hydroxy-2-nonenal|Cadmium|Clozapine|Curcumin|Ketoconazole|Lipopolysaccharides|Manganese|manganese chloride|Melatonin|Paraquat|Particulate Matter|Resveratrol|Rotenone|Valproic Acid|Zidovudine,0,
"cellular response to 2,3,7,8-tetrachlorodibenzodioxine",GO:1904613,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
cellular response to acid chemical,GO:0071229,Parkinson Disease,MESH:D010300,0,,2,BDNF|NGF
cellular response to acid chemical,GO:0071229,Parkinsonian Disorders,MESH:D020734,0,,1,NGF
cellular response to aldehyde,GO:0110096,Parkinson Disease,MESH:D010300,1,Acrolein,0,
cellular response to aldehyde,GO:0110096,Parkinsonian Disorders,MESH:D020734,1,Plant Extracts,0,
cellular response to aldosterone,GO:1904045,Parkinson Disease,MESH:D010300,0,,1,IGF1R
cellular response to alkaloid,GO:0071312,Parkinson Disease,MESH:D010300,0,,2,DDC|TH
cellular response to alkaloid,GO:0071312,Parkinsonian Disorders,MESH:D020734,0,,2,DDC|TH
cellular response to amino acid starvation,GO:0034198,Parkinson Disease,MESH:D010300,0,,2,MAP3K5|SLC38A2
cellular response to amino acid starvation,GO:0034198,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ATXN3
cellular response to amino acid stimulus,GO:0071230,Parkinson Disease,MESH:D010300,0,,1,TNF
cellular response to ammonium ion,GO:0071242,Parkinson Disease,MESH:D010300,0,,1,SLC18A2
cellular response to ammonium ion,GO:0071242,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,1,SLC18A2
cellular response to ammonium ion,GO:0071242,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,1,SLC18A2
cellular response to amphetamine,GO:0071419,Parkinson Disease,MESH:D010300,1,Methamphetamine,0,
cellular response to amphetamine,GO:0071419,"Parkinson Disease, Secondary",MESH:D010302,1,Methamphetamine,0,
cellular response to amphetamine,GO:0071419,Parkinsonian Disorders,MESH:D020734,0,,1,CAT-2
cellular response to amyloid-beta,GO:1904646,Parkinson Disease,MESH:D010300,1,Sirolimus,2,IGF1R|TNF
cellular response to amyloid-beta,GO:1904646,Parkinsonian Disorders,MESH:D020734,0,,2,ATP1A3|PARP1
cellular response to angiotensin,GO:1904385,Parkinson Disease,MESH:D010300,0,,2,IGF1R|SLC30A10
cellular response to angiotensin,GO:1904385,Parkinsonian Disorders,MESH:D020734,0,,2,PRKCD|SLC30A10
cellular response to arsenic-containing substance,GO:0071243,Parkinson Disease,MESH:D010300,0,,1,HMOX1
cellular response to arsenic-containing substance,GO:0071243,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
cellular response to arsenic-containing substance,GO:0071243,Parkinsonian Disorders,MESH:D020734,2,coenzyme Q10|Resveratrol,0,
cellular response to arsenite(3-),GO:1903841,Parkinson Disease,MESH:D010300,0,,1,SLC38A2
cellular response to ATP,GO:0071318,Parkinson Disease,MESH:D010300,0,,1,SOD1
cellular response to blue light,GO:0071483,"Parkinson Disease, Secondary",MESH:D010302,2,3-methyladenine|Resveratrol,0,
cellular response to blue light,GO:0071483,Parkinsonian Disorders,MESH:D020734,2,Plant Extracts|Resveratrol,0,
cellular response to brain-derived neurotrophic factor stimulus,GO:1990416,Parkinson Disease,MESH:D010300,0,,1,MAPT
cellular response to brain-derived neurotrophic factor stimulus,GO:1990416,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
cellular response to brain-derived neurotrophic factor stimulus,GO:1990416,Parkinsonian Disorders,MESH:D020734,0,,1,MAPT
cellular response to cadmium ion,GO:0071276,Parkinson Disease,MESH:D010300,0,,2,HMOX1|SOD1
cellular response to cadmium ion,GO:0071276,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
cellular response to caffeine,GO:0071313,Parkinson Disease,MESH:D010300,0,,1,PPARGC1A
cellular response to calcium ion,GO:0071277,Parkinson Disease,MESH:D010300,1,Lead,2,EDN1|TRPM2
cellular response to cAMP,GO:0071320,Parkinson Disease,MESH:D010300,0,,1,FBP1
cellular response to catecholamine stimulus,GO:0071870,Parkinson Disease,MESH:D010300,0,,1,DRD1
cellular response to cell-matrix adhesion,GO:0071460,Parkinson Disease,MESH:D010300,0,,1,GSTP1
cellular response to chemical stimulus,GO:0070887,Parkinson Disease,MESH:D010300,2,Atrazine|Ketoconazole,0,
cellular response to chemical stimulus,GO:0070887,"Parkinson Disease, Secondary",MESH:D010302,1,Atrazine,0,
cellular response to chemical stimulus,GO:0070887,Parkinsonian Disorders,MESH:D020734,1,Ketoconazole,0,
cellular response to chemical stress,GO:0062197,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
cellular response to chromate,GO:0071247,Parkinsonian Disorders,MESH:D020734,1,coenzyme Q10,0,
cellular response to cisplatin,GO:0072719,Parkinson Disease,MESH:D010300,1,Aspirin,1,HMOX1
cellular response to cisplatin,GO:0072719,"Parkinson Disease, Secondary",MESH:D010302,2,3-methyladenine|Flurbiprofen,0,
cellular response to cisplatin,GO:0072719,Parkinsonian Disorders,MESH:D020734,2,coenzyme Q10|Indomethacin,0,
cellular response to copper ion,GO:0071280,Parkinson Disease,MESH:D010300,1,Copper,1,SNCA
cellular response to copper ion,GO:0071280,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
cellular response to copper ion,GO:0071280,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
cellular response to copper ion,GO:0071280,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SNCA
cellular response to copper ion,GO:0071280,Parkinsonian Disorders,MESH:D020734,0,,1,SNCA
cellular response to corticotropin-releasing hormone stimulus,GO:0071376,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
cellular response to curcumin,GO:1904644,Parkinson Disease,MESH:D010300,0,,1,LRRK2
cellular response to curcumin,GO:1904644,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
cellular response to curcumin,GO:1904644,Parkinsonian Disorders,MESH:D020734,0,,1,LRRK2
cellular response to cytokine stimulus,GO:0071345,Parkinson Disease,MESH:D010300,0,,1,IL6
cellular response to cytokine stimulus,GO:0071345,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
cellular response to dexamethasone stimulus,GO:0071549,Parkinson Disease,MESH:D010300,0,,4,DDIT4|GDNF|IGF1R|IL6
cellular response to dexamethasone stimulus,GO:0071549,"Parkinson Disease, Secondary",MESH:D010302,0,,1,GDNF
cellular response to dexamethasone stimulus,GO:0071549,Parkinsonian Disorders,MESH:D020734,0,,1,GDNF
cellular response to DNA damage stimulus,GO:0006974,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
cellular response to DNA damage stimulus,GO:0006974,Parkinson Disease,MESH:D010300,40,"1-Methyl-4-phenylpyridinium|Acrolein|Air Pollutants|Atrazine|Benomyl|beta-N-methylamino-L-alanine|Caffeine|carbidopa, levodopa drug combination|Carbon Tetrachloride|Chlorpyrifos|Copper|Diazepam|Diazinon|Ditiocarb|Endosulfan|Estradiol|Iron|Lead|Lipopolysaccharides|Maneb|Manganese|Melatonin|Methamphetamine|Metoclopramide|Omite|Organophosphates|Ozone|Paclitaxel|Paraquat|Particulate Matter|Permethrin|Pesticides|Polychlorinated Biphenyls|Rotenone|Sirolimus|Soot|tetrachloroisophthalonitrile|Vehicle Emissions|Water Pollutants, Chemical|Zinc",1,MAPT
cellular response to DNA damage stimulus,GO:0006974,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
cellular response to DNA damage stimulus,GO:0006974,"Parkinson Disease, Secondary",MESH:D010302,26,"Atrazine|Benzo(a)pyrene|carbidopa, levodopa drug combination|Diazepam|Dichlorvos|Ditiocarb|Doxorubicin|Flurbiprofen|Maneb|Manganese|Melatonin|Methamphetamine|Methotrexate|Metoclopramide|Nicotine|Paraquat|Pesticides|Phenytoin|PQQ Cofactor|Pyridostigmine Bromide|Resveratrol|Rotenone|Silymarin|Trazodone|Valproic Acid|Vincristine",0,
cellular response to DNA damage stimulus,GO:0006974,Parkinsonian Disorders,MESH:D020734,27,"1-Methyl-4-phenylpyridinium|4-hydroxy-2-nonenal|Amphotericin B|Arecoline|Cadmium|carbidopa, levodopa drug combination|coenzyme Q10|crocin|Curcumin|cypermethrin|Lipopolysaccharides|mancozeb|Maneb|Manganese|manganese chloride|Melatonin|oleuropein|Paraquat|Particulate Matter|Permethrin|Plant Extracts|Plant Preparations|Resveratrol|Rotenone|Silymarin|Valproic Acid|Zidovudine",3,MAPT|PARP1|PRKCD
cellular response to dopamine,GO:1903351,Parkinson Disease,MESH:D010300,0,,2,LRRK2|PRKN
cellular response to dopamine,GO:1903351,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
cellular response to dopamine,GO:1903351,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
cellular response to dopamine,GO:1903351,Parkinsonian Disorders,MESH:D020734,0,,3,DOP1R2|LRRK2|PRKN
cellular response to electrical stimulus,GO:0071257,Parkinson Disease,MESH:D010300,2,Nitric Oxide|Ziram,0,
cellular response to electrical stimulus,GO:0071257,"Parkinson Disease, Secondary",MESH:D010302,1,Ziram,0,
cellular response to epidermal growth factor stimulus,GO:0071364,Parkinson Disease,MESH:D010300,0,,1,GSTP1
cellular response to epinephrine stimulus,GO:0071872,Parkinson Disease,MESH:D010300,0,,2,NOS1|SNCA
cellular response to epinephrine stimulus,GO:0071872,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
cellular response to epinephrine stimulus,GO:0071872,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
cellular response to epinephrine stimulus,GO:0071872,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SNCA
cellular response to epinephrine stimulus,GO:0071872,Parkinsonian Disorders,MESH:D020734,0,,1,SNCA
cellular response to estradiol stimulus,GO:0071392,Parkinson Disease,MESH:D010300,0,,3,IGF1R|IL6|PPARGC1A
cellular response to ethanol,GO:0071361,Parkinson Disease,MESH:D010300,0,,2,DRD2|SOD2
cellular response to ethanol,GO:0071361,Parkinsonian Disorders,MESH:D020734,0,,2,DRD2|PRL
cellular response to external biotic stimulus,GO:0071217,Parkinson Disease,MESH:D010300,1,Ozone,0,
cellular response to fatty acid,GO:0071398,Parkinson Disease,MESH:D010300,2,Reactive Nitrogen Species|Reactive Oxygen Species,3,ALDH2|EDN1|PPARGC1A
cellular response to fatty acid,GO:0071398,Parkinsonian Disorders,MESH:D020734,0,,1,PRKCD
cellular response to fibroblast growth factor stimulus,GO:0044344,Parkinson Disease,MESH:D010300,0,,1,SNCA
cellular response to fibroblast growth factor stimulus,GO:0044344,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
cellular response to fibroblast growth factor stimulus,GO:0044344,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
cellular response to fibroblast growth factor stimulus,GO:0044344,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SNCA
cellular response to fibroblast growth factor stimulus,GO:0044344,Parkinsonian Disorders,MESH:D020734,0,,1,SNCA
cellular response to fluid shear stress,GO:0071498,Parkinson Disease,MESH:D010300,1,Sirolimus,0,
cellular response to follicle-stimulating hormone stimulus,GO:0071372,Parkinson Disease,MESH:D010300,0,,2,EDN1|PPARGC1A
cellular response to fructose stimulus,GO:0071332,Parkinson Disease,MESH:D010300,0,,1,PPARGC1A
cellular response to gamma radiation,GO:0071480,Parkinson Disease,MESH:D010300,4,Lead|Lipopolysaccharides|Melatonin|Reactive Oxygen Species,0,
cellular response to gamma radiation,GO:0071480,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
cellular response to gamma radiation,GO:0071480,Parkinsonian Disorders,MESH:D020734,3,Cadmium|Lipopolysaccharides|Melatonin,0,
cellular response to glucocorticoid stimulus,GO:0071385,Parkinson Disease,MESH:D010300,0,,2,EDN1|GSTP1
cellular response to glucose starvation,GO:0042149,Parkinsonian Disorders,MESH:D020734,0,,1,PRKCD
cellular response to glucose stimulus,GO:0071333,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
cellular response to glucose stimulus,GO:0071333,Parkinson Disease,MESH:D010300,0,,3,IGF1R|PPARGC1A|TH
cellular response to glucose stimulus,GO:0071333,Parkinsonian Disorders,MESH:D020734,0,,2,POLG|TH
cellular response to glyoxal,GO:0036471,Parkinson Disease,MESH:D010300,0,,1,PARK7
cellular response to glyoxal,GO:0036471,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
cellular response to glyoxal,GO:0036471,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
cellular response to growth factor stimulus,GO:0071363,Parkinson Disease,MESH:D010300,0,,4,DDC|INSR|NOS1|TH
cellular response to growth factor stimulus,GO:0071363,Parkinson Disease 13,MESH:C565204,0,,1,HTRA2
cellular response to growth factor stimulus,GO:0071363,Parkinsonian Disorders,MESH:D020734,0,,3,DDC|HTRA2|TH
cellular response to heat,GO:0034605,Parkinson Disease,MESH:D010300,0,,3,HMOX1|HSPA1A|MAPT
cellular response to heat,GO:0034605,Parkinson Disease 13,MESH:C565204,0,,1,HTRA2
cellular response to heat,GO:0034605,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,2,ATXN3|MAPT
cellular response to heat,GO:0034605,Parkinsonian Disorders,MESH:D020734,0,,2,HTRA2|MAPT
cellular response to hepatocyte growth factor stimulus,GO:0035729,Parkinson Disease,MESH:D010300,0,,2,HGF|IL6
cellular response to high light intensity,GO:0071486,Parkinson Disease,MESH:D010300,5,Apomorphine|Ketoconazole|Metoclopramide|Minocycline|Pergolide,0,
cellular response to high light intensity,GO:0071486,"Parkinson Disease, Secondary",MESH:D010302,4,Apomorphine|Ethosuximide|Metoclopramide|Minocycline,0,
cellular response to high light intensity,GO:0071486,Parkinsonian Disorders,MESH:D020734,5,Apomorphine|Bupropion|Diazoxide|Ketoconazole|Pergolide,0,
cellular response to hormone stimulus,GO:0032870,Parkinson Disease,MESH:D010300,0,,2,AIF1|ALDH2
cellular response to hormone stimulus,GO:0032870,Parkinsonian Disorders,MESH:D020734,0,,1,PRL
cellular response to human chorionic gonadotropin stimulus,GO:0044751,Parkinson Disease,MESH:D010300,0,,1,EDN1
cellular response to hydrogen peroxide,GO:0070301,Parkinson Disease,MESH:D010300,2,Melatonin|Pentoxifylline,6,EDN1|IL6|MAP3K5|NQO1|PARK7|TRPM2
cellular response to hydrogen peroxide,GO:0070301,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
cellular response to hydrogen peroxide,GO:0070301,"Parkinson Disease, Secondary",MESH:D010302,2,Doxorubicin|Melatonin,0,
cellular response to hydrogen peroxide,GO:0070301,Parkinsonian Disorders,MESH:D020734,1,Melatonin,2,PARK7|PRKCD
cellular response to hydrogen sulfide,GO:1904881,Parkinson Disease,MESH:D010300,0,,2,PINK1|PRKN
cellular response to hydrogen sulfide,GO:1904881,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
cellular response to hydrogen sulfide,GO:1904881,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
cellular response to hydrogen sulfide,GO:1904881,Parkinsonian Disorders,MESH:D020734,0,,2,PINK1|PRKN
cellular response to hydroperoxide,GO:0071447,Parkinson Disease,MESH:D010300,0,,1,AIF1
cellular response to hydroperoxide,GO:0071447,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
cellular response to hydroperoxide,GO:0071447,Parkinsonian Disorders,MESH:D020734,0,,1,PRKCD
cellular response to hypoxia,GO:0071456,Parkinson Disease,MESH:D010300,0,,6,DNM1L|DRD1|EDN1|PARK7|PINK1|PPARGC1A
cellular response to hypoxia,GO:0071456,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
cellular response to hypoxia,GO:0071456,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
cellular response to hypoxia,GO:0071456,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
cellular response to hypoxia,GO:0071456,Parkinsonian Disorders,MESH:D020734,3,Curcumin|Plant Extracts|Resveratrol,3,PARK7|PINK1|PRL
cellular response to inorganic substance,GO:0071241,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
cellular response to inorganic substance,GO:0071241,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
cellular response to insulin-like growth factor stimulus,GO:1990314,Parkinson Disease,MESH:D010300,0,,1,IGF1R
cellular response to insulin stimulus,GO:0032869,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
cellular response to insulin stimulus,GO:0032869,Parkinson Disease,MESH:D010300,0,,5,DRD1|FBP1|GSTP1|IGF1R|INSR
cellular response to insulin stimulus,GO:0032869,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
cellular response to insulin stimulus,GO:0032869,Parkinsonian Disorders,MESH:D020734,2,Plant Extracts|Resveratrol,2,PARP1|PRKCD
cellular response to interferon-beta,GO:0035458,Parkinson Disease 13,MESH:C565204,0,,1,HTRA2
cellular response to interferon-beta,GO:0035458,Parkinsonian Disorders,MESH:D020734,0,,1,HTRA2
cellular response to interleukin-1,GO:0071347,Parkinson Disease,MESH:D010300,0,,4,EDN1|FGB|HSPA9|IL6
cellular response to interleukin-1,GO:0071347,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
cellular response to interleukin-17,GO:0097398,Parkinson Disease,MESH:D010300,0,,1,IL6
cellular response to interleukin-6,GO:0071354,Parkinson Disease,MESH:D010300,0,,1,PPARGC1A
cellular response to ionizing radiation,GO:0071479,Parkinson Disease,MESH:D010300,1,Reactive Oxygen Species,1,TNF
cellular response to ionizing radiation,GO:0071479,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
cellular response to ionizing radiation,GO:0071479,Parkinsonian Disorders,MESH:D020734,4,Curcumin|Malondialdehyde|Plant Extracts|Resveratrol,0,
cellular response to ionomycin,GO:1904637,Parkinson Disease,MESH:D010300,0,,1,PPARGC1A
cellular response to iron ion,GO:0071281,Parkinson Disease,MESH:D010300,0,,1,HFE
cellular response to iron ion starvation,GO:0010106,Parkinson Disease,MESH:D010300,0,,1,HFE
cellular response to lead ion,GO:0071284,Parkinson Disease,MESH:D010300,1,Lead,0,
cellular response to lead ion,GO:0071284,"Parkinson Disease, Secondary",MESH:D010302,1,Verapamil,0,
cellular response to lead ion,GO:0071284,Parkinsonian Disorders,MESH:D020734,1,Verapamil,0,
cellular response to leptin stimulus,GO:0044320,Parkinson Disease,MESH:D010300,0,,1,FGB
cellular response to leukemia inhibitory factor,GO:1990830,Parkinson Disease,MESH:D010300,0,,1,MIR181C
cellular response to L-glutamate,GO:1905232,Parkinson Disease,MESH:D010300,0,,1,PRKN
cellular response to L-glutamate,GO:1905232,"Parkinson Disease, Secondary",MESH:D010302,0,,2,PRKN|SHH
cellular response to L-glutamate,GO:1905232,Parkinsonian Disorders,MESH:D020734,0,,1,PRKN
cellular response to L-glutamine,GO:1904845,Parkinson Disease,MESH:D010300,0,,1,PRKN
cellular response to L-glutamine,GO:1904845,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
cellular response to L-glutamine,GO:1904845,Parkinsonian Disorders,MESH:D020734,0,,1,PRKN
cellular response to light stimulus,GO:0071482,"Parkinson Disease, Secondary",MESH:D010302,1,Chlorpromazine,0,
cellular response to light stimulus,GO:0071482,Parkinsonian Disorders,MESH:D020734,1,Chlorpromazine,0,
cellular response to lipid,GO:0071396,Parkinson Disease,MESH:D010300,0,,1,DNM1L
cellular response to lipopolysaccharide,GO:0071222,Parkinson Disease,MESH:D010300,2,Lipopolysaccharides|Ozone,8,AIF1|DEFA4|GSTP1|IL6|MIR181C|PARK7|PPARGC1A|TNF
cellular response to lipopolysaccharide,GO:0071222,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
cellular response to lipopolysaccharide,GO:0071222,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
cellular response to lipopolysaccharide,GO:0071222,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Plant Extracts,1,PARK7
cellular response to lithium ion,GO:0071285,Parkinson Disease,MESH:D010300,0,,1,GSTA4
cellular response to lithium ion,GO:0071285,"Parkinson Disease, Secondary",MESH:D010302,0,,2,NOS2|SHH
cellular response to luteinizing hormone stimulus,GO:0071373,Parkinson Disease,MESH:D010300,0,,1,EDN1
cellular response to magnesium ion,GO:0071286,Parkinson Disease,MESH:D010300,0,,1,FBP1
cellular response to magnetism,GO:0071259,Parkinson Disease,MESH:D010300,1,Nitric Oxide,0,
cellular response to manganese ion,GO:0071287,Parkinson Disease,MESH:D010300,0,,4,ATP13A2|LRRK2|PRKN|TH
cellular response to manganese ion,GO:0071287,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
cellular response to manganese ion,GO:0071287,"Parkinson Disease, Secondary",MESH:D010302,0,,2,ATP13A2|PRKN
cellular response to manganese ion,GO:0071287,Parkinsonian Disorders,MESH:D020734,1,manganese chloride,4,ATP13A2|LRRK2|PRKN|TH
cellular response to mechanical stimulus,GO:0071260,Parkinson Disease,MESH:D010300,0,,6,IGF1R|IGF2|KCNJ4|MAG|NOS1|SLC38A2
cellular response to metal ion,GO:0071248,Parkinson Disease,MESH:D010300,0,,1,NQO1
cellular response to methotrexate,GO:0071414,"Parkinson Disease, Secondary",MESH:D010302,1,Methotrexate,0,
cellular response to mineralocorticoid stimulus,GO:0071389,Parkinson Disease,MESH:D010300,0,,1,EDN1
cellular response to misfolded protein,GO:0071218,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ATXN3
cellular response to molecule of bacterial origin,GO:0071219,Parkinson Disease,MESH:D010300,0,,1,TNF
cellular response to morphine,GO:0071315,Parkinson Disease,MESH:D010300,0,,1,AIF1
cellular response to mycotoxin,GO:0036146,Parkinson Disease,MESH:D010300,1,4-phenylbutyric acid,0,
cellular response to nerve growth factor stimulus,GO:1990090,Parkinson Disease,MESH:D010300,0,,2,BDNF|MAPT
cellular response to nerve growth factor stimulus,GO:1990090,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
cellular response to nerve growth factor stimulus,GO:1990090,Parkinsonian Disorders,MESH:D020734,0,,2,MAPT|PARP1
cellular response to nicotine,GO:0071316,Parkinson Disease,MESH:D010300,0,,2,TH|TNF
cellular response to nicotine,GO:0071316,"Parkinson Disease, Secondary",MESH:D010302,2,3-methyladenine|Nicotine,0,
cellular response to nicotine,GO:0071316,Parkinsonian Disorders,MESH:D020734,0,,1,TH
cellular response to nitric oxide,GO:0071732,Parkinson Disease,MESH:D010300,1,mangiferin,0,
cellular response to nitrite,GO:0071250,Parkinson Disease,MESH:D010300,0,,1,PPARGC1A
cellular response to nitrosative stress,GO:0071500,Parkinson Disease,MESH:D010300,3,Free Radicals|Ozone|Particulate Matter,0,
cellular response to nitrosative stress,GO:0071500,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
cellular response to norepinephrine stimulus,GO:0071874,Parkinson Disease,MESH:D010300,0,,1,BDNF
cellular response to nutrient,GO:0031670,Parkinson Disease,MESH:D010300,0,,1,HMOX1
cellular response to nutrient levels,GO:0031669,Parkinson Disease,MESH:D010300,0,,1,IL6
cellular response to nutrient levels,GO:0031669,"PARKINSON DISEASE 18, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:614251,0,,1,EIF4G1
cellular response to nutrient levels,GO:0031669,Wolff-Parkinson-White Syndrome,MESH:D014927,0,,1,PRKAG2
cellular response to organic cyclic compound,GO:0071407,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
cellular response to osmotic stress,GO:0071470,"Parkinson Disease, Secondary",MESH:D010302,1,Verapamil,0,
cellular response to osmotic stress,GO:0071470,Parkinsonian Disorders,MESH:D020734,1,Verapamil,0,
cellular response to oxidative stress,GO:0034599,Parkinson Disease,MESH:D010300,14,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Air Pollutants|Glutathione Disulfide|Lead|Lipopolysaccharides|mangiferin|Nitric Oxide|Nitrogen Dioxide|Ozone|Paraquat|Particulate Matter|Reactive Oxygen Species|Soot|Vehicle Emissions",13,AIF1|ATP13A2|HSPA1A|LRRK2|NQO1|PARK7|PINK1|PPARGC1A|PRKN|RPL23A|SNCA|SOD1|SOD2
cellular response to oxidative stress,GO:0034599,Parkinson Disease 13,MESH:C565204,0,,1,HTRA2
cellular response to oxidative stress,GO:0034599,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
cellular response to oxidative stress,GO:0034599,"PARKINSON DISEASE 22, AUTOSOMAL DOMINANT",OMIM:616710,0,,1,CHCHD2
cellular response to oxidative stress,GO:0034599,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
cellular response to oxidative stress,GO:0034599,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
cellular response to oxidative stress,GO:0034599,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
cellular response to oxidative stress,GO:0034599,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
cellular response to oxidative stress,GO:0034599,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
cellular response to oxidative stress,GO:0034599,"Parkinson Disease, Secondary",MESH:D010302,6,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Carbamazepine|Carbon Monoxide|Doxorubicin|Paraquat|Resveratrol",3,ATP13A2|PRKN|SNCA
cellular response to oxidative stress,GO:0034599,Parkinsonian Disorders,MESH:D020734,10,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|4-hydroxy-2-nonenal|Cadmium|Curcumin|Lipopolysaccharides|Malondialdehyde|Paraquat|Particulate Matter|Plant Extracts|Resveratrol",11,ATP13A2|GSR|HTRA2|LRRK2|PARK7|PARP1|PINK1|PRKCD|PRKN|PRKRA|SNCA
cellular response to ozone,GO:0071457,Parkinson Disease,MESH:D010300,1,Ozone,0,
cellular response to paraquat,GO:0072756,Parkinson Disease,MESH:D010300,2,Benserazide|Paraquat,0,
cellular response to paraquat,GO:0072756,"Parkinson Disease, Secondary",MESH:D010302,2,Benserazide|Paraquat,0,
cellular response to paraquat,GO:0072756,Parkinsonian Disorders,MESH:D020734,2,Benserazide|Paraquat,0,
cellular response to peptide hormone stimulus,GO:0071375,Parkinson Disease,MESH:D010300,0,,1,EDN1
cellular response to phorbol 13-acetate 12-myristate,GO:1904628,Parkinson Disease,MESH:D010300,0,,1,FBP1
cellular response to platelet-derived growth factor stimulus,GO:0036120,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
cellular response to platelet-derived growth factor stimulus,GO:0036120,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
cellular response to potassium ion,GO:0035865,Parkinson Disease,MESH:D010300,0,,3,BDNF|PPARGC1A|SOD1
cellular response to progesterone stimulus,GO:0071393,Parkinson Disease,MESH:D010300,0,,1,IGF1R
cellular response to prolactin,GO:1990646,Parkinson Disease,MESH:D010300,0,,1,IL6
cellular response to raffinose,GO:0097403,Parkinson Disease,MESH:D010300,0,,1,FBP1
cellular response to reactive nitrogen species,GO:1902170,Parkinson Disease,MESH:D010300,0,,1,MAP3K5
cellular response to reactive oxygen species,GO:0034614,Parkinson Disease,MESH:D010300,2,Melatonin|Reactive Oxygen Species,3,LRRK2|MAPT|PARK7
cellular response to reactive oxygen species,GO:0034614,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
cellular response to reactive oxygen species,GO:0034614,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
cellular response to reactive oxygen species,GO:0034614,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
cellular response to reactive oxygen species,GO:0034614,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
cellular response to reactive oxygen species,GO:0034614,Parkinsonian Disorders,MESH:D020734,2,ginsenoside Re|Melatonin,4,DJ-1BETA|LRRK2|MAPT|PARK7
cellular response to redox state,GO:0071461,Parkinson Disease,MESH:D010300,2,Lead|Reactive Oxygen Species,0,
cellular response to redox state,GO:0071461,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
cellular response to redox state,GO:0071461,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
cellular response to resveratrol,GO:1904639,Parkinson Disease,MESH:D010300,0,,2,ALDH2|PPARGC1A
cellular response to retinoic acid,GO:0071300,Parkinson Disease,MESH:D010300,0,,2,DRD2|TNF
cellular response to retinoic acid,GO:0071300,Parkinson Disease 13,MESH:C565204,0,,1,HTRA2
cellular response to retinoic acid,GO:0071300,Parkinsonian Disorders,MESH:D020734,0,,4,ALDH1A2|ATP1A3|DRD2|HTRA2
cellular response to rotenone,GO:1904648,Parkinson Disease,MESH:D010300,1,Rotenone,0,
cellular response to rotenone,GO:1904648,"Parkinson Disease, Secondary",MESH:D010302,1,Rotenone,0,
cellular response to rotenone,GO:1904648,Parkinsonian Disorders,MESH:D020734,1,Rotenone,0,
cellular response to sodium arsenite,GO:1903936,Parkinsonian Disorders,MESH:D020734,1,Indomethacin,0,
cellular response to starvation,GO:0009267,Parkinson Disease,MESH:D010300,0,,2,GBA1|LRRK2
cellular response to starvation,GO:0009267,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
cellular response to starvation,GO:0009267,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
cellular response to starvation,GO:0009267,Parkinsonian Disorders,MESH:D020734,0,,2,GBA1|LRRK2
cellular response to steroid hormone stimulus,GO:0071383,Parkinson Disease,MESH:D010300,0,,1,HSPA1A
cellular response to steroid hormone stimulus,GO:0071383,Parkinsonian Disorders,MESH:D020734,0,,1,ATP1A3
cellular response to stress,GO:0033554,Parkinson Disease,MESH:D010300,3,Aspirin|Copper|Zinc,1,MAP3K5
cellular response to stress,GO:0033554,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Indomethacin,0,
cellular response to superoxide,GO:0071451,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
cellular response to temperature stimulus,GO:0071502,Parkinson Disease,MESH:D010300,0,,1,TRPM2
cellular response to testosterone stimulus,GO:0071394,Parkinson Disease,MESH:D010300,0,,1,IGF1R
cellular response to thyroid hormone stimulus,GO:0097067,Parkinson Disease,MESH:D010300,0,,1,PPARGC1A
cellular response to thyroid hormone stimulus,GO:0097067,Parkinsonian Disorders,MESH:D020734,0,,1,ATP1A3
cellular response to toxic substance,GO:0097237,Parkinson Disease,MESH:D010300,6,"Chlorpyrifos|Dopamine|Manganese|Propranolol|Reactive Oxygen Species|Water Pollutants, Chemical",4,EDN1|PINK1|PRKN|TNF
cellular response to toxic substance,GO:0097237,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
cellular response to toxic substance,GO:0097237,"Parkinson Disease, Secondary",MESH:D010302,6,Benzo(a)pyrene|Doxorubicin|Manganese|Nicotine|Resveratrol|sodium bisulfide,1,PRKN
cellular response to toxic substance,GO:0097237,Parkinsonian Disorders,MESH:D020734,3,Dopamine|Manganese|Resveratrol,2,PINK1|PRKN
cellular response to toxic substance,GO:0097237,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Propranolol,0,
cellular response to transforming growth factor beta stimulus,GO:0071560,Parkinson Disease,MESH:D010300,0,,3,EDN1|IGF1R|PPARGC1A
cellular response to transforming growth factor beta stimulus,GO:0071560,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
cellular response to tumor cell,GO:0071228,Parkinson Disease,MESH:D010300,1,mangiferin,0,
cellular response to tumor necrosis factor,GO:0071356,Parkinson Disease,MESH:D010300,0,,7,BDNF|EDN1|GBA1|IL6|LRRK2|MAP3K5|PPARGC1A
cellular response to tumor necrosis factor,GO:0071356,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
cellular response to tumor necrosis factor,GO:0071356,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
cellular response to tumor necrosis factor,GO:0071356,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
cellular response to tumor necrosis factor,GO:0071356,Parkinsonian Disorders,MESH:D020734,0,,2,GBA1|LRRK2
cellular response to type II interferon,GO:0071346,Parkinson Disease,MESH:D010300,0,,3,AIF1|EDN1|TNF
cellular response to type II interferon,GO:0071346,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
cellular response to type II interferon,GO:0071346,Parkinsonian Disorders,MESH:D020734,0,,1,GAPDH
cellular response to unfolded protein,GO:0034620,Parkinson Disease,MESH:D010300,3,4-phenylbutyric acid|Particulate Matter|Sirolimus,4,HSC70-3|HSPA1A|HSPA9|PRKN
cellular response to unfolded protein,GO:0034620,"Parkinson Disease, Secondary",MESH:D010302,1,3-methyladenine,1,PRKN
cellular response to unfolded protein,GO:0034620,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,1,PRKN
cellular response to UV,GO:0034644,"Parkinson Disease, Secondary",MESH:D010302,1,Chlorpromazine,0,
cellular response to UV,GO:0034644,Parkinsonian Disorders,MESH:D020734,1,Chlorpromazine,2,PARP1|PRKCD
cellular response to UV-A,GO:0071492,"Parkinson Disease, Secondary",MESH:D010302,1,Amiodarone,0,
cellular response to UV-A,GO:0071492,Parkinsonian Disorders,MESH:D020734,2,Amiodarone|Plant Extracts,0,
cellular response to UV-A,GO:0071492,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
cellular response to UV-B,GO:0071493,Parkinson Disease,MESH:D010300,3,Chlorpyrifos|Ketoconazole|Reactive Oxygen Species,0,
cellular response to UV-B,GO:0071493,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
cellular response to UV-B,GO:0071493,Parkinsonian Disorders,MESH:D020734,3,Ketoconazole|Malondialdehyde|Resveratrol,0,
cellular response to virus,GO:0098586,Parkinson Disease,MESH:D010300,0,,1,IL6
cellular response to virus,GO:0098586,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
cellular response to virus,GO:0098586,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
cellular response to vitamin D,GO:0071305,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
cellular response to xenobiotic stimulus,GO:0071466,Parkinson Disease,MESH:D010300,5,Eugenol|Ketoconazole|Paclitaxel|Particulate Matter|Vehicle Emissions,7,DDC|EDN1|FBP1|GSTM1|NQO1|SLC18A2|TH
cellular response to xenobiotic stimulus,GO:0071466,"PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:613643,0,,1,UCHL1
cellular response to xenobiotic stimulus,GO:0071466,"Parkinson Disease, Secondary",MESH:D010302,4,3-methyladenine|Doxorubicin|geraniol|Verapamil,2,NOS2|SLC18A2
cellular response to xenobiotic stimulus,GO:0071466,Parkinsonian Disorders,MESH:D020734,5,Creatine|geraniol|Ketoconazole|Particulate Matter|Verapamil,3,DDC|SLC18A2|TH
cellular response to X-ray,GO:0071481,Parkinson Disease,MESH:D010300,2,Caffeine|Reactive Oxygen Species,0,
cellular response to zinc ion,GO:0071294,Parkinson Disease,MESH:D010300,1,Zinc,1,ATP13A2
cellular response to zinc ion,GO:0071294,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ATP13A2
cellular response to zinc ion,GO:0071294,Parkinsonian Disorders,MESH:D020734,0,,2,ATP13A2|PARP1
cellular response to zinc ion starvation,GO:0034224,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
cellular senescence,GO:0090398,Parkinson Disease,MESH:D010300,15,1-Methyl-4-phenylpyridinium|Air Pollutants|Aspirin|Caffeine|Chlorpyrifos|Diazinon|Estradiol|Maneb|Methamphetamine|Nitric Oxide|Paclitaxel|Paraquat|Particulate Matter|Sirolimus|Vehicle Emissions,2,IGF1R|MAP3K5
cellular senescence,GO:0090398,"Parkinson Disease, Secondary",MESH:D010302,10,3-methyladenine|Doxorubicin|Maneb|Methamphetamine|Nicotine|Nifedipine|Paraquat|Resveratrol|Ritonavir|Valproic Acid,0,
cellular senescence,GO:0090398,Parkinsonian Disorders,MESH:D020734,10,1-Methyl-4-phenylpyridinium|Disulfiram|mancozeb|Maneb|Paraquat|Particulate Matter|Plant Extracts|Resveratrol|Ritonavir|Valproic Acid,1,PRKCD
cellular sodium ion homeostasis,GO:0006883,Parkinsonian Disorders,MESH:D020734,0,,1,ATP1A3
cellular zinc ion homeostasis,GO:0006882,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
cellular zinc ion homeostasis,GO:0006882,Parkinson Disease,MESH:D010300,5,Astemizole|Copper|Ditiocarb|Zinc|Ziram,2,ATP13A2|SLC30A10
cellular zinc ion homeostasis,GO:0006882,"Parkinson Disease, Secondary",MESH:D010302,2,Ditiocarb|Ziram,1,ATP13A2
cellular zinc ion homeostasis,GO:0006882,Parkinsonian Disorders,MESH:D020734,1,Disulfiram,2,ATP13A2|SLC30A10
cell volume homeostasis,GO:0006884,Parkinson Disease,MESH:D010300,5,Eicosapentaenoic Acid|Iron|Lipopolysaccharides|Ozone|Paraquat,0,
cell volume homeostasis,GO:0006884,"Parkinson Disease, Secondary",MESH:D010302,3,Doxorubicin|Paraquat|Vincristine,0,
cell volume homeostasis,GO:0006884,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Paraquat,0,
central nervous system control of baroreceptor feedback,GO:0003019,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
central nervous system development,GO:0007417,Parkinson Disease,MESH:D010300,0,,3,GBA1|GSTP1|PRKN
central nervous system development,GO:0007417,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
central nervous system development,GO:0007417,"Parkinson Disease, Secondary",MESH:D010302,1,Methotrexate,2,PRKN|SHH
central nervous system development,GO:0007417,Parkinsonian Disorders,MESH:D020734,0,,2,GBA1|PRKN
central nervous system maturation,GO:0021626,"PARKINSONISM WITH SPASTICITY, X-LINKED",OMIM:300911,0,,1,ATP6AP2
central nervous system myelination,GO:0022010,Parkinson Disease,MESH:D010300,2,Lead|Particulate Matter,2,CNTNAP2|MAG
central nervous system myelination,GO:0022010,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,1,ALDH1A2
central nervous system myelin formation,GO:0032289,Parkinson Disease,MESH:D010300,0,,1,MAG
central nervous system myelin maintenance,GO:0032286,Parkinson Disease,MESH:D010300,1,Methamphetamine,0,
central nervous system myelin maintenance,GO:0032286,"Parkinson Disease, Secondary",MESH:D010302,1,Methamphetamine,0,
central nervous system neuron development,GO:0021954,Parkinson Disease,MESH:D010300,0,,2,MAP2|MAPT
central nervous system neuron development,GO:0021954,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
central nervous system neuron development,GO:0021954,Parkinsonian Disorders,MESH:D020734,0,,1,MAPT
central nervous system neuron differentiation,GO:0021953,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
central nervous system neuron differentiation,GO:0021953,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
central nervous system projection neuron axonogenesis,GO:0021952,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
centriole-centriole cohesion,GO:0010457,Parkinsonian Disorders,MESH:D020734,0,,1,DCTN1
centrosome duplication,GO:0051298,Parkinson Disease,MESH:D010300,1,Estradiol,0,
centrosome duplication,GO:0051298,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
centrosome separation,GO:0051299,"Parkinson Disease, Secondary",MESH:D010302,1,Oxcarbazepine,0,
ceramide biosynthetic process,GO:0046513,Parkinson Disease,MESH:D010300,3,Carbon Tetrachloride|Particulate Matter|Vehicle Emissions,1,GBA1
ceramide biosynthetic process,GO:0046513,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
ceramide biosynthetic process,GO:0046513,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,1,GBA1
ceramide metabolic process,GO:0006672,Parkinson Disease,MESH:D010300,1,Paraquat,0,
ceramide metabolic process,GO:0006672,Parkinson Disease 13,MESH:C565204,0,,1,HTRA2
ceramide metabolic process,GO:0006672,"Parkinson Disease, Secondary",MESH:D010302,1,Paraquat,0,
ceramide metabolic process,GO:0006672,Parkinsonian Disorders,MESH:D020734,1,Paraquat,1,HTRA2
ceramide translocation,GO:0099040,Parkinson Disease,MESH:D010300,0,,1,ABCB1
ceramide translocation,GO:0099040,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ABCB1
cerebellar granule cell precursor proliferation,GO:0021930,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
cerebellar Purkinje cell differentiation,GO:0021702,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ATXN2
cerebellar Purkinje cell layer formation,GO:0021694,Parkinson Disease,MESH:D010300,0,,1,GBA1
cerebellar Purkinje cell layer formation,GO:0021694,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
cerebellar Purkinje cell layer formation,GO:0021694,Parkinsonian Disorders,MESH:D020734,0,,1,GBA1
cerebellar Purkinje cell layer morphogenesis,GO:0021692,Parkinson Disease,MESH:D010300,0,,1,CNTNAP2
cerebellum development,GO:0021549,Parkinson Disease,MESH:D010300,0,,5,AIF1|CNTNAP2|IGF1R|INSR|PPARGC1A
cerebellum development,GO:0021549,"Parkinson Disease, Secondary",MESH:D010302,1,Phenytoin,0,
cerebellum formation,GO:0021588,Parkinson Disease,MESH:D010300,0,,1,ATP13A2
cerebellum formation,GO:0021588,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ATP13A2
cerebellum formation,GO:0021588,Parkinsonian Disorders,MESH:D020734,0,,1,ATP13A2
cerebral cortex development,GO:0021987,Parkinson Disease,MESH:D010300,1,Reactive Oxygen Species,3,CNTNAP2|SLC38A2|TH
cerebral cortex development,GO:0021987,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
cerebral cortex development,GO:0021987,Parkinsonian Disorders,MESH:D020734,0,,2,ATP1A3|TH
cerebral cortex GABAergic interneuron migration,GO:0021853,Parkinson Disease,MESH:D010300,0,,2,DRD1|DRD2
cerebral cortex GABAergic interneuron migration,GO:0021853,"Parkinson Disease, Secondary",MESH:D010302,1,Carbon Monoxide,0,
cerebral cortex GABAergic interneuron migration,GO:0021853,Parkinsonian Disorders,MESH:D020734,0,,1,DRD2
cGMP biosynthetic process,GO:0006182,Parkinson Disease,MESH:D010300,2,Caffeine|Nitric Oxide,0,
cGMP biosynthetic process,GO:0006182,"Parkinson Disease, Secondary",MESH:D010302,2,Carbon Monoxide|Resveratrol,0,
cGMP biosynthetic process,GO:0006182,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Resveratrol,0,
cGMP biosynthetic process,GO:0006182,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
cGMP-mediated signaling,GO:0019934,Parkinson Disease,MESH:D010300,1,Nitric Oxide,0,
cGMP-mediated signaling,GO:0019934,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
cGMP-mediated signaling,GO:0019934,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
cGMP metabolic process,GO:0046068,Parkinson Disease,MESH:D010300,1,Aluminum,0,
cGMP metabolic process,GO:0046068,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
changes to DNA methylation involved in embryo development,GO:1901538,Parkinson Disease,MESH:D010300,1,Pesticides,0,
changes to DNA methylation involved in embryo development,GO:1901538,"Parkinson Disease, Secondary",MESH:D010302,1,Pesticides,0,
chaperone cofactor-dependent protein refolding,GO:0051085,Parkinson Disease,MESH:D010300,0,,4,GAK|HSC70-3|HSPA1A|HSPA9
chaperone-mediated autophagy,GO:0061684,Parkinson Disease,MESH:D010300,1,Paraquat,0,
chaperone-mediated autophagy,GO:0061684,"Parkinson Disease, Secondary",MESH:D010302,1,Paraquat,0,
chaperone-mediated autophagy,GO:0061684,Parkinsonian Disorders,MESH:D020734,1,Paraquat,0,
chaperone-mediated protein complex assembly,GO:0051131,Parkinson Disease,MESH:D010300,0,,1,HSPA1A
chaperone-mediated protein complex assembly,GO:0051131,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
chemical synaptic transmission,GO:0007268,Parkinson Disease,MESH:D010300,9,Amphetamine|Clonazepam|Clozapine|Diazepam|Dopamine|Lead|Lithium|Nitric Oxide|Quetiapine Fumarate,3,CNTNAP2|SLC18A2|SNCA
chemical synaptic transmission,GO:0007268,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
chemical synaptic transmission,GO:0007268,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
chemical synaptic transmission,GO:0007268,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
chemical synaptic transmission,GO:0007268,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ATXN3
chemical synaptic transmission,GO:0007268,"Parkinson Disease, Secondary",MESH:D010302,7,Diazepam|Lithium|Meperidine|Nicotine|Nifedipine|Olanzapine|Risperidone,2,SLC18A2|SNCA
chemical synaptic transmission,GO:0007268,Parkinsonian Disorders,MESH:D020734,8,Baclofen|Clonazepam|Clozapine|Dopamine|Olanzapine|Quetiapine Fumarate|Quinpirole|Risperidone,4,PDYN|PNOC|SLC18A2|SNCA
chemical synaptic transmission,GO:0007268,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Lithium,0,
"chemical synaptic transmission, postsynaptic",GO:0099565,Parkinsonian Disorders,MESH:D020734,1,Rimonabant,0,
chemoattraction of axon,GO:0061642,Parkinson Disease,MESH:D010300,0,,1,GDNF
chemoattraction of axon,GO:0061642,"Parkinson Disease, Secondary",MESH:D010302,0,,1,GDNF
chemoattraction of axon,GO:0061642,Parkinsonian Disorders,MESH:D020734,0,,1,GDNF
chemokine (C-C motif) ligand 17 production,GO:0044809,Parkinsonian Disorders,MESH:D020734,1,Plant Extracts,0,
chemokine (C-C motif) ligand 4 production,GO:0071606,Parkinson Disease,MESH:D010300,1,Vehicle Emissions,0,
chemosensory behavior,GO:0007635,Parkinson Disease,MESH:D010300,3,Caffeine|Chlorpyrifos|Methamphetamine,0,
chemosensory behavior,GO:0007635,"Parkinson Disease, Secondary",MESH:D010302,7,Benzo(a)pyrene|Carbamazepine|Fluoxetine|Methamphetamine|Nicotine|Resveratrol|Valproic Acid,0,
chemosensory behavior,GO:0007635,Parkinsonian Disorders,MESH:D020734,4,Baclofen|Resveratrol|Rimonabant|Valproic Acid,0,
chemotaxis,GO:0006935,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
chemotaxis,GO:0006935,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
chemotaxis,GO:0006935,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,0,
chemotaxis,GO:0006935,Parkinsonian Disorders,MESH:D020734,4,Cadmium|Curcumin|Particulate Matter|Valproic Acid,0,
chitin-based cuticle development,GO:0040003,Parkinson Disease,MESH:D010300,0,,2,CPR64AA|CPR66D
chloride ion homeostasis,GO:0055064,Parkinson Disease,MESH:D010300,2,Atrazine|Permethrin,0,
chloride ion homeostasis,GO:0055064,"Parkinson Disease, Secondary",MESH:D010302,2,Atrazine|Resveratrol,0,
chloride ion homeostasis,GO:0055064,Parkinsonian Disorders,MESH:D020734,3,cypermethrin|Permethrin|Resveratrol,0,
chloride transmembrane transport,GO:1902476,Parkinson Disease,MESH:D010300,1,Ozone,0,
chloride transmembrane transport,GO:1902476,"Parkinson Disease, Secondary",MESH:D010302,1,Verapamil,0,
chloride transmembrane transport,GO:1902476,Parkinsonian Disorders,MESH:D020734,2,Phenol|Verapamil,0,
chloride transport,GO:0006821,"Parkinson Disease, Secondary",MESH:D010302,2,Nicotine|Resveratrol,0,
chloride transport,GO:0006821,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
cholecystokinin signaling pathway,GO:0038188,Parkinsonian Disorders,MESH:D020734,1,Plant Extracts,0,
cholesterol biosynthetic process,GO:0006695,Parkinson Disease,MESH:D010300,16,Caffeine|Carbon Tetrachloride|Clozapine|Eicosapentaenoic Acid|Estradiol|Lipopolysaccharides|mangiferin|Particulate Matter|Pioglitazone|Polychlorinated Biphenyls|Sirolimus|Smoke|Soot|Tea|Vehicle Emissions|Zinc,0,
cholesterol biosynthetic process,GO:0006695,"Parkinson Disease, Secondary",MESH:D010302,9,Amiodarone|Doxorubicin|geraniol|Haloperidol|Nicotine|Resveratrol|Ritonavir|Silymarin|thymoquinone,0,
cholesterol biosynthetic process,GO:0006695,Parkinsonian Disorders,MESH:D020734,22,Amiodarone|Aripiprazole|Cadmium|Clozapine|coenzyme Q10|Curcumin|Docosahexaenoic Acids|Donepezil|geraniol|Haloperidol|Lipopolysaccharides|mancozeb|Muscimol|oleuropein|Particulate Matter|Plant Extracts|Plant Preparations|Resveratrol|Rimonabant|Ritonavir|Silymarin|Zidovudine,0,
cholesterol biosynthetic process,GO:0006695,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Amiodarone|Isoproterenol,0,
cholesterol efflux,GO:0033344,Parkinsonian Disorders,MESH:D020734,1,Plant Preparations,0,
cholesterol homeostasis,GO:0042632,Parkinson Disease,MESH:D010300,14,Acrolein|Air Pollutants|Carbon Tetrachloride|Chlorpyrifos|Copper|Dicamba|Lipopolysaccharides|Manganese|Melatonin|Ozone|Particulate Matter|Permethrin|Pioglitazone|Zinc,1,MAG
cholesterol homeostasis,GO:0042632,"Parkinson Disease, Secondary",MESH:D010302,9,Doxorubicin|geraniol|Manganese|Melatonin|Nicotine|Olanzapine|Resveratrol|Silymarin|thymoquinone,0,
cholesterol homeostasis,GO:0042632,Parkinsonian Disorders,MESH:D020734,13,Curcumin|cypermethrin|geraniol|Lipopolysaccharides|Manganese|Melatonin|Olanzapine|Particulate Matter|Permethrin|Plant Extracts|Plant Preparations|Resveratrol|Silymarin,0,
cholesterol metabolic process,GO:0008203,Parkinson Disease,MESH:D010300,25,"4-phenylbutyric acid|Acrolein|Air Pollutants|Aspirin|Atrazine|Caffeine|Carbon Tetrachloride|Chlorpyrifos|Ditiocarb|Estradiol|Hydrocarbons, Chlorinated|Iron|Lead|Lipopolysaccharides|mangiferin|Melatonin|Organophosphorus Compounds|Ozone|Particulate Matter|Permethrin|Pesticides|Pioglitazone|Polychlorinated Biphenyls|Sirolimus|Ziram",2,CYP2D6|GBA1
cholesterol metabolic process,GO:0008203,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
cholesterol metabolic process,GO:0008203,"Parkinson Disease, Secondary",MESH:D010302,19,"3-methyladenine|Amiodarone|Atrazine|Benzo(a)pyrene|Ditiocarb|Doxorubicin|geraniol|Hydrocarbons, Chlorinated|Lamotrigine|Melatonin|Nicotine|Organophosphorus Compounds|Pesticides|Resveratrol|Ribavirin|Silymarin|thymoquinone|Valproic Acid|Ziram",1,PON1
cholesterol metabolic process,GO:0008203,Parkinsonian Disorders,MESH:D020734,18,Amiodarone|Amphotericin B|Cadmium|coenzyme Q10|crocin|Curcumin|cypermethrin|geraniol|Indomethacin|Lipopolysaccharides|mancozeb|Melatonin|Particulate Matter|Permethrin|Plant Extracts|Resveratrol|Silymarin|Valproic Acid,1,GBA1
cholesterol metabolic process,GO:0008203,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Amiodarone|Isoproterenol,0,
choline biosynthetic process,GO:0042425,Parkinson Disease,MESH:D010300,1,Endosulfan,0,
choline metabolic process,GO:0019695,Parkinson Disease,MESH:D010300,2,Atrazine|Lead,0,
choline metabolic process,GO:0019695,"Parkinson Disease, Secondary",MESH:D010302,2,Atrazine|geraniol,1,BCHE
choline metabolic process,GO:0019695,Parkinsonian Disorders,MESH:D020734,2,geraniol|Indomethacin,0,
choline transport,GO:0015871,Parkinson Disease,MESH:D010300,2,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium",0,
choline transport,GO:0015871,"Parkinson Disease, Secondary",MESH:D010302,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
choline transport,GO:0015871,Parkinsonian Disorders,MESH:D020734,3,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Clonidine",0,
choline transport,GO:0015871,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Procainamide,0,
chondrocyte development,GO:0002063,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
chondrocyte differentiation,GO:0002062,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
chondrocyte differentiation,GO:0002062,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
chondrocyte hypertrophy,GO:0003415,Parkinson Disease,MESH:D010300,1,4-phenylbutyric acid,0,
chondrocyte proliferation,GO:0035988,Parkinson Disease,MESH:D010300,1,4-phenylbutyric acid,0,
chondroitin sulfate biosynthetic process,GO:0030206,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
chordate embryonic development,GO:0043009,Parkinson Disease,MESH:D010300,0,,2,ATP13A2|RPL6
chordate embryonic development,GO:0043009,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ATP13A2
chordate embryonic development,GO:0043009,Parkinsonian Disorders,MESH:D020734,0,,1,ATP13A2
chorion development,GO:0060717,Parkinson Disease,MESH:D010300,1,Melatonin,0,
chorion development,GO:0060717,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
chorion development,GO:0060717,Parkinsonian Disorders,MESH:D020734,1,Melatonin,0,
chorionic trophoblast cell differentiation,GO:0060718,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
chromatin organization,GO:0006325,Parkinson Disease,MESH:D010300,3,1-Methyl-4-phenylpyridinium|Carbon Tetrachloride|Lead,0,
chromatin organization,GO:0006325,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
chromatin organization,GO:0006325,Parkinsonian Disorders,MESH:D020734,2,1-Methyl-4-phenylpyridinium|Resveratrol,0,
chromatin remodeling,GO:0006338,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
chromatin remodeling,GO:0006338,Parkinson Disease,MESH:D010300,2,Melatonin|Permethrin,5,GAK|LRRK2|MAP2|MTA1|PINK1
chromatin remodeling,GO:0006338,"PARKINSON DISEASE 19A, JUVENILE-ONSET",OMIM:615528,0,,1,DNAJC6
chromatin remodeling,GO:0006338,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
chromatin remodeling,GO:0006338,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
chromatin remodeling,GO:0006338,"Parkinson Disease, Secondary",MESH:D010302,2,Doxorubicin|Melatonin,0,
chromatin remodeling,GO:0006338,Parkinsonian Disorders,MESH:D020734,2,Melatonin|Permethrin,2,LRRK2|PINK1
chromosome condensation,GO:0030261,Parkinson Disease,MESH:D010300,2,1-Methyl-4-phenylpyridinium|Oxidopamine,1,NCAPG2
chromosome condensation,GO:0030261,"Parkinson Disease, Secondary",MESH:D010302,1,Oxidopamine,0,
chromosome condensation,GO:0030261,Parkinsonian Disorders,MESH:D020734,3,1-Methyl-4-phenylpyridinium|Oxidopamine|Plant Extracts,0,
chromosome organization,GO:0051276,Parkinson Disease,MESH:D010300,2,Methamphetamine|Permethrin,0,
chromosome organization,GO:0051276,"Parkinson Disease, Secondary",MESH:D010302,3,Methamphetamine|Methotrexate|Oxcarbazepine,0,
chromosome organization,GO:0051276,Parkinsonian Disorders,MESH:D020734,1,Permethrin,0,
chromosome segregation,GO:0007059,Parkinson Disease,MESH:D010300,1,Paclitaxel,0,
chromosome segregation,GO:0007059,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
chronic inflammatory response,GO:0002544,Parkinson Disease,MESH:D010300,0,,1,BDNF
chronic inflammatory response to antigenic stimulus,GO:0002439,Parkinson Disease,MESH:D010300,0,,1,TNF
cilium disassembly,GO:0061523,Parkinsonian Disorders,MESH:D020734,1,Malondialdehyde,0,
cilium organization,GO:0044782,Parkinson Disease,MESH:D010300,0,,1,NECTIN2
circadian behavior,GO:0048512,Parkinson Disease,MESH:D010300,0,,1,BDNF
circadian regulation of gene expression,GO:0032922,Parkinson Disease,MESH:D010300,2,Melatonin|Rotenone,3,DRD2|MTA1|PPARGC1A
circadian regulation of gene expression,GO:0032922,"Parkinson Disease, Secondary",MESH:D010302,4,Melatonin|Resveratrol|Rotenone|Valproic Acid,0,
circadian regulation of gene expression,GO:0032922,Parkinsonian Disorders,MESH:D020734,4,Melatonin|Resveratrol|Rotenone|Valproic Acid,1,DRD2
circadian rhythm,GO:0007623,Parkinson Disease,MESH:D010300,0,,4,BDNF|DDC|NGF|TNF
circadian rhythm,GO:0007623,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
circadian rhythm,GO:0007623,Parkinsonian Disorders,MESH:D020734,0,,4,ATP1A3|DDC|NGF|PRL
circadian sleep/wake cycle,GO:0042745,Parkinson Disease,MESH:D010300,0,,2,CNTNAP2|TH
circadian sleep/wake cycle,GO:0042745,Parkinsonian Disorders,MESH:D020734,0,,1,TH
"circadian sleep/wake cycle, sleep",GO:0050802,Parkinson Disease,MESH:D010300,1,Melatonin,0,
"circadian sleep/wake cycle, sleep",GO:0050802,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
"circadian sleep/wake cycle, sleep",GO:0050802,Parkinsonian Disorders,MESH:D020734,1,Melatonin,0,
"circadian sleep/wake cycle, wakefulness",GO:0042746,Parkinson Disease,MESH:D010300,1,Melatonin,0,
"circadian sleep/wake cycle, wakefulness",GO:0042746,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
"circadian sleep/wake cycle, wakefulness",GO:0042746,Parkinsonian Disorders,MESH:D020734,1,Melatonin,0,
circulatory system development,GO:0072359,Parkinson Disease,MESH:D010300,3,Air Pollutants|Melatonin|Particulate Matter,0,
circulatory system development,GO:0072359,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
circulatory system development,GO:0072359,Parkinsonian Disorders,MESH:D020734,2,Melatonin|Particulate Matter,0,
citrate metabolic process,GO:0006101,"Parkinson Disease, Secondary",MESH:D010302,2,Doxorubicin|Resveratrol,0,
citrate metabolic process,GO:0006101,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
citrate transport,GO:0015746,"Parkinson Disease, Secondary",MESH:D010302,2,Benzo(a)pyrene|Doxorubicin,0,
citrulline biosynthetic process,GO:0019240,Parkinson Disease,MESH:D010300,1,Polychlorinated Biphenyls,0,
citrulline metabolic process,GO:0000052,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
citrulline metabolic process,GO:0000052,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
clathrin coat assembly,GO:0048268,Parkinson Disease,MESH:D010300,0,,1,GAK
clathrin coat disassembly,GO:0072318,Parkinson Disease,MESH:D010300,0,,1,GAK
clathrin coat disassembly,GO:0072318,"PARKINSON DISEASE 19A, JUVENILE-ONSET",OMIM:615528,0,,1,DNAJC6
clathrin-dependent endocytosis,GO:0072583,Parkinson Disease,MESH:D010300,0,,1,GAK
clathrin-dependent endocytosis,GO:0072583,"PARKINSON DISEASE 19A, JUVENILE-ONSET",OMIM:615528,0,,1,DNAJC6
clustering of voltage-gated potassium channels,GO:0045163,Parkinson Disease,MESH:D010300,0,,1,CNTNAP2
cobalamin metabolic process,GO:0009235,Parkinsonian Disorders,MESH:D020734,1,Curcumin,0,
cocaine metabolic process,GO:0050783,"Parkinson Disease, Secondary",MESH:D010302,0,,1,BCHE
coenzyme A metabolic process,GO:0015936,Parkinson Disease,MESH:D010300,2,Air Pollutants|Particulate Matter,0,
coenzyme A metabolic process,GO:0015936,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
cognition,GO:0050890,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
cognition,GO:0050890,Parkinson Disease,MESH:D010300,25,"Air Pollutants|Aluminum|beta-N-methylamino-L-alanine|Carbidopa|Chlorpyrifos|Diazinon|Fungicides, Industrial|Lead|Levodopa|Lipopolysaccharides|Manganese|Melatonin|Methamphetamine|Nitrogen Dioxide|nootkatone|Organophosphates|Particulate Matter|Pesticides|Pioglitazone|Polychlorinated Biphenyls|Reserpine|Rotenone|Sirolimus|Soot|Vehicle Emissions",6,BDNF|HLA-DRA|INS|SLC6A3|TH|TNF
cognition,GO:0050890,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
cognition,GO:0050890,"Parkinson Disease, Secondary",MESH:D010302,12,Benzo(a)pyrene|Carbidopa|Carbon Monoxide|Levodopa|Manganese|Melatonin|Methamphetamine|Nicotine|Pesticides|Reserpine|Rotenone|thymoquinone,0,
cognition,GO:0050890,Parkinsonian Disorders,MESH:D020734,11,Cadmium|Carbidopa|Curcumin|Donepezil|Levodopa|Lipopolysaccharides|Manganese|Melatonin|Particulate Matter|Reserpine|Rotenone,2,ATP1A3|TH
cognition,GO:0050890,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
collagen-activated tyrosine kinase receptor signaling pathway,GO:0038063,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
collagen biosynthetic process,GO:0032964,Parkinson Disease,MESH:D010300,8,Carbon Tetrachloride|Coffee|Melatonin|Paraquat|Particulate Matter|Sirolimus|Vehicle Emissions|Zinc,0,
collagen biosynthetic process,GO:0032964,"Parkinson Disease, Secondary",MESH:D010302,6,Amiodarone|Doxorubicin|Melatonin|Paraquat|Resveratrol|thymoquinone,0,
collagen biosynthetic process,GO:0032964,Parkinsonian Disorders,MESH:D020734,8,Amiodarone|Cadmium|Coffee|crocin|Melatonin|Paraquat|Particulate Matter|Resveratrol,0,
collagen biosynthetic process,GO:0032964,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Amiodarone|Isoproterenol,0,
collagen catabolic process,GO:0030574,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
collagen catabolic process,GO:0030574,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
collagen fibril organization,GO:0030199,Parkinson Disease,MESH:D010300,18,Air Pollutants|Atrazine|Carbon Tetrachloride|Eugenol|Herbicides|Lead|Lipopolysaccharides|Lithium|Lithium Carbonate|Melatonin|Methamphetamine|Paraquat|Particulate Matter|Permethrin|Pioglitazone|Sirolimus|Soot|Vehicle Emissions,1,COL19A1
collagen fibril organization,GO:0030199,"Parkinson Disease, Secondary",MESH:D010302,12,Amiodarone|Atrazine|Doxorubicin|Lithium|Lithium Carbonate|Melatonin|Methamphetamine|Nicotine|Paraquat|Resveratrol|Valproic Acid|Vincristine,0,
collagen fibril organization,GO:0030199,Parkinsonian Disorders,MESH:D020734,12,Amiodarone|baicalin|Cadmium|crocin|Curcumin|Lipopolysaccharides|Melatonin|Paraquat|Particulate Matter|Permethrin|Resveratrol|Valproic Acid,0,
collagen fibril organization,GO:0030199,Wolff-Parkinson-White Syndrome,MESH:D014927,3,Amiodarone|Isoproterenol|Lithium,0,
collagen metabolic process,GO:0032963,Parkinson Disease,MESH:D010300,2,Carbon Tetrachloride|Particulate Matter,0,
collagen metabolic process,GO:0032963,"Parkinson Disease, Secondary",MESH:D010302,1,Silymarin,0,
collagen metabolic process,GO:0032963,Parkinsonian Disorders,MESH:D020734,2,Particulate Matter|Silymarin,1,PRKCD
collagen metabolic process,GO:0032963,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
collateral sprouting,GO:0048668,Parkinson Disease,MESH:D010300,0,,2,BDNF|NOS1
columnar/cuboidal epithelial cell maturation,GO:0002069,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
columnar/cuboidal epithelial cell maturation,GO:0002069,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
commissural neuron axon guidance,GO:0071679,Parkinson Disease,MESH:D010300,0,,1,GDNF
commissural neuron axon guidance,GO:0071679,"Parkinson Disease, Secondary",MESH:D010302,0,,2,GDNF|SHH
commissural neuron axon guidance,GO:0071679,Parkinsonian Disorders,MESH:D020734,0,,1,GDNF
commissural neuron differentiation in spinal cord,GO:0021528,Parkinson Disease,MESH:D010300,0,,1,DRAXIN
common myeloid progenitor cell proliferation,GO:0035726,Parkinson Disease,MESH:D010300,0,,1,GSTP1
compound eye development,GO:0048749,Parkinson Disease,MESH:D010300,0,,1,PINK1
compound eye development,GO:0048749,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
compound eye development,GO:0048749,Parkinsonian Disorders,MESH:D020734,0,,1,PINK1
compound eye development,GO:0048749,"PARKINSONISM WITH SPASTICITY, X-LINKED",OMIM:300911,0,,1,ATP6AP2
compound eye pigmentation,GO:0048072,Parkinson Disease,MESH:D010300,0,,1,RAB32
conditioned place preference,GO:1990708,Parkinson Disease,MESH:D010300,1,Methamphetamine,1,BDNF
conditioned place preference,GO:1990708,"Parkinson Disease, Secondary",MESH:D010302,1,Methamphetamine,0,
conditioned taste aversion,GO:0001661,Parkinson Disease,MESH:D010300,0,,1,DRD1
conditioned taste aversion,GO:0001661,Parkinsonian Disorders,MESH:D020734,1,Rimonabant,0,
copper ion homeostasis,GO:0055070,Parkinson Disease,MESH:D010300,2,Copper|Manganese,0,
copper ion homeostasis,GO:0055070,"Parkinson Disease, Secondary",MESH:D010302,1,Manganese,0,
copper ion homeostasis,GO:0055070,Parkinsonian Disorders,MESH:D020734,4,Cadmium|coenzyme Q10|Manganese|manganese chloride,0,
copper ion import across plasma membrane,GO:0098705,Parkinson Disease,MESH:D010300,1,Ziram,0,
copper ion import across plasma membrane,GO:0098705,"Parkinson Disease, Secondary",MESH:D010302,1,Ziram,0,
copper ion transport,GO:0006825,Parkinson Disease,MESH:D010300,1,Manganese,0,
copper ion transport,GO:0006825,"Parkinson Disease, Secondary",MESH:D010302,1,Manganese,0,
copper ion transport,GO:0006825,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Manganese,0,
coreceptor-mediated virion attachment to host cell,GO:0046814,Parkinson Disease,MESH:D010300,0,,1,NECTIN2
corpus callosum development,GO:0022038,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
corpus callosum development,GO:0022038,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
cortical actin cytoskeleton organization,GO:0030866,Parkinson Disease,MESH:D010300,0,,1,TNF
corticosterone secretion,GO:0035934,Parkinson Disease,MESH:D010300,2,Caffeine|Eicosapentaenoic Acid,0,
corticosterone secretion,GO:0035934,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Indomethacin,0,
cortisol biosynthetic process,GO:0034651,Parkinson Disease,MESH:D010300,1,Polychlorinated Biphenyls,0,
cortisol biosynthetic process,GO:0034651,"Parkinson Disease, Secondary",MESH:D010302,2,Fluoxetine|Venlafaxine Hydrochloride,0,
cortisol metabolic process,GO:0034650,Parkinson Disease,MESH:D010300,1,Lead,0,
cortisol metabolic process,GO:0034650,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
coumarin metabolic process,GO:0009804,Parkinson Disease,MESH:D010300,0,,1,CYP2D6
cranial skeletal system development,GO:1904888,Parkinson Disease,MESH:D010300,0,,1,EDN1
cranial skeletal system development,GO:1904888,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,0,
cranial skeletal system development,GO:1904888,Parkinsonian Disorders,MESH:D020734,1,Valproic Acid,0,
creatine biosynthetic process,GO:0006601,Parkinson Disease,MESH:D010300,3,1-Methyl-4-phenylpyridinium|Endosulfan|Sirolimus,0,
creatine biosynthetic process,GO:0006601,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
creatine biosynthetic process,GO:0006601,Parkinsonian Disorders,MESH:D020734,5,1-Methyl-4-phenylpyridinium|Creatine|Curcumin|oleuropein|Plant Extracts,0,
creatine metabolic process,GO:0006600,Parkinson Disease,MESH:D010300,1,Lead,0,
creatine metabolic process,GO:0006600,"Parkinson Disease, Secondary",MESH:D010302,2,Doxorubicin|Ribavirin,0,
creatine metabolic process,GO:0006600,Parkinsonian Disorders,MESH:D020734,4,Creatine|Curcumin|Indomethacin|Plant Extracts,0,
creatinine catabolic process,GO:0006602,Parkinsonian Disorders,MESH:D020734,1,manganese chloride,0,
creatinine metabolic process,GO:0046449,Parkinson Disease,MESH:D010300,23,4-phenylbutyric acid|Air Pollutants|Atrazine|Carbidopa|Carbon Tetrachloride|Chlorpyrifos|Dicamba|Lead|Lipopolysaccharides|Lithium Carbonate|mangiferin|Melatonin|Methamphetamine|Ozone|Paraquat|Particulate Matter|Pentoxifylline|Phorate|Pioglitazone|Probenecid|Rotenone|Trichloroethylene|Vehicle Emissions,0,
creatinine metabolic process,GO:0046449,"Parkinson Disease, Secondary",MESH:D010302,21,Amlodipine|Atrazine|Benzo(a)pyrene|Carbidopa|Doxorubicin|Lithium Carbonate|Melatonin|Methamphetamine|Methotrexate|Nifedipine|Paraquat|Resveratrol|Ribavirin|Rotenone|Silymarin|sodium bisulfide|thymoquinone|Trichloroethylene|Valproic Acid|Venlafaxine Hydrochloride|Verapamil,0,
creatinine metabolic process,GO:0046449,Parkinsonian Disorders,MESH:D020734,22,Amlodipine|baicalin|Cadmium|Carbidopa|coenzyme Q10|Creatine|crocin|Curcumin|Indomethacin|Lipopolysaccharides|Melatonin|Paraquat|Particulate Matter|Plant Extracts|Plant Preparations|Probenecid|Resveratrol|Rotenone|Silymarin|taxifolin|Valproic Acid|Verapamil,0,
cuticle hydrocarbon biosynthetic process,GO:0006723,Parkinson Disease,MESH:D010300,0,,1,CPR
cyclooxygenase pathway,GO:0019371,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
cyclooxygenase pathway,GO:0019371,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
cyclooxygenase pathway,GO:0019371,Parkinsonian Disorders,MESH:D020734,3,Indomethacin|Lipopolysaccharides|Resveratrol,0,
cysteine biosynthetic process,GO:0019344,Parkinson Disease,MESH:D010300,3,Chlorpyrifos|Paraquat|Permethrin,0,
cysteine biosynthetic process,GO:0019344,"Parkinson Disease, Secondary",MESH:D010302,1,Paraquat,0,
cysteine biosynthetic process,GO:0019344,Parkinsonian Disorders,MESH:D020734,2,Paraquat|Permethrin,0,
cysteine metabolic process,GO:0006534,Parkinson Disease,MESH:D010300,1,Atrazine,0,
cysteine metabolic process,GO:0006534,"Parkinson Disease, Secondary",MESH:D010302,2,Atrazine|Benzo(a)pyrene,0,
cysteine metabolic process,GO:0006534,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
cytidine biosynthetic process,GO:0046088,Parkinson Disease,MESH:D010300,1,Polychlorinated Biphenyls,0,
cytokine-mediated signaling pathway,GO:0019221,Parkinson Disease,MESH:D010300,2,Nitrogen Dioxide|Particulate Matter,1,IL6
cytokine-mediated signaling pathway,GO:0019221,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
cytokine production,GO:0001816,Parkinson Disease,MESH:D010300,2,Insecticides|Polychlorinated Biphenyls,1,NQO1
cytokine production involved in immune response,GO:0002367,Parkinson Disease,MESH:D010300,4,Atrazine|Nitrogen Dioxide|Ozone|Particulate Matter,0,
cytokine production involved in immune response,GO:0002367,"Parkinson Disease, Secondary",MESH:D010302,2,Atrazine|Carbon Monoxide,0,
cytokine production involved in immune response,GO:0002367,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
cytokine production involved in inflammatory response,GO:0002534,Parkinson Disease,MESH:D010300,11,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Air Pollutants|Iron|Lead|Lipopolysaccharides|Manganese|Ozone|Particulate Matter|Soot|Vehicle Emissions|Zinc",0,
cytokine production involved in inflammatory response,GO:0002534,"Parkinson Disease, Secondary",MESH:D010302,3,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Manganese|Poly I-C",0,
cytokine production involved in inflammatory response,GO:0002534,Parkinsonian Disorders,MESH:D020734,6,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Curcumin|ginsenoside Re|Lipopolysaccharides|Manganese|Particulate Matter",0,
cytokinesis,GO:0000910,Parkinson Disease,MESH:D010300,1,Paclitaxel,0,
cytokinetic process,GO:0032506,Parkinson Disease,MESH:D010300,2,Herbicides|Insecticides,0,
cytolysis,GO:0019835,Parkinson Disease,MESH:D010300,3,Lipopolysaccharides|Ozone|Paraquat,0,
cytolysis,GO:0019835,"Parkinson Disease, Secondary",MESH:D010302,1,Paraquat,0,
cytolysis,GO:0019835,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Paraquat,0,
cytoplasmic microtubule organization,GO:0031122,Parkinson Disease,MESH:D010300,2,"2,4,5-Trichlorophenoxyacetic Acid|Paclitaxel",1,MAPT
cytoplasmic microtubule organization,GO:0031122,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
cytoplasmic microtubule organization,GO:0031122,Parkinsonian Disorders,MESH:D020734,0,,2,DCTN1|MAPT
cytoplasmic sequestering of NF-kappaB,GO:0007253,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
cytoplasmic sequestering of NF-kappaB,GO:0007253,"Parkinson Disease, Secondary",MESH:D010302,2,Resveratrol|Silymarin,0,
cytoplasmic sequestering of NF-kappaB,GO:0007253,Parkinsonian Disorders,MESH:D020734,3,Lipopolysaccharides|Resveratrol|Silymarin,0,
cytoplasmic sequestering of NF-kappaB,GO:0007253,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
cytoplasmic translation,GO:0002181,Parkinson Disease,MESH:D010300,0,,4,RPL14|RPL23A|RPL6|RPS8
cytoplasm protein quality control by the ubiquitin-proteasome system,GO:0071629,Parkinson Disease,MESH:D010300,8,Benomyl|cyanazine|Dieldrin|Endosulfan|methyldithiocarbamate|Omite|triflumizol|Ziram,0,
cytoplasm protein quality control by the ubiquitin-proteasome system,GO:0071629,"Parkinson Disease, Secondary",MESH:D010302,2,Dieldrin|Ziram,0,
cytosine metabolic process,GO:0019858,Parkinson Disease,MESH:D010300,1,Polychlorinated Biphenyls,0,
cytosine metabolic process,GO:0019858,"Parkinson Disease, Secondary",MESH:D010302,1,Ribavirin,0,
cytosine metabolic process,GO:0019858,Parkinsonian Disorders,MESH:D020734,1,Indomethacin,0,
"cytoskeletal rearrangement involved in phagocytosis, engulfment",GO:0060097,Parkinson Disease,MESH:D010300,2,Particulate Matter|Vehicle Emissions,0,
"cytoskeletal rearrangement involved in phagocytosis, engulfment",GO:0060097,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
cytoskeleton organization,GO:0007010,Parkinson Disease,MESH:D010300,1,Soot,1,NECTIN2
D-aspartate import across plasma membrane,GO:0070779,Parkinson Disease,MESH:D010300,0,,1,GFAP
D-aspartate import across plasma membrane,GO:0070779,Parkinsonian Disorders,MESH:D020734,0,,1,PRKCD
deactivation of rhodopsin mediated signaling,GO:0016059,Parkinson Disease,MESH:D010300,0,,1,RDGA
decidualization,GO:0046697,Parkinson Disease,MESH:D010300,3,Copper|Estradiol|Lead,0,
decidualization,GO:0046697,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
decidualization,GO:0046697,Parkinsonian Disorders,MESH:D020734,1,cypermethrin,1,PARP1
defecation,GO:0030421,Parkinson Disease,MESH:D010300,1,Methamphetamine,0,
defecation,GO:0030421,"Parkinson Disease, Secondary",MESH:D010302,1,Methamphetamine,0,
defecation rhythm,GO:0035882,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|mangiferin,0,
defecation rhythm,GO:0035882,"Parkinson Disease, Secondary",MESH:D010302,1,Verapamil,0,
defecation rhythm,GO:0035882,Parkinsonian Disorders,MESH:D020734,2,Clonidine|Verapamil,0,
defense response,GO:0006952,Parkinson Disease,MESH:D010300,0,,2,HSPA1A|TNF
defense response to bacterium,GO:0042742,Parkinson Disease,MESH:D010300,0,,4,DEFA4|FCER2|MAP3K5|TNF
defense response to bacterium,GO:0042742,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
defense response to bacterium,GO:0042742,Parkinsonian Disorders,MESH:D020734,0,,1,PRKCD
defense response to fungus,GO:0050832,Parkinson Disease,MESH:D010300,0,,1,DEFA4
defense response to fungus,GO:0050832,Parkinsonian Disorders,MESH:D020734,0,,1,GAPDH
defense response to Gram-negative bacterium,GO:0050829,Parkinson Disease,MESH:D010300,0,,2,DEFA4|IL6
defense response to Gram-negative bacterium,GO:0050829,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,1,NOS2
defense response to Gram-negative bacterium,GO:0050829,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
defense response to Gram-positive bacterium,GO:0050830,Parkinson Disease,MESH:D010300,2,Air Pollutants|Particulate Matter,3,DEFA4|IL6|TNF
defense response to Gram-positive bacterium,GO:0050830,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
defense response to Gram-positive bacterium,GO:0050830,Parkinsonian Disorders,MESH:D020734,2,Particulate Matter|Resveratrol,0,
defense response to protozoan,GO:0042832,Parkinson Disease,MESH:D010300,0,,1,IL6
defense response to protozoan,GO:0042832,Parkinsonian Disorders,MESH:D020734,1,ginsenoside Re,0,
defense response to virus,GO:0051607,Parkinson Disease,MESH:D010300,1,Particulate Matter,2,DDIT4|IL6
defense response to virus,GO:0051607,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
dehydroascorbic acid transport,GO:0070837,Parkinson Disease,MESH:D010300,0,,1,SLC2A14
dehydroepiandrosterone secretion,GO:0035942,Parkinsonian Disorders,MESH:D020734,1,Docosahexaenoic Acids,0,
dendrite arborization,GO:0140059,Parkinson Disease,MESH:D010300,2,Particulate Matter|Sirolimus,1,CNTNAP2
dendrite arborization,GO:0140059,"Parkinson Disease, Secondary",MESH:D010302,2,Nicotine|Valproic Acid,0,
dendrite arborization,GO:0140059,Parkinsonian Disorders,MESH:D020734,2,Particulate Matter|Valproic Acid,0,
dendrite development,GO:0016358,Parkinson Disease,MESH:D010300,3,Chlorpyrifos|Estradiol|Lead,2,BDNF|MAP2
dendrite extension,GO:0097484,Parkinson Disease,MESH:D010300,3,Estradiol|Oxidopamine|Particulate Matter,1,BDNF
dendrite extension,GO:0097484,"Parkinson Disease, Secondary",MESH:D010302,2,Oxidopamine|Resveratrol,0,
dendrite extension,GO:0097484,Parkinsonian Disorders,MESH:D020734,3,Oxidopamine|Particulate Matter|Resveratrol,0,
dendrite morphogenesis,GO:0048813,Parkinson Disease,MESH:D010300,0,,1,MAP2
dendritic cell chemotaxis,GO:0002407,Parkinson Disease,MESH:D010300,0,,1,TRPM2
dendritic cell differentiation,GO:0097028,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,1,TRPM2
dendritic cell differentiation,GO:0097028,"Parkinson Disease, Secondary",MESH:D010302,1,Poly I-C,0,
dendritic cell differentiation,GO:0097028,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Plant Preparations,0,
dendritic cell homeostasis,GO:0036145,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
dendritic cell migration,GO:0036336,Parkinson Disease,MESH:D010300,3,Melatonin|Particulate Matter|Vehicle Emissions,0,
dendritic cell migration,GO:0036336,"Parkinson Disease, Secondary",MESH:D010302,2,Doxorubicin|Melatonin,0,
dendritic cell migration,GO:0036336,Parkinsonian Disorders,MESH:D020734,2,Melatonin|Particulate Matter,0,
dendritic cell proliferation,GO:0044565,Parkinson Disease,MESH:D010300,1,4-phenylbutyric acid,0,
dendritic spine development,GO:0060996,Parkinson Disease,MESH:D010300,4,Estradiol|Lead|Lithium|Methamphetamine,1,CNTNAP2
dendritic spine development,GO:0060996,"Parkinson Disease, Secondary",MESH:D010302,2,Lithium|Methamphetamine,0,
dendritic spine development,GO:0060996,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Lithium,0,
dendritic spine maintenance,GO:0097062,Parkinson Disease,MESH:D010300,2,Lead|Methamphetamine,3,CNTNAP2|IGF1R|INSR
dendritic spine maintenance,GO:0097062,"Parkinson Disease, Secondary",MESH:D010302,1,Methamphetamine,0,
dendritic spine morphogenesis,GO:0060997,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
dendritic spine morphogenesis,GO:0060997,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
dendritic spine organization,GO:0097061,Parkinson Disease,MESH:D010300,0,,1,CNTNAP2
dentate gyrus development,GO:0021542,Parkinson Disease,MESH:D010300,0,,1,DRD1
dentate gyrus development,GO:0021542,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,0,
dentate gyrus development,GO:0021542,Parkinsonian Disorders,MESH:D020734,1,Valproic Acid,0,
deoxycytidine metabolic process,GO:0046092,Parkinsonian Disorders,MESH:D020734,1,Indomethacin,0,
deoxyguanosine metabolic process,GO:0042453,Parkinson Disease,MESH:D010300,1,Iron,0,
deoxyguanosine metabolic process,GO:0042453,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
deoxyribonucleoside metabolic process,GO:0009120,Parkinsonian Disorders,MESH:D020734,1,Indomethacin,0,
deoxyuridine metabolic process,GO:0046096,Parkinson Disease,MESH:D010300,1,1-Methyl-4-phenylpyridinium,0,
deoxyuridine metabolic process,GO:0046096,Parkinsonian Disorders,MESH:D020734,1,1-Methyl-4-phenylpyridinium,0,
dephosphorylation,GO:0016311,Parkinson Disease,MESH:D010300,0,,2,FBP1|GAK
dephosphorylation,GO:0016311,"PARKINSON DISEASE 19A, JUVENILE-ONSET",OMIM:615528,0,,1,DNAJC6
dermatan sulfate biosynthetic process,GO:0030208,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
detection of chemical stimulus involved in sensory perception,GO:0050907,"Parkinson Disease, Secondary",MESH:D010302,1,geraniol,0,
detection of chemical stimulus involved in sensory perception,GO:0050907,Parkinsonian Disorders,MESH:D020734,1,geraniol,0,
detection of chemical stimulus involved in sensory perception of bitter taste,GO:0001580,Parkinson Disease,MESH:D010300,1,Probenecid,0,
detection of chemical stimulus involved in sensory perception of bitter taste,GO:0001580,Parkinsonian Disorders,MESH:D020734,1,Probenecid,0,
detection of chemical stimulus involved in sensory perception of pain,GO:0050968,Parkinson Disease,MESH:D010300,1,mangiferin,0,
detection of increased carbon dioxide by carotid body chemoreceptor signaling,GO:0003035,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
detection of mechanical stimulus involved in sensory perception,GO:0050974,Parkinson Disease,MESH:D010300,1,Lead,0,
detection of mechanical stimulus involved in sensory perception of pain,GO:0050966,Parkinson Disease,MESH:D010300,4,Dopamine|Ketoconazole|Nitric Oxide|Paclitaxel,1,TNF
detection of mechanical stimulus involved in sensory perception of pain,GO:0050966,Parkinsonian Disorders,MESH:D020734,5,coenzyme Q10|Dopamine|Indomethacin|Ketoconazole|Rimonabant,0,
detection of oxidative stress,GO:0070994,Parkinson Disease,MESH:D010300,53,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Acrolein|Air Pollutants|Aluminum|Aspirin|Atrazine|Benomyl|Carbidopa|carbidopa, levodopa drug combination|Carbon Tetrachloride|Chlorpyrifos|Clozapine|Copper|Diazinon|Eicosapentaenoic Acid|Endosulfan|Estradiol|Eugenol|Glutathione Disulfide|Hexachlorocyclohexane|Homocysteine|Iron|Ketoconazole|Lead|Levodopa|Lipid Peroxides|Lipofuscin|Lipopolysaccharides|Manganese|Melatonin|Methamphetamine|Methyldopa|Mirtazapine|Nitric Oxide|Nitrites|Ozone|Paclitaxel|Paraquat|Particulate Matter|pendimethalin|Permethrin|Pioglitazone|Reactive Oxygen Species|Reserpine|Rivastigmine|ropinirole|Rotenone|Sirolimus|Trichloroethylene|Vehicle Emissions|Water Pollutants, Chemical|Zinc",1,PARK7
detection of oxidative stress,GO:0070994,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
detection of oxidative stress,GO:0070994,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
detection of oxidative stress,GO:0070994,"Parkinson Disease, Secondary",MESH:D010302,38,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|3-methyladenine|Amiodarone|Amlodipine|Atrazine|Benzo(a)pyrene|Buspirone|Carbamazepine|Carbidopa|carbidopa, levodopa drug combination|Chlorpromazine|Cytarabine|Dichlorvos|Doxorubicin|Famotidine|Fluoxetine|geraniol|Lamotrigine|Levodopa|Manganese|Melatonin|Methamphetamine|Methotrexate|Methyldopa|Nicotine|Nifedipine|Paraquat|Phenytoin|Reserpine|Resveratrol|Ritonavir|Rotenone|Silymarin|sodium bisulfide|Trichloroethylene|Valproic Acid|Verapamil|Vincristine",0,
detection of oxidative stress,GO:0070994,Parkinsonian Disorders,MESH:D020734,47,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|4-hydroxy-2-nonenal|Amiodarone|Amitriptyline|Amlodipine|baicalin|Buspirone|Cadmium|Carbidopa|carbidopa, levodopa drug combination|Chlorpromazine|Clonidine|Clozapine|coenzyme Q10|Curcumin|cypermethrin|Disulfiram|Docosahexaenoic Acids|Donepezil|Felbamate|geraniol|ginsenoside Re|Indomethacin|Ketoconazole|Levodopa|Lipopolysaccharides|Malondialdehyde|Manganese|manganese chloride|Melatonin|Paraquat|Particulate Matter|Permethrin|Plant Extracts|Plant Preparations|Reserpine|Resveratrol|Ritonavir|Rivastigmine|ropinirole|Rotenone|Silymarin|taxifolin|Valproic Acid|Verapamil|Zidovudine",1,PARK7
detection of oxidative stress,GO:0070994,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Amiodarone|Isoproterenol,0,
detection of oxygen,GO:0003032,Parkinson Disease,MESH:D010300,0,,1,SOD2
detection of temperature stimulus involved in sensory perception of pain,GO:0050965,Parkinson Disease,MESH:D010300,2,Ketoconazole|Paclitaxel,0,
detection of temperature stimulus involved in sensory perception of pain,GO:0050965,"Parkinson Disease, Secondary",MESH:D010302,2,Carbon Monoxide|Vincristine,0,
detection of temperature stimulus involved in sensory perception of pain,GO:0050965,Parkinsonian Disorders,MESH:D020734,3,coenzyme Q10|Ketoconazole|Rimonabant,0,
detection of visible light,GO:0009584,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
determination of adult lifespan,GO:0008340,Parkinson Disease,MESH:D010300,5,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Endosulfan|Paraquat|Particulate Matter|Sirolimus",4,GBA1|LRRK2|SOD1|SOD2
determination of adult lifespan,GO:0008340,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
determination of adult lifespan,GO:0008340,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
determination of adult lifespan,GO:0008340,"Parkinson Disease, Secondary",MESH:D010302,5,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Dichlorvos|Mianserin|Paraquat|Resveratrol",0,
determination of adult lifespan,GO:0008340,Parkinsonian Disorders,MESH:D020734,5,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Paraquat|Particulate Matter|Plant Extracts|Resveratrol",4,ATP1A3|GBA1|LRRK2|POLG
determination of bilateral symmetry,GO:0009855,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A2
determination of left/right asymmetry in lateral mesoderm,GO:0003140,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
determination of left/right symmetry,GO:0007368,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
determination of left/right symmetry,GO:0007368,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A2
detoxification,GO:0098754,"Parkinson Disease, Secondary",MESH:D010302,1,geraniol,0,
detoxification,GO:0098754,Parkinsonian Disorders,MESH:D020734,1,geraniol,0,
detoxification of arsenic-containing substance,GO:0071722,Parkinson Disease,MESH:D010300,1,Glutathione Disulfide,0,
detoxification of arsenic-containing substance,GO:0071722,Parkinsonian Disorders,MESH:D020734,1,baicalin,0,
detoxification of copper ion,GO:0010273,Parkinson Disease,MESH:D010300,0,,1,PARK7
detoxification of copper ion,GO:0010273,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
detoxification of copper ion,GO:0010273,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
detoxification of hydrogen peroxide,GO:0061691,Parkinson Disease,MESH:D010300,0,,1,PARK7
detoxification of hydrogen peroxide,GO:0061691,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
detoxification of hydrogen peroxide,GO:0061691,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
detoxification of iron ion,GO:1990461,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
detoxification of mercury ion,GO:0050787,Parkinson Disease,MESH:D010300,0,,1,PARK7
detoxification of mercury ion,GO:0050787,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
detoxification of mercury ion,GO:0050787,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
detoxification of nitrogen compound,GO:0051410,Parkinson Disease,MESH:D010300,1,Nitric Oxide,0,
detoxification of zinc ion,GO:0010312,Parkinson Disease,MESH:D010300,0,,1,SLC30A10
detoxification of zinc ion,GO:0010312,Parkinsonian Disorders,MESH:D020734,0,,1,SLC30A10
developmental growth,GO:0048589,Parkinson Disease,MESH:D010300,5,Dieldrin|Hexachlorocyclohexane|Nitrates|Polychlorinated Biphenyls|Propranolol,0,
developmental growth,GO:0048589,"Parkinson Disease, Secondary",MESH:D010302,2,Benzo(a)pyrene|Dieldrin,1,SHH
developmental growth,GO:0048589,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
developmental growth,GO:0048589,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Propranolol,0,
developmental growth involved in morphogenesis,GO:0060560,Parkinson Disease,MESH:D010300,1,Copper,0,
developmental growth involved in morphogenesis,GO:0060560,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
developmental pigmentation,GO:0048066,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
developmental process,GO:0032502,Parkinson Disease,MESH:D010300,4,Air Pollutants|Melatonin|Organophosphorus Compounds|Particulate Matter,0,
developmental process,GO:0032502,"Parkinson Disease, Secondary",MESH:D010302,4,Cytarabine|Melatonin|Organophosphorus Compounds|Verapamil,0,
developmental process,GO:0032502,Parkinsonian Disorders,MESH:D020734,3,Melatonin|Particulate Matter|Verapamil,0,
developmental process involved in reproduction,GO:0003006,Parkinson Disease,MESH:D010300,2,"Hydrocarbons, Chlorinated|Lead",0,
developmental process involved in reproduction,GO:0003006,"Parkinson Disease, Secondary",MESH:D010302,2,"Fluoxetine|Hydrocarbons, Chlorinated",0,
developmental process involved in reproduction,GO:0003006,Parkinsonian Disorders,MESH:D020734,1,Indomethacin,0,
development of symbiont in host,GO:0044114,Parkinson Disease,MESH:D010300,1,Manganese,0,
development of symbiont in host,GO:0044114,"Parkinson Disease, Secondary",MESH:D010302,1,Manganese,0,
development of symbiont in host,GO:0044114,Parkinsonian Disorders,MESH:D020734,2,Manganese|manganese chloride,0,
D-gluconate metabolic process,GO:0019521,Parkinson Disease,MESH:D010300,1,Trichloroethylene,0,
D-gluconate metabolic process,GO:0019521,"Parkinson Disease, Secondary",MESH:D010302,1,Trichloroethylene,0,
diacylglycerol biosynthetic process,GO:0006651,Parkinson Disease,MESH:D010300,1,Oxidopamine,0,
diacylglycerol biosynthetic process,GO:0006651,"Parkinson Disease, Secondary",MESH:D010302,1,Oxidopamine,0,
diacylglycerol biosynthetic process,GO:0006651,Parkinsonian Disorders,MESH:D020734,1,Oxidopamine,0,
diacylglycerol metabolic process,GO:0046339,Parkinson Disease,MESH:D010300,0,,1,RDGA
diakinesis,GO:0000241,Parkinson Disease,MESH:D010300,1,Permethrin,0,
diakinesis,GO:0000241,Parkinsonian Disorders,MESH:D020734,1,Permethrin,0,
diestrus,GO:0060207,Parkinson Disease,MESH:D010300,1,"Fungicides, Industrial",0,
digestion,GO:0007586,Parkinson Disease,MESH:D010300,0,,1,PPARGC1A
digestive tract development,GO:0048565,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
digestive tract mesoderm development,GO:0007502,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
digestive tract morphogenesis,GO:0048546,Parkinson Disease,MESH:D010300,2,Atrazine|Rotenone,0,
digestive tract morphogenesis,GO:0048546,"Parkinson Disease, Secondary",MESH:D010302,2,Atrazine|Rotenone,1,SHH
digestive tract morphogenesis,GO:0048546,Parkinsonian Disorders,MESH:D020734,1,Rotenone,1,ALDH1A2
dihydrofolate biosynthetic process,GO:0006761,"Parkinson Disease, Secondary",MESH:D010302,1,Methotrexate,0,
directional locomotion,GO:0033058,Parkinson Disease,MESH:D010300,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
directional locomotion,GO:0033058,"Parkinson Disease, Secondary",MESH:D010302,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
directional locomotion,GO:0033058,Parkinsonian Disorders,MESH:D020734,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
disruption of membrane integrity in another organism,GO:0051673,Parkinson Disease,MESH:D010300,0,,1,DEFA4
DNA ADP-ribosylation,GO:0030592,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
DNA alkylation,GO:0006305,Parkinsonian Disorders,MESH:D020734,1,Disulfiram,0,
DNA amplification,GO:0006277,Parkinson Disease,MESH:D010300,1,Paclitaxel,0,
DNA amplification,GO:0006277,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
DNA biosynthetic process,GO:0071897,Parkinson Disease,MESH:D010300,6,"1-Methyl-4-phenylpyridinium|2,4,5-Trichlorophenoxyacetic Acid|Atrazine|Chlorpyrifos|Lipopolysaccharides|Pioglitazone",0,
DNA biosynthetic process,GO:0071897,"Parkinson Disease, Secondary",MESH:D010302,5,Atrazine|Doxorubicin|geraniol|Resveratrol|sodium bisulfide,0,
DNA biosynthetic process,GO:0071897,Parkinsonian Disorders,MESH:D020734,4,1-Methyl-4-phenylpyridinium|geraniol|Lipopolysaccharides|Resveratrol,1,POLG
DNA catabolic process,GO:0006308,Parkinson Disease,MESH:D010300,6,Aspirin|Carbon Tetrachloride|Copper|Paraquat|Particulate Matter|Propranolol,0,
DNA catabolic process,GO:0006308,"Parkinson Disease, Secondary",MESH:D010302,5,Chlorpromazine|Cytarabine|Doxorubicin|Paraquat|Resveratrol,0,
DNA catabolic process,GO:0006308,Parkinsonian Disorders,MESH:D020734,9,Cadmium|Chlorpromazine|Curcumin|Paraquat|Particulate Matter|Plant Extracts|Resveratrol|Rimonabant|Zidovudine,0,
DNA catabolic process,GO:0006308,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Isoproterenol|Propranolol,0,
"DNA catabolic process, endonucleolytic",GO:0000737,Parkinson Disease,MESH:D010300,23,"1-Methyl-4-phenylpyridinium|Atrazine|Caffeine|carbidopa, levodopa drug combination|Carbon Tetrachloride|Chlorpyrifos|Copper|Diazinon|Eugenol|Iron|Lipopolysaccharides|Maneb|Melatonin|Methamphetamine|Paraquat|Particulate Matter|pendimethalin|Permethrin|Reactive Oxygen Species|Rotenone|Trichloroethylene|Vehicle Emissions|Zinc",0,
"DNA catabolic process, endonucleolytic",GO:0000737,"Parkinson Disease, Secondary",MESH:D010302,16,"3-methyladenine|Atrazine|Benzo(a)pyrene|Carbamazepine|carbidopa, levodopa drug combination|Doxorubicin|Maneb|Melatonin|Methamphetamine|Paraquat|Resveratrol|Rotenone|Silymarin|thymoquinone|Trichloroethylene|Valproic Acid",0,
"DNA catabolic process, endonucleolytic",GO:0000737,Parkinsonian Disorders,MESH:D020734,18,"1-Methyl-4-phenylpyridinium|4-hydroxy-2-nonenal|Cadmium|carbidopa, levodopa drug combination|coenzyme Q10|Curcumin|Disulfiram|Lipopolysaccharides|mancozeb|Maneb|Melatonin|Paraquat|Particulate Matter|Permethrin|Resveratrol|Rotenone|Silymarin|Valproic Acid",0,
"DNA catabolic process, endonucleolytic",GO:0000737,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
DNA damage checkpoint signaling,GO:0000077,Parkinsonian Disorders,MESH:D020734,1,Plant Extracts,0,
DNA double-strand break processing,GO:0000729,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
DNA duplex unwinding,GO:0032508,Parkinson Disease,MESH:D010300,1,Mirtazapine,0,
DNA hypermethylation,GO:0044026,Parkinson Disease,MESH:D010300,1,Vehicle Emissions,0,
DNA hypomethylation,GO:0044028,Parkinson Disease,MESH:D010300,3,Particulate Matter|Soot|Vehicle Emissions,0,
DNA hypomethylation,GO:0044028,Parkinsonian Disorders,MESH:D020734,2,Curcumin|Particulate Matter,0,
DNA integration,GO:0015074,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
DNA metabolic process,GO:0006259,Parkinson Disease,MESH:D010300,1,Carbon Tetrachloride,0,
DNA metabolic process,GO:0006259,"Parkinson Disease, Secondary",MESH:D010302,2,Benzo(a)pyrene|Doxorubicin,0,
DNA metabolic process,GO:0006259,Parkinsonian Disorders,MESH:D020734,1,Plant Preparations,2,PARP1|POLG
DNA methylation,GO:0006306,Parkinson Disease,MESH:D010300,18,Air Pollutants|Amphetamine|Clozapine|Copper|Dieldrin|Estradiol|Homocysteine|Lead|Lipopolysaccharides|Nitrogen Dioxide|Ozone|Particulate Matter|Permethrin|Pesticides|Rotenone|Soot|Vehicle Emissions|Zinc,0,
DNA methylation,GO:0006306,"Parkinson Disease, Secondary",MESH:D010302,9,Benzo(a)pyrene|Carbon Monoxide|Cytarabine|Dieldrin|Doxorubicin|Haloperidol|Pesticides|Rotenone|Valproic Acid,0,
DNA methylation,GO:0006306,Parkinsonian Disorders,MESH:D020734,8,Cadmium|Clozapine|Haloperidol|Lipopolysaccharides|Particulate Matter|Permethrin|Rotenone|Valproic Acid,0,
DNA methylation,GO:0006306,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Procainamide,0,
DNA methylation involved in embryo development,GO:0043045,Parkinson Disease,MESH:D010300,1,Pesticides,0,
DNA methylation involved in embryo development,GO:0043045,"Parkinson Disease, Secondary",MESH:D010302,1,Pesticides,0,
DNA methylation involved in gamete generation,GO:0043046,Parkinson Disease,MESH:D010300,2,Lead|Smoke,0,
DNA methylation involved in gamete generation,GO:0043046,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
DNA methylation on cytosine,GO:0032776,Parkinson Disease,MESH:D010300,5,Dieldrin|Estradiol|Lead|Permethrin|Vehicle Emissions,0,
DNA methylation on cytosine,GO:0032776,"Parkinson Disease, Secondary",MESH:D010302,2,Benzo(a)pyrene|Dieldrin,0,
DNA methylation on cytosine,GO:0032776,Parkinsonian Disorders,MESH:D020734,1,Permethrin,0,
DNA methylation on cytosine within a CG sequence,GO:0010424,Parkinson Disease,MESH:D010300,16,Air Pollutants|Atrazine|Dicamba|Dieldrin|Endosulfan|Estradiol|Herbicides|Insecticides|Lead|Nitrogen Dioxide|Ozone|Particulate Matter|Pesticides|Rotenone|Soot|Vehicle Emissions,0,
DNA methylation on cytosine within a CG sequence,GO:0010424,"Parkinson Disease, Secondary",MESH:D010302,7,Atrazine|Benzo(a)pyrene|Dieldrin|Doxorubicin|Nicotine|Pesticides|Rotenone,0,
DNA methylation on cytosine within a CG sequence,GO:0010424,Parkinsonian Disorders,MESH:D020734,5,Cadmium|cypermethrin|Particulate Matter|Phenol|Rotenone,0,
DNA methylation or demethylation,GO:0044728,Parkinson Disease,MESH:D010300,1,Lead,0,
DNA modification,GO:0006304,Parkinson Disease,MESH:D010300,19,Air Pollutants|Aspirin|Carbon Tetrachloride|Chlorpyrifos|Copper|Eicosapentaenoic Acid|Iron|Lipopolysaccharides|Lithium|Lithium Carbonate|Paraquat|Particulate Matter|Pesticides|Polychlorinated Biphenyls|Reactive Oxygen Species|Rotenone|Trichloroethylene|Vehicle Emissions|Zinc,0,
DNA modification,GO:0006304,"Parkinson Disease, Secondary",MESH:D010302,13,Benzo(a)pyrene|Doxorubicin|geraniol|Lithium|Lithium Carbonate|Methotrexate|Paraquat|Pesticides|Resveratrol|Rotenone|Silymarin|Trichloroethylene|Valproic Acid,0,
DNA modification,GO:0006304,Parkinsonian Disorders,MESH:D020734,16,baicalin|Cadmium|Curcumin|cypermethrin|Docosahexaenoic Acids|geraniol|Lipopolysaccharides|manganese chloride|Paraquat|Particulate Matter|Plant Extracts|Resveratrol|Rotenone|sesamin|Silymarin|Valproic Acid,0,
DNA modification,GO:0006304,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Lithium,0,
DNA recombination,GO:0006310,Parkinsonian Disorders,MESH:D020734,1,Zidovudine,0,
DNA repair,GO:0006281,Parkinson Disease,MESH:D010300,5,Lead|Particulate Matter|Pesticides|Smoke|Vehicle Emissions,2,HSPA1A|PARK7
DNA repair,GO:0006281,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
DNA repair,GO:0006281,"Parkinson Disease, Secondary",MESH:D010302,2,Pesticides|Resveratrol,0,
DNA repair,GO:0006281,Parkinsonian Disorders,MESH:D020734,4,Cadmium|Particulate Matter|Resveratrol|Zidovudine,2,PARK7|PARP1
DNA replication,GO:0006260,Parkinson Disease,MESH:D010300,1,Dieldrin,0,
DNA replication,GO:0006260,"Parkinson Disease, Secondary",MESH:D010302,4,Benzo(a)pyrene|Dieldrin|Doxorubicin|Ritonavir,0,
DNA replication,GO:0006260,Parkinsonian Disorders,MESH:D020734,2,Ritonavir|Zidovudine,1,POLG
DNA replication proofreading,GO:0045004,Parkinsonian Disorders,MESH:D020734,0,,1,POLG
DNA synthesis involved in DNA replication,GO:0090592,Parkinson Disease,MESH:D010300,2,Homocysteine|Permethrin,0,
DNA synthesis involved in DNA replication,GO:0090592,Parkinsonian Disorders,MESH:D020734,2,Indomethacin|Permethrin,0,
DNA synthesis involved in mitotic DNA replication,GO:1904860,Parkinsonian Disorders,MESH:D020734,1,Lopinavir,0,
DNA-templated DNA replication,GO:0006261,Parkinsonian Disorders,MESH:D020734,0,,1,POLG
DNA-templated transcription,GO:0006351,Parkinson Disease,MESH:D010300,1,1-Methyl-4-phenylpyridinium,0,
DNA-templated transcription,GO:0006351,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
DNA-templated transcription,GO:0006351,Parkinsonian Disorders,MESH:D020734,1,1-Methyl-4-phenylpyridinium,0,
DNA-templated transcription initiation,GO:0006352,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,TBP
DNA-templated viral transcription,GO:0039695,Parkinsonian Disorders,MESH:D020734,1,baicalin,0,
dopamine biosynthetic process,GO:0042416,Parkinson Disease,MESH:D010300,13,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Atrazine|Copper|Dopamine|Levodopa|Maneb|Melatonin|Methamphetamine|Minocycline|Paraquat|Reserpine|Rotenone",4,DDC|SLC6A3|SNCA|TH
dopamine biosynthetic process,GO:0042416,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
dopamine biosynthetic process,GO:0042416,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
dopamine biosynthetic process,GO:0042416,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
dopamine biosynthetic process,GO:0042416,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
dopamine biosynthetic process,GO:0042416,"Parkinson Disease, Secondary",MESH:D010302,15,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Atrazine|Benzo(a)pyrene|Haloperidol|Levodopa|Maneb|Melatonin|Methamphetamine|Minocycline|Nicotine|Paraquat|Reserpine|Resveratrol|Rotenone|Sulpiride",1,SNCA
dopamine biosynthetic process,GO:0042416,Parkinsonian Disorders,MESH:D020734,17,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|crocin|Curcumin|Dopamine|Haloperidol|Levodopa|Maneb|manganese chloride|Melatonin|Paraquat|Plant Extracts|Quinpirole|Reserpine|Resveratrol|Rotenone|SCH 23390",4,CAT-2|DDC|SNCA|TH
dopamine biosynthetic process,GO:0042416,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
dopamine biosynthetic process from tyrosine,GO:0006585,Parkinson Disease,MESH:D010300,1,Dopamine,2,DDC|TH
dopamine biosynthetic process from tyrosine,GO:0006585,Parkinsonian Disorders,MESH:D020734,1,Dopamine,3,CAT-2|DDC|TH
dopamine catabolic process,GO:0042420,Parkinson Disease,MESH:D010300,3,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Dopamine|Rotenone",3,MAOA|MAOB|SLC6A3
dopamine catabolic process,GO:0042420,"Parkinson Disease, Secondary",MESH:D010302,4,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Homovanillic Acid|Rotenone|Sulpiride",0,
dopamine catabolic process,GO:0042420,Parkinsonian Disorders,MESH:D020734,6,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Curcumin|Dopamine|Homovanillic Acid|Rotenone|SCH 23390",0,
dopamine catabolic process,GO:0042420,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
dopamine metabolic process,GO:0042417,Parkinson Disease,MESH:D010300,20,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Air Pollutants|carbidopa, levodopa drug combination|Chlorpyrifos|Dopamine|Levodopa|Manganese|Methamphetamine|Methomyl|Oxidopamine|Paraquat|Particulate Matter|Permethrin|Probenecid|Reserpine|Roflumilast|Rotenone|Tolcapone|Zinc",5,DDC|DRD1|DRD2|PRKN|SNCA
dopamine metabolic process,GO:0042417,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
dopamine metabolic process,GO:0042417,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
dopamine metabolic process,GO:0042417,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
dopamine metabolic process,GO:0042417,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,2,NR4A2|SNCAIP
dopamine metabolic process,GO:0042417,"Parkinson Disease, Secondary",MESH:D010302,19,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|3-methyladenine|carbidopa, levodopa drug combination|Flunarizine|Fluoxetine|geraniol|Homovanillic Acid|Levodopa|Manganese|Methamphetamine|Nicotine|Oxidopamine|Paraquat|Pargyline|Reserpine|Resveratrol|Rotenone|Valproic Acid|Venlafaxine Hydrochloride",2,PRKN|SNCA
dopamine metabolic process,GO:0042417,Parkinsonian Disorders,MESH:D020734,26,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|baicalin|carbidopa, levodopa drug combination|Curcumin|cypermethrin|Dopamine|Flunarizine|geraniol|ginsenoside Re|Homovanillic Acid|Indomethacin|Levodopa|Manganese|manganese chloride|Oxidopamine|Paraquat|Particulate Matter|Permethrin|Plant Extracts|Probenecid|Reserpine|Resveratrol|Rotenone|taxifolin|Valproic Acid",4,DDC|DRD2|PRKN|SNCA
dopamine receptor signaling pathway,GO:0007212,Parkinson Disease,MESH:D010300,0,,2,DRD1|DRD2
dopamine receptor signaling pathway,GO:0007212,Parkinsonian Disorders,MESH:D020734,0,,2,DOP1R2|DRD2
dopaminergic neuron differentiation,GO:0071542,Parkinson Disease,MESH:D010300,4,Air Pollutants|Copper|Dopamine|Particulate Matter,3,BDNF|PARK7|PINK1
dopaminergic neuron differentiation,GO:0071542,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
dopaminergic neuron differentiation,GO:0071542,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
dopaminergic neuron differentiation,GO:0071542,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
dopaminergic neuron differentiation,GO:0071542,"Parkinson Disease, Mitochondrial",MESH:C564015,0,,1,FMC1
dopaminergic neuron differentiation,GO:0071542,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,2,FMC1|SHH
dopaminergic neuron differentiation,GO:0071542,Parkinsonian Disorders,MESH:D020734,2,Dopamine|Particulate Matter,2,PARK7|PINK1
dopamine secretion,GO:0014046,Parkinson Disease,MESH:D010300,5,Amphetamine|Dopamine|Estradiol|Iron|Methamphetamine,1,PINK1
dopamine secretion,GO:0014046,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
dopamine secretion,GO:0014046,"Parkinson Disease, Secondary",MESH:D010302,3,Flunarizine|Haloperidol|Methamphetamine,0,
dopamine secretion,GO:0014046,Parkinsonian Disorders,MESH:D020734,5,Dopamine|Flunarizine|Haloperidol|manganese chloride|SCH 23390,1,PINK1
"dopamine secretion, neurotransmission",GO:0061527,Parkinson Disease,MESH:D010300,3,Dieldrin|Dopamine|Manganese,0,
"dopamine secretion, neurotransmission",GO:0061527,"Parkinson Disease, Secondary",MESH:D010302,3,Benzo(a)pyrene|Dieldrin|Manganese,0,
"dopamine secretion, neurotransmission",GO:0061527,Parkinsonian Disorders,MESH:D020734,2,Dopamine|Manganese,0,
dopamine transport,GO:0015872,Parkinson Disease,MESH:D010300,1,Methamphetamine,3,DRD1|SLC18A2|SLC6A3
dopamine transport,GO:0015872,"Parkinson Disease, Secondary",MESH:D010302,1,Methamphetamine,1,SLC18A2
dopamine transport,GO:0015872,Parkinsonian Disorders,MESH:D020734,0,,1,SLC18A2
dopamine transport,GO:0015872,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
dopamine uptake,GO:0090494,Parkinson Disease,MESH:D010300,5,1-Methyl-4-phenylpyridinium|Amphetamine|Dopamine|Lipopolysaccharides|Rotenone,1,SLC6A3
dopamine uptake,GO:0090494,"Parkinson Disease, Secondary",MESH:D010302,1,Rotenone,0,
dopamine uptake,GO:0090494,Parkinsonian Disorders,MESH:D020734,4,1-Methyl-4-phenylpyridinium|Dopamine|Lipopolysaccharides|Rotenone,0,
dopamine uptake,GO:0090494,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
dopamine uptake involved in synaptic transmission,GO:0051583,Parkinson Disease,MESH:D010300,0,,5,DRD2|PARK7|PRKN|SLC6A3|SNCA
dopamine uptake involved in synaptic transmission,GO:0051583,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
dopamine uptake involved in synaptic transmission,GO:0051583,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
dopamine uptake involved in synaptic transmission,GO:0051583,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
dopamine uptake involved in synaptic transmission,GO:0051583,"Parkinson Disease, Secondary",MESH:D010302,0,,2,PRKN|SNCA
dopamine uptake involved in synaptic transmission,GO:0051583,Parkinsonian Disorders,MESH:D020734,0,,4,DRD2|PARK7|PRKN|SNCA
dopamine uptake involved in synaptic transmission,GO:0051583,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
dorsal spinal cord development,GO:0021516,Parkinson Disease,MESH:D010300,0,,2,DRAXIN|GDNF
dorsal spinal cord development,GO:0021516,"Parkinson Disease, Secondary",MESH:D010302,0,,1,GDNF
dorsal spinal cord development,GO:0021516,Parkinsonian Disorders,MESH:D020734,0,,1,GDNF
"dorsal/ventral axis specification, ovarian follicular epithelium",GO:0008069,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
dorsal/ventral neural tube patterning,GO:0021904,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
dorsal/ventral pattern formation,GO:0009953,Parkinson Disease,MESH:D010300,1,Tea,2,DDIT4|EDN1
dorsal/ventral pattern formation,GO:0009953,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
double-strand break repair,GO:0006302,Parkinson Disease,MESH:D010300,0,,1,MTA1
double-strand break repair,GO:0006302,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
double-strand break repair involved in meiotic recombination,GO:1990918,Parkinson Disease,MESH:D010300,1,Atrazine,0,
double-strand break repair involved in meiotic recombination,GO:1990918,"Parkinson Disease, Secondary",MESH:D010302,1,Atrazine,0,
double-strand break repair via homologous recombination,GO:0000724,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,0,
double-strand break repair via homologous recombination,GO:0000724,Parkinsonian Disorders,MESH:D020734,1,Valproic Acid,0,
double-strand break repair via nonhomologous end joining,GO:0006303,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
doxorubicin transport,GO:1900753,"Parkinson Disease, Secondary",MESH:D010302,2,Doxorubicin|Verapamil,0,
doxorubicin transport,GO:1900753,Parkinsonian Disorders,MESH:D020734,1,Verapamil,0,
D-ribose metabolic process,GO:0006014,Parkinson Disease,MESH:D010300,1,Methomyl,0,
D-ribose metabolic process,GO:0006014,Parkinsonian Disorders,MESH:D020734,1,Indomethacin,0,
drinking behavior,GO:0042756,Parkinson Disease,MESH:D010300,9,Carbidopa|Carbon Tetrachloride|Gabapentin|Lead|Levodopa|Methamphetamine|Methyldopa|Reserpine|Zinc,1,DRD2
drinking behavior,GO:0042756,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
drinking behavior,GO:0042756,"Parkinson Disease, Secondary",MESH:D010302,11,Carbidopa|Doxorubicin|geraniol|Levodopa|Methamphetamine|Methyldopa|Nicotine|Poly I-C|Reserpine|Silymarin|Valproic Acid,0,
drinking behavior,GO:0042756,Parkinsonian Disorders,MESH:D020734,8,Cadmium|Carbidopa|geraniol|Levodopa|Plant Extracts|Reserpine|Silymarin|Valproic Acid,1,DRD2
D-xylose metabolic process,GO:0042732,Parkinson Disease,MESH:D010300,1,Methomyl,0,
ear development,GO:0043583,Parkinsonian Disorders,MESH:D020734,0,,1,PRKRA
eating behavior,GO:0042755,Parkinson Disease,MESH:D010300,4,Aprepitant|Maneb|Paraquat|Rotenone,2,DRD1|TH
eating behavior,GO:0042755,"PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:613643,0,,1,UCHL1
eating behavior,GO:0042755,"Parkinson Disease, Secondary",MESH:D010302,7,geraniol|Maneb|Nicotine|Paraquat|Paroxetine|Rotenone|Silymarin,0,
eating behavior,GO:0042755,Parkinsonian Disorders,MESH:D020734,8,baicalin|geraniol|Maneb|Paraquat|Paroxetine|Plant Extracts|Rotenone|Silymarin,1,TH
ecdysone metabolic process,GO:0008205,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
eclosion,GO:0007562,Parkinson Disease,MESH:D010300,1,tetrachloroisophthalonitrile,0,
eclosion,GO:0007562,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
ectodermal cell fate commitment,GO:0001712,Parkinson Disease,MESH:D010300,1,Atrazine,0,
ectodermal cell fate commitment,GO:0001712,"Parkinson Disease, Secondary",MESH:D010302,1,Atrazine,0,
ectoderm development,GO:0007398,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
ectopic germ cell programmed cell death,GO:0035234,Parkinson Disease,MESH:D010300,0,,2,PINK1|SOD1
ectopic germ cell programmed cell death,GO:0035234,Parkinson Disease 13,MESH:C565204,0,,1,HTRA2
ectopic germ cell programmed cell death,GO:0035234,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
ectopic germ cell programmed cell death,GO:0035234,Parkinsonian Disorders,MESH:D020734,0,,2,HTRA2|PINK1
eggshell formation,GO:0030703,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
elastic fiber assembly,GO:0048251,Parkinson Disease,MESH:D010300,1,Ozone,0,
electron transport chain,GO:0022900,Parkinson Disease,MESH:D010300,6,Chlorpyrifos|Melatonin|Nitric Oxide|Particulate Matter|Rivastigmine|Rotenone,0,
electron transport chain,GO:0022900,"Parkinson Disease, Secondary",MESH:D010302,5,geraniol|Melatonin|Nifedipine|Rotenone|Silymarin,0,
electron transport chain,GO:0022900,Parkinsonian Disorders,MESH:D020734,7,Amoxapine|geraniol|Melatonin|Particulate Matter|Rivastigmine|Rotenone|Silymarin,0,
embryo development,GO:0009790,Parkinson Disease,MESH:D010300,10,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Air Pollutants|Caffeine|Chlorpyrifos|Estradiol|Particulate Matter|pendimethalin|Propranolol|Tea|Ziram",0,
embryo development,GO:0009790,"Parkinson Disease, Secondary",MESH:D010302,7,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Benzo(a)pyrene|Doxorubicin|Resveratrol|Valproic Acid|Verapamil|Ziram",1,SHH
embryo development,GO:0009790,Parkinsonian Disorders,MESH:D020734,8,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Cadmium|coenzyme Q10|Particulate Matter|Resveratrol|Rimonabant|Valproic Acid|Verapamil",0,
embryo development,GO:0009790,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Isoproterenol|Propranolol,0,
embryo development ending in birth or egg hatching,GO:0009792,Parkinson Disease,MESH:D010300,2,Atrazine|Copper,0,
embryo development ending in birth or egg hatching,GO:0009792,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,TBP
embryo development ending in birth or egg hatching,GO:0009792,"Parkinson Disease, Secondary",MESH:D010302,2,Atrazine|Benzo(a)pyrene,0,
embryo implantation,GO:0007566,Parkinson Disease,MESH:D010300,7,Carbon Disulfide|Endosulfan|Estradiol|Herbicides|Paraquat|Polychlorinated Biphenyls|Sirolimus,1,SOD1
embryo implantation,GO:0007566,"Parkinson Disease, Secondary",MESH:D010302,3,Benzo(a)pyrene|Paraquat|Resveratrol,0,
embryo implantation,GO:0007566,Parkinsonian Disorders,MESH:D020734,5,Carbon Disulfide|cypermethrin|mancozeb|Paraquat|Resveratrol,0,
embryonic body morphogenesis,GO:0010172,Parkinson Disease,MESH:D010300,2,Estradiol|pendimethalin,0,
embryonic brain development,GO:1990403,Parkinson Disease,MESH:D010300,2,Air Pollutants|Particulate Matter,1,CNTNAP2
embryonic brain development,GO:1990403,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
embryonic camera-type eye development,GO:0031076,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A2
embryonic camera-type eye morphogenesis,GO:0048596,Parkinson Disease,MESH:D010300,0,,1,TH
embryonic camera-type eye morphogenesis,GO:0048596,Parkinsonian Disorders,MESH:D020734,0,,1,TH
embryonic cleavage,GO:0040016,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
embryonic cleavage,GO:0040016,Parkinson Disease,MESH:D010300,2,beta-N-methylamino-L-alanine|Lipopolysaccharides,0,
embryonic cleavage,GO:0040016,"Parkinson Disease, Secondary",MESH:D010302,2,Resveratrol|Verapamil,0,
embryonic cleavage,GO:0040016,Parkinsonian Disorders,MESH:D020734,4,Lipopolysaccharides|Resveratrol|Rimonabant|Verapamil,0,
embryonic digestive tract development,GO:0048566,Parkinson Disease,MESH:D010300,0,,1,TNF
embryonic digestive tract development,GO:0048566,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A2
embryonic digestive tract morphogenesis,GO:0048557,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
embryonic digit morphogenesis,GO:0042733,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
embryonic eye morphogenesis,GO:0048048,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A1
embryonic foregut morphogenesis,GO:0048617,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
embryonic forelimb morphogenesis,GO:0035115,Parkinson Disease,MESH:D010300,1,Caffeine,0,
embryonic forelimb morphogenesis,GO:0035115,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
embryonic forelimb morphogenesis,GO:0035115,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A2
embryonic heart tube development,GO:0035050,Parkinson Disease,MESH:D010300,0,,1,EDN1
embryonic heart tube development,GO:0035050,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
embryonic hemopoiesis,GO:0035162,Parkinson Disease,MESH:D010300,1,Nitric Oxide,0,
embryonic hemopoiesis,GO:0035162,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
embryonic hindlimb morphogenesis,GO:0035116,Parkinson Disease,MESH:D010300,1,Caffeine,0,
embryonic hindlimb morphogenesis,GO:0035116,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
embryonic limb morphogenesis,GO:0030326,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
embryonic limb morphogenesis,GO:0030326,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A2
embryonic liver development,GO:1990402,Parkinson Disease,MESH:D010300,0,,1,INSR
embryonic liver development,GO:1990402,Parkinsonian Disorders,MESH:D020734,1,Rimonabant,0,
embryonic morphogenesis,GO:0048598,"Parkinson Disease, Secondary",MESH:D010302,4,Benzo(a)pyrene|Fluoxetine|Resveratrol|Ribavirin,1,SHH
embryonic morphogenesis,GO:0048598,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
embryonic organ development,GO:0048568,Parkinson Disease,MESH:D010300,1,pendimethalin,1,GDNF
embryonic organ development,GO:0048568,"Parkinson Disease, Secondary",MESH:D010302,2,Buspirone|Tacrine,2,GDNF|SHH
embryonic organ development,GO:0048568,Parkinsonian Disorders,MESH:D020734,1,Buspirone,1,GDNF
embryonic pattern specification,GO:0009880,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
embryonic placenta development,GO:0001892,Parkinson Disease,MESH:D010300,1,Particulate Matter,1,IGF2
embryonic placenta development,GO:0001892,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Particulate Matter,0,
embryonic placenta morphogenesis,GO:0060669,Parkinson Disease,MESH:D010300,2,Particulate Matter|Vehicle Emissions,1,IGF2
embryonic placenta morphogenesis,GO:0060669,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
embryonic skeletal system development,GO:0048706,Parkinson Disease,MESH:D010300,1,Benomyl,0,
embryonic skeletal system development,GO:0048706,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
embryonic skeletal system morphogenesis,GO:0048704,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
embryonic viscerocranium morphogenesis,GO:0048703,Parkinson Disease,MESH:D010300,0,,1,EDN1
embryonic viscerocranium morphogenesis,GO:0048703,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A2
endocannabinoid signaling pathway,GO:0071926,Parkinsonian Disorders,MESH:D020734,1,Docosahexaenoic Acids,0,
endochondral ossification,GO:0001958,Parkinson Disease,MESH:D010300,1,Rotenone,0,
endochondral ossification,GO:0001958,"Parkinson Disease, Secondary",MESH:D010302,1,Rotenone,0,
endochondral ossification,GO:0001958,Parkinsonian Disorders,MESH:D020734,1,Rotenone,0,
endocrine pancreas development,GO:0031018,Parkinson Disease,MESH:D010300,0,,1,IL6
endocrine signaling,GO:0038002,Parkinson Disease,MESH:D010300,2,Carbamates|Pesticides,0,
endocrine signaling,GO:0038002,"Parkinson Disease, Secondary",MESH:D010302,1,Pesticides,0,
endocytic recycling,GO:0032456,Parkinson Disease,MESH:D010300,0,,2,SLC18A2|VPS35
endocytic recycling,GO:0032456,PARKINSON DISEASE 17,OMIM:614203,0,,1,VPS35
endocytic recycling,GO:0032456,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SLC18A2
endocytic recycling,GO:0032456,Parkinsonian Disorders,MESH:D020734,0,,1,SLC18A2
endocytosis,GO:0006897,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,3,KST|LRRK2|VPS35
endocytosis,GO:0006897,PARKINSON DISEASE 17,OMIM:614203,0,,1,VPS35
endocytosis,GO:0006897,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
endocytosis,GO:0006897,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
endocytosis,GO:0006897,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Plant Extracts,1,LRRK2
endoplasmic reticulum calcium ion homeostasis,GO:0032469,Parkinson Disease,MESH:D010300,3,1-Methyl-4-phenylpyridinium|Lead|Ozone,0,
endoplasmic reticulum calcium ion homeostasis,GO:0032469,Parkinsonian Disorders,MESH:D020734,2,1-Methyl-4-phenylpyridinium|Procaine,0,
endoplasmic reticulum cisternal network maintenance,GO:0071785,Parkinsonian Disorders,MESH:D020734,1,Curcumin,0,
endoplasmic reticulum organization,GO:0007029,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
endoplasmic reticulum organization,GO:0007029,Parkinson Disease,MESH:D010300,7,beta-N-methylamino-L-alanine|Caffeine|Carbon Tetrachloride|Lead|Maneb|Paraquat|Sirolimus,3,GAK|LRRK2|RTNL1
endoplasmic reticulum organization,GO:0007029,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
endoplasmic reticulum organization,GO:0007029,"Parkinson Disease, Secondary",MESH:D010302,3,Carbon Monoxide|Maneb|Paraquat,0,
endoplasmic reticulum organization,GO:0007029,Parkinsonian Disorders,MESH:D020734,2,Maneb|Paraquat,1,LRRK2
endoplasmic reticulum to cytosol transport,GO:1903513,Parkinson Disease,MESH:D010300,1,4-phenylbutyric acid,0,
endoplasmic reticulum tubular network membrane organization,GO:1990809,Parkinson Disease,MESH:D010300,0,,1,RTNL1
endoplasmic reticulum tubular network organization,GO:0071786,Parkinson Disease,MESH:D010300,0,,1,RTNL1
endoplasmic reticulum unfolded protein response,GO:0030968,Parkinson Disease,MESH:D010300,1,4-phenylbutyric acid,1,HSC70-3
endoplasmic reticulum unfolded protein response,GO:0030968,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
endosomal lumen acidification,GO:0048388,Parkinson Disease,MESH:D010300,2,Iron|Manganese,0,
endosomal lumen acidification,GO:0048388,"Parkinson Disease, Secondary",MESH:D010302,1,Manganese,0,
endosomal lumen acidification,GO:0048388,Parkinsonian Disorders,MESH:D020734,1,Manganese,0,
endosomal lumen acidification,GO:0048388,"PARKINSONISM WITH SPASTICITY, X-LINKED",OMIM:300911,0,,1,ATP6AP2
endosomal transport,GO:0016197,"PARKINSONISM WITH SPASTICITY, X-LINKED",OMIM:300911,0,,1,ATP6AP2
endosome to lysosome transport,GO:0008333,Parkinson Disease,MESH:D010300,0,,1,RAB32
endosome to melanosome transport,GO:0035646,Parkinson Disease,MESH:D010300,0,,1,RAB32
endosome to plasma membrane protein transport,GO:0099638,Parkinson Disease,MESH:D010300,0,,1,VPS35
endosome to plasma membrane protein transport,GO:0099638,PARKINSON DISEASE 17,OMIM:614203,0,,1,VPS35
endosome transport via multivesicular body sorting pathway,GO:0032509,Parkinson Disease,MESH:D010300,0,,1,KST
endothelial cell activation,GO:0042118,Parkinson Disease,MESH:D010300,1,Copper,0,
endothelial cell apoptotic process,GO:0072577,Parkinson Disease,MESH:D010300,0,,2,MAP3K5|TNF
endothelial cell-cell adhesion,GO:0071603,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
endothelial cell-cell adhesion,GO:0071603,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
endothelial cell-matrix adhesion,GO:0090673,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
endothelial cell-matrix adhesion,GO:0090673,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
endothelial cell migration,GO:0043542,Parkinson Disease,MESH:D010300,1,Acrolein,0,
endothelial cell morphogenesis,GO:0001886,Parkinson Disease,MESH:D010300,0,,1,COL19A1
endothelial cell proliferation,GO:0001935,Parkinson Disease,MESH:D010300,0,,1,HMOX1
endothelial cell proliferation,GO:0001935,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
endothelial to hematopoietic transition,GO:0098508,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
endothelial to hematopoietic transition,GO:0098508,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
endothelial tube formation,GO:0120331,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
endothelial tube lumen extension,GO:0097498,Parkinsonian Disorders,MESH:D020734,1,annonacin,0,
endothelial tube lumen extension involved in blood vessel lumen ensheathment,GO:1902355,Parkinson Disease,MESH:D010300,2,Particulate Matter|Vehicle Emissions,0,
endothelial tube lumen extension involved in blood vessel lumen ensheathment,GO:1902355,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
endothelial tube morphogenesis,GO:0061154,Parkinson Disease,MESH:D010300,1,Ketoconazole,0,
endothelial tube morphogenesis,GO:0061154,"Parkinson Disease, Secondary",MESH:D010302,2,Nicotine|Resveratrol,0,
endothelial tube morphogenesis,GO:0061154,Parkinsonian Disorders,MESH:D020734,3,Curcumin|Ketoconazole|Resveratrol,0,
endothelin receptor signaling pathway,GO:0086100,Parkinson Disease,MESH:D010300,1,Particulate Matter,1,EDN1
endothelin receptor signaling pathway,GO:0086100,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
endothelin receptor signaling pathway involved in heart process,GO:0086101,Parkinson Disease,MESH:D010300,0,,1,EDN1
energy homeostasis,GO:0097009,Parkinson Disease,MESH:D010300,2,Air Pollutants|Ozone,2,FBP1|PPARGC1A
energy homeostasis,GO:0097009,"PARKINSON DISEASE 18, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:614251,0,,1,EIF4G1
energy homeostasis,GO:0097009,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
energy homeostasis,GO:0097009,Parkinsonian Disorders,MESH:D020734,2,Creatine|Resveratrol,0,
energy reserve metabolic process,GO:0006112,Parkinson Disease,MESH:D010300,2,Air Pollutants|Particulate Matter,0,
energy reserve metabolic process,GO:0006112,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
enteric nervous system development,GO:0048484,Parkinson Disease,MESH:D010300,0,,1,GDNF
enteric nervous system development,GO:0048484,"Parkinson Disease, Secondary",MESH:D010302,0,,1,GDNF
enteric nervous system development,GO:0048484,Parkinsonian Disorders,MESH:D020734,0,,1,GDNF
entrainment of circadian clock by photoperiod,GO:0043153,Parkinson Disease,MESH:D010300,0,,1,MTA1
entry into host,GO:0044409,Parkinson Disease,MESH:D010300,1,Endosulfan,0,
entry of bacterium into host cell,GO:0035635,Parkinson Disease,MESH:D010300,1,Ketoconazole,0,
entry of bacterium into host cell,GO:0035635,Parkinsonian Disorders,MESH:D020734,2,Indomethacin|Ketoconazole,0,
eosinophil activation involved in immune response,GO:0002278,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
eosinophil activation involved in immune response,GO:0002278,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
eosinophil differentiation,GO:0030222,Parkinson Disease,MESH:D010300,1,Lead,0,
eosinophil extravasation,GO:0072682,Parkinson Disease,MESH:D010300,5,Air Pollutants|Ozone|Particulate Matter|Soot|Vehicle Emissions,0,
eosinophil extravasation,GO:0072682,"Parkinson Disease, Secondary",MESH:D010302,2,Resveratrol|sodium bisulfide,0,
eosinophil extravasation,GO:0072682,Parkinsonian Disorders,MESH:D020734,2,Particulate Matter|Resveratrol,0,
eosinophil homeostasis,GO:1990959,Parkinson Disease,MESH:D010300,4,Air Pollutants|Atrazine|Particulate Matter|Vehicle Emissions,0,
eosinophil homeostasis,GO:1990959,"Parkinson Disease, Secondary",MESH:D010302,2,Atrazine|geraniol,0,
eosinophil homeostasis,GO:1990959,Parkinsonian Disorders,MESH:D020734,3,geraniol|Lopinavir|Particulate Matter,0,
eosinophil migration,GO:0072677,Parkinson Disease,MESH:D010300,6,Air Pollutants|Lipopolysaccharides|Ozone|Particulate Matter|Soot|Vehicle Emissions,0,
eosinophil migration,GO:0072677,"Parkinson Disease, Secondary",MESH:D010302,1,Methotrexate,0,
eosinophil migration,GO:0072677,Parkinsonian Disorders,MESH:D020734,3,Cadmium|Lipopolysaccharides|Particulate Matter,0,
ephrin receptor signaling pathway,GO:0048013,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
epiboly,GO:0090504,Parkinson Disease,MESH:D010300,2,Melatonin|Tea,0,
epiboly,GO:0090504,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
epiboly,GO:0090504,Parkinsonian Disorders,MESH:D020734,1,Melatonin,0,
epiboly involved in gastrulation with mouth forming second,GO:0055113,Parkinson Disease,MESH:D010300,1,Estradiol,0,
epicardial cell to mesenchymal cell transition,GO:0003347,Parkinson Disease,MESH:D010300,1,Paraquat,0,
epicardial cell to mesenchymal cell transition,GO:0003347,"Parkinson Disease, Secondary",MESH:D010302,1,Paraquat,0,
epicardial cell to mesenchymal cell transition,GO:0003347,Parkinsonian Disorders,MESH:D020734,1,Paraquat,0,
epidermal cell differentiation,GO:0009913,Parkinson Disease,MESH:D010300,0,,1,GAK
epidermal growth factor receptor signaling pathway,GO:0007173,Parkinson Disease,MESH:D010300,0,,3,IGF1R|INSR|SLC30A10
epidermal growth factor receptor signaling pathway,GO:0007173,Parkinsonian Disorders,MESH:D020734,0,,1,SLC30A10
epidermis development,GO:0008544,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
epidermis morphogenesis,GO:0048730,Parkinson Disease,MESH:D010300,1,Caffeine,0,
epidermis morphogenesis,GO:0048730,"Parkinson Disease, Secondary",MESH:D010302,1,3-methyladenine,0,
epididymis development,GO:1905867,Parkinson Disease,MESH:D010300,1,Pesticides,0,
epididymis development,GO:1905867,"Parkinson Disease, Secondary",MESH:D010302,1,Pesticides,0,
epigenetic regulation of gene expression,GO:0040029,Parkinson Disease,MESH:D010300,3,Dieldrin|Permethrin|Rotenone,0,
epigenetic regulation of gene expression,GO:0040029,"Parkinson Disease, Secondary",MESH:D010302,2,Dieldrin|Rotenone,0,
epigenetic regulation of gene expression,GO:0040029,Parkinsonian Disorders,MESH:D020734,3,Cadmium|Permethrin|Rotenone,0,
epinephrine biosynthetic process,GO:0042418,Parkinson Disease,MESH:D010300,0,,1,TH
epinephrine biosynthetic process,GO:0042418,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
epinephrine biosynthetic process,GO:0042418,Parkinsonian Disorders,MESH:D020734,0,,1,TH
epinephrine metabolic process,GO:0042414,Parkinson Disease,MESH:D010300,3,Air Pollutants|Ozone|Particulate Matter,0,
epinephrine metabolic process,GO:0042414,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
epithelial cell apoptotic process,GO:1904019,Parkinson Disease,MESH:D010300,0,,1,HMOX1
epithelial cell-cell adhesion,GO:0090136,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
epithelial cell-cell adhesion,GO:0090136,Parkinsonian Disorders,MESH:D020734,2,Curcumin|Resveratrol,0,
epithelial cell development,GO:0002064,Parkinson Disease,MESH:D010300,0,,1,GAK
epithelial cell migration,GO:0010631,Parkinson Disease,MESH:D010300,1,Ozone,0,
epithelial cell proliferation,GO:0050673,Parkinson Disease,MESH:D010300,0,,2,DRD2|HGF
epithelial cell proliferation,GO:0050673,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
epithelial cell proliferation,GO:0050673,Parkinsonian Disorders,MESH:D020734,0,,2,DRD2|PRL
epithelial cell proliferation involved in lung morphogenesis,GO:0060502,Parkinson Disease,MESH:D010300,1,Ozone,0,
epithelial cell proliferation involved in prostate gland development,GO:0060767,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
epithelial cell proliferation involved in salivary gland morphogenesis,GO:0060664,Parkinson Disease,MESH:D010300,0,,2,IL6|TNF
epithelial cell proliferation involved in salivary gland morphogenesis,GO:0060664,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
epithelial fluid transport,GO:0042045,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,1,EDN1
epithelial fluid transport,GO:0042045,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
epithelial-mesenchymal cell signaling,GO:0060684,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
epithelial-mesenchymal signaling involved in prostate gland development,GO:0060738,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
epithelial structure maintenance,GO:0010669,Parkinson Disease,MESH:D010300,3,Chlorpyrifos|Melatonin|Vehicle Emissions,0,
epithelial structure maintenance,GO:0010669,"Parkinson Disease, Secondary",MESH:D010302,2,Benzo(a)pyrene|Melatonin,0,
epithelial structure maintenance,GO:0010669,Parkinsonian Disorders,MESH:D020734,1,Melatonin,0,
epithelial to mesenchymal transition,GO:0001837,Parkinson Disease,MESH:D010300,5,Air Pollutants|Lipopolysaccharides|Ozone|Paraquat|Particulate Matter,1,HGF
epithelial to mesenchymal transition,GO:0001837,"Parkinson Disease, Secondary",MESH:D010302,3,Benzo(a)pyrene|Paraquat|Resveratrol,0,
epithelial to mesenchymal transition,GO:0001837,Parkinsonian Disorders,MESH:D020734,4,Lipopolysaccharides|Paraquat|Particulate Matter|Resveratrol,0,
epithelial tube branching involved in lung morphogenesis,GO:0060441,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
epoxygenase P450 pathway,GO:0019373,Parkinson Disease,MESH:D010300,0,,1,CYP2E1
epoxygenase P450 pathway,GO:0019373,"Parkinson Disease, Secondary",MESH:D010302,2,Nifedipine|Verapamil,0,
epoxygenase P450 pathway,GO:0019373,Parkinsonian Disorders,MESH:D020734,1,Verapamil,0,
equilibrioception,GO:0050957,Parkinson Disease,MESH:D010300,1,Rotenone,0,
equilibrioception,GO:0050957,"Parkinson Disease, Secondary",MESH:D010302,1,Rotenone,0,
equilibrioception,GO:0050957,Parkinsonian Disorders,MESH:D020734,1,Rotenone,0,
ERAD pathway,GO:0036503,Parkinson Disease,MESH:D010300,0,,1,PRKN
ERAD pathway,GO:0036503,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
ERAD pathway,GO:0036503,Parkinsonian Disorders,MESH:D020734,0,,1,PRKN
ERK1 and ERK2 cascade,GO:0070371,Parkinson Disease,MESH:D010300,2,mangiferin|Reactive Oxygen Species,2,CNTNAP2|EDN1
ERK1 and ERK2 cascade,GO:0070371,"Parkinson Disease, Secondary",MESH:D010302,3,Poly I-C|Resveratrol|Sertraline,0,
ERK1 and ERK2 cascade,GO:0070371,Parkinsonian Disorders,MESH:D020734,4,ginsenoside Re|Plant Extracts|Resveratrol|Sertraline,1,ATP1A3
ER overload response,GO:0006983,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
ER overload response,GO:0006983,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
ER overload response,GO:0006983,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
erythrocyte aggregation,GO:0034117,Parkinson Disease,MESH:D010300,2,Air Pollutants|Particulate Matter,0,
erythrocyte aggregation,GO:0034117,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
erythrocyte development,GO:0048821,Parkinson Disease,MESH:D010300,2,Lead|Pesticides,0,
erythrocyte development,GO:0048821,"Parkinson Disease, Secondary",MESH:D010302,1,Pesticides,0,
erythrocyte differentiation,GO:0030218,Parkinson Disease,MESH:D010300,0,,2,HSPA9|NCAPG2
erythrocyte differentiation,GO:0030218,Parkinsonian Disorders,MESH:D020734,1,Phenol,0,
erythrocyte homeostasis,GO:0034101,Parkinson Disease,MESH:D010300,5,Chlorpyrifos|Iron|Lead|Rotenone|Zinc,1,HMOX1
erythrocyte homeostasis,GO:0034101,"Parkinson Disease, Secondary",MESH:D010302,5,Benzo(a)pyrene|Doxorubicin|geraniol|Rotenone|thymoquinone,0,
erythrocyte homeostasis,GO:0034101,Parkinsonian Disorders,MESH:D020734,4,Cadmium|geraniol|Indomethacin|Rotenone,0,
erythrocyte maturation,GO:0043249,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|Rotenone,0,
erythrocyte maturation,GO:0043249,"Parkinson Disease, Secondary",MESH:D010302,2,Resveratrol|Rotenone,0,
erythrocyte maturation,GO:0043249,Parkinsonian Disorders,MESH:D020734,2,Resveratrol|Rotenone,0,
erythromycin metabolic process,GO:1901113,Parkinson Disease,MESH:D010300,1,Ketoconazole,0,
erythromycin metabolic process,GO:1901113,Parkinsonian Disorders,MESH:D020734,1,Ketoconazole,0,
erythrophore differentiation,GO:0048773,Parkinson Disease,MESH:D010300,0,,1,SOD2
esophagus smooth muscle contraction,GO:0014846,Parkinson Disease,MESH:D010300,1,Biperiden,0,
esophagus smooth muscle contraction,GO:0014846,"Parkinson Disease, Secondary",MESH:D010302,1,Biperiden,0,
esophagus smooth muscle contraction,GO:0014846,Parkinsonian Disorders,MESH:D020734,1,Biperiden,0,
establishment of blood-brain barrier,GO:0060856,Parkinson Disease,MESH:D010300,1,Diazepam,0,
establishment of blood-brain barrier,GO:0060856,"Parkinson Disease, Secondary",MESH:D010302,1,Diazepam,0,
establishment of body hair or bristle planar orientation,GO:0048104,"PARKINSONISM WITH SPASTICITY, X-LINKED",OMIM:300911,0,,1,ATP6AP2
establishment of cell polarity,GO:0030010,Parkinson Disease,MESH:D010300,3,Lipopolysaccharides|Particulate Matter|Vehicle Emissions,2,IGF1R|MAP2
establishment of cell polarity,GO:0030010,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Particulate Matter,0,
establishment of endothelial barrier,GO:0061028,Parkinsonian Disorders,MESH:D020734,1,Procaine,0,
establishment of endothelial blood-brain barrier,GO:0014045,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,0,
establishment of endothelial blood-brain barrier,GO:0014045,Parkinsonian Disorders,MESH:D020734,1,Valproic Acid,0,
establishment of endothelial intestinal barrier,GO:0090557,Parkinson Disease,MESH:D010300,3,Lipopolysaccharides|Methamphetamine|Particulate Matter,0,
establishment of endothelial intestinal barrier,GO:0090557,"Parkinson Disease, Secondary",MESH:D010302,2,Methamphetamine|Valproic Acid,0,
establishment of endothelial intestinal barrier,GO:0090557,Parkinsonian Disorders,MESH:D020734,3,Lipopolysaccharides|Particulate Matter|Valproic Acid,0,
establishment of epithelial cell polarity,GO:0090162,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
establishment of imaginal disc-derived wing hair orientation,GO:0001737,"PARKINSONISM WITH SPASTICITY, X-LINKED",OMIM:300911,0,,1,ATP6AP2
establishment of localization in cell,GO:0051649,Parkinson Disease,MESH:D010300,0,,3,NECTIN2|NOS1|PINK1
establishment of localization in cell,GO:0051649,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
establishment of localization in cell,GO:0051649,Parkinsonian Disorders,MESH:D020734,0,,1,PINK1
establishment of meiotic spindle localization,GO:0051295,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
establishment of meiotic spindle localization,GO:0051295,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
establishment of meiotic spindle localization,GO:0051295,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Resveratrol,0,
establishment of mitochondrion localization,GO:0051654,Parkinson Disease,MESH:D010300,1,1-Methyl-4-phenylpyridinium,2,NECTIN2|PINK1
establishment of mitochondrion localization,GO:0051654,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
establishment of mitochondrion localization,GO:0051654,Parkinsonian Disorders,MESH:D020734,1,1-Methyl-4-phenylpyridinium,1,PINK1
establishment of mitotic spindle orientation,GO:0000132,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
establishment of mitotic spindle orientation,GO:0000132,Parkinsonian Disorders,MESH:D020734,0,,1,DCTN1
establishment of organelle localization,GO:0051656,Parkinson Disease,MESH:D010300,1,Melatonin,0,
establishment of organelle localization,GO:0051656,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
establishment of organelle localization,GO:0051656,Parkinsonian Disorders,MESH:D020734,1,Melatonin,0,
establishment of planar polarity,GO:0001736,"PARKINSONISM WITH SPASTICITY, X-LINKED",OMIM:300911,0,,1,ATP6AP2
establishment of protein localization,GO:0045184,Parkinson Disease,MESH:D010300,0,,1,NOS1
establishment of protein localization to chromatin,GO:0071169,"Parkinson Disease, Secondary",MESH:D010302,1,Methotrexate,0,
establishment of protein localization to membrane,GO:0090150,Parkinson Disease,MESH:D010300,2,Rotenone|Soot,0,
establishment of protein localization to membrane,GO:0090150,"Parkinson Disease, Secondary",MESH:D010302,1,Rotenone,0,
establishment of protein localization to membrane,GO:0090150,Parkinsonian Disorders,MESH:D020734,1,Rotenone,0,
establishment of protein localization to mitochondrion,GO:0072655,Parkinson Disease,MESH:D010300,0,,1,PINK1
establishment of protein localization to mitochondrion,GO:0072655,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
establishment of protein localization to mitochondrion,GO:0072655,Parkinsonian Disorders,MESH:D020734,0,,1,PINK1
establishment of protein localization to plasma membrane,GO:0061951,Parkinson Disease,MESH:D010300,5,Desipramine|Pioglitazone|Propranolol|Reserpine|Sirolimus,0,
establishment of protein localization to plasma membrane,GO:0061951,"Parkinson Disease, Secondary",MESH:D010302,7,bromperidol|Haloperidol|Nortriptyline|Paroxetine|Reserpine|Resveratrol|Thioridazine,0,
establishment of protein localization to plasma membrane,GO:0061951,Parkinsonian Disorders,MESH:D020734,8,Disulfiram|Haloperidol|Paroxetine|Quinpirole|Reserpine|Resveratrol|SCH 23390|Thioridazine,0,
establishment of protein localization to plasma membrane,GO:0061951,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Isoproterenol|Propranolol,0,
establishment of skin barrier,GO:0061436,Parkinson Disease,MESH:D010300,1,Ketoconazole,2,GAK|GBA1
establishment of skin barrier,GO:0061436,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
establishment of skin barrier,GO:0061436,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
establishment of skin barrier,GO:0061436,Parkinsonian Disorders,MESH:D020734,3,Indomethacin|Ketoconazole|Resveratrol,1,GBA1
establishment or maintenance of transmembrane electrochemical gradient,GO:0010248,Parkinsonian Disorders,MESH:D020734,0,,1,ATP1A3
estradiol secretion,GO:0035938,Parkinson Disease,MESH:D010300,3,Dieldrin|Estradiol|Lipopolysaccharides,0,
estradiol secretion,GO:0035938,"Parkinson Disease, Secondary",MESH:D010302,1,Dieldrin,0,
estradiol secretion,GO:0035938,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
estrogen biosynthetic process,GO:0006703,Parkinson Disease,MESH:D010300,3,Atrazine|Estradiol|Ketoconazole,0,
estrogen biosynthetic process,GO:0006703,"Parkinson Disease, Secondary",MESH:D010302,3,Atrazine|Benzo(a)pyrene|Nicotine,0,
estrogen biosynthetic process,GO:0006703,Parkinsonian Disorders,MESH:D020734,3,Cadmium|cypermethrin|Ketoconazole,0,
estrogen catabolic process,GO:0006711,Parkinsonian Disorders,MESH:D020734,1,Plant Extracts,0,
estrogen metabolic process,GO:0008210,Parkinson Disease,MESH:D010300,8,"4-phenylbutyric acid|Atrazine|Chlorpyrifos|Copper|Estradiol|Herbicides|Melatonin|Water Pollutants, Chemical",1,CYP2D6
estrogen metabolic process,GO:0008210,"Parkinson Disease, Secondary",MESH:D010302,7,Atrazine|Benzo(a)pyrene|Doxorubicin|Lamotrigine|Melatonin|Methotrexate|Resveratrol,0,
estrogen metabolic process,GO:0008210,Parkinsonian Disorders,MESH:D020734,5,Curcumin|cypermethrin|Melatonin|Plant Extracts|Resveratrol,0,
estrogen secretion,GO:0035937,Parkinson Disease,MESH:D010300,4,4-phenylbutyric acid|Chlorpyrifos|Copper|Estradiol,0,
estrogen secretion,GO:0035937,Parkinsonian Disorders,MESH:D020734,2,cypermethrin|Plant Extracts,0,
estrone secretion,GO:0035943,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
estrone secretion,GO:0035943,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
estrous cycle,GO:0044849,Parkinson Disease,MESH:D010300,3,"Caffeine|Estradiol|Fungicides, Industrial",2,IGF1R|TRPM2
estrous cycle,GO:0044849,"Parkinson Disease, Secondary",MESH:D010302,1,Vincristine,0,
estrous cycle,GO:0044849,Parkinsonian Disorders,MESH:D020734,1,Curcumin,1,ALDH1A1
estrus,GO:0060209,Parkinson Disease,MESH:D010300,1,"Fungicides, Industrial",0,
ethanolamine biosynthetic process,GO:0046335,Parkinson Disease,MESH:D010300,1,Permethrin,0,
ethanolamine biosynthetic process,GO:0046335,Parkinsonian Disorders,MESH:D020734,1,Permethrin,0,
ethanolamine metabolic process,GO:0006580,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
ethanolamine metabolic process,GO:0006580,"Parkinson Disease, Secondary",MESH:D010302,2,Benzo(a)pyrene|Methotrexate,0,
ethanol catabolic process,GO:0006068,Parkinson Disease,MESH:D010300,0,,1,ALDH2
ethanol catabolic process,GO:0006068,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ADH1C
ethanol metabolic process,GO:0006067,Parkinson Disease,MESH:D010300,0,,2,ALDH2|GPDH1
ether lipid biosynthetic process,GO:0008611,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,0,
ether lipid biosynthetic process,GO:0008611,Parkinsonian Disorders,MESH:D020734,1,Valproic Acid,0,
evoked excitatory postsynaptic potential,GO:0098817,Parkinson Disease,MESH:D010300,2,Caffeine|Ziram,0,
evoked excitatory postsynaptic potential,GO:0098817,"Parkinson Disease, Secondary",MESH:D010302,1,Ziram,0,
evoked excitatory postsynaptic potential,GO:0098817,Parkinsonian Disorders,MESH:D020734,2,Baclofen|Bupropion,0,
excitatory chemical synaptic transmission,GO:0098976,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
excitatory chemical synaptic transmission,GO:0098976,Parkinson Disease,MESH:D010300,2,beta-N-methylamino-L-alanine|Methamphetamine,1,CNTNAP2
excitatory chemical synaptic transmission,GO:0098976,"Parkinson Disease, Secondary",MESH:D010302,1,Methamphetamine,0,
excitatory postsynaptic potential,GO:0060079,Parkinson Disease,MESH:D010300,6,"2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine|Amphetamine|Dopamine|Oxidopamine|Propranolol|Testosterone",5,BDNF|CNTNAP2|DRD2|LRRK2|SNCA
excitatory postsynaptic potential,GO:0060079,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
excitatory postsynaptic potential,GO:0060079,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
excitatory postsynaptic potential,GO:0060079,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
excitatory postsynaptic potential,GO:0060079,"Parkinson Disease, Secondary",MESH:D010302,7,Carbamazepine|Haloperidol|Lamotrigine|Nicotine|Oxidopamine|Phenytoin|Sulpiride,1,SNCA
excitatory postsynaptic potential,GO:0060079,Parkinsonian Disorders,MESH:D020734,8,"2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine|Baclofen|Cadmium|Dopamine|Haloperidol|Oxidopamine|Raclopride|SCH 23390",3,DRD2|LRRK2|SNCA
excitatory postsynaptic potential,GO:0060079,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Isoproterenol|Propranolol,0,
excitatory synapse assembly,GO:1904861,Parkinson Disease,MESH:D010300,0,,1,CNTNAP2
excretion,GO:0007588,Parkinson Disease,MESH:D010300,2,Probenecid|Sirolimus,0,
excretion,GO:0007588,"Parkinson Disease, Secondary",MESH:D010302,1,Nifedipine,0,
excretion,GO:0007588,Parkinsonian Disorders,MESH:D020734,2,Curcumin|Probenecid,0,
execution phase of apoptosis,GO:0097194,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
execution phase of apoptosis,GO:0097194,Parkinson Disease,MESH:D010300,1,beta-N-methylamino-L-alanine,0,
execution phase of apoptosis,GO:0097194,Parkinson Disease 13,MESH:C565204,0,,1,HTRA2
execution phase of apoptosis,GO:0097194,Parkinsonian Disorders,MESH:D020734,0,,1,HTRA2
exocrine pancreas development,GO:0031017,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
exocrine pancreas development,GO:0031017,Parkinson Disease,MESH:D010300,0,,3,IGF1R|IGF2|INSR
exosomal secretion,GO:1990182,Parkinson Disease,MESH:D010300,4,Lead|Methamphetamine|Particulate Matter|Rotenone,0,
exosomal secretion,GO:1990182,"Parkinson Disease, Secondary",MESH:D010302,2,Methamphetamine|Rotenone,0,
exosomal secretion,GO:1990182,Parkinsonian Disorders,MESH:D020734,2,Particulate Matter|Rotenone,0,
exploration behavior,GO:0035640,Parkinson Disease,MESH:D010300,18,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Air Pollutants|Atrazine|Chlorpyrifos|Diazepam|Diazinon|Lead|Melatonin|Methamphetamine|Minocycline|Oxidopamine|Paraquat|Particulate Matter|Pioglitazone|Rotenone|Smoke|Vehicle Emissions|Zinc",1,LRRK2
exploration behavior,GO:0035640,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
exploration behavior,GO:0035640,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ATXN3
exploration behavior,GO:0035640,"Parkinson Disease, Secondary",MESH:D010302,15,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Atrazine|Diazepam|Fluoxetine|Haloperidol|Melatonin|Methamphetamine|Minocycline|Nicotine|Oxidopamine|Paraquat|Resveratrol|Rotenone|Valproic Acid|Venlafaxine Hydrochloride",0,
exploration behavior,GO:0035640,Parkinsonian Disorders,MESH:D020734,13,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|6-methyl-2-(phenylethynyl)pyridine|Cadmium|Haloperidol|mancozeb|Melatonin|Oxidopamine|Paraquat|Particulate Matter|Resveratrol|Rimonabant|Rotenone|Valproic Acid",1,LRRK2
export across plasma membrane,GO:0140115,Parkinson Disease,MESH:D010300,0,,1,ABCB1
export across plasma membrane,GO:0140115,"Parkinson Disease, Secondary",MESH:D010302,1,Verapamil,1,ABCB1
export across plasma membrane,GO:0140115,Parkinsonian Disorders,MESH:D020734,1,Verapamil,0,
export from cell,GO:0140352,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
export from cell,GO:0140352,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
external genitalia morphogenesis,GO:0035261,Parkinson Disease,MESH:D010300,1,Caffeine,0,
extracellular exosome assembly,GO:0071971,Parkinson Disease,MESH:D010300,1,Lead,0,
extracellular exosome biogenesis,GO:0097734,Parkinson Disease,MESH:D010300,0,,1,ATP13A2
extracellular exosome biogenesis,GO:0097734,"Parkinson Disease, Secondary",MESH:D010302,0,,1,ATP13A2
extracellular exosome biogenesis,GO:0097734,Parkinsonian Disorders,MESH:D020734,0,,1,ATP13A2
extracellular matrix assembly,GO:0085029,Parkinson Disease,MESH:D010300,1,Carbon Tetrachloride,0,
extracellular matrix assembly,GO:0085029,"Parkinson Disease, Secondary",MESH:D010302,1,Silymarin,0,
extracellular matrix assembly,GO:0085029,Parkinsonian Disorders,MESH:D020734,1,Silymarin,0,
extracellular matrix disassembly,GO:0022617,Parkinson Disease,MESH:D010300,1,Carbon Tetrachloride,0,
extracellular matrix organization,GO:0030198,Parkinson Disease,MESH:D010300,1,Carbon Tetrachloride,3,COL19A1|GFAP|TNF
extracellular structure organization,GO:0043062,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
extracellular vesicle biogenesis,GO:0140112,Parkinson Disease,MESH:D010300,2,Ozone|Paraquat,0,
extracellular vesicle biogenesis,GO:0140112,"Parkinson Disease, Secondary",MESH:D010302,1,Paraquat,0,
extracellular vesicle biogenesis,GO:0140112,Parkinsonian Disorders,MESH:D020734,1,Paraquat,0,
extraembryonic membrane development,GO:1903867,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
extraembryonic membrane development,GO:1903867,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
extrinsic apoptotic signaling pathway,GO:0097191,Parkinson Disease,MESH:D010300,0,,1,TNF
extrinsic apoptotic signaling pathway,GO:0097191,"Parkinson Disease, Secondary",MESH:D010302,1,Sertraline,0,
extrinsic apoptotic signaling pathway,GO:0097191,Parkinsonian Disorders,MESH:D020734,1,Sertraline,0,
extrinsic apoptotic signaling pathway in absence of ligand,GO:0097192,Parkinson Disease,MESH:D010300,0,,1,NGF
extrinsic apoptotic signaling pathway in absence of ligand,GO:0097192,Parkinsonian Disorders,MESH:D020734,0,,1,NGF
extrinsic apoptotic signaling pathway via death domain receptors,GO:0008625,Parkinson Disease,MESH:D010300,0,,2,NGF|TNF
extrinsic apoptotic signaling pathway via death domain receptors,GO:0008625,Parkinsonian Disorders,MESH:D020734,1,Plant Extracts,1,NGF
eye development,GO:0001654,Parkinson Disease,MESH:D010300,1,Melatonin,0,
eye development,GO:0001654,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
eye development,GO:0001654,Parkinsonian Disorders,MESH:D020734,2,Melatonin|Rimonabant,0,
eyelid development in camera-type eye,GO:0061029,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,0,
eyelid development in camera-type eye,GO:0061029,Parkinsonian Disorders,MESH:D020734,1,Valproic Acid,0,
eye morphogenesis,GO:0048592,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
eye photoreceptor cell development,GO:0042462,Parkinson Disease,MESH:D010300,0,,1,TH
eye photoreceptor cell development,GO:0042462,Parkinsonian Disorders,MESH:D020734,0,,1,TH
eye pigmentation,GO:0048069,"PARKINSONISM WITH SPASTICITY, X-LINKED",OMIM:300911,0,,1,ATP6AP2
eye pigment granule organization,GO:0008057,Parkinson Disease,MESH:D010300,0,,1,RAB32
face development,GO:0060324,Parkinson Disease,MESH:D010300,2,Air Pollutants|Particulate Matter,0,
face development,GO:0060324,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,1,ALDH1A2
face morphogenesis,GO:0060325,Parkinson Disease,MESH:D010300,0,,1,EDN1
face morphogenesis,GO:0060325,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A2
fat cell differentiation,GO:0045444,Parkinson Disease,MESH:D010300,6,Chlorpyrifos|Estradiol|Pioglitazone|Reactive Oxygen Species|Rivastigmine|Tea,2,CNTNAP2|INSR
fat cell differentiation,GO:0045444,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
fat cell differentiation,GO:0045444,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
fat cell differentiation,GO:0045444,Parkinsonian Disorders,MESH:D020734,4,Cadmium|Indomethacin|Resveratrol|Rivastigmine,0,
fat cell proliferation,GO:0070341,Parkinson Disease,MESH:D010300,3,Air Pollutants|Lipopolysaccharides|Particulate Matter,0,
fat cell proliferation,GO:0070341,Parkinsonian Disorders,MESH:D020734,3,Cadmium|Lipopolysaccharides|Particulate Matter,0,
fat pad development,GO:0060613,"Parkinson Disease, Secondary",MESH:D010302,2,Olanzapine|Resveratrol,0,
fat pad development,GO:0060613,Parkinsonian Disorders,MESH:D020734,3,Docosahexaenoic Acids|Olanzapine|Resveratrol,0,
fatty acid beta-oxidation,GO:0006635,Parkinson Disease,MESH:D010300,2,mangiferin|Rotenone,0,
fatty acid beta-oxidation,GO:0006635,"Parkinson Disease, Secondary",MESH:D010302,4,Benzo(a)pyrene|Olanzapine|Resveratrol|Rotenone,0,
fatty acid beta-oxidation,GO:0006635,Parkinsonian Disorders,MESH:D020734,3,Olanzapine|Resveratrol|Rotenone,0,
fatty acid biosynthetic process,GO:0006633,Parkinson Disease,MESH:D010300,10,Estradiol|Fatty Acids|Lipopolysaccharides|mangiferin|Methomyl|Oxidopamine|Ozone|Particulate Matter|Vehicle Emissions|Zinc,0,
fatty acid biosynthetic process,GO:0006633,"Parkinson Disease, Secondary",MESH:D010302,3,Benzo(a)pyrene|Oxidopamine|Resveratrol,0,
fatty acid biosynthetic process,GO:0006633,Parkinsonian Disorders,MESH:D020734,7,Docosahexaenoic Acids|ginsenoside Re|Lipopolysaccharides|Oxidopamine|Particulate Matter|Plant Extracts|Resveratrol,0,
fatty acid biosynthetic process,GO:0006633,Wolff-Parkinson-White Syndrome,MESH:D014927,0,,1,PRKAG2
fatty acid catabolic process,GO:0009062,Parkinson Disease,MESH:D010300,2,Air Pollutants|Vehicle Emissions,0,
fatty acid derivative biosynthetic process,GO:1901570,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
fatty acid derivative biosynthetic process,GO:1901570,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
fatty acid derivative catabolic process,GO:1901569,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
fatty acid derivative metabolic process,GO:1901568,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
fatty acid derivative metabolic process,GO:1901568,"Parkinson Disease, Secondary",MESH:D010302,1,Haloperidol,0,
fatty acid derivative metabolic process,GO:1901568,Parkinsonian Disorders,MESH:D020734,1,Haloperidol,0,
fatty acid homeostasis,GO:0055089,Parkinson Disease,MESH:D010300,4,Atrazine|Eicosapentaenoic Acid|Fatty Acids|mangiferin,1,INS
fatty acid homeostasis,GO:0055089,"Parkinson Disease, Secondary",MESH:D010302,5,Atrazine|Dichlorvos|geraniol|Resveratrol|Sulpiride,0,
fatty acid homeostasis,GO:0055089,Parkinsonian Disorders,MESH:D020734,5,Cadmium|Docosahexaenoic Acids|geraniol|Plant Extracts|Resveratrol,0,
fatty acid metabolic process,GO:0006631,Parkinson Disease,MESH:D010300,12,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Air Pollutants|Chlorpyrifos|Eicosapentaenoic Acid|Fatty Acids|Manganese|Ozone|Paclitaxel|Particulate Matter|Polychlorinated Biphenyls|tetrachloroisophthalonitrile|Ziram",3,CYP2E1|SNCA|TH
fatty acid metabolic process,GO:0006631,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
fatty acid metabolic process,GO:0006631,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
fatty acid metabolic process,GO:0006631,"Parkinson Disease, Secondary",MESH:D010302,8,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Amiodarone|Benzo(a)pyrene|Doxorubicin|Manganese|Resveratrol|Ribavirin|Ziram",1,SNCA
fatty acid metabolic process,GO:0006631,Parkinsonian Disorders,MESH:D020734,9,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Amiodarone|Cadmium|Docosahexaenoic Acids|Indomethacin|Manganese|manganese chloride|Particulate Matter|Resveratrol",2,SNCA|TH
fatty acid metabolic process,GO:0006631,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Amiodarone|Isoproterenol,0,
fatty acid oxidation,GO:0019395,Parkinson Disease,MESH:D010300,2,Aspirin|Vehicle Emissions,2,CP|PPARGC1A
fatty acid oxidation,GO:0019395,"Parkinson Disease, Secondary",MESH:D010302,4,Amiodarone|Methotrexate|Olanzapine|Resveratrol,0,
fatty acid oxidation,GO:0019395,Parkinsonian Disorders,MESH:D020734,6,Amiodarone|Docosahexaenoic Acids|Indomethacin|Olanzapine|Resveratrol|Zidovudine,0,
fatty acid oxidation,GO:0019395,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
fatty acid transport,GO:0015908,Parkinson Disease,MESH:D010300,3,1-Methyl-4-phenylpyridinium|Fatty Acids|mangiferin,0,
fatty acid transport,GO:0015908,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
fatty acid transport,GO:0015908,Parkinsonian Disorders,MESH:D020734,2,1-Methyl-4-phenylpyridinium|Resveratrol,0,
Fc-epsilon receptor signaling pathway,GO:0038095,Parkinson Disease,MESH:D010300,0,,1,FCER2
Fc-epsilon receptor signaling pathway,GO:0038095,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
Fc-epsilon receptor signaling pathway,GO:0038095,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0038096,Parkinson Disease,MESH:D010300,1,Iron,1,FCER2
Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0038096,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0038096,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0038096,Parkinsonian Disorders,MESH:D020734,1,Amphotericin B,1,PRKCD
Fc receptor-mediated immune complex endocytosis,GO:0160006,Parkinson Disease,MESH:D010300,0,,1,FCER2
fear-induced aggressive behavior,GO:0002122,Parkinsonian Disorders,MESH:D020734,1,Curcumin,0,
fear response,GO:0042596,Parkinson Disease,MESH:D010300,0,,1,BDNF
fear response,GO:0042596,Parkinsonian Disorders,MESH:D020734,0,,1,ATP1A3
feeding behavior,GO:0007631,Parkinson Disease,MESH:D010300,9,Carbidopa|Chlorpyrifos|Lead|Levodopa|Methamphetamine|Ozone|Paraquat|Reserpine|Zinc,3,BDNF|DRD1|DRD2
feeding behavior,GO:0007631,Parkinson Disease 11,MESH:C564345,0,,1,GIGYF2
feeding behavior,GO:0007631,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
feeding behavior,GO:0007631,"Parkinson Disease, Secondary",MESH:D010302,8,Carbidopa|Cytarabine|Doxorubicin|Levodopa|Methamphetamine|Paraquat|Reserpine|Valproic Acid,0,
feeding behavior,GO:0007631,Parkinsonian Disorders,MESH:D020734,7,Cadmium|Carbidopa|Curcumin|Levodopa|Paraquat|Reserpine|Valproic Acid,1,DRD2
female genitalia morphogenesis,GO:0048807,Parkinson Disease,MESH:D010300,1,Caffeine,0,
female germ-line cyst formation,GO:0048135,Parkinson Disease,MESH:D010300,1,"Fungicides, Industrial",0,
female germ-line cyst formation,GO:0048135,Parkinsonian Disorders,MESH:D020734,1,cypermethrin,0,
female germ-line stem cell population maintenance,GO:0036099,Parkinson Disease,MESH:D010300,0,,1,FAX
female gonad development,GO:0008585,Parkinson Disease,MESH:D010300,2,Atrazine|Estradiol,0,
female gonad development,GO:0008585,"Parkinson Disease, Secondary",MESH:D010302,2,Atrazine|Nicotine,0,
female mating behavior,GO:0060180,Parkinson Disease,MESH:D010300,1,Estradiol,0,
female meiosis I,GO:0007144,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
female meiosis II,GO:0007147,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
female meiotic chromosome movement towards spindle pole,GO:0016345,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
female pregnancy,GO:0007565,Parkinson Disease,MESH:D010300,4,Air Pollutants|Caffeine|Polychlorinated Biphenyls|Rotenone,7,CP|HFE|IGF2|MAPT|MTA1|NOS1|SLC38A2
female pregnancy,GO:0007565,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
female pregnancy,GO:0007565,"Parkinson Disease, Secondary",MESH:D010302,1,Rotenone,0,
female pregnancy,GO:0007565,Parkinsonian Disorders,MESH:D020734,1,Rotenone,4,GAPDH|MAPT|PNOC|PRL
ferroptosis,GO:0097707,Parkinson Disease,MESH:D010300,11,1-Methyl-4-phenylpyridinium|4-phenylbutyric acid|Acrolein|Carbon Tetrachloride|Iron|Lead|Lipid Peroxides|Maneb|Paraquat|Particulate Matter|Rotenone,0,
ferroptosis,GO:0097707,"Parkinson Disease, Secondary",MESH:D010302,5,Doxorubicin|Maneb|Paraquat|Resveratrol|Rotenone,0,
ferroptosis,GO:0097707,Parkinsonian Disorders,MESH:D020734,8,1-Methyl-4-phenylpyridinium|Cadmium|Malondialdehyde|Maneb|Paraquat|Particulate Matter|Resveratrol|Rotenone,0,
fertilization,GO:0009566,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
fertilization,GO:0009566,Parkinson Disease,MESH:D010300,5,beta-N-methylamino-L-alanine|Chlorpyrifos|Copper|Melatonin|pendimethalin,2,NECTIN2|PARK7
fertilization,GO:0009566,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
fertilization,GO:0009566,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
fertilization,GO:0009566,Parkinsonian Disorders,MESH:D020734,2,coenzyme Q10|Melatonin,1,PARK7
fibrinolysis,GO:0042730,Parkinson Disease,MESH:D010300,0,,1,FGB
fibroblast activation,GO:0072537,Parkinson Disease,MESH:D010300,2,Paraquat|tetrachloroisophthalonitrile,0,
fibroblast activation,GO:0072537,"Parkinson Disease, Secondary",MESH:D010302,2,Paraquat|sodium bisulfide,0,
fibroblast activation,GO:0072537,Parkinsonian Disorders,MESH:D020734,1,Paraquat,0,
fibroblast growth factor receptor signaling pathway,GO:0008543,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
fibroblast migration,GO:0010761,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
fibroblast migration,GO:0010761,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
fibroblast proliferation,GO:0048144,Parkinson Disease,MESH:D010300,1,Selegiline,0,
fibroblast proliferation,GO:0048144,Parkinsonian Disorders,MESH:D020734,2,Curcumin|Selegiline,0,
fibroblast proliferation,GO:0048144,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
filopodium assembly,GO:0046847,Parkinson Disease,MESH:D010300,2,Clozapine|Manganese,0,
filopodium assembly,GO:0046847,"Parkinson Disease, Secondary",MESH:D010302,2,Haloperidol|Manganese,0,
filopodium assembly,GO:0046847,Parkinsonian Disorders,MESH:D020734,4,Citalopram|Clozapine|Haloperidol|Manganese,0,
fin regeneration,GO:0031101,Parkinson Disease,MESH:D010300,0,,1,HSPA9
fin regeneration,GO:0031101,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A2
flagellated sperm motility,GO:0030317,Parkinson Disease,MESH:D010300,3,Chlorpyrifos|Melatonin|Nitric Oxide,0,
flagellated sperm motility,GO:0030317,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
flagellated sperm motility,GO:0030317,Parkinsonian Disorders,MESH:D020734,3,Melatonin|Plant Extracts|Rimonabant,0,
flavin adenine dinucleotide metabolic process,GO:0072387,Parkinson Disease,MESH:D010300,1,Trichloroethylene,0,
flavin adenine dinucleotide metabolic process,GO:0072387,"Parkinson Disease, Secondary",MESH:D010302,1,Trichloroethylene,0,
flavone metabolic process,GO:0051552,Parkinson Disease,MESH:D010300,0,,1,PPARGC1A
flight behavior,GO:0007629,Parkinson Disease,MESH:D010300,0,,1,GPDH1
foam cell differentiation,GO:0090077,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
foam cell differentiation,GO:0090077,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
focal adhesion assembly,GO:0048041,Parkinson Disease,MESH:D010300,1,Estradiol,0,
folate import across plasma membrane,GO:1904447,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,0,
folate import across plasma membrane,GO:1904447,Parkinsonian Disorders,MESH:D020734,1,Valproic Acid,0,
folic acid metabolic process,GO:0046655,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
folic acid metabolic process,GO:0046655,"Parkinson Disease, Secondary",MESH:D010302,1,Methotrexate,0,
folic acid metabolic process,GO:0046655,Parkinsonian Disorders,MESH:D020734,1,Curcumin,0,
folic acid transport,GO:0015884,Parkinson Disease,MESH:D010300,2,Homocysteine|Lipopolysaccharides,0,
folic acid transport,GO:0015884,"Parkinson Disease, Secondary",MESH:D010302,2,Methotrexate|Trifluoperazine,0,
folic acid transport,GO:0015884,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Trifluoperazine,0,
follicle-stimulating hormone secretion,GO:0046884,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
follicle-stimulating hormone secretion,GO:0046884,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
forebrain development,GO:0030900,Parkinson Disease,MESH:D010300,0,,3,DRAXIN|DRD2|PPARGC1A
forebrain development,GO:0030900,Parkinson Disease 13,MESH:C565204,0,,1,HTRA2
forebrain development,GO:0030900,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
forebrain development,GO:0030900,Parkinsonian Disorders,MESH:D020734,0,,3,ALDH1A2|DRD2|HTRA2
forebrain morphogenesis,GO:0048853,Parkinson Disease,MESH:D010300,1,Homocysteine,1,GAK
forebrain neuron differentiation,GO:0021879,Parkinson Disease,MESH:D010300,1,Methamphetamine,0,
forebrain neuron differentiation,GO:0021879,"Parkinson Disease, Secondary",MESH:D010302,1,Methamphetamine,0,
forebrain regionalization,GO:0021871,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
formate metabolic process,GO:0015942,Parkinson Disease,MESH:D010300,1,Endosulfan,0,
formation of anatomical boundary,GO:0048859,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
forward locomotion,GO:0043056,Parkinson Disease,MESH:D010300,2,Dopamine|Methomyl,0,
forward locomotion,GO:0043056,Parkinsonian Disorders,MESH:D020734,1,Dopamine,0,
free ubiquitin chain polymerization,GO:0010994,Parkinson Disease,MESH:D010300,0,,1,PRKN
free ubiquitin chain polymerization,GO:0010994,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
free ubiquitin chain polymerization,GO:0010994,Parkinsonian Disorders,MESH:D020734,0,,1,PRKN
fructosamine biosynthetic process,GO:0030391,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
fructosamine biosynthetic process,GO:0030391,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
fructosamine catabolic process,GO:0030392,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A1
"fructose 1,6-bisphosphate metabolic process",GO:0030388,Parkinson Disease,MESH:D010300,1,Trichloroethylene,1,FBP1
"fructose 1,6-bisphosphate metabolic process",GO:0030388,"Parkinson Disease, Secondary",MESH:D010302,1,Trichloroethylene,0,
fructose 6-phosphate metabolic process,GO:0006002,Parkinson Disease,MESH:D010300,0,,2,FBP1|TALDO1
fructose biosynthetic process,GO:0046370,Parkinson Disease,MESH:D010300,1,Permethrin,0,
fructose biosynthetic process,GO:0046370,Parkinsonian Disorders,MESH:D020734,1,Permethrin,0,
fructose catabolic process,GO:0006001,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A1
fructose metabolic process,GO:0006000,Parkinson Disease,MESH:D010300,0,,1,FBP1
fructose metabolic process,GO:0006000,"Parkinson Disease, Secondary",MESH:D010302,1,Ribavirin,0,
fucose metabolic process,GO:0006004,Parkinson Disease,MESH:D010300,1,Zinc,0,
fucosylation,GO:0036065,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
fumarate metabolic process,GO:0006106,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
fungiform papilla development,GO:0061196,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
fungiform papilla formation,GO:0061198,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
fungiform papilla morphogenesis,GO:0061197,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
fusion of virus membrane with host plasma membrane,GO:0019064,Parkinson Disease,MESH:D010300,0,,1,NECTIN2
G0 to G1 transition,GO:0045023,Parkinson Disease,MESH:D010300,5,Aluminum|Caffeine|Copper|Manganese|Paclitaxel,0,
G0 to G1 transition,GO:0045023,"Parkinson Disease, Secondary",MESH:D010302,5,Benzo(a)pyrene|Doxorubicin|Flurbiprofen|Manganese|Resveratrol,0,
G0 to G1 transition,GO:0045023,Parkinsonian Disorders,MESH:D020734,8,Cadmium|Curcumin|cypermethrin|Disulfiram|Manganese|manganese chloride|Plant Extracts|Resveratrol,0,
G1 phase,GO:0051318,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|Minocycline,0,
G1 phase,GO:0051318,"Parkinson Disease, Secondary",MESH:D010302,1,Minocycline,0,
G1/S transition of mitotic cell cycle,GO:0000082,Parkinson Disease,MESH:D010300,1,Estradiol,0,
G1/S transition of mitotic cell cycle,GO:0000082,"Parkinson Disease, Secondary",MESH:D010302,1,Cytarabine,0,
G2/M transition of mitotic cell cycle,GO:0000086,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
G2/M transition of mitotic cell cycle,GO:0000086,Parkinson Disease,MESH:D010300,12,Acrolein|Aluminum|beta-N-methylamino-L-alanine|Caffeine|Chlorpyrifos|Copper|Estradiol|Manganese|Melatonin|Methamphetamine|Paclitaxel|Zinc,1,ABCB1
G2/M transition of mitotic cell cycle,GO:0000086,"Parkinson Disease, Secondary",MESH:D010302,7,Benzo(a)pyrene|Doxorubicin|Flurbiprofen|Manganese|Melatonin|Methamphetamine|Resveratrol,1,ABCB1
G2/M transition of mitotic cell cycle,GO:0000086,Parkinsonian Disorders,MESH:D020734,9,Cadmium|Curcumin|cypermethrin|Disulfiram|Manganese|manganese chloride|Melatonin|Plant Extracts|Resveratrol,0,
G2 phase,GO:0051319,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
galactose biosynthetic process,GO:0046369,Parkinson Disease,MESH:D010300,1,Permethrin,0,
galactose biosynthetic process,GO:0046369,Parkinsonian Disorders,MESH:D020734,1,Permethrin,0,
galactose metabolic process,GO:0006012,Parkinson Disease,MESH:D010300,3,Atrazine|Melatonin|Methomyl,1,PPARGC1A
galactose metabolic process,GO:0006012,"Parkinson Disease, Secondary",MESH:D010302,4,Atrazine|Doxorubicin|Melatonin|Resveratrol,0,
galactose metabolic process,GO:0006012,Parkinsonian Disorders,MESH:D020734,2,Melatonin|Resveratrol,0,
gamma-aminobutyric acid biosynthetic process,GO:0009449,"Parkinson Disease, Secondary",MESH:D010302,3,Dichlorvos|Idazoxan|Nicotine,0,
gamma-aminobutyric acid biosynthetic process,GO:0009449,Parkinsonian Disorders,MESH:D020734,5,6-methyl-2-(phenylethynyl)pyridine|Curcumin|Idazoxan|Plant Preparations|Quinpirole,1,ALDH1A1
gamma-aminobutyric acid import,GO:0051939,Parkinson Disease,MESH:D010300,1,Propranolol,0,
gamma-aminobutyric acid import,GO:0051939,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Isoproterenol|Propranolol,0,
gamma-aminobutyric acid metabolic process,GO:0009448,Parkinson Disease,MESH:D010300,4,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Chlorpyrifos|Levodopa|Melatonin",0,
gamma-aminobutyric acid metabolic process,GO:0009448,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
gamma-aminobutyric acid metabolic process,GO:0009448,"Parkinson Disease, Secondary",MESH:D010302,4,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Levodopa|Melatonin|Valproic Acid",0,
gamma-aminobutyric acid metabolic process,GO:0009448,Parkinsonian Disorders,MESH:D020734,7,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Baclofen|Levodopa|Melatonin|Muscimol|Plant Extracts|Valproic Acid",0,
gamma-aminobutyric acid secretion,GO:0014051,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
gamma-aminobutyric acid signaling pathway,GO:0007214,Parkinson Disease,MESH:D010300,1,Polychlorinated Biphenyls,1,BDNF
gamma-aminobutyric acid signaling pathway,GO:0007214,Parkinsonian Disorders,MESH:D020734,1,Baclofen,1,ATP1A3
ganglioside biosynthetic process,GO:0001574,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
ganglioside biosynthetic process,GO:0001574,Parkinson Disease,MESH:D010300,1,beta-N-methylamino-L-alanine,0,
gap junction-mediated intercellular transport,GO:1990349,Parkinson Disease,MESH:D010300,1,Hexachlorocyclohexane,0,
gap junction-mediated intercellular transport,GO:1990349,"Parkinson Disease, Secondary",MESH:D010302,3,Benzo(a)pyrene|Nicotine|Resveratrol,0,
gap junction-mediated intercellular transport,GO:1990349,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Resveratrol,0,
gastric motility,GO:0035482,"Parkinson Disease, Secondary",MESH:D010302,1,Fluoxetine,0,
gastrulation,GO:0007369,Parkinson Disease,MESH:D010300,1,Tea,0,
gastrulation,GO:0007369,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,TBP
GDP metabolic process,GO:0046710,Parkinson Disease,MESH:D010300,1,Trichloroethylene,0,
GDP metabolic process,GO:0046710,"Parkinson Disease, Secondary",MESH:D010302,1,Trichloroethylene,0,
gene expression,GO:0010467,Parkinson Disease,MESH:D010300,6,Air Pollutants|Nitric Oxide|Nitrogen Dioxide|Ozone|Particulate Matter|Soot,7,CNTNAP2|CP|DDC|EDN1|GFAP|IL6|SOD1
gene expression,GO:0010467,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
gene expression,GO:0010467,"Parkinson Disease, Secondary",MESH:D010302,2,Benzo(a)pyrene|Doxorubicin,1,SHH
gene expression,GO:0010467,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Particulate Matter,1,DDC
general adaptation syndrome,GO:0051866,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
generation of neurons,GO:0048699,Parkinson Disease,MESH:D010300,0,,1,MAPT
generation of neurons,GO:0048699,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
generation of neurons,GO:0048699,Parkinsonian Disorders,MESH:D020734,0,,1,MAPT
generation of ovulation cycle rhythm,GO:0060112,Parkinson Disease,MESH:D010300,1,Estradiol,0,
generation of precursor metabolites and energy,GO:0006091,Parkinson Disease,MESH:D010300,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
generation of precursor metabolites and energy,GO:0006091,"Parkinson Disease, Secondary",MESH:D010302,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
generation of precursor metabolites and energy,GO:0006091,Parkinsonian Disorders,MESH:D020734,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
genomic imprinting,GO:0071514,Parkinson Disease,MESH:D010300,1,Pesticides,1,IGF2
genomic imprinting,GO:0071514,"Parkinson Disease, Secondary",MESH:D010302,1,Pesticides,0,
germ cell development,GO:0007281,Parkinson Disease,MESH:D010300,2,"Fungicides, Industrial|Particulate Matter",0,
germ cell development,GO:0007281,Parkinsonian Disorders,MESH:D020734,2,Particulate Matter|taxifolin,0,
germinal center B cell differentiation,GO:0002314,Parkinson Disease,MESH:D010300,0,,1,IL6
gland morphogenesis,GO:0022612,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|tetrachloroisophthalonitrile,0,
glial cell activation,GO:0061900,Parkinson Disease,MESH:D010300,8,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Air Pollutants|Aprepitant|Manganese|Minocycline|Paclitaxel|Particulate Matter|Rotenone",0,
glial cell activation,GO:0061900,"Parkinson Disease, Secondary",MESH:D010302,5,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|geraniol|Manganese|Minocycline|Rotenone",0,
glial cell activation,GO:0061900,Parkinsonian Disorders,MESH:D020734,6,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|geraniol|Manganese|manganese chloride|Particulate Matter|Rotenone",0,
glial cell-derived neurotrophic factor receptor signaling pathway,GO:0035860,Parkinson Disease,MESH:D010300,0,,1,GDNF
glial cell-derived neurotrophic factor receptor signaling pathway,GO:0035860,"Parkinson Disease, Secondary",MESH:D010302,0,,1,GDNF
glial cell-derived neurotrophic factor receptor signaling pathway,GO:0035860,Parkinsonian Disorders,MESH:D020734,0,,1,GDNF
glial cell differentiation,GO:0010001,Parkinsonian Disorders,MESH:D020734,1,Curcumin,0,
glial cell fate commitment,GO:0021781,Parkinson Disease,MESH:D010300,1,Propranolol,0,
glial cell fate commitment,GO:0021781,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Propranolol,0,
glial cell growth,GO:0042065,Parkinson Disease,MESH:D010300,2,Particulate Matter|Vehicle Emissions,0,
glial cell growth,GO:0042065,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
glial cell proliferation,GO:0014009,Parkinson Disease,MESH:D010300,0,,1,CNTNAP2
globus pallidus development,GO:0021759,Parkinson Disease,MESH:D010300,1,Manganese,0,
globus pallidus development,GO:0021759,"Parkinson Disease, Secondary",MESH:D010302,1,Manganese,0,
globus pallidus development,GO:0021759,Parkinsonian Disorders,MESH:D020734,1,Manganese,0,
glomerular basement membrane development,GO:0032836,Parkinson Disease,MESH:D010300,1,Caffeine,0,
glomerular endothelium development,GO:0072011,Parkinson Disease,MESH:D010300,0,,1,EDN1
glomerular filtration,GO:0003094,Parkinson Disease,MESH:D010300,10,Aspirin|Domperidone|Dopamine|Lead|Lipopolysaccharides|Naproxen|Nitric Oxide|Particulate Matter|Pesticides|Trichloroethylene,1,EDN1
glomerular filtration,GO:0003094,"Parkinson Disease, Secondary",MESH:D010302,6,Amlodipine|Diltiazem|Nicotine|Nifedipine|Pesticides|Trichloroethylene,0,
glomerular filtration,GO:0003094,Parkinsonian Disorders,MESH:D020734,8,Amlodipine|Amphotericin B|Cadmium|Clonidine|Dopamine|Indomethacin|Lipopolysaccharides|Particulate Matter,0,
glomerular filtration,GO:0003094,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Diltiazem|Isoproterenol,0,
glucagon secretion,GO:0070091,Parkinson Disease,MESH:D010300,0,,1,IL6
glucocorticoid metabolic process,GO:0008211,Parkinson Disease,MESH:D010300,1,Ozone,0,
glucocorticoid secretion,GO:0035933,Parkinson Disease,MESH:D010300,1,4-phenylbutyric acid,0,
gluconeogenesis,GO:0006094,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
gluconeogenesis,GO:0006094,Parkinson Disease,MESH:D010300,8,1-Methyl-4-phenylpyridinium|Atrazine|Carbon Tetrachloride|Endosulfan|Fatty Acids|Glutathione Disulfide|Permethrin|Trichloroethylene,3,ENO2|FBP1|PPARGC1A
gluconeogenesis,GO:0006094,"Parkinson Disease, Secondary",MESH:D010302,6,Atrazine|Diltiazem|Nicotine|Nifedipine|Resveratrol|Trichloroethylene,0,
gluconeogenesis,GO:0006094,Parkinsonian Disorders,MESH:D020734,5,1-Methyl-4-phenylpyridinium|Cephaloridine|ginsenoside Re|Permethrin|Resveratrol,1,GAPDH
gluconeogenesis,GO:0006094,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Diltiazem|Isoproterenol,0,
glucose 6-phosphate metabolic process,GO:0051156,Parkinson Disease,MESH:D010300,1,Rotenone,0,
glucose 6-phosphate metabolic process,GO:0051156,"Parkinson Disease, Secondary",MESH:D010302,3,Amiodarone|Doxorubicin|Rotenone,0,
glucose 6-phosphate metabolic process,GO:0051156,Parkinsonian Disorders,MESH:D020734,2,Amiodarone|Rotenone,0,
glucose 6-phosphate metabolic process,GO:0051156,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
glucose catabolic process,GO:0006007,Parkinson Disease,MESH:D010300,4,Estradiol|Ketoconazole|Manganese|Permethrin,0,
glucose catabolic process,GO:0006007,"Parkinson Disease, Secondary",MESH:D010302,2,Manganese|Resveratrol,0,
glucose catabolic process,GO:0006007,Parkinsonian Disorders,MESH:D020734,5,Curcumin|Ketoconazole|Manganese|Permethrin|Resveratrol,0,
glucose catabolic process to lactate,GO:0019659,Parkinson Disease,MESH:D010300,1,Atrazine,0,
glucose catabolic process to lactate,GO:0019659,"Parkinson Disease, Secondary",MESH:D010302,1,Atrazine,0,
glucose homeostasis,GO:0042593,Parkinson Disease,MESH:D010300,15,4-phenylbutyric acid|Air Pollutants|Atrazine|Chlorpyrifos|Diazinon|Dicamba|Estradiol|Lead|Lipopolysaccharides|Melatonin|Nitrogen Dioxide|Particulate Matter|Pentoxifylline|Rotenone|Zinc,6,CP|IGF1R|IL6|INS|INSR|PARK7
glucose homeostasis,GO:0042593,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
glucose homeostasis,GO:0042593,"Parkinson Disease, Secondary",MESH:D010302,11,Atrazine|Benzo(a)pyrene|Carbamazepine|Dichlorvos|geraniol|Melatonin|Nicotine|Resveratrol|Rotenone|Sulpiride|thymoquinone,0,
glucose homeostasis,GO:0042593,Parkinsonian Disorders,MESH:D020734,12,Cadmium|Centella asiatica extract|Curcumin|cypermethrin|geraniol|Lipopolysaccharides|Melatonin|Particulate Matter|Plant Extracts|Plant Preparations|Resveratrol|Rotenone,1,PARK7
glucose import,GO:0046323,Parkinson Disease,MESH:D010300,8,Air Pollutants|Hexachlorocyclohexane|Lead|Lipopolysaccharides|Paraquat|Particulate Matter|Permethrin|Pioglitazone,2,DRD1|SLC2A14
glucose import,GO:0046323,"Parkinson Disease, Secondary",MESH:D010302,4,3-methyladenine|Doxorubicin|Paraquat|Valproic Acid,0,
glucose import,GO:0046323,Parkinsonian Disorders,MESH:D020734,9,Cadmium|ginsenoside Re|Lipopolysaccharides|Paraquat|Particulate Matter|Permethrin|Plant Extracts|Rimonabant|Valproic Acid,0,
glucose import across plasma membrane,GO:0098708,Parkinson Disease,MESH:D010300,1,Sirolimus,0,
glucose import across plasma membrane,GO:0098708,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
glucose import across plasma membrane,GO:0098708,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
glucose import in response to insulin stimulus,GO:0044381,Parkinson Disease,MESH:D010300,1,Pioglitazone,0,
glucose metabolic process,GO:0006006,Parkinson Disease,MESH:D010300,16,Acrolein|Air Pollutants|Atrazine|Chlorpyrifos|Eicosapentaenoic Acid|Endosulfan|Lead|Lipopolysaccharides|Melatonin|Nitrogen Dioxide|Ozone|Particulate Matter|Pioglitazone|tetrachloroisophthalonitrile|Zinc|Ziram,3,IGF2|INS|TNF
glucose metabolic process,GO:0006006,"Parkinson Disease, Secondary",MESH:D010302,9,Amiodarone|Atrazine|Benzo(a)pyrene|Diltiazem|Doxorubicin|Exenatide|Melatonin|Resveratrol|Ziram,0,
glucose metabolic process,GO:0006006,Parkinsonian Disorders,MESH:D020734,8,Amiodarone|Cadmium|Lipopolysaccharides|mancozeb|Melatonin|Particulate Matter|Procaine|Resveratrol,1,GAPDH
glucose metabolic process,GO:0006006,Wolff-Parkinson-White Syndrome,MESH:D014927,3,Amiodarone|Diltiazem|Isoproterenol,0,
glucose transmembrane transport,GO:1904659,Parkinson Disease,MESH:D010300,1,Estradiol,1,SLC2A14
glucose transmembrane transport,GO:1904659,"Parkinson Disease, Secondary",MESH:D010302,1,3-methyladenine,0,
glucose transmembrane transport,GO:1904659,Parkinsonian Disorders,MESH:D020734,3,Cadmium|ginsenoside Re|Plant Extracts,0,
glucosylceramide biosynthetic process,GO:0006679,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
glucosylceramide biosynthetic process,GO:0006679,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
glucosylceramide catabolic process,GO:0006680,Parkinson Disease,MESH:D010300,0,,1,GBA1
glucosylceramide catabolic process,GO:0006680,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
glucosylceramide catabolic process,GO:0006680,Parkinsonian Disorders,MESH:D020734,0,,1,GBA1
glucosylceramide metabolic process,GO:0006678,Parkinson Disease,MESH:D010300,0,,1,GBA1
glucosylceramide metabolic process,GO:0006678,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
glucosylceramide metabolic process,GO:0006678,Parkinsonian Disorders,MESH:D020734,0,,1,GBA1
glucuronate biosynthetic process,GO:0046399,Parkinson Disease,MESH:D010300,1,Permethrin,0,
glucuronate biosynthetic process,GO:0046399,Parkinsonian Disorders,MESH:D020734,1,Permethrin,0,
glucuronate metabolic process,GO:0019585,Parkinson Disease,MESH:D010300,1,Atrazine,0,
glucuronate metabolic process,GO:0019585,"Parkinson Disease, Secondary",MESH:D010302,1,Atrazine,0,
glutamate biosynthetic process,GO:0006537,Parkinson Disease,MESH:D010300,7,Carbon Tetrachloride|Chlorpyrifos|Endosulfan|Levodopa|Paraquat|Rotenone|valbenazine,0,
glutamate biosynthetic process,GO:0006537,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
glutamate biosynthetic process,GO:0006537,"Parkinson Disease, Secondary",MESH:D010302,3,Levodopa|Paraquat|Rotenone,0,
glutamate biosynthetic process,GO:0006537,Parkinsonian Disorders,MESH:D020734,5,6-methyl-2-(phenylethynyl)pyridine|Levodopa|Paraquat|Quinpirole|Rotenone,0,
glutamate catabolic process,GO:0006538,Parkinson Disease,MESH:D010300,1,Rotenone,0,
glutamate catabolic process,GO:0006538,"Parkinson Disease, Secondary",MESH:D010302,1,Rotenone,0,
glutamate catabolic process,GO:0006538,Parkinsonian Disorders,MESH:D020734,1,Rotenone,0,
glutamate metabolic process,GO:0006536,Parkinson Disease,MESH:D010300,5,Caffeine|Endosulfan|Methamphetamine|Ozone|Particulate Matter,0,
glutamate metabolic process,GO:0006536,"Parkinson Disease, Secondary",MESH:D010302,3,Doxorubicin|Methamphetamine|Valproic Acid,0,
glutamate metabolic process,GO:0006536,Parkinsonian Disorders,MESH:D020734,2,Particulate Matter|Valproic Acid,0,
glutamate metabolic process,GO:0006536,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
glutamatergic neuron differentiation,GO:1905962,Parkinson Disease,MESH:D010300,0,,1,CNTNAP2
glutamate secretion,GO:0014047,Parkinson Disease,MESH:D010300,0,,1,BDNF
glutamate secretion,GO:0014047,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
glutamine biosynthetic process,GO:0006542,Parkinson Disease,MESH:D010300,2,Carbon Tetrachloride|Endosulfan,0,
glutamine catabolic process,GO:0006543,Parkinson Disease,MESH:D010300,1,Rotenone,0,
glutamine catabolic process,GO:0006543,"Parkinson Disease, Secondary",MESH:D010302,1,Rotenone,0,
glutamine catabolic process,GO:0006543,Parkinsonian Disorders,MESH:D020734,1,Rotenone,0,
glutamine metabolic process,GO:0006541,Parkinson Disease,MESH:D010300,2,Endosulfan|Particulate Matter,0,
glutamine metabolic process,GO:0006541,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
glutamine transport,GO:0006868,Parkinson Disease,MESH:D010300,0,,1,SLC38A2
glutathione biosynthetic process,GO:0006750,Parkinson Disease,MESH:D010300,44,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|2,4,5-Trichlorophenoxyacetic Acid|4-phenylbutyric acid|Acrolein|Air Pollutants|Aluminum|Aspirin|Atrazine|Caffeine|Carbon Tetrachloride|Chlorpyrifos|Clozapine|Copper|Dopamine|Endosulfan|Glutathione Disulfide|Hexachlorocyclohexane|Iron|Ketoconazole|Lead|Lipopolysaccharides|Lithium Carbonate|Maneb|Manganese|mangiferin|Melatonin|Methamphetamine|Oxidopamine|Ozone|Paraquat|Particulate Matter|Pioglitazone|Polychlorinated Biphenyls|ropinirole|Rotenone|Selegiline|Sirolimus|Smoke|Soot|Testosterone|Vehicle Emissions|Water Pollutants, Chemical|Zinc",0,
glutathione biosynthetic process,GO:0006750,"Parkinson Disease, Secondary",MESH:D010302,30,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Amiodarone|Atrazine|Benzo(a)pyrene|Chlorpromazine|Cimetidine|Dichlorvos|Doxorubicin|Exenatide|Famotidine|geraniol|Lithium Carbonate|Maneb|Manganese|Melatonin|Methamphetamine|Methotrexate|Nicotine|Oxidopamine|Paraquat|Phenytoin|PQQ Cofactor|Resveratrol|Rotenone|Silymarin|sodium bisulfide|Tacrine|thymoquinone|Valproic Acid|Venlafaxine Hydrochloride",0,
glutathione biosynthetic process,GO:0006750,Parkinsonian Disorders,MESH:D020734,36,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|4-hydroxy-2-nonenal|Amiodarone|Arecoline|Cadmium|Centella asiatica extract|Chlorpromazine|Clozapine|coenzyme Q10|crocin|Curcumin|cypermethrin|Docosahexaenoic Acids|Dopamine|geraniol|ginsenoside Re|Indomethacin|Ketoconazole|Lipopolysaccharides|mancozeb|Maneb|Manganese|manganese chloride|Melatonin|Oxidopamine|Paraquat|Particulate Matter|Plant Extracts|Plant Preparations|Resveratrol|ropinirole|Rotenone|Selegiline|Silymarin|Valproic Acid",0,
glutathione biosynthetic process,GO:0006750,Wolff-Parkinson-White Syndrome,MESH:D014927,3,Amiodarone|Isoproterenol|Quinidine,0,
glutathione catabolic process,GO:0006751,Parkinson Disease,MESH:D010300,1,Carbon Tetrachloride,0,
glutathione catabolic process,GO:0006751,"Parkinson Disease, Secondary",MESH:D010302,2,Risperidone|Trifluoperazine,0,
glutathione catabolic process,GO:0006751,Parkinsonian Disorders,MESH:D020734,4,coenzyme Q10|Curcumin|Risperidone|Trifluoperazine,0,
glutathione catabolic process,GO:0006751,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
glutathione derivative biosynthetic process,GO:1901687,Parkinson Disease,MESH:D010300,9,"Carbon Tetrachloride|Chlorpyrifos|Copper|Eugenol|Glutathione Disulfide|Ketoconazole|pendimethalin|Rotenone|Water Pollutants, Chemical",2,GSTM1|GSTP1
glutathione derivative biosynthetic process,GO:1901687,"Parkinson Disease, Secondary",MESH:D010302,6,Benzo(a)pyrene|Fluoxetine|geraniol|Methotrexate|Resveratrol|Rotenone,0,
glutathione derivative biosynthetic process,GO:1901687,Parkinsonian Disorders,MESH:D020734,6,cypermethrin|geraniol|Ketoconazole|Plant Extracts|Resveratrol|Rotenone,0,
glutathione metabolic process,GO:0006749,Parkinson Disease,MESH:D010300,55,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|4-phenylbutyric acid|Acrolein|Air Pollutants|Aluminum|Aspirin|Atrazine|Caffeine|carbidopa, levodopa drug combination|Carbon Tetrachloride|Chlorpyrifos|Copper|Ditiocarb|Eicosapentaenoic Acid|Endosulfan|Estradiol|Eugenol|Glutathione Disulfide|Homocysteine|Iron|Ketoconazole|Lead|Lipopolysaccharides|Maneb|Manganese|mangiferin|Melatonin|Mirtazapine|Naproxen|Oxidopamine|Ozone|Paclitaxel|Paraquat|Particulate Matter|pendimethalin|Permethrin|Pioglitazone|Pramipexole|Probenecid|Propranolol|Reactive Oxygen Species|Reserpine|Rivastigmine|Roflumilast|Rotenone|Sirolimus|Smoke|Soot|Tea|Testosterone|tetrachloroisophthalonitrile|Trichloroethylene|Vehicle Emissions|Zinc",5,GSTA4|GSTM1|GSTP1|SOD1|SOD2
glutathione metabolic process,GO:0006749,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Pramipexole,0,
glutathione metabolic process,GO:0006749,"Parkinson Disease, Secondary",MESH:D010302,36,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|3-methyladenine|Amlodipine|Atrazine|Benzo(a)pyrene|Carbamazepine|carbidopa, levodopa drug combination|Dichlorvos|Ditiocarb|Doxorubicin|Famotidine|Fluoxetine|geraniol|Maneb|Manganese|Melatonin|Methotrexate|Nicotine|Nifedipine|Oxidopamine|Paraquat|Paroxetine|PQQ Cofactor|Reserpine|Resveratrol|Ribavirin|Rotenone|Sertraline|Silymarin|sodium bisulfide|thymoquinone|Trazodone|Trichloroethylene|Valproic Acid|Verapamil|Vincristine",0,
glutathione metabolic process,GO:0006749,Parkinsonian Disorders,MESH:D020734,44,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Amitriptyline|Amlodipine|baicalin|Cadmium|carbidopa, levodopa drug combination|coenzyme Q10|crocin|Curcumin|cypermethrin|Disulfiram|Docosahexaenoic Acids|Donepezil|Felbamate|geraniol|Indomethacin|Ketoconazole|linsidomine|Lipopolysaccharides|Malondialdehyde|mancozeb|Maneb|Manganese|manganese chloride|Melatonin|Oxidopamine|Paraquat|Paroxetine|Particulate Matter|Permethrin|Plant Extracts|Plant Preparations|Pramipexole|Probenecid|Reserpine|Resveratrol|Rivastigmine|Rotenone|Sertraline|Silymarin|taxifolin|Valproic Acid|Verapamil",1,GSR
glutathione metabolic process,GO:0006749,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Isoproterenol|Propranolol,0,
glutathione transport,GO:0034635,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
glutathione transport,GO:0034635,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
glutathione transport,GO:0034635,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Resveratrol,0,
glyceraldehyde-3-phosphate biosynthetic process,GO:0046166,Parkinsonian Disorders,MESH:D020734,0,,1,GAPDH
glyceraldehyde-3-phosphate metabolic process,GO:0019682,Parkinson Disease,MESH:D010300,0,,1,TALDO1
glycerol-3-phosphate biosynthetic process,GO:0046167,Parkinson Disease,MESH:D010300,1,Permethrin,1,GPDH1
glycerol-3-phosphate biosynthetic process,GO:0046167,Parkinsonian Disorders,MESH:D020734,1,Permethrin,0,
glycerol-3-phosphate catabolic process,GO:0046168,Parkinson Disease,MESH:D010300,0,,1,GPDH1
glycerol-3-phosphate metabolic process,GO:0006072,Parkinson Disease,MESH:D010300,1,Rotenone,1,GPDH1
glycerol-3-phosphate metabolic process,GO:0006072,"Parkinson Disease, Secondary",MESH:D010302,2,Doxorubicin|Rotenone,0,
glycerol-3-phosphate metabolic process,GO:0006072,Parkinsonian Disorders,MESH:D020734,1,Rotenone,0,
glycerol biosynthetic process,GO:0006114,Parkinson Disease,MESH:D010300,1,Permethrin,0,
glycerol biosynthetic process,GO:0006114,Parkinsonian Disorders,MESH:D020734,1,Permethrin,0,
glycerol biosynthetic process from pyruvate,GO:0046327,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
glycerol biosynthetic process from pyruvate,GO:0046327,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
glycerolipid biosynthetic process,GO:0045017,Parkinson Disease,MESH:D010300,1,Fatty Acids,0,
glycerol metabolic process,GO:0006071,"Parkinson Disease, Secondary",MESH:D010302,1,Amiodarone,0,
glycerol metabolic process,GO:0006071,Parkinsonian Disorders,MESH:D020734,1,Amiodarone,0,
glycerol metabolic process,GO:0006071,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
glycerol transmembrane transport,GO:0015793,Parkinson Disease,MESH:D010300,1,Caffeine,0,
glycerol transmembrane transport,GO:0015793,Parkinsonian Disorders,MESH:D020734,1,Plant Extracts,0,
glycerophosphate shuttle,GO:0006127,Parkinson Disease,MESH:D010300,0,,1,GPDH1
glycerophospholipid biosynthetic process,GO:0046474,Parkinson Disease,MESH:D010300,1,Paraquat,0,
glycerophospholipid biosynthetic process,GO:0046474,"Parkinson Disease, Secondary",MESH:D010302,1,Paraquat,0,
glycerophospholipid biosynthetic process,GO:0046474,Parkinsonian Disorders,MESH:D020734,1,Paraquat,0,
glycerophospholipid metabolic process,GO:0006650,Parkinson Disease,MESH:D010300,5,1-Methyl-4-phenylpyridinium|Air Pollutants|Lipopolysaccharides|Particulate Matter|Vehicle Emissions,0,
glycerophospholipid metabolic process,GO:0006650,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
glycerophospholipid metabolic process,GO:0006650,Parkinsonian Disorders,MESH:D020734,4,1-Methyl-4-phenylpyridinium|Indomethacin|Lipopolysaccharides|Particulate Matter,0,
glycine betaine transport,GO:0031460,Parkinson Disease,MESH:D010300,0,,1,SLC38A2
glycine biosynthetic process,GO:0006545,Parkinson Disease,MESH:D010300,1,Permethrin,0,
glycine biosynthetic process,GO:0006545,Parkinsonian Disorders,MESH:D020734,1,Permethrin,0,
glycine metabolic process,GO:0006544,Parkinson Disease,MESH:D010300,1,Endosulfan,0,
glycine metabolic process,GO:0006544,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
glycine metabolic process,GO:0006544,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
glycogen biosynthetic process,GO:0005978,Parkinson Disease,MESH:D010300,5,Lipopolysaccharides|Lithium Carbonate|mangiferin|Pioglitazone|Sirolimus,0,
glycogen biosynthetic process,GO:0005978,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,TBP
glycogen biosynthetic process,GO:0005978,"Parkinson Disease, Secondary",MESH:D010302,2,Lithium Carbonate|Nicotine,0,
glycogen biosynthetic process,GO:0005978,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Plant Extracts,0,
glycogen catabolic process,GO:0005980,Parkinson Disease,MESH:D010300,4,Caffeine|Dopamine|Naproxen|Propranolol,0,
glycogen catabolic process,GO:0005980,"Parkinson Disease, Secondary",MESH:D010302,3,Diltiazem|Methotrexate|Nifedipine,0,
glycogen catabolic process,GO:0005980,Parkinsonian Disorders,MESH:D020734,1,Dopamine,0,
glycogen catabolic process,GO:0005980,Wolff-Parkinson-White Syndrome,MESH:D014927,3,Diltiazem|Isoproterenol|Propranolol,0,
glycogen metabolic process,GO:0005977,Parkinson Disease,MESH:D010300,5,Air Pollutants|Chlorpyrifos|Ozone|Particulate Matter|Rotenone,0,
glycogen metabolic process,GO:0005977,"Parkinson Disease, Secondary",MESH:D010302,1,Rotenone,0,
glycogen metabolic process,GO:0005977,Parkinsonian Disorders,MESH:D020734,5,Cadmium|cypermethrin|Particulate Matter|Plant Extracts|Rotenone,0,
glycogen metabolic process,GO:0005977,Wolff-Parkinson-White Syndrome,MESH:D014927,0,,1,PRKAG2
glycolate biosynthetic process,GO:0046295,Parkinson Disease,MESH:D010300,1,Permethrin,1,PARK7
glycolate biosynthetic process,GO:0046295,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
glycolate biosynthetic process,GO:0046295,Parkinsonian Disorders,MESH:D020734,1,Permethrin,2,DJ-1BETA|PARK7
glycolipid biosynthetic process,GO:0009247,Parkinson Disease,MESH:D010300,1,Paraquat,0,
glycolipid biosynthetic process,GO:0009247,"Parkinson Disease, Secondary",MESH:D010302,1,Paraquat,0,
glycolipid biosynthetic process,GO:0009247,Parkinsonian Disorders,MESH:D020734,1,Paraquat,0,
glycolytic process,GO:0006096,Parkinson Disease,MESH:D010300,11,Aspirin|Estradiol|Lead|Lipopolysaccharides|Melatonin|Paraquat|Permethrin|Propranolol|Rotenone|Sirolimus|Vehicle Emissions,2,ENO2|GPDH1
glycolytic process,GO:0006096,"Parkinson Disease, Secondary",MESH:D010302,7,3-methyladenine|Diltiazem|Doxorubicin|Melatonin|Paraquat|Pyridostigmine Bromide|Rotenone,0,
glycolytic process,GO:0006096,Parkinsonian Disorders,MESH:D020734,7,Cadmium|coenzyme Q10|Lipopolysaccharides|Melatonin|Paraquat|Permethrin|Rotenone,1,GAPDH
glycolytic process,GO:0006096,Wolff-Parkinson-White Syndrome,MESH:D014927,4,Diltiazem|Isoproterenol|Propranolol|Quinidine,0,
glycoprotein biosynthetic process,GO:0009101,"Parkinson Disease, Secondary",MESH:D010302,1,Cimetidine,0,
glycoprotein metabolic process,GO:0009100,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,0,
glycoprotein metabolic process,GO:0009100,Parkinsonian Disorders,MESH:D020734,1,Valproic Acid,0,
glycosaminoglycan metabolic process,GO:0030203,Parkinson Disease,MESH:D010300,1,Carbon Tetrachloride,0,
glycoside metabolic process,GO:0016137,Parkinson Disease,MESH:D010300,0,,1,TH
glycoside metabolic process,GO:0016137,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
glycoside metabolic process,GO:0016137,Parkinsonian Disorders,MESH:D020734,1,oleuropein,1,TH
glycoside metabolic process,GO:0016137,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
glycosphingolipid biosynthetic process,GO:0006688,Parkinson Disease,MESH:D010300,2,Ketoconazole|Ozone,0,
glycosphingolipid biosynthetic process,GO:0006688,Parkinsonian Disorders,MESH:D020734,1,Ketoconazole,0,
glycosylation,GO:0070085,Parkinson Disease,MESH:D010300,4,Apomorphine|Aspirin|Dopamine|Propranolol,0,
glycosylation,GO:0070085,"Parkinson Disease, Secondary",MESH:D010302,3,Apomorphine|Flupenthixol|Haloperidol,0,
glycosylation,GO:0070085,Parkinsonian Disorders,MESH:D020734,4,Apomorphine|Dopamine|Haloperidol|Pimozide,0,
glycosylation,GO:0070085,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Propranolol,0,
glyoxal catabolic process,GO:1903190,Parkinson Disease,MESH:D010300,0,,1,PARK7
glyoxal catabolic process,GO:1903190,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
glyoxal catabolic process,GO:1903190,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
glyoxal metabolic process,GO:1903189,Parkinson Disease,MESH:D010300,0,,1,PARK7
glyoxal metabolic process,GO:1903189,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
glyoxal metabolic process,GO:1903189,Parkinsonian Disorders,MESH:D020734,0,,2,DJ-1BETA|PARK7
Golgi lumen acidification,GO:0061795,"PARKINSONISM WITH SPASTICITY, X-LINKED",OMIM:300911,0,,1,ATP6AP2
Golgi organization,GO:0007030,Parkinson Disease,MESH:D010300,2,Maneb|Paraquat,3,BAG5|GAK|LRRK2
Golgi organization,GO:0007030,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
Golgi organization,GO:0007030,"Parkinson Disease, Secondary",MESH:D010302,2,Maneb|Paraquat,0,
Golgi organization,GO:0007030,Parkinsonian Disorders,MESH:D020734,2,Maneb|Paraquat,1,LRRK2
Golgi to endosome transport,GO:0006895,"PARKINSON DISEASE 23, AUTOSOMAL RECESSIVE EARLY-ONSET",OMIM:616840,0,,1,VPS13C
Golgi to lysosome transport,GO:0090160,Parkinson Disease,MESH:D010300,0,,1,GAK
gonadotropin secretion,GO:0032274,Parkinsonian Disorders,MESH:D020734,1,cypermethrin,0,
GPI anchor biosynthetic process,GO:0006506,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
G protein-coupled receptor internalization,GO:0002031,Parkinson Disease,MESH:D010300,0,,1,DRD2
G protein-coupled receptor internalization,GO:0002031,Parkinsonian Disorders,MESH:D020734,0,,1,DRD2
G protein-coupled receptor signaling pathway,GO:0007186,Parkinson Disease,MESH:D010300,0,,6,DRD1|DRD2|EDN1|IGF2R|INS|INSR
G protein-coupled receptor signaling pathway,GO:0007186,"Parkinson Disease, Secondary",MESH:D010302,0,,2,CNR2|RGS2
G protein-coupled receptor signaling pathway,GO:0007186,Parkinsonian Disorders,MESH:D020734,0,,2,DOP1R2|DRD2
G protein-coupled receptor signaling pathway coupled to cGMP nucleotide second messenger,GO:0007199,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
"G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger",GO:0007187,Parkinson Disease,MESH:D010300,0,,1,DRD1
"G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger",GO:0007187,"Parkinson Disease, Secondary",MESH:D010302,0,,1,CNR2
G protein-coupled serotonin receptor signaling pathway,GO:0098664,Parkinson Disease,MESH:D010300,0,,1,DRD1
granulocyte activation,GO:0036230,Parkinson Disease,MESH:D010300,1,Reactive Oxygen Species,0,
granuloma formation,GO:0002432,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
granulosa cell proliferation,GO:1990739,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
granulosa cell proliferation,GO:1990739,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
grooming behavior,GO:0007625,Parkinson Disease,MESH:D010300,9,"2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine|Chlorpyrifos|Diazepam|Lead|Manganese|mangiferin|Melatonin|Pioglitazone|Rotenone",3,CNTNAP2|DRD1|DRD2
grooming behavior,GO:0007625,"Parkinson Disease, Secondary",MESH:D010302,6,Diazepam|Manganese|Melatonin|Nicotine|Rotenone|Valproic Acid,0,
grooming behavior,GO:0007625,Parkinsonian Disorders,MESH:D020734,8,"2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine|Cadmium|Donepezil|Manganese|Melatonin|Rimonabant|Rotenone|Valproic Acid",1,DRD2
growth,GO:0040007,Parkinson Disease,MESH:D010300,4,Copper|Estradiol|Lipopolysaccharides|Rotenone,0,
growth,GO:0040007,"Parkinson Disease, Secondary",MESH:D010302,2,Benzo(a)pyrene|Rotenone,0,
growth,GO:0040007,Parkinsonian Disorders,MESH:D020734,3,Cadmium|Lipopolysaccharides|Rotenone,0,
growth involved in heart morphogenesis,GO:0003241,Parkinson Disease,MESH:D010300,1,Estradiol,0,
growth plate cartilage chondrocyte proliferation,GO:0003419,Parkinson Disease,MESH:D010300,1,Manganese,0,
growth plate cartilage chondrocyte proliferation,GO:0003419,"Parkinson Disease, Secondary",MESH:D010302,1,Manganese,0,
growth plate cartilage chondrocyte proliferation,GO:0003419,Parkinsonian Disorders,MESH:D020734,1,Manganese,0,
growth plate cartilage development,GO:0003417,Parkinsonian Disorders,MESH:D020734,1,Disulfiram,0,
growth plate cartilage morphogenesis,GO:0003422,Parkinson Disease,MESH:D010300,1,Rotenone,0,
growth plate cartilage morphogenesis,GO:0003422,"Parkinson Disease, Secondary",MESH:D010302,1,Rotenone,0,
growth plate cartilage morphogenesis,GO:0003422,Parkinsonian Disorders,MESH:D020734,1,Rotenone,0,
GTP biosynthetic process,GO:0006183,Parkinson Disease,MESH:D010300,1,Polychlorinated Biphenyls,0,
GTP metabolic process,GO:0046039,Parkinson Disease,MESH:D010300,1,Trichloroethylene,1,LRRK2
GTP metabolic process,GO:0046039,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
GTP metabolic process,GO:0046039,"Parkinson Disease, Secondary",MESH:D010302,1,Trichloroethylene,0,
GTP metabolic process,GO:0046039,Parkinsonian Disorders,MESH:D020734,0,,1,LRRK2
guanine biosynthetic process,GO:0046099,Parkinson Disease,MESH:D010300,1,1-Methyl-4-phenylpyridinium,0,
guanine biosynthetic process,GO:0046099,Parkinsonian Disorders,MESH:D020734,1,1-Methyl-4-phenylpyridinium,0,
guanine deglycation,GO:0106044,Parkinson Disease,MESH:D010300,0,,1,PARK7
guanine deglycation,GO:0106044,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
guanine deglycation,GO:0106044,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
"guanine deglycation, glyoxal removal",GO:0106046,Parkinson Disease,MESH:D010300,0,,1,PARK7
"guanine deglycation, glyoxal removal",GO:0106046,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
"guanine deglycation, glyoxal removal",GO:0106046,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
"guanine deglycation, methylglyoxal removal",GO:0106045,Parkinson Disease,MESH:D010300,0,,1,PARK7
"guanine deglycation, methylglyoxal removal",GO:0106045,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
"guanine deglycation, methylglyoxal removal",GO:0106045,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
guanine metabolic process,GO:0046098,Parkinson Disease,MESH:D010300,1,Melatonin,0,
guanine metabolic process,GO:0046098,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
guanine metabolic process,GO:0046098,Parkinsonian Disorders,MESH:D020734,1,Melatonin,0,
guanine metabolic process,GO:0046098,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
habenula development,GO:0021986,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
habituation,GO:0046959,Parkinson Disease,MESH:D010300,0,,1,DRD1
habituation,GO:0046959,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
habituation,GO:0046959,Parkinsonian Disorders,MESH:D020734,0,,2,ATP1A3|CAT-2
hair follicle development,GO:0001942,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
hair follicle morphogenesis,GO:0031069,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
halogenated hydrocarbon metabolic process,GO:0042197,Parkinson Disease,MESH:D010300,0,,1,CYP2E1
hatching,GO:0035188,Parkinson Disease,MESH:D010300,14,Air Pollutants|Atrazine|Benomyl|Caffeine|Chlorpyrifos|Endosulfan|Estradiol|Hexachlorocyclohexane|Paraquat|Particulate Matter|Sirolimus|valbenazine|Zinc|Ziram,0,
hatching,GO:0035188,"Parkinson Disease, Secondary",MESH:D010302,7,Atrazine|Benzo(a)pyrene|Carbamazepine|Doxorubicin|Paraquat|Valproic Acid|Ziram,0,
hatching,GO:0035188,Parkinsonian Disorders,MESH:D020734,6,Cadmium|Ethylenebis(dithiocarbamates)|Paraquat|Particulate Matter|Plant Extracts|Valproic Acid,0,
head development,GO:0060322,Parkinson Disease,MESH:D010300,7,Atrazine|caramiphen|Herbicides|Lead|Melatonin|Organophosphorus Compounds|Smoke,0,
head development,GO:0060322,"Parkinson Disease, Secondary",MESH:D010302,6,Atrazine|Benzo(a)pyrene|Melatonin|Organophosphorus Compounds|Pyridostigmine Bromide|Valproic Acid,0,
head development,GO:0060322,Parkinsonian Disorders,MESH:D020734,2,Melatonin|Valproic Acid,0,
head morphogenesis,GO:0060323,"PARKINSONISM WITH SPASTICITY, X-LINKED",OMIM:300911,0,,1,ATP6AP2
heart contraction,GO:0060047,Parkinson Disease,MESH:D010300,11,Air Pollutants|Caffeine|Copper|Lead|Manganese|Nitrogen Dioxide|Ozone|Paraquat|Particulate Matter|Propranolol|Ziram,2,DNM1L|SOD1
heart contraction,GO:0060047,"Parkinson Disease, Secondary",MESH:D010302,10,Amiodarone|Doxorubicin|geraniol|Manganese|Nicotine|Nifedipine|Paraquat|sodium bisulfide|Verapamil|Ziram,0,
heart contraction,GO:0060047,Parkinsonian Disorders,MESH:D020734,8,Amiodarone|Arecoline|Cadmium|geraniol|Manganese|Paraquat|Particulate Matter|Verapamil,0,
heart contraction,GO:0060047,Wolff-Parkinson-White Syndrome,MESH:D014927,4,Amiodarone|Flecainide|Isoproterenol|Propranolol,0,
heart development,GO:0007507,Parkinson Disease,MESH:D010300,11,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Air Pollutants|Caffeine|Copper|Manganese|Melatonin|Oxidopamine|Particulate Matter|pendimethalin|Rotenone|Trichloroethylene",3,EDN1|SOD2|TH
heart development,GO:0007507,"Parkinson Disease, Secondary",MESH:D010302,9,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Benzo(a)pyrene|Manganese|Melatonin|Methotrexate|Oxidopamine|Resveratrol|Rotenone|Trichloroethylene",1,SHH
heart development,GO:0007507,Parkinsonian Disorders,MESH:D020734,8,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Cadmium|Manganese|Melatonin|Oxidopamine|Particulate Matter|Resveratrol|Rotenone",2,ALDH1A2|TH
heart development,GO:0007507,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
heart formation,GO:0060914,Parkinson Disease,MESH:D010300,1,Homocysteine,0,
heart growth,GO:0060419,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
heart looping,GO:0001947,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
heart looping,GO:0001947,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A2
heart morphogenesis,GO:0003007,Parkinson Disease,MESH:D010300,0,,3,INSR|SOD2|TH
heart morphogenesis,GO:0003007,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
heart morphogenesis,GO:0003007,Parkinsonian Disorders,MESH:D020734,0,,2,ALDH1A2|TH
heart process,GO:0003015,Parkinson Disease,MESH:D010300,1,Ozone,1,EDN1
heat acclimation,GO:0010286,Parkinson Disease,MESH:D010300,1,Reserpine,0,
heat acclimation,GO:0010286,"Parkinson Disease, Secondary",MESH:D010302,2,Reserpine|Resveratrol,0,
heat acclimation,GO:0010286,Parkinsonian Disorders,MESH:D020734,2,Reserpine|Resveratrol,0,
heat dissipation,GO:0031653,Parkinsonian Disorders,MESH:D020734,1,Rimonabant,0,
heat generation,GO:0031649,Parkinson Disease,MESH:D010300,1,Methamphetamine,0,
heat generation,GO:0031649,"Parkinson Disease, Secondary",MESH:D010302,1,Methamphetamine,0,
heat shock-mediated polytene chromosome puffing,GO:0035080,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
helper T cell enhancement of B cell mediated immune response,GO:0035399,"Parkinson Disease, Secondary",MESH:D010302,1,Dichlorvos,0,
helper T cell extravasation,GO:0035684,Parkinson Disease,MESH:D010300,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
helper T cell extravasation,GO:0035684,"Parkinson Disease, Secondary",MESH:D010302,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
helper T cell extravasation,GO:0035684,Parkinsonian Disorders,MESH:D020734,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
hematopoietic progenitor cell differentiation,GO:0002244,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
hematopoietic stem cell differentiation,GO:0060218,Parkinson Disease,MESH:D010300,0,,3,IL6|MIR181C|NOS1
hematopoietic stem cell differentiation,GO:0060218,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,1,CNR2
hematopoietic stem cell differentiation,GO:0060218,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Resveratrol,0,
hematopoietic stem cell migration,GO:0035701,"Parkinson Disease, Secondary",MESH:D010302,0,,1,CNR2
hematopoietic stem cell migration to bone marrow,GO:0097241,"Parkinson Disease, Secondary",MESH:D010302,0,,1,CNR2
hematopoietic stem cell proliferation,GO:0071425,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|Pesticides,1,GBA1
hematopoietic stem cell proliferation,GO:0071425,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
hematopoietic stem cell proliferation,GO:0071425,"Parkinson Disease, Secondary",MESH:D010302,2,Cytarabine|Pesticides,0,
hematopoietic stem cell proliferation,GO:0071425,Parkinsonian Disorders,MESH:D020734,1,cypermethrin,1,GBA1
heme biosynthetic process,GO:0006783,Parkinson Disease,MESH:D010300,0,,1,HSC70-3
heme biosynthetic process,GO:0006783,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
heme catabolic process,GO:0042167,Parkinson Disease,MESH:D010300,0,,1,HMOX1
heme catabolic process,GO:0042167,"Parkinson Disease, Secondary",MESH:D010302,1,Carbon Monoxide,0,
heme catabolic process,GO:0042167,Parkinsonian Disorders,MESH:D020734,1,Curcumin,0,
heme metabolic process,GO:0042168,Parkinson Disease,MESH:D010300,1,Iron,1,HMOX1
heme metabolic process,GO:0042168,Parkinsonian Disorders,MESH:D020734,1,Indomethacin,0,
heme oxidation,GO:0006788,Parkinson Disease,MESH:D010300,0,,1,HMOX1
heme oxidation,GO:0006788,"Parkinson Disease, Secondary",MESH:D010302,1,Cimetidine,0,
hemocyte proliferation,GO:0035172,Parkinson Disease,MESH:D010300,1,Dicamba,0,
hemoglobin biosynthetic process,GO:0042541,Parkinson Disease,MESH:D010300,9,Air Pollutants|Chlorpyrifos|Eugenol|Lead|Lithium Carbonate|Nitrogen Dioxide|Particulate Matter|Pesticides|Sirolimus,0,
hemoglobin biosynthetic process,GO:0042541,"Parkinson Disease, Secondary",MESH:D010302,3,Doxorubicin|Lithium Carbonate|Pesticides,0,
hemoglobin biosynthetic process,GO:0042541,Parkinsonian Disorders,MESH:D020734,3,Particulate Matter|Phenol|Plant Extracts,0,
hemoglobin catabolic process,GO:0042540,Parkinsonian Disorders,MESH:D020734,1,Curcumin,0,
hemoglobin metabolic process,GO:0020027,Parkinson Disease,MESH:D010300,5,Chlorpyrifos|Iron|Lipopolysaccharides|Particulate Matter|Zinc,0,
hemoglobin metabolic process,GO:0020027,"Parkinson Disease, Secondary",MESH:D010302,2,Carbon Monoxide|Doxorubicin,0,
hemoglobin metabolic process,GO:0020027,Parkinsonian Disorders,MESH:D020734,4,Curcumin|Indomethacin|Lipopolysaccharides|Particulate Matter,0,
hemopoiesis,GO:0030097,Parkinson Disease,MESH:D010300,1,Lead,3,HSPA9|PINK1|SOD2
hemopoiesis,GO:0030097,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
hemopoiesis,GO:0030097,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,1,CNR2
hemopoiesis,GO:0030097,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Resveratrol,1,PINK1
hemostasis,GO:0007599,Parkinson Disease,MESH:D010300,0,,1,FGB
hepatic immune response,GO:0002384,Parkinson Disease,MESH:D010300,0,,1,IL6
hepaticobiliary system process,GO:0061007,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
hepatic stellate cell activation,GO:0035733,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,0,
hepatic stellate cell activation,GO:0035733,Parkinsonian Disorders,MESH:D020734,1,Valproic Acid,0,
hepatocyte differentiation,GO:0070365,Parkinson Disease,MESH:D010300,1,Carbon Tetrachloride,0,
hepatocyte growth factor receptor signaling pathway,GO:0048012,Parkinson Disease,MESH:D010300,0,,3,HGF|IGF1R|INSR
hepatocyte homeostasis,GO:0036333,Parkinson Disease,MESH:D010300,1,Carbon Tetrachloride,0,
hepatocyte homeostasis,GO:0036333,"Parkinson Disease, Secondary",MESH:D010302,1,Amlodipine,0,
hepatocyte homeostasis,GO:0036333,Parkinsonian Disorders,MESH:D020734,1,Amlodipine,0,
hepatocyte proliferation,GO:0072574,Parkinson Disease,MESH:D010300,1,Estradiol,1,IL6
hepoxilin biosynthetic process,GO:0051122,Parkinson Disease,MESH:D010300,0,,2,GSTM1|GSTP1
heterochromatin formation,GO:0031507,Parkinson Disease,MESH:D010300,1,Atrazine,0,
heterochromatin formation,GO:0031507,"Parkinson Disease, Secondary",MESH:D010302,1,Atrazine,0,
heterochromatin organization,GO:0070828,Parkinson Disease,MESH:D010300,0,,1,MTHFR
heterocycle metabolic process,GO:0046483,Parkinson Disease,MESH:D010300,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
heterocycle metabolic process,GO:0046483,"Parkinson Disease, Secondary",MESH:D010302,4,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Benzo(a)pyrene|Methotrimeprazine|Ribavirin",0,
heterocycle metabolic process,GO:0046483,Parkinsonian Disorders,MESH:D020734,2,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Indomethacin",0,
heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0007157,Parkinson Disease,MESH:D010300,0,,1,CEACAM6
heterotypic cell-cell adhesion,GO:0034113,Parkinson Disease,MESH:D010300,2,Lipopolysaccharides|Particulate Matter,0,
heterotypic cell-cell adhesion,GO:0034113,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
heterotypic cell-cell adhesion,GO:0034113,Parkinsonian Disorders,MESH:D020734,6,Docosahexaenoic Acids|Donepezil|Lipopolysaccharides|mancozeb|Particulate Matter|sesamin,0,
hexitol metabolic process,GO:0006059,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
hexose metabolic process,GO:0019318,Parkinson Disease,MESH:D010300,1,Zinc,0,
hexose transmembrane transport,GO:0008645,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
hexose transmembrane transport,GO:0008645,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
high-density lipoprotein particle assembly,GO:0034380,Parkinson Disease,MESH:D010300,2,Carbon Tetrachloride|Chlorpyrifos,0,
hindbrain development,GO:0030902,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
hindbrain development,GO:0030902,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A2
hindbrain morphogenesis,GO:0021575,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A2
hindgut morphogenesis,GO:0007442,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
hindlimb morphogenesis,GO:0035137,"Parkinson Disease, Secondary",MESH:D010302,1,Amiodarone,0,
hindlimb morphogenesis,GO:0035137,Parkinsonian Disorders,MESH:D020734,1,Amiodarone,1,HOTAIR
hindlimb morphogenesis,GO:0035137,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
hippocampal neuron apoptotic process,GO:0110088,Parkinson Disease,MESH:D010300,0,,1,DRAXIN
hippocampus development,GO:0021766,Parkinson Disease,MESH:D010300,2,Air Pollutants|Particulate Matter,3,DRD1|IGF1R|INSR
hippocampus development,GO:0021766,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
histamine biosynthetic process,GO:0001694,Parkinson Disease,MESH:D010300,3,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Polychlorinated Biphenyls",0,
histamine biosynthetic process,GO:0001694,"Parkinson Disease, Secondary",MESH:D010302,2,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Famotidine",0,
histamine biosynthetic process,GO:0001694,Parkinsonian Disorders,MESH:D020734,2,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium",0,
histamine metabolic process,GO:0001692,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
histamine metabolic process,GO:0001692,Parkinsonian Disorders,MESH:D020734,2,Indomethacin|Lipopolysaccharides,0,
histamine secretion,GO:0001821,Parkinson Disease,MESH:D010300,1,Estradiol,1,EDN1
histamine secretion,GO:0001821,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
histamine secretion,GO:0001821,Parkinsonian Disorders,MESH:D020734,3,Plant Extracts|Plant Preparations|Resveratrol,0,
histamine secretion by mast cell,GO:0002553,Parkinson Disease,MESH:D010300,0,,1,SLC18A2
histamine secretion by mast cell,GO:0002553,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SLC18A2
histamine secretion by mast cell,GO:0002553,Parkinsonian Disorders,MESH:D020734,1,Plant Extracts,1,SLC18A2
histamine secretion involved in inflammatory response,GO:0002441,"Parkinson Disease, Secondary",MESH:D010302,1,geraniol,0,
histamine secretion involved in inflammatory response,GO:0002441,Parkinsonian Disorders,MESH:D020734,1,geraniol,0,
histamine secretion mediated by immunoglobulin,GO:0097280,Parkinson Disease,MESH:D010300,6,Apomorphine|Astemizole|Homocysteine|Lipopolysaccharides|Lithium|Propranolol,0,
histamine secretion mediated by immunoglobulin,GO:0097280,"Parkinson Disease, Secondary",MESH:D010302,9,Apomorphine|Cimetidine|Doxorubicin|Famotidine|Lithium|Nifedipine|Perphenazine|Sulpiride|Trifluoperazine,0,
histamine secretion mediated by immunoglobulin,GO:0097280,Parkinsonian Disorders,MESH:D020734,7,Apomorphine|Clonidine|Indomethacin|Lipopolysaccharides|Perphenazine|Quinpirole|Trifluoperazine,0,
histamine secretion mediated by immunoglobulin,GO:0097280,Wolff-Parkinson-White Syndrome,MESH:D014927,3,Isoproterenol|Lithium|Propranolol,0,
histamine uptake,GO:0051615,Parkinson Disease,MESH:D010300,0,,1,SLC18A2
histamine uptake,GO:0051615,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SLC18A2
histamine uptake,GO:0051615,Parkinsonian Disorders,MESH:D020734,0,,1,SLC18A2
histidine biosynthetic process,GO:0000105,Parkinson Disease,MESH:D010300,1,Permethrin,0,
histidine biosynthetic process,GO:0000105,Parkinsonian Disorders,MESH:D020734,1,Permethrin,0,
histone acetylation,GO:0016573,Parkinson Disease,MESH:D010300,2,Estradiol|Lead,0,
histone arginine methylation,GO:0034969,"Parkinson Disease, Secondary",MESH:D010302,1,Ribavirin,0,
histone H2A-K119 monoubiquitination,GO:0036353,Parkinson Disease,MESH:D010300,1,Rotenone,0,
histone H2A-K119 monoubiquitination,GO:0036353,"Parkinson Disease, Secondary",MESH:D010302,1,Rotenone,0,
histone H2A-K119 monoubiquitination,GO:0036353,Parkinsonian Disorders,MESH:D020734,1,Rotenone,0,
histone H2A ubiquitination,GO:0033522,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
histone H3 acetylation,GO:0043966,Parkinson Disease,MESH:D010300,5,Benomyl|Carbon Tetrachloride|Lipopolysaccharides|Paraquat|Rotenone,0,
histone H3 acetylation,GO:0043966,"Parkinson Disease, Secondary",MESH:D010302,7,Doxorubicin|Fluoxetine|Paraquat|Resveratrol|Rotenone|Valproic Acid|Venlafaxine Hydrochloride,0,
histone H3 acetylation,GO:0043966,Parkinsonian Disorders,MESH:D020734,7,Curcumin|Lipopolysaccharides|manganese chloride|Paraquat|Resveratrol|Rotenone|Valproic Acid,0,
histone H3 acetylation,GO:0043966,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
histone H3 deacetylation,GO:0070932,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,0,
histone H3 deacetylation,GO:0070932,Parkinsonian Disorders,MESH:D020734,1,Valproic Acid,0,
histone H3-K14 acetylation,GO:0044154,Parkinson Disease,MESH:D010300,3,1-Methyl-4-phenylpyridinium|Caffeine|Lipopolysaccharides,0,
histone H3-K14 acetylation,GO:0044154,"Parkinson Disease, Secondary",MESH:D010302,3,Doxorubicin|Nicotine|Resveratrol,0,
histone H3-K14 acetylation,GO:0044154,Parkinsonian Disorders,MESH:D020734,4,1-Methyl-4-phenylpyridinium|Curcumin|Lipopolysaccharides|Resveratrol,0,
histone H3-K18 acetylation,GO:0043971,Parkinson Disease,MESH:D010300,1,Manganese,0,
histone H3-K18 acetylation,GO:0043971,"Parkinson Disease, Secondary",MESH:D010302,1,Manganese,0,
histone H3-K18 acetylation,GO:0043971,Parkinsonian Disorders,MESH:D020734,2,Manganese|manganese chloride,0,
histone H3-K23 acetylation,GO:0043972,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
histone H3-K23 acetylation,GO:0043972,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
histone H3-K27 acetylation,GO:0043974,Parkinson Disease,MESH:D010300,3,Caffeine|Carbon Tetrachloride|Estradiol,0,
histone H3-K27 acetylation,GO:0043974,"Parkinson Disease, Secondary",MESH:D010302,2,Nicotine|Resveratrol,0,
histone H3-K27 acetylation,GO:0043974,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
histone H3-K27 trimethylation,GO:0098532,Parkinson Disease,MESH:D010300,3,"Fungicides, Industrial|Lead|Smoke",0,
histone H3-K27 trimethylation,GO:0098532,"Parkinson Disease, Secondary",MESH:D010302,2,Benzo(a)pyrene|Resveratrol,0,
histone H3-K27 trimethylation,GO:0098532,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
histone H3-K36 dimethylation,GO:0097676,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
histone H3-K36 dimethylation,GO:0097676,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
histone H3-K36 trimethylation,GO:0097198,Parkinson Disease,MESH:D010300,1,Reactive Oxygen Species,0,
histone H3-K4 acetylation,GO:0043973,Parkinson Disease,MESH:D010300,1,Estradiol,0,
histone H3-K4 demethylation,GO:0034720,"Parkinson Disease, Secondary",MESH:D010302,1,Phenelzine,0,
histone H3-K4 demethylation,GO:0034720,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
histone H3-K4 dimethylation,GO:0044648,Parkinson Disease,MESH:D010300,2,Iron|Lead,0,
histone H3-K4 dimethylation,GO:0044648,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
histone H3-K4 trimethylation,GO:0080182,Parkinson Disease,MESH:D010300,9,"Acrolein|Atrazine|Carbon Tetrachloride|Estradiol|Fungicides, Industrial|Lead|Paraquat|Permethrin|Sirolimus",0,
histone H3-K4 trimethylation,GO:0080182,"Parkinson Disease, Secondary",MESH:D010302,2,Atrazine|Paraquat,0,
histone H3-K4 trimethylation,GO:0080182,Parkinsonian Disorders,MESH:D020734,4,Cadmium|Paraquat|Permethrin|Zidovudine,0,
histone H3-K56 acetylation,GO:0097043,Parkinson Disease,MESH:D010300,1,Carbon Tetrachloride,0,
histone H3-K9 acetylation,GO:0043970,Parkinson Disease,MESH:D010300,5,"Acrolein|Caffeine|Estradiol|Fungicides, Industrial|Lead",0,
histone H3-K9 acetylation,GO:0043970,"Parkinson Disease, Secondary",MESH:D010302,4,Doxorubicin|Nicotine|Poly I-C|Resveratrol,0,
histone H3-K9 acetylation,GO:0043970,Parkinsonian Disorders,MESH:D020734,3,Plant Extracts|Resveratrol|Zidovudine,0,
histone H3-K9 dimethylation,GO:0036123,Parkinson Disease,MESH:D010300,6,Amphetamine|Copper|Iron|Lead|Nitric Oxide|Reactive Oxygen Species,0,
histone H3-K9 dimethylation,GO:0036123,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
histone H3-K9 dimethylation,GO:0036123,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Rimonabant,0,
histone H3-K9 methylation,GO:0051567,Parkinson Disease,MESH:D010300,1,Nitric Oxide,0,
histone H3-K9 methylation,GO:0051567,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
histone H3-K9 trimethylation,GO:0036124,Parkinson Disease,MESH:D010300,4,Carbon Tetrachloride|Melatonin|Permethrin|Zinc,0,
histone H3-K9 trimethylation,GO:0036124,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
histone H3-K9 trimethylation,GO:0036124,Parkinsonian Disorders,MESH:D020734,2,Melatonin|Permethrin,0,
histone H3-R17 methylation,GO:0034971,"Parkinson Disease, Secondary",MESH:D010302,1,Ribavirin,0,
histone H4 acetylation,GO:0043967,Parkinson Disease,MESH:D010300,1,Amphetamine,0,
histone H4 acetylation,GO:0043967,"Parkinson Disease, Secondary",MESH:D010302,2,Doxorubicin|Valproic Acid,0,
histone H4 acetylation,GO:0043967,Parkinsonian Disorders,MESH:D020734,3,Curcumin|manganese chloride|Valproic Acid,0,
histone H4 deacetylation,GO:0070933,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,0,
histone H4 deacetylation,GO:0070933,Parkinsonian Disorders,MESH:D020734,1,Valproic Acid,0,
histone H4-K12 acetylation,GO:0043983,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
histone H4-K16 acetylation,GO:0043984,Parkinson Disease,MESH:D010300,1,Carbon Tetrachloride,0,
histone H4-K20 trimethylation,GO:0034773,Parkinson Disease,MESH:D010300,2,Carbon Tetrachloride|Zinc,0,
histone H4-R3 methylation,GO:0043985,Parkinson Disease,MESH:D010300,1,Endosulfan,0,
histone H4-R3 methylation,GO:0043985,"Parkinson Disease, Secondary",MESH:D010302,1,Ribavirin,0,
histone modification,GO:0016570,Parkinson Disease,MESH:D010300,2,Particulate Matter|Soot,0,
histone modification,GO:0016570,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
homeostasis of number of cells,GO:0048872,Parkinson Disease,MESH:D010300,1,Methamphetamine,1,GBA1
homeostasis of number of cells,GO:0048872,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,2,ATXN2|GBA1
homeostasis of number of cells,GO:0048872,"Parkinson Disease, Secondary",MESH:D010302,2,Methamphetamine|Valproic Acid,0,
homeostasis of number of cells,GO:0048872,Parkinsonian Disorders,MESH:D020734,2,Indomethacin|Valproic Acid,1,GBA1
homeostasis of number of cells within a tissue,GO:0048873,Parkinson Disease,MESH:D010300,1,Manganese,0,
homeostasis of number of cells within a tissue,GO:0048873,Parkinson Disease 11,MESH:C564345,0,,1,GIGYF2
homeostasis of number of cells within a tissue,GO:0048873,"Parkinson Disease, Secondary",MESH:D010302,2,Manganese|Methotrexate,0,
homeostasis of number of cells within a tissue,GO:0048873,Parkinsonian Disorders,MESH:D020734,2,Manganese|manganese chloride,0,
homocysteine biosynthetic process,GO:0071268,Parkinson Disease,MESH:D010300,1,Homocysteine,0,
homocysteine metabolic process,GO:0050667,Parkinson Disease,MESH:D010300,2,Homocysteine|Lead,1,MTHFR
homocysteine metabolic process,GO:0050667,"Parkinson Disease, Secondary",MESH:D010302,1,geraniol,0,
homocysteine metabolic process,GO:0050667,Parkinsonian Disorders,MESH:D020734,1,geraniol,0,
homocysteine metabolic process,GO:0050667,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
homologous chromosome orientation involved in meiotic metaphase I plate congression,GO:0031619,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
homologous chromosome orientation involved in meiotic metaphase I plate congression,GO:0031619,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
homologous chromosome orientation involved in meiotic metaphase I plate congression,GO:0031619,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Resveratrol,0,
homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007156,Parkinson Disease,MESH:D010300,0,,3,CEACAM6|CHP|NECTIN2
homotypic cell-cell adhesion,GO:0034109,Parkinson Disease,MESH:D010300,3,Acrolein|Paraquat|Particulate Matter,0,
homotypic cell-cell adhesion,GO:0034109,"Parkinson Disease, Secondary",MESH:D010302,1,Paraquat,0,
homotypic cell-cell adhesion,GO:0034109,Parkinsonian Disorders,MESH:D020734,3,4-hydroxy-2-nonenal|Paraquat|Particulate Matter,0,
hormone biosynthetic process,GO:0042446,Parkinson Disease,MESH:D010300,0,,1,HFE
hormone metabolic process,GO:0042445,Parkinson Disease,MESH:D010300,2,Lipopolysaccharides|Polychlorinated Biphenyls,0,
hormone metabolic process,GO:0042445,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
hormone secretion,GO:0046879,Parkinson Disease,MESH:D010300,1,Nitrates,0,
host-mediated regulation of intestinal microbiota composition,GO:0048874,Parkinson Disease,MESH:D010300,8,Air Pollutants|Chlorpyrifos|Lead|Lipopolysaccharides|Manganese|Methamphetamine|Particulate Matter|Permethrin,0,
host-mediated regulation of intestinal microbiota composition,GO:0048874,"Parkinson Disease, Secondary",MESH:D010302,5,Carbamazepine|Doxorubicin|Manganese|Methamphetamine|Pyridostigmine Bromide,0,
host-mediated regulation of intestinal microbiota composition,GO:0048874,Parkinsonian Disorders,MESH:D020734,5,Cadmium|Lipopolysaccharides|Manganese|Particulate Matter|Permethrin,0,
humoral immune response,GO:0006959,Parkinson Disease,MESH:D010300,3,Hexachlorocyclohexane|Lead|Polychlorinated Biphenyls,3,BST1|IL6|TNF
humoral immune response mediated by circulating immunoglobulin,GO:0002455,Parkinsonian Disorders,MESH:D020734,1,ginsenoside Re,0,
hyaloid vascular plexus regression,GO:1990384,Parkinson Disease,MESH:D010300,0,,3,DRD2|SLC6A3|TH
hyaloid vascular plexus regression,GO:1990384,Parkinsonian Disorders,MESH:D020734,0,,2,DRD2|TH
hyaloid vascular plexus regression,GO:1990384,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
hyaluronan metabolic process,GO:0030212,Parkinson Disease,MESH:D010300,1,Carbon Tetrachloride,0,
hydrocarbon metabolic process,GO:0120252,Parkinson Disease,MESH:D010300,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
hydrocarbon metabolic process,GO:0120252,"Parkinson Disease, Secondary",MESH:D010302,3,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Benzo(a)pyrene|Ribavirin",0,
hydrocarbon metabolic process,GO:0120252,Parkinsonian Disorders,MESH:D020734,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
hydrogen peroxide biosynthetic process,GO:0050665,Parkinson Disease,MESH:D010300,18,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Acrolein|Carbon Tetrachloride|Chlorpyrifos|Eicosapentaenoic Acid|Estradiol|Homocysteine|Lead|Lipopolysaccharides|Manganese|Melatonin|Nitric Oxide|Paraquat|Particulate Matter|Permethrin|Rotenone|Water Pollutants, Chemical",3,MAOB|SOD1|SOD2
hydrogen peroxide biosynthetic process,GO:0050665,"Parkinson Disease, Secondary",MESH:D010302,9,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Doxorubicin|Manganese|Melatonin|Paraquat|Pargyline|Resveratrol|Rotenone|Silymarin",0,
hydrogen peroxide biosynthetic process,GO:0050665,Parkinsonian Disorders,MESH:D020734,18,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Cadmium|Curcumin|Diazoxide|Docosahexaenoic Acids|echinacoside|Lipopolysaccharides|Manganese|manganese chloride|Melatonin|Paraquat|Particulate Matter|Permethrin|Plant Extracts|Resveratrol|Rotenone|Silymarin",0,
hydrogen peroxide biosynthetic process,GO:0050665,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
hydrogen peroxide catabolic process,GO:0042744,Parkinson Disease,MESH:D010300,4,Copper|Manganese|Paraquat|Rotenone,1,HBG1
hydrogen peroxide catabolic process,GO:0042744,"Parkinson Disease, Secondary",MESH:D010302,3,Manganese|Paraquat|Rotenone,0,
hydrogen peroxide catabolic process,GO:0042744,Parkinsonian Disorders,MESH:D020734,3,Manganese|Paraquat|Rotenone,0,
hydrogen peroxide metabolic process,GO:0042743,Parkinson Disease,MESH:D010300,13,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Air Pollutants|Atrazine|Carbidopa|Carbon Tetrachloride|Chlorpyrifos|Estradiol|Levodopa|Manganese|Nitric Oxide|Ozone|Paraquat|Soot",2,PARK7|SOD2
hydrogen peroxide metabolic process,GO:0042743,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
hydrogen peroxide metabolic process,GO:0042743,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
hydrogen peroxide metabolic process,GO:0042743,"Parkinson Disease, Secondary",MESH:D010302,8,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Atrazine|Carbidopa|Doxorubicin|Levodopa|Manganese|Paraquat|Resveratrol",0,
hydrogen peroxide metabolic process,GO:0042743,Parkinsonian Disorders,MESH:D020734,9,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Cadmium|Carbidopa|Curcumin|Levodopa|Manganese|manganese chloride|Paraquat|Resveratrol",1,PARK7
hydrogen sulfide biosynthetic process,GO:0070814,Parkinson Disease,MESH:D010300,1,Caffeine,0,
hydrogen sulfide biosynthetic process,GO:0070814,"Parkinson Disease, Secondary",MESH:D010302,1,sodium bisulfide,0,
hydrogen sulfide biosynthetic process,GO:0070814,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
hydroxyproline transport,GO:0034589,Parkinson Disease,MESH:D010300,1,Carbon Tetrachloride,0,
hypermethylation of CpG island,GO:0044027,Parkinson Disease,MESH:D010300,2,Polychlorinated Biphenyls|Trichloroethylene,0,
hypermethylation of CpG island,GO:0044027,"Parkinson Disease, Secondary",MESH:D010302,3,Nicotine|Resveratrol|Trichloroethylene,0,
hypermethylation of CpG island,GO:0044027,Parkinsonian Disorders,MESH:D020734,2,Curcumin|Resveratrol,0,
hypersensitivity,GO:0002524,Parkinson Disease,MESH:D010300,3,Melatonin|Trichloroethylene|Vehicle Emissions,0,
hypersensitivity,GO:0002524,"Parkinson Disease, Secondary",MESH:D010302,2,Melatonin|Trichloroethylene,0,
hypersensitivity,GO:0002524,Parkinsonian Disorders,MESH:D020734,1,Melatonin,0,
hypoblast development,GO:0090008,Parkinson Disease,MESH:D010300,1,Estradiol,0,
hypomethylation of CpG island,GO:0044029,Parkinson Disease,MESH:D010300,3,Air Pollutants|Estradiol|Nitrogen Dioxide,0,
hypomethylation of CpG island,GO:0044029,Parkinsonian Disorders,MESH:D020734,1,Curcumin,0,
hypoxanthine biosynthetic process,GO:0046101,Parkinson Disease,MESH:D010300,1,Endosulfan,0,
hypoxanthine metabolic process,GO:0046100,Parkinson Disease,MESH:D010300,1,Melatonin,0,
hypoxanthine metabolic process,GO:0046100,"Parkinson Disease, Secondary",MESH:D010302,2,Melatonin|Ribavirin,0,
hypoxanthine metabolic process,GO:0046100,Parkinsonian Disorders,MESH:D020734,2,Indomethacin|Melatonin,0,
icosanoid biosynthetic process,GO:0046456,Parkinson Disease,MESH:D010300,1,Ozone,0,
icosanoid metabolic process,GO:0006690,Parkinson Disease,MESH:D010300,2,Eicosapentaenoic Acid|Paclitaxel,0,
icosanoid metabolic process,GO:0006690,Parkinsonian Disorders,MESH:D020734,1,Docosahexaenoic Acids,0,
icosanoid secretion,GO:0032309,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
icosanoid secretion,GO:0032309,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
I-kappaB kinase/NF-kappaB signaling,GO:0007249,Parkinson Disease,MESH:D010300,4,Lipopolysaccharides|mangiferin|Reactive Oxygen Species|Zinc,0,
I-kappaB kinase/NF-kappaB signaling,GO:0007249,Parkinsonian Disorders,MESH:D020734,3,ginsenoside Re|Lipopolysaccharides|Plant Extracts,0,
I-kappaB phosphorylation,GO:0007252,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
I-kappaB phosphorylation,GO:0007252,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
I-kappaB phosphorylation,GO:0007252,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Resveratrol,0,
imaginal disc-derived wing hair organization,GO:0035317,"PARKINSONISM WITH SPASTICITY, X-LINKED",OMIM:300911,0,,1,ATP6AP2
imaginal disc-derived wing morphogenesis,GO:0007476,Parkinson Disease,MESH:D010300,0,,1,CP
immune response,GO:0006955,Parkinson Disease,MESH:D010300,1,Zinc,6,AIF1|CHP|HLA-DRA|IGF1R|IL6|TNF
immune response,GO:0006955,"Parkinson Disease, Secondary",MESH:D010302,0,,1,CNR2
immune response,GO:0006955,Parkinsonian Disorders,MESH:D020734,0,,1,PRKRA
immune system development,GO:0002520,Parkinson Disease,MESH:D010300,1,"Water Pollutants, Chemical",0,
immune system process,GO:0002376,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
immunoglobulin mediated immune response,GO:0016064,Parkinson Disease,MESH:D010300,1,Trichloroethylene,0,
immunoglobulin mediated immune response,GO:0016064,"Parkinson Disease, Secondary",MESH:D010302,1,Trichloroethylene,0,
immunoglobulin mediated immune response,GO:0016064,Parkinsonian Disorders,MESH:D020734,1,4-hydroxy-2-nonenal,1,PRKCD
immunoglobulin production,GO:0002377,Parkinson Disease,MESH:D010300,4,Hexachlorocyclohexane|Lead|Ozone|Polychlorinated Biphenyls,0,
immunoglobulin production involved in immunoglobulin-mediated immune response,GO:0002381,Parkinson Disease,MESH:D010300,4,Atrazine|Manganese|Particulate Matter|Vehicle Emissions,0,
immunoglobulin production involved in immunoglobulin-mediated immune response,GO:0002381,"Parkinson Disease, Secondary",MESH:D010302,2,Atrazine|Manganese,0,
immunoglobulin production involved in immunoglobulin-mediated immune response,GO:0002381,Parkinsonian Disorders,MESH:D020734,3,Manganese|Particulate Matter|Plant Extracts,0,
import across plasma membrane,GO:0098739,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
import across plasma membrane,GO:0098739,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
import across plasma membrane,GO:0098739,Parkinson Disease,MESH:D010300,3,beta-N-methylamino-L-alanine|Estradiol|Ketoconazole,0,
import across plasma membrane,GO:0098739,"Parkinson Disease, Secondary",MESH:D010302,1,Amiodarone,0,
import across plasma membrane,GO:0098739,Parkinsonian Disorders,MESH:D020734,2,Amiodarone|Ketoconazole,0,
import across plasma membrane,GO:0098739,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
import into cell,GO:0098657,Parkinson Disease,MESH:D010300,10,Copper|Fatty Acids|Iron|Lipopolysaccharides|Methamphetamine|Particulate Matter|Probenecid|Sirolimus|Vehicle Emissions|Zinc,0,
import into cell,GO:0098657,"Parkinson Disease, Secondary",MESH:D010302,4,3-methyladenine|Chlorpromazine|Methamphetamine|Methotrexate,0,
import into cell,GO:0098657,Parkinsonian Disorders,MESH:D020734,5,Chlorpromazine|Lipopolysaccharides|Particulate Matter|Probenecid|Rimonabant,0,
import into nucleus,GO:0051170,Parkinson Disease,MESH:D010300,2,Lead|Lipopolysaccharides,0,
import into nucleus,GO:0051170,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
inclusion body assembly,GO:0070841,"Parkinson Disease, Secondary",MESH:D010302,1,Amiodarone,0,
inclusion body assembly,GO:0070841,Parkinsonian Disorders,MESH:D020734,1,Amiodarone,0,
inclusion body assembly,GO:0070841,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
indole metabolic process,GO:0042431,Parkinson Disease,MESH:D010300,1,Atrazine,0,
indole metabolic process,GO:0042431,"Parkinson Disease, Secondary",MESH:D010302,3,Atrazine|Benzo(a)pyrene|Doxorubicin,0,
indole metabolic process,GO:0042431,Parkinsonian Disorders,MESH:D020734,1,Indomethacin,0,
induction by virus of host autophagy,GO:0039520,"Parkinson Disease, Secondary",MESH:D010302,1,3-methyladenine,0,
induction of bacterial agglutination,GO:0043152,Parkinson Disease,MESH:D010300,0,,1,FGB
inflammasome complex assembly,GO:0140632,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
inflammasome complex assembly,GO:0140632,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
inflammatory cell apoptotic process,GO:0006925,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
inflammatory cell apoptotic process,GO:0006925,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
inflammatory response,GO:0006954,Parkinson Disease,MESH:D010300,33,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Acrolein|Air Pollutants|Aluminum|Aspirin|Atrazine|Caffeine|Carbon Tetrachloride|Chlorpyrifos|Copper|Diazinon|Estradiol|Hexachlorocyclohexane|Iron|Lead|Lipopolysaccharides|Melatonin|Methamphetamine|Minocycline|Nitric Oxide|Nitrites|Ozone|Paclitaxel|Paraquat|Particulate Matter|Pioglitazone|Rotenone|Sirolimus|Soot|Trichloroethylene|Vehicle Emissions|Zinc",7,AIF1|CNTNAP2|CP|GSTP1|IL6|PARK7|TNF
inflammatory response,GO:0006954,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
inflammatory response,GO:0006954,"Parkinson Disease, Secondary",MESH:D010302,26,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|3-methyladenine|Amiodarone|Amlodipine|Atrazine|Benzo(a)pyrene|Buspirone|Carbon Monoxide|Doxorubicin|Melatonin|Methamphetamine|Methotrexate|Minocycline|Nicotine|Paraquat|Paroxetine|Resveratrol|Rotenone|Silymarin|sodium bisulfide|thymoquinone|Trazodone|Trichloroethylene|Valproic Acid|Verapamil|Vincristine",2,CNR2|NOS2
inflammatory response,GO:0006954,Parkinsonian Disorders,MESH:D020734,24,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Amiodarone|Amlodipine|baicalin|Buspirone|Cadmium|coenzyme Q10|crocin|Curcumin|Disulfiram|Docosahexaenoic Acids|Indomethacin|Lipopolysaccharides|Melatonin|Paraquat|Paroxetine|Particulate Matter|Plant Extracts|Resveratrol|Rotenone|Silymarin|Valproic Acid|Verapamil",1,PARK7
inflammatory response,GO:0006954,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Amiodarone|Isoproterenol,0,
inflammatory response to antigenic stimulus,GO:0002437,Parkinson Disease,MESH:D010300,3,Air Pollutants|Particulate Matter|Vehicle Emissions,0,
inflammatory response to antigenic stimulus,GO:0002437,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
inflammatory response to antigenic stimulus,GO:0002437,Parkinsonian Disorders,MESH:D020734,2,Particulate Matter|Resveratrol,0,
inflammatory response to wounding,GO:0090594,Parkinson Disease,MESH:D010300,0,,2,IL6|TNF
inhibitory chemical synaptic transmission,GO:0098977,Parkinson Disease,MESH:D010300,0,,1,CNTNAP2
inhibitory postsynaptic potential,GO:0060080,Parkinson Disease,MESH:D010300,3,Amphetamine|Clozapine|Diazepam,1,BDNF
inhibitory postsynaptic potential,GO:0060080,"Parkinson Disease, Secondary",MESH:D010302,7,Chlorpromazine|Diazepam|Fluoxetine|Haloperidol|Nicotine|Risperidone|Sulpiride,0,
inhibitory postsynaptic potential,GO:0060080,Parkinsonian Disorders,MESH:D020734,8,Baclofen|Chlorpromazine|Clonidine|Clozapine|Haloperidol|Quinpirole|Rimonabant|Risperidone,0,
inhibitory synapse assembly,GO:1904862,Parkinson Disease,MESH:D010300,0,,1,CNTNAP2
initiation of primordial ovarian follicle growth,GO:0001544,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
initiation of primordial ovarian follicle growth,GO:0001544,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
innate immune response,GO:0045087,Parkinson Disease,MESH:D010300,2,4-phenylbutyric acid|Lipopolysaccharides,5,DEFA4|FGB|MAP3K5|NQO1|SOD2
innate immune response,GO:0045087,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,2,GAPDH|PARP1
innate immune response in mucosa,GO:0002227,Parkinson Disease,MESH:D010300,0,,1,DEFA4
innate immune response in mucosa,GO:0002227,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
inner cell mass cell proliferation,GO:0001833,Parkinson Disease,MESH:D010300,0,,1,NCAPG2
inner cell mass cell proliferation,GO:0001833,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
inner cell mass cell proliferation,GO:0001833,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
inner ear development,GO:0048839,Parkinson Disease,MESH:D010300,0,,1,BDNF
inner ear development,GO:0048839,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
inner mitochondrial membrane organization,GO:0007007,Parkinson Disease,MESH:D010300,0,,1,HSPA9
innervation,GO:0060384,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
innervation,GO:0060384,Parkinson Disease,MESH:D010300,1,beta-N-methylamino-L-alanine,0,
innervation,GO:0060384,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
inorganic cation import across plasma membrane,GO:0098659,Parkinson Disease,MESH:D010300,2,1-Methyl-4-phenylpyridinium|Reactive Oxygen Species,0,
inorganic cation import across plasma membrane,GO:0098659,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
inorganic cation import across plasma membrane,GO:0098659,Parkinsonian Disorders,MESH:D020734,3,1-Methyl-4-phenylpyridinium|Cadmium|Resveratrol,0,
inorganic cation transmembrane transport,GO:0098662,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
inorganic cation transmembrane transport,GO:0098662,Parkinson Disease,MESH:D010300,2,Ketoconazole|Nitric Oxide,0,
inorganic cation transmembrane transport,GO:0098662,"Parkinson Disease, Secondary",MESH:D010302,1,Amiodarone,0,
inorganic cation transmembrane transport,GO:0098662,Parkinsonian Disorders,MESH:D020734,2,Amiodarone|Ketoconazole,0,
inorganic cation transmembrane transport,GO:0098662,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
inorganic ion homeostasis,GO:0098771,Parkinson Disease,MESH:D010300,2,Copper|Lead,0,
inosine biosynthetic process,GO:0046103,Parkinson Disease,MESH:D010300,1,1-Methyl-4-phenylpyridinium,0,
inosine biosynthetic process,GO:0046103,Parkinsonian Disorders,MESH:D020734,1,1-Methyl-4-phenylpyridinium,0,
inosine metabolic process,GO:0046102,Parkinson Disease,MESH:D010300,2,Endosulfan|Melatonin,0,
inosine metabolic process,GO:0046102,"Parkinson Disease, Secondary",MESH:D010302,2,Melatonin|Ribavirin,0,
inosine metabolic process,GO:0046102,Parkinsonian Disorders,MESH:D020734,1,Melatonin,0,
inositol biosynthetic process,GO:0006021,Parkinson Disease,MESH:D010300,1,Permethrin,0,
inositol biosynthetic process,GO:0006021,Parkinsonian Disorders,MESH:D020734,1,Permethrin,0,
inositol metabolic process,GO:0006020,Parkinson Disease,MESH:D010300,2,Lead|Methomyl,0,
inositol metabolic process,GO:0006020,"Parkinson Disease, Secondary",MESH:D010302,1,Methotrexate,0,
inositol phosphate metabolic process,GO:0043647,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
insecticide catabolic process,GO:0046701,Parkinson Disease,MESH:D010300,1,Rotenone,0,
insecticide catabolic process,GO:0046701,"Parkinson Disease, Secondary",MESH:D010302,1,Rotenone,0,
insecticide catabolic process,GO:0046701,Parkinsonian Disorders,MESH:D020734,1,Rotenone,0,
insulin-like growth factor receptor signaling pathway,GO:0048009,Parkinson Disease,MESH:D010300,0,,4,IGF1R|IGF2|IGF2R|INSR
insulin-like growth factor receptor signaling pathway,GO:0048009,Parkinson Disease 11,MESH:C564345,0,,1,GIGYF2
insulin metabolic process,GO:1901142,Parkinson Disease,MESH:D010300,4,Manganese|Ozone|Particulate Matter|Zinc,0,
insulin metabolic process,GO:1901142,"Parkinson Disease, Secondary",MESH:D010302,3,Manganese|Resveratrol|thymoquinone,0,
insulin metabolic process,GO:1901142,Parkinsonian Disorders,MESH:D020734,5,Cadmium|Manganese|Particulate Matter|Plant Extracts|Resveratrol,0,
insulin processing,GO:0030070,Parkinson Disease,MESH:D010300,1,Paraquat,0,
insulin processing,GO:0030070,"Parkinson Disease, Secondary",MESH:D010302,1,Paraquat,0,
insulin processing,GO:0030070,Parkinsonian Disorders,MESH:D020734,1,Paraquat,0,
insulin receptor signaling pathway,GO:0008286,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
insulin receptor signaling pathway,GO:0008286,Parkinson Disease,MESH:D010300,0,,4,IGF1R|IGF2|INS|INSR
insulin receptor signaling pathway,GO:0008286,Parkinsonian Disorders,MESH:D020734,1,Plant Preparations,0,
insulin receptor signaling pathway via phosphatidylinositol 3-kinase,GO:0038028,"Parkinson Disease, Secondary",MESH:D010302,1,Verapamil,0,
insulin receptor signaling pathway via phosphatidylinositol 3-kinase,GO:0038028,Parkinsonian Disorders,MESH:D020734,1,Verapamil,0,
insulin secretion,GO:0030073,Parkinson Disease,MESH:D010300,1,Polychlorinated Biphenyls,2,PARK7|SLC18A2
insulin secretion,GO:0030073,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
insulin secretion,GO:0030073,"Parkinson Disease, Secondary",MESH:D010302,2,Fluoxetine|Paroxetine,1,SLC18A2
insulin secretion,GO:0030073,Parkinsonian Disorders,MESH:D020734,2,ginsenoside Re|Paroxetine,2,PARK7|SLC18A2
intein-mediated protein splicing,GO:0016539,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
interferon-mediated signaling pathway,GO:0140888,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
interleukin-10 production,GO:0032613,Parkinson Disease,MESH:D010300,3,Lipopolysaccharides|Particulate Matter|Vehicle Emissions,0,
interleukin-10 production,GO:0032613,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Particulate Matter,1,PRKCD
interleukin-12 production,GO:0032615,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
interleukin-12 production,GO:0032615,"Parkinson Disease, Secondary",MESH:D010302,1,Poly I-C,0,
interleukin-12 production,GO:0032615,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Plant Preparations,1,PRKCD
interleukin-13 production,GO:0032616,Parkinson Disease,MESH:D010300,1,Lead,0,
interleukin-17 production,GO:0032620,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
interleukin-17 production,GO:0032620,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
interleukin-1 beta production,GO:0032611,Parkinson Disease,MESH:D010300,3,Lipopolysaccharides|Soot|Vehicle Emissions,0,
interleukin-1 beta production,GO:0032611,Parkinsonian Disorders,MESH:D020734,2,ginsenoside Re|Lipopolysaccharides,0,
interleukin-1 production,GO:0032612,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
interleukin-1 production,GO:0032612,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
interleukin-23 production,GO:0032627,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
interleukin-23 production,GO:0032627,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
interleukin-27 production,GO:0032631,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
interleukin-27 production,GO:0032631,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
interleukin-2 production,GO:0032623,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
interleukin-2 production,GO:0032623,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
interleukin-5 production,GO:0032634,Parkinson Disease,MESH:D010300,2,Particulate Matter|Vehicle Emissions,0,
interleukin-5 production,GO:0032634,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
interleukin-6-mediated signaling pathway,GO:0070102,Parkinson Disease,MESH:D010300,0,,1,IL6
interleukin-6 production,GO:0032635,Parkinson Disease,MESH:D010300,7,Air Pollutants|Lipopolysaccharides|mangiferin|Nitrogen Dioxide|Ozone|Soot|Vehicle Emissions,1,TNF
interleukin-6 production,GO:0032635,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
interleukin-8 production,GO:0032637,Parkinson Disease,MESH:D010300,2,Soot|Vehicle Emissions,0,
inter-male aggressive behavior,GO:0002121,Parkinson Disease,MESH:D010300,1,Estradiol,0,
intermediate filament-based process,GO:0045103,Parkinson Disease,MESH:D010300,0,,1,GFAP
intermediate filament cytoskeleton organization,GO:0045104,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,ATXN3
intermediate filament cytoskeleton organization,GO:0045104,Parkinsonian Disorders,MESH:D020734,1,Malondialdehyde,0,
intermediate filament organization,GO:0045109,Parkinson Disease,MESH:D010300,0,,1,GFAP
intermediate filament organization,GO:0045109,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
intestinal absorption,GO:0050892,Parkinsonian Disorders,MESH:D020734,2,Cadmium|ginsenoside Re,0,
intestinal D-glucose absorption,GO:0001951,Parkinson Disease,MESH:D010300,1,Lead,0,
intestinal epithelial cell differentiation,GO:0060575,"Parkinson Disease, Secondary",MESH:D010302,1,geraniol,0,
intestinal epithelial cell differentiation,GO:0060575,Parkinsonian Disorders,MESH:D020734,1,geraniol,0,
intestinal epithelial structure maintenance,GO:0060729,Parkinson Disease,MESH:D010300,3,Lipopolysaccharides|Methamphetamine|Pioglitazone,0,
intestinal epithelial structure maintenance,GO:0060729,"Parkinson Disease, Secondary",MESH:D010302,1,Methamphetamine,0,
intestinal epithelial structure maintenance,GO:0060729,Parkinsonian Disorders,MESH:D020734,2,Curcumin|Lipopolysaccharides,0,
intestinal motility,GO:0120054,Parkinson Disease,MESH:D010300,1,Rotenone,0,
intestinal motility,GO:0120054,"Parkinson Disease, Secondary",MESH:D010302,3,Fluoxetine|Nicotine|Rotenone,0,
intestinal motility,GO:0120054,Parkinsonian Disorders,MESH:D020734,1,Rotenone,0,
intestinal stem cell homeostasis,GO:0036335,Parkinson Disease,MESH:D010300,0,,1,HSC70-3
intestine smooth muscle contraction,GO:0014827,Parkinson Disease,MESH:D010300,1,Propranolol,0,
intestine smooth muscle contraction,GO:0014827,"Parkinson Disease, Secondary",MESH:D010302,1,Verapamil,0,
intestine smooth muscle contraction,GO:0014827,Parkinsonian Disorders,MESH:D020734,2,ginsenoside Re|Verapamil,0,
intestine smooth muscle contraction,GO:0014827,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Propranolol,0,
intracellular distribution of mitochondria,GO:0048312,Parkinson Disease,MESH:D010300,0,,4,DNM1L|LRRK2|MAPT|PINK1
intracellular distribution of mitochondria,GO:0048312,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
intracellular distribution of mitochondria,GO:0048312,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
intracellular distribution of mitochondria,GO:0048312,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
intracellular distribution of mitochondria,GO:0048312,"Parkinson Disease, Secondary",MESH:D010302,2,Valproic Acid|Vincristine,0,
intracellular distribution of mitochondria,GO:0048312,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Valproic Acid,3,LRRK2|MAPT|PINK1
intracellular estrogen receptor signaling pathway,GO:0030520,Parkinson Disease,MESH:D010300,1,Estradiol,0,
intracellular estrogen receptor signaling pathway,GO:0030520,Parkinsonian Disorders,MESH:D020734,1,ginsenoside Re,0,
intracellular pH elevation,GO:0051454,Parkinson Disease,MESH:D010300,1,Carbon Tetrachloride,0,
intracellular pH reduction,GO:0051452,Parkinson Disease,MESH:D010300,1,Carbon Tetrachloride,0,
intracellular pH reduction,GO:0051452,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
intracellular pH reduction,GO:0051452,"PARKINSONISM WITH SPASTICITY, X-LINKED",OMIM:300911,0,,1,ATP6AP2
intracellular protein transport,GO:0006886,Parkinson Disease,MESH:D010300,0,,5,DRD1|GFAP|HSPA9|RAB32|VPS35
intracellular protein transport,GO:0006886,PARKINSON DISEASE 17,OMIM:614203,0,,1,VPS35
intracellular receptor signaling pathway,GO:0030522,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
intracellular signal transduction,GO:0035556,Parkinson Disease,MESH:D010300,1,Zinc,9,CNTNAP2|DDIT4|DRD2|EDN1|HMOX1|LRRK2|PINK1|RDGA|TCL1B
intracellular signal transduction,GO:0035556,Parkinson Disease 13,MESH:C565204,0,,1,HTRA2
intracellular signal transduction,GO:0035556,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
intracellular signal transduction,GO:0035556,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
intracellular signal transduction,GO:0035556,"Parkinson Disease, Secondary",MESH:D010302,0,,1,NOS2
intracellular signal transduction,GO:0035556,Parkinsonian Disorders,MESH:D020734,0,,5,DRD2|HTRA2|LRRK2|PINK1|PRKCD
intracellular signal transduction,GO:0035556,Wolff-Parkinson-White Syndrome,MESH:D014927,0,,1,PRKAG2
intracellular transport,GO:0046907,Parkinson Disease,MESH:D010300,0,,2,GAK|MAPT
intracellular transport,GO:0046907,"PARKINSON DISEASE 19A, JUVENILE-ONSET",OMIM:615528,0,,1,DNAJC6
intracellular transport,GO:0046907,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
intracellular transport,GO:0046907,Parkinsonian Disorders,MESH:D020734,0,,1,MAPT
intrahepatic bile duct development,GO:0035622,Parkinson Disease,MESH:D010300,1,Zinc,1,GAK
intrahepatic bile duct development,GO:0035622,"PARKINSONISM WITH SPASTICITY, X-LINKED",OMIM:300911,0,,1,ATP6AP2
intrinsic apoptotic signaling pathway,GO:0097193,Parkinson Disease 13,MESH:C565204,0,,1,HTRA2
intrinsic apoptotic signaling pathway,GO:0097193,"Parkinson Disease, Secondary",MESH:D010302,1,Sertraline,0,
intrinsic apoptotic signaling pathway,GO:0097193,Parkinsonian Disorders,MESH:D020734,2,Plant Extracts|Sertraline,1,HTRA2
intrinsic apoptotic signaling pathway in response to DNA damage,GO:0008630,Parkinson Disease,MESH:D010300,0,,3,HMOX1|SOD2|TNF
intrinsic apoptotic signaling pathway in response to DNA damage,GO:0008630,Parkinson Disease 13,MESH:C565204,0,,1,HTRA2
intrinsic apoptotic signaling pathway in response to DNA damage,GO:0008630,Parkinsonian Disorders,MESH:D020734,0,,1,HTRA2
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:0042771,Parkinson Disease,MESH:D010300,0,,1,DDIT4
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress,GO:0070059,Parkinson Disease,MESH:D010300,0,,1,MAP3K5
intrinsic apoptotic signaling pathway in response to oxidative stress,GO:0008631,Parkinson Disease,MESH:D010300,1,Reactive Oxygen Species,4,ALDH2|MAP3K5|MAPT|SOD2
intrinsic apoptotic signaling pathway in response to oxidative stress,GO:0008631,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
intrinsic apoptotic signaling pathway in response to oxidative stress,GO:0008631,Parkinsonian Disorders,MESH:D020734,0,,2,MAPT|PRKCD
in utero embryonic development,GO:0001701,Parkinson Disease,MESH:D010300,0,,3,CNTNAP2|EDN1|IGF2
ionotropic glutamate receptor signaling pathway,GO:0035235,Parkinsonian Disorders,MESH:D020734,0,,1,ATP1A3
iron import into cell,GO:0033212,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
iron import into cell,GO:0033212,Parkinson Disease,MESH:D010300,4,1-Methyl-4-phenylpyridinium|Iron|Maneb|Paraquat,0,
iron import into cell,GO:0033212,"Parkinson Disease, Secondary",MESH:D010302,3,Maneb|Paraquat|Resveratrol,0,
iron import into cell,GO:0033212,Parkinsonian Disorders,MESH:D020734,6,1-Methyl-4-phenylpyridinium|3-n-butylphthalide|Docosahexaenoic Acids|Maneb|Paraquat|Resveratrol,0,
iron ion export across plasma membrane,GO:1903988,Parkinson Disease,MESH:D010300,2,Carbon Tetrachloride|Oxidopamine,0,
iron ion export across plasma membrane,GO:1903988,"Parkinson Disease, Secondary",MESH:D010302,1,Oxidopamine,0,
iron ion export across plasma membrane,GO:1903988,Parkinsonian Disorders,MESH:D020734,1,Oxidopamine,0,
iron ion homeostasis,GO:0055072,Parkinson Disease,MESH:D010300,7,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Atrazine|Carbon Tetrachloride|Iron|Lipopolysaccharides|Ozone|Zinc",0,
iron ion homeostasis,GO:0055072,"Parkinson Disease, Secondary",MESH:D010302,4,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Atrazine|Doxorubicin|Valproic Acid",0,
iron ion homeostasis,GO:0055072,Parkinsonian Disorders,MESH:D020734,4,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Cadmium|Lipopolysaccharides|Valproic Acid",0,
iron ion import across plasma membrane,GO:0098711,Parkinson Disease,MESH:D010300,3,Iron|Manganese|Zinc,0,
iron ion import across plasma membrane,GO:0098711,"Parkinson Disease, Secondary",MESH:D010302,1,Manganese,0,
iron ion import across plasma membrane,GO:0098711,Parkinsonian Disorders,MESH:D020734,1,Manganese,0,
iron ion transmembrane transport,GO:0034755,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
iron ion transport,GO:0006826,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
iron ion transport,GO:0006826,Parkinson Disease,MESH:D010300,3,Iron|mangiferin|Ozone,3,CP|HFE|RDGA
iron ion transport,GO:0006826,"Parkinson Disease, Secondary",MESH:D010302,2,Diltiazem|Verapamil,0,
iron ion transport,GO:0006826,Parkinsonian Disorders,MESH:D020734,1,Verapamil,0,
iron ion transport,GO:0006826,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Diltiazem,0,
iron-sulfur cluster assembly,GO:0016226,Parkinson Disease,MESH:D010300,0,,1,HSPA9
irritable aggressive behavior,GO:0002123,Parkinsonian Disorders,MESH:D020734,1,Curcumin,0,
isocitrate metabolic process,GO:0006102,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
isoleucine biosynthetic process,GO:0009097,Parkinson Disease,MESH:D010300,3,Endosulfan|Permethrin|Polychlorinated Biphenyls,0,
isoleucine biosynthetic process,GO:0009097,Parkinsonian Disorders,MESH:D020734,1,Permethrin,0,
isoleucine metabolic process,GO:0006549,Parkinson Disease,MESH:D010300,1,Endosulfan,0,
isoquinoline alkaloid metabolic process,GO:0033076,Parkinson Disease,MESH:D010300,0,,3,CYP2D6|DDC|TH
isoquinoline alkaloid metabolic process,GO:0033076,Parkinsonian Disorders,MESH:D020734,0,,2,DDC|TH
JNK cascade,GO:0007254,Parkinson Disease,MESH:D010300,2,mangiferin|Reactive Oxygen Species,3,LRRK2|MAP3K5|TNF
JNK cascade,GO:0007254,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
JNK cascade,GO:0007254,"Parkinson Disease, Secondary",MESH:D010302,3,Doxorubicin|Resveratrol|Sertraline,0,
JNK cascade,GO:0007254,Parkinsonian Disorders,MESH:D020734,5,Curcumin|cypermethrin|Plant Extracts|Resveratrol|Sertraline,1,LRRK2
JUN phosphorylation,GO:0007258,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
JUN phosphorylation,GO:0007258,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
juvenile hormone metabolic process,GO:0006716,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
keratinocyte activation,GO:0032980,Parkinson Disease,MESH:D010300,1,Eugenol,0,
keratinocyte differentiation,GO:0030216,Parkinson Disease,MESH:D010300,1,Air Pollutants,1,GAK
kidney development,GO:0001822,Parkinson Disease,MESH:D010300,0,,1,DDC
kidney development,GO:0001822,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
kidney development,GO:0001822,Parkinsonian Disorders,MESH:D020734,1,Cadmium,3,ALDH1A1|ALDH1A2|DDC
killing by host of symbiont cells,GO:0051873,Parkinsonian Disorders,MESH:D020734,0,,1,GAPDH
killing of cells of another organism,GO:0031640,Parkinson Disease,MESH:D010300,0,,1,DEFA4
killing of cells of another organism,GO:0031640,Parkinsonian Disorders,MESH:D020734,0,,1,GAPDH
kinesis,GO:0042465,Parkinson Disease,MESH:D010300,1,Melatonin,0,
kinesis,GO:0042465,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
kinesis,GO:0042465,Parkinsonian Disorders,MESH:D020734,2,manganese chloride|Melatonin,0,
Kit signaling pathway,GO:0038109,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
kynurenic acid metabolic process,GO:0034275,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|Phorate,0,
kynurenic acid metabolic process,GO:0034275,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
kynurenic acid metabolic process,GO:0034275,Parkinsonian Disorders,MESH:D020734,2,Indomethacin|Rimonabant,0,
labyrinthine layer development,GO:0060711,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
lactate biosynthetic process,GO:0019249,Parkinson Disease,MESH:D010300,12,1-Methyl-4-phenylpyridinium|Air Pollutants|Atrazine|Carbon Tetrachloride|Clozapine|Copper|Eicosapentaenoic Acid|Endosulfan|Paraquat|Particulate Matter|Rotenone|Tolcapone,1,PARK7
lactate biosynthetic process,GO:0019249,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
lactate biosynthetic process,GO:0019249,"Parkinson Disease, Secondary",MESH:D010302,9,Atrazine|Chlorpromazine|geraniol|Haloperidol|Nicotine|Paraquat|Resveratrol|Risperidone|Rotenone,0,
lactate biosynthetic process,GO:0019249,Parkinsonian Disorders,MESH:D020734,13,1-Methyl-4-phenylpyridinium|Bupropion|Chlorpromazine|Clozapine|Docosahexaenoic Acids|geraniol|Haloperidol|manganese chloride|Paraquat|Particulate Matter|Resveratrol|Risperidone|Rotenone,1,PARK7
lactate biosynthetic process from pyruvate,GO:0019244,Parkinson Disease,MESH:D010300,2,"Rotenone|Water Pollutants, Chemical",0,
lactate biosynthetic process from pyruvate,GO:0019244,"Parkinson Disease, Secondary",MESH:D010302,1,Rotenone,0,
lactate biosynthetic process from pyruvate,GO:0019244,Parkinsonian Disorders,MESH:D020734,1,Rotenone,0,
lactate metabolic process,GO:0006089,Parkinson Disease,MESH:D010300,10,"Acrolein|Chlorpyrifos|Endosulfan|Lead|Lipopolysaccharides|Paraquat|Particulate Matter|Rotenone|Water Pollutants, Chemical|Zinc",0,
lactate metabolic process,GO:0006089,"Parkinson Disease, Secondary",MESH:D010302,5,Doxorubicin|Exenatide|Paraquat|Resveratrol|Rotenone,0,
lactate metabolic process,GO:0006089,Parkinsonian Disorders,MESH:D020734,6,Cadmium|Lipopolysaccharides|Paraquat|Particulate Matter|Resveratrol|Rotenone,0,
lactate transport,GO:0015727,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
lactation,GO:0007595,Parkinson Disease,MESH:D010300,0,,2,CP|SLC6A3
lactation,GO:0007595,Parkinsonian Disorders,MESH:D020734,0,,1,PRL
lactation,GO:0007595,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
lactic acid secretion,GO:0046722,Parkinson Disease,MESH:D010300,3,1-Methyl-4-phenylpyridinium|Lipopolysaccharides|Rotenone,0,
lactic acid secretion,GO:0046722,"Parkinson Disease, Secondary",MESH:D010302,1,Rotenone,0,
lactic acid secretion,GO:0046722,Parkinsonian Disorders,MESH:D020734,4,1-Methyl-4-phenylpyridinium|Cadmium|Lipopolysaccharides|Rotenone,0,
lactone catabolic process,GO:1901335,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PON1
lactone metabolic process,GO:1901334,Parkinson Disease,MESH:D010300,2,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Methomyl",0,
lactone metabolic process,GO:1901334,"Parkinson Disease, Secondary",MESH:D010302,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
lactone metabolic process,GO:1901334,Parkinsonian Disorders,MESH:D020734,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
lactose metabolic process,GO:0005988,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
L-alanine biosynthetic process,GO:0042852,Parkinson Disease,MESH:D010300,1,1-Methyl-4-phenylpyridinium,0,
L-alanine biosynthetic process,GO:0042852,Parkinsonian Disorders,MESH:D020734,1,1-Methyl-4-phenylpyridinium,0,
"L-alanine catabolic process, by transamination",GO:0019481,Parkinson Disease,MESH:D010300,1,Carbon Tetrachloride,0,
"L-alanine catabolic process, by transamination",GO:0019481,Parkinsonian Disorders,MESH:D020734,1,Plant Extracts,0,
lamellipodium assembly,GO:0030032,Parkinson Disease,MESH:D010300,1,Estradiol,0,
lamellipodium morphogenesis,GO:0072673,Parkinson Disease,MESH:D010300,1,Manganese,0,
lamellipodium morphogenesis,GO:0072673,"Parkinson Disease, Secondary",MESH:D010302,1,Manganese,0,
lamellipodium morphogenesis,GO:0072673,Parkinsonian Disorders,MESH:D020734,1,Manganese,0,
large intestinal transit,GO:0120056,Parkinson Disease,MESH:D010300,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
large intestinal transit,GO:0120056,"Parkinson Disease, Secondary",MESH:D010302,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
large intestinal transit,GO:0120056,Parkinsonian Disorders,MESH:D020734,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
larval behavior,GO:0030537,Parkinson Disease,MESH:D010300,1,Pesticides,0,
larval behavior,GO:0030537,"Parkinson Disease, Secondary",MESH:D010302,2,Benzo(a)pyrene|Pesticides,0,
larval development,GO:0002164,Parkinson Disease,MESH:D010300,7,Benomyl|Chlorpyrifos|Estradiol|Particulate Matter|tetrachloroisophthalonitrile|valbenazine|Vehicle Emissions,0,
larval development,GO:0002164,"Parkinson Disease, Secondary",MESH:D010302,4,3-methyladenine|Benzo(a)pyrene|Methotrexate|Valproic Acid,0,
larval development,GO:0002164,Parkinsonian Disorders,MESH:D020734,3,Cadmium|Particulate Matter|Valproic Acid,0,
larval feeding behavior,GO:0030536,"Parkinson Disease, Secondary",MESH:D010302,1,Fluoxetine,0,
larval feeding behavior,GO:0030536,Parkinsonian Disorders,MESH:D020734,1,Rimonabant,0,
larval heart development,GO:0007508,Parkinson Disease,MESH:D010300,1,Benomyl,0,
larval locomotory behavior,GO:0008345,Parkinson Disease,MESH:D010300,12,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Air Pollutants|Chlorpyrifos|Copper|Endosulfan|Hexachlorocyclohexane|Minocycline|Particulate Matter|Rotenone|tetrachloroisophthalonitrile|Ziram",0,
larval locomotory behavior,GO:0008345,"Parkinson Disease, Secondary",MESH:D010302,5,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Minocycline|Rotenone|Valproic Acid|Ziram",0,
larval locomotory behavior,GO:0008345,Parkinsonian Disorders,MESH:D020734,5,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Particulate Matter|Rotenone|Valproic Acid",1,DJ-1BETA
larval lymph gland hemopoiesis,GO:0035167,Parkinson Disease,MESH:D010300,0,,1,RPS8
L-ascorbic acid biosynthetic process,GO:0019853,Parkinson Disease,MESH:D010300,4,Atrazine|Carbon Tetrachloride|Polychlorinated Biphenyls|Zinc,0,
L-ascorbic acid biosynthetic process,GO:0019853,"Parkinson Disease, Secondary",MESH:D010302,4,Atrazine|Benzo(a)pyrene|Silymarin|thymoquinone,0,
L-ascorbic acid biosynthetic process,GO:0019853,Parkinsonian Disorders,MESH:D020734,3,Cadmium|manganese chloride|Silymarin,0,
L-ascorbic acid biosynthetic process,GO:0019853,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
L-ascorbic acid metabolic process,GO:0019852,Parkinson Disease,MESH:D010300,2,Iron|Maneb,0,
L-ascorbic acid metabolic process,GO:0019852,"Parkinson Disease, Secondary",MESH:D010302,3,Maneb|Resveratrol|Vincristine,0,
L-ascorbic acid metabolic process,GO:0019852,Parkinsonian Disorders,MESH:D020734,4,Cadmium|Indomethacin|Maneb|Resveratrol,1,ATP1A3
L-ascorbic acid metabolic process,GO:0019852,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
L-asparagine biosynthetic process,GO:0070981,Parkinson Disease,MESH:D010300,1,1-Methyl-4-phenylpyridinium,0,
L-asparagine biosynthetic process,GO:0070981,Parkinsonian Disorders,MESH:D020734,1,1-Methyl-4-phenylpyridinium,0,
late distal convoluted tubule development,GO:0072068,Parkinson Disease,MESH:D010300,0,,1,PPARGC1A
L-dopa metabolic process,GO:1903184,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|Levodopa,0,
L-dopa metabolic process,GO:1903184,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
L-dopa metabolic process,GO:1903184,"Parkinson Disease, Secondary",MESH:D010302,1,Levodopa,0,
L-dopa metabolic process,GO:1903184,Parkinsonian Disorders,MESH:D020734,1,Levodopa,0,
lead ion transport,GO:0015692,Parkinson Disease,MESH:D010300,2,Lead|Zinc,0,
learned vocalization behavior or vocal learning,GO:0098598,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
learned vocalization behavior or vocal learning,GO:0098598,Parkinsonian Disorders,MESH:D020734,1,mancozeb,0,
learning,GO:0007612,Parkinson Disease,MESH:D010300,10,Air Pollutants|Chlorpyrifos|Lead|Lipopolysaccharides|Manganese|mangiferin|Minocycline|Particulate Matter|Rotenone|Zinc,6,BDNF|CNTNAP2|DRD1|INSR|PRKN|TH
learning,GO:0007612,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
learning,GO:0007612,"Parkinson Disease, Secondary",MESH:D010302,7,Benzo(a)pyrene|Carbon Monoxide|Manganese|Minocycline|Nicotine|Resveratrol|Rotenone,2,BCHE|PRKN
learning,GO:0007612,Parkinsonian Disorders,MESH:D020734,8,Donepezil|Lipopolysaccharides|Manganese|manganese chloride|Particulate Matter|Plant Extracts|Resveratrol|Rotenone,3,ATP1A3|PRKN|TH
learning,GO:0007612,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
learning or memory,GO:0007611,Parkinson Disease,MESH:D010300,10,Air Pollutants|Lead|Minocycline|Organophosphates|Ozone|Particulate Matter|Pesticides|Polychlorinated Biphenyls|Vehicle Emissions|Zinc,2,BDNF|MAPT
learning or memory,GO:0007611,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,2,MAPT|NR4A2
learning or memory,GO:0007611,"Parkinson Disease, Secondary",MESH:D010302,5,Benzo(a)pyrene|Minocycline|Pesticides|Poly I-C|Tacrine,0,
learning or memory,GO:0007611,Parkinsonian Disorders,MESH:D020734,3,3-n-butylphthalide|Cadmium|Particulate Matter,1,MAPT
left lung development,GO:0060459,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
leptin-mediated signaling pathway,GO:0033210,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
leucine biosynthetic process,GO:0009098,Parkinson Disease,MESH:D010300,1,Permethrin,0,
leucine biosynthetic process,GO:0009098,Parkinsonian Disorders,MESH:D020734,1,Permethrin,0,
leucine catabolic process,GO:0006552,"Parkinson Disease, Secondary",MESH:D010302,1,geraniol,0,
leucine catabolic process,GO:0006552,Parkinsonian Disorders,MESH:D020734,1,geraniol,0,
leucine metabolic process,GO:0006551,Parkinson Disease,MESH:D010300,1,Endosulfan,0,
leukocyte activation,GO:0045321,Parkinson Disease,MESH:D010300,1,Reactive Oxygen Species,1,EDN1
leukocyte activation,GO:0045321,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
leukocyte adhesion to vascular endothelial cell,GO:0061756,Parkinson Disease,MESH:D010300,2,Lipopolysaccharides|Particulate Matter,0,
leukocyte adhesion to vascular endothelial cell,GO:0061756,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Particulate Matter,0,
leukocyte adhesive activation,GO:0050902,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
leukocyte adhesive activation,GO:0050902,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
leukocyte cell-cell adhesion,GO:0007159,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
leukocyte cell-cell adhesion,GO:0007159,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
leukocyte chemotaxis,GO:0030595,Parkinson Disease,MESH:D010300,7,Aspirin|Homocysteine|Ketoconazole|Lipopolysaccharides|Minocycline|Nitric Oxide|Pentoxifylline,0,
leukocyte chemotaxis,GO:0030595,"Parkinson Disease, Secondary",MESH:D010302,5,Chlorpromazine|Doxorubicin|Minocycline|Nicotine|Vincristine,1,CNR2
leukocyte chemotaxis,GO:0030595,Parkinsonian Disorders,MESH:D020734,7,Amphotericin B|Cephaloridine|Chlorpromazine|Indomethacin|Ketoconazole|Lipopolysaccharides|Procaine,0,
leukocyte chemotaxis,GO:0030595,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
leukocyte chemotaxis involved in inflammatory response,GO:0002232,Parkinson Disease,MESH:D010300,6,Carbon Tetrachloride|Lipopolysaccharides|Ozone|Paraquat|Probenecid|Soot,0,
leukocyte chemotaxis involved in inflammatory response,GO:0002232,"Parkinson Disease, Secondary",MESH:D010302,2,Paraquat|Resveratrol,0,
leukocyte chemotaxis involved in inflammatory response,GO:0002232,Parkinsonian Disorders,MESH:D020734,5,Indomethacin|Lipopolysaccharides|Paraquat|Probenecid|Resveratrol,0,
leukocyte chemotaxis involved in inflammatory response,GO:0002232,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
leukocyte degranulation,GO:0043299,Parkinson Disease,MESH:D010300,5,Bromocriptine|Desipramine|Lipopolysaccharides|Pentoxifylline|Reserpine,0,
leukocyte degranulation,GO:0043299,"Parkinson Disease, Secondary",MESH:D010302,4,Diphenhydramine|Nicotine|Nifedipine|Reserpine,0,
leukocyte degranulation,GO:0043299,Parkinsonian Disorders,MESH:D020734,3,Bromocriptine|Lipopolysaccharides|Reserpine,0,
leukocyte homeostasis,GO:0001776,Parkinson Disease,MESH:D010300,10,Acrolein|Chlorpyrifos|Lead|Lipopolysaccharides|Lithium Carbonate|Nitrogen Dioxide|Particulate Matter|Polychlorinated Biphenyls|Rotenone|Soot,0,
leukocyte homeostasis,GO:0001776,"Parkinson Disease, Secondary",MESH:D010302,6,Carbon Monoxide|Doxorubicin|Lithium Carbonate|Resveratrol|Rotenone|thymoquinone,0,
leukocyte homeostasis,GO:0001776,Parkinsonian Disorders,MESH:D020734,7,Cadmium|Indomethacin|Lipopolysaccharides|Particulate Matter|Plant Extracts|Resveratrol|Rotenone,0,
leukocyte mediated cytotoxicity,GO:0001909,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
leukocyte migration,GO:0050900,Parkinson Disease,MESH:D010300,6,Air Pollutants|Hexachlorocyclohexane|Lipopolysaccharides|Paraquat|Particulate Matter|Vehicle Emissions,1,TNF
leukocyte migration,GO:0050900,"Parkinson Disease, Secondary",MESH:D010302,2,Benzo(a)pyrene|Paraquat,0,
leukocyte migration,GO:0050900,Parkinsonian Disorders,MESH:D020734,3,Lipopolysaccharides|Paraquat|Particulate Matter,0,
leukocyte migration involved in immune response,GO:0002522,Parkinson Disease,MESH:D010300,4,Estradiol|Particulate Matter|Testosterone|Vehicle Emissions,0,
leukocyte migration involved in immune response,GO:0002522,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
leukocyte migration involved in inflammatory response,GO:0002523,Parkinson Disease,MESH:D010300,26,4-phenylbutyric acid|Air Pollutants|Aspirin|Atrazine|Caffeine|Carbon Tetrachloride|Chlorpyrifos|Copper|Estradiol|Iron|Ketoconazole|Lead|Lipopolysaccharides|Melatonin|Nitrogen Dioxide|Ozone|Paraquat|Particulate Matter|Permethrin|Pioglitazone|Smoke|Soot|Testosterone|Trichloroethylene|Vehicle Emissions|Zinc,1,TNF
leukocyte migration involved in inflammatory response,GO:0002523,"Parkinson Disease, Secondary",MESH:D010302,22,3-methyladenine|Amiodarone|Atrazine|Benzo(a)pyrene|Carbon Monoxide|Cimetidine|Doxorubicin|Famotidine|Fluoxetine|geraniol|Haloperidol|Melatonin|Methotrexate|Paraquat|Phenytoin|Resveratrol|Risperidone|Silymarin|sodium bisulfide|thymoquinone|Trichloroethylene|Valproic Acid,0,
leukocyte migration involved in inflammatory response,GO:0002523,Parkinsonian Disorders,MESH:D020734,23,Amiodarone|baicalin|Cadmium|coenzyme Q10|crocin|Curcumin|geraniol|Haloperidol|Indomethacin|Ketoconazole|Lipopolysaccharides|Melatonin|oleuropein|Paraquat|Particulate Matter|Permethrin|Plant Extracts|Resveratrol|Risperidone|Silymarin|taxifolin|Valproic Acid|Zidovudine,0,
leukocyte migration involved in inflammatory response,GO:0002523,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Amiodarone|Isoproterenol,0,
leukocyte proliferation,GO:0070661,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
leukocyte proliferation,GO:0070661,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
leukocyte proliferation,GO:0070661,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Plant Extracts,0,
leukocyte tethering or rolling,GO:0050901,Parkinson Disease,MESH:D010300,3,Lipopolysaccharides|Melatonin|Nitric Oxide,1,TNF
leukocyte tethering or rolling,GO:0050901,"Parkinson Disease, Secondary",MESH:D010302,4,Amlodipine|Famotidine|Melatonin|Nicotine,0,
leukocyte tethering or rolling,GO:0050901,Parkinsonian Disorders,MESH:D020734,5,Amlodipine|Indomethacin|linsidomine|Lipopolysaccharides|Melatonin,0,
leukotriene B4 biosynthetic process,GO:0097251,Parkinson Disease,MESH:D010300,1,Aluminum,0,
leukotriene biosynthetic process,GO:0019370,Parkinson Disease,MESH:D010300,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
leukotriene biosynthetic process,GO:0019370,"Parkinson Disease, Secondary",MESH:D010302,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
leukotriene biosynthetic process,GO:0019370,Parkinsonian Disorders,MESH:D020734,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
Lewy body formation,GO:0140121,Parkinson Disease,MESH:D010300,1,Rotenone,0,
Lewy body formation,GO:0140121,"Parkinson Disease, Secondary",MESH:D010302,1,Rotenone,0,
Lewy body formation,GO:0140121,Parkinsonian Disorders,MESH:D020734,1,Rotenone,0,
Leydig cell differentiation,GO:0033327,Parkinson Disease,MESH:D010300,3,Lithium|Paraquat|Ziram,0,
Leydig cell differentiation,GO:0033327,"Parkinson Disease, Secondary",MESH:D010302,4,Lithium|Nicotine|Paraquat|Ziram,0,
Leydig cell differentiation,GO:0033327,Parkinsonian Disorders,MESH:D020734,3,crocin|cypermethrin|Paraquat,0,
Leydig cell differentiation,GO:0033327,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Lithium,0,
Leydig cell proliferation,GO:0160024,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
Leydig cell proliferation,GO:0160024,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
L-glutamate biosynthetic process,GO:0097054,Parkinson Disease,MESH:D010300,1,1-Methyl-4-phenylpyridinium,0,
L-glutamate biosynthetic process,GO:0097054,"Parkinson Disease, Secondary",MESH:D010302,1,Idazoxan,0,
L-glutamate biosynthetic process,GO:0097054,Parkinsonian Disorders,MESH:D020734,2,1-Methyl-4-phenylpyridinium|Idazoxan,0,
L-glutamate import,GO:0051938,Parkinson Disease,MESH:D010300,1,Paraquat,0,
L-glutamate import,GO:0051938,"Parkinson Disease, Secondary",MESH:D010302,2,Paraquat|Valproic Acid,0,
L-glutamate import,GO:0051938,Parkinsonian Disorders,MESH:D020734,3,manganese chloride|Paraquat|Valproic Acid,0,
L-glutamine import across plasma membrane,GO:1903803,Parkinson Disease,MESH:D010300,0,,1,SLC38A2
limb bud formation,GO:0060174,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
limb development,GO:0060173,"Parkinson Disease, Secondary",MESH:D010302,1,Cytarabine,1,SHH
limbic system development,GO:0021761,Parkinson Disease,MESH:D010300,0,,1,CNTNAP2
linoleic acid metabolic process,GO:0043651,Parkinson Disease,MESH:D010300,1,Permethrin,1,GSTP1
linoleic acid metabolic process,GO:0043651,Parkinsonian Disorders,MESH:D020734,1,Permethrin,0,
lipid biosynthetic process,GO:0008610,Parkinson Disease,MESH:D010300,14,Aspirin|Caffeine|Clozapine|Estradiol|Fatty Acids|Iron|Ketoconazole|Levodopa|Manganese|Paraquat|Propranolol|Sirolimus|Testosterone|Zinc,0,
lipid biosynthetic process,GO:0008610,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
lipid biosynthetic process,GO:0008610,"Parkinson Disease, Secondary",MESH:D010302,14,Amiodarone|Benzo(a)pyrene|Chlorpromazine|Doxorubicin|Fluoxetine|Indinavir|Levodopa|Manganese|Methotrexate|Paraquat|Resveratrol|Silymarin|Tacrine|Valproic Acid,0,
lipid biosynthetic process,GO:0008610,Parkinsonian Disorders,MESH:D020734,14,Amiodarone|Chlorpromazine|Clozapine|Curcumin|Indomethacin|Ketoconazole|Levodopa|Manganese|Paraquat|Plant Extracts|Resveratrol|Silymarin|Valproic Acid|Zidovudine,0,
lipid biosynthetic process,GO:0008610,Wolff-Parkinson-White Syndrome,MESH:D014927,3,Amiodarone|Isoproterenol|Propranolol,0,
lipid catabolic process,GO:0016042,Parkinson Disease,MESH:D010300,62,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|4-phenylbutyric acid|Acrolein|Air Pollutants|Aluminum|Aspirin|Atrazine|Bromocriptine|Caffeine|Carbidopa|carbidopa, levodopa drug combination|Carbon Tetrachloride|Chlorpyrifos|Coffee|Copper|Diazepam|Diazinon|Ditiocarb|Dopamine|Eicosapentaenoic Acid|Endosulfan|Estradiol|Eugenol|Fatty Acids|Hexachlorocyclohexane|Homocysteine|Iron|Ketoconazole|Lead|Levodopa|Lipid Peroxides|Lipopolysaccharides|Lithium|Lithium Carbonate|Maneb|Manganese|mangiferin|Melatonin|Methamphetamine|Minocycline|Oxidopamine|Ozone|Paraquat|Particulate Matter|Pentoxifylline|Permethrin|Pioglitazone|Propranolol|Reserpine|Rivastigmine|Roflumilast|Rotenone|Sirolimus|Soot|Tea|Testosterone|tetrachloroisophthalonitrile|Trichloroethylene|Vehicle Emissions|Water Pollutants, Chemical|Zinc",1,CP
lipid catabolic process,GO:0016042,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
lipid catabolic process,GO:0016042,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
lipid catabolic process,GO:0016042,"Parkinson Disease, Secondary",MESH:D010302,44,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|3-methyladenine|Amiodarone|Amlodipine|Atrazine|Benzo(a)pyrene|Carbidopa|carbidopa, levodopa drug combination|Cimetidine|Diazepam|Dichlorvos|Ditiocarb|Doxorubicin|Exenatide|Famotidine|Fluoxetine|geraniol|Levodopa|Lithium|Lithium Carbonate|Maneb|Manganese|Melatonin|Methamphetamine|Methotrexate|Minocycline|Nicotine|Octreotide|Oxidopamine|Paraquat|PQQ Cofactor|Reserpine|Resveratrol|Ritonavir|Rotenone|Silymarin|sodium bisulfide|Sulpiride|Tacrine|thymoquinone|Trichloroethylene|Valproic Acid|Venlafaxine Hydrochloride|Verapamil",0,
lipid catabolic process,GO:0016042,Parkinsonian Disorders,MESH:D020734,56,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|4-hydroxy-2-nonenal|6-methyl-2-(phenylethynyl)pyridine|Amiodarone|Amlodipine|baicalin|Bromocriptine|Cadmium|Carbidopa|carbidopa, levodopa drug combination|Centella asiatica extract|Clonidine|coenzyme Q10|Coffee|crocin|Curcumin|cypermethrin|Docosahexaenoic Acids|Donepezil|Dopamine|geraniol|ginsenoside Re|Indomethacin|Ketoconazole|Levodopa|linsidomine|Lipopolysaccharides|M40401|Malondialdehyde|mancozeb|Maneb|Manganese|manganese chloride|Melatonin|Muscimol|N-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide|oleuropein|Oxidopamine|Paraquat|Particulate Matter|Permethrin|Plant Extracts|Plant Preparations|Procaine|Reserpine|Resveratrol|Rimonabant|Ritonavir|Rivastigmine|Rotenone|SCH 23390|Silymarin|taxifolin|Valproic Acid|Verapamil",0,
lipid catabolic process,GO:0016042,Wolff-Parkinson-White Syndrome,MESH:D014927,5,Amiodarone|Isoproterenol|Lithium|Propranolol|Quinidine,0,
lipid droplet disassembly,GO:1905691,"Parkinson Disease, Secondary",MESH:D010302,1,3-methyladenine,0,
lipid droplet formation,GO:0140042,Parkinson Disease,MESH:D010300,22,4-phenylbutyric acid|Air Pollutants|Atrazine|Caffeine|Carbon Tetrachloride|Chlorpyrifos|Copper|Diazinon|Ditiocarb|Eicosapentaenoic Acid|Estradiol|Iron|Lipopolysaccharides|Melatonin|Organophosphorus Compounds|Paclitaxel|Particulate Matter|Permethrin|Pioglitazone|Rotenone|Sirolimus|Smoke,0,
lipid droplet formation,GO:0140042,"Parkinson Disease, Secondary",MESH:D010302,16,3-methyladenine|Amiodarone|Atrazine|Benzo(a)pyrene|Ditiocarb|Doxorubicin|Exenatide|Melatonin|Methotrexate|Nicotine|Olanzapine|Organophosphorus Compounds|Resveratrol|Rotenone|Silymarin|Valproic Acid,0,
lipid droplet formation,GO:0140042,Parkinsonian Disorders,MESH:D020734,16,Amiodarone|Cadmium|crocin|Curcumin|Indomethacin|linsidomine|Lipopolysaccharides|Melatonin|Olanzapine|Particulate Matter|Permethrin|Resveratrol|Rimonabant|Rotenone|Silymarin|Valproic Acid,0,
lipid droplet formation,GO:0140042,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
lipid droplet organization,GO:0034389,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
lipid droplet organization,GO:0034389,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
lipid glycosylation,GO:0030259,Parkinson Disease,MESH:D010300,0,,1,GBA1
lipid glycosylation,GO:0030259,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
lipid glycosylation,GO:0030259,Parkinsonian Disorders,MESH:D020734,0,,1,GBA1
lipid homeostasis,GO:0055088,Parkinson Disease,MESH:D010300,2,Fatty Acids|Maneb,1,ATP13A2
lipid homeostasis,GO:0055088,"Parkinson Disease, Secondary",MESH:D010302,5,Fluoxetine|geraniol|Maneb|PQQ Cofactor|Resveratrol,1,ATP13A2
lipid homeostasis,GO:0055088,Parkinsonian Disorders,MESH:D020734,4,geraniol|Maneb|Plant Extracts|Resveratrol,1,ATP13A2
lipid hydroxylation,GO:0002933,Parkinson Disease,MESH:D010300,0,,1,CYP2E1
lipid import into cell,GO:0140354,Parkinson Disease,MESH:D010300,2,Atrazine|Fatty Acids,0,
lipid import into cell,GO:0140354,"Parkinson Disease, Secondary",MESH:D010302,1,Atrazine,0,
lipid localization,GO:0010876,Parkinson Disease,MESH:D010300,1,Homocysteine,0,
lipid metabolic process,GO:0006629,Parkinson Disease,MESH:D010300,11,Acrolein|Air Pollutants|Atrazine|Copper|Eicosapentaenoic Acid|Fatty Acids|Ketoconazole|Lead|Lipid Peroxides|Particulate Matter|Pioglitazone,2,GBA1|MAG
lipid metabolic process,GO:0006629,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
lipid metabolic process,GO:0006629,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
lipid metabolic process,GO:0006629,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,2,ADH1C|GBA1
lipid metabolic process,GO:0006629,"Parkinson Disease, Secondary",MESH:D010302,6,Amiodarone|Atrazine|Chlorpromazine|Fluoxetine|Methotrexate|Valproic Acid,0,
lipid metabolic process,GO:0006629,Parkinsonian Disorders,MESH:D020734,8,Amiodarone|Cadmium|Chlorpromazine|Docosahexaenoic Acids|Ketoconazole|Malondialdehyde|Particulate Matter|Valproic Acid,1,GBA1
lipid metabolic process,GO:0006629,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
lipid oxidation,GO:0034440,Parkinson Disease,MESH:D010300,48,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|4-phenylbutyric acid|6,7-dihydroxyflavone|Acrolein|Air Pollutants|Aspirin|Atrazine|Caffeine|Carbon Tetrachloride|Chlorpyrifos|Copper|Diazinon|Ditiocarb|Endosulfan|Estradiol|Eugenol|Iron|Lead|Levodopa|Lipid Peroxides|Lipopolysaccharides|Lithium Carbonate|Maneb|mangiferin|Melatonin|Methamphetamine|Mirtazapine|Oxidopamine|Ozone|Paclitaxel|Paraquat|Particulate Matter|pendimethalin|Pentoxifylline|Permethrin|Pesticides|Pioglitazone|Pramipexole|Reactive Oxygen Species|Roflumilast|Rotenone|Sirolimus|Tea|Testosterone|Vehicle Emissions|Water Pollutants, Chemical|Zinc",0,
lipid oxidation,GO:0034440,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,2,Levodopa|Pramipexole,0,
lipid oxidation,GO:0034440,"Parkinson Disease, Secondary",MESH:D010302,37,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|3-methyladenine|Amlodipine|Atrazine|Benzo(a)pyrene|Buspirone|Carbamazepine|Dichlorvos|Ditiocarb|Doxorubicin|Exenatide|Famotidine|Fluoxetine|geraniol|Haloperidol|Levodopa|Lithium Carbonate|Maneb|Melatonin|Methamphetamine|Methotrexate|Nicotine|Oxidopamine|Paraquat|Paroxetine|Pesticides|PQQ Cofactor|Pyridostigmine Bromide|Resveratrol|Rotenone|saxagliptin|Silymarin|sodium bisulfide|thymoquinone|Valproic Acid|Verapamil|Vincristine",0,
lipid oxidation,GO:0034440,Parkinsonian Disorders,MESH:D020734,42,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside|4-hydroxy-2-nonenal|Amitriptyline|Amlodipine|baicalin|Buspirone|Cadmium|coenzyme Q10|crocin|Curcumin|cypermethrin|Docosahexaenoic Acids|geraniol|ginsenoside Re|Haloperidol|Indomethacin|Levodopa|linsidomine|Lipopolysaccharides|Malondialdehyde|mancozeb|Maneb|manganese chloride|Melatonin|oleuropein|Oxidopamine|Paraquat|Paroxetine|Particulate Matter|Permethrin|Plant Extracts|Plant Preparations|Pramipexole|Resveratrol|Rotenone|sesamin|Silymarin|taxifolin|Valproic Acid|Verapamil",0,
lipid oxidation,GO:0034440,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
lipid phosphorylation,GO:0046834,Parkinson Disease,MESH:D010300,0,,1,RDGA
lipid storage,GO:0019915,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,1,GBA1
lipid storage,GO:0019915,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
lipid storage,GO:0019915,Parkinsonian Disorders,MESH:D020734,2,Indomethacin|Plant Extracts,1,GBA1
lipid transport,GO:0006869,Parkinson Disease,MESH:D010300,0,,1,MAG
lipid transport,GO:0006869,"PARKINSON DISEASE 23, AUTOSOMAL RECESSIVE EARLY-ONSET",OMIM:616840,0,,1,VPS13C
lipoate metabolic process,GO:0009106,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
lipopolysaccharide biosynthetic process,GO:0009103,Parkinson Disease,MESH:D010300,2,Diazinon|Lipopolysaccharides,0,
lipopolysaccharide biosynthetic process,GO:0009103,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
lipopolysaccharide metabolic process,GO:0008653,Parkinson Disease,MESH:D010300,2,Lipopolysaccharides|Methamphetamine,0,
lipopolysaccharide metabolic process,GO:0008653,"Parkinson Disease, Secondary",MESH:D010302,1,Methamphetamine,0,
lipopolysaccharide metabolic process,GO:0008653,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
lipopolysaccharide transport,GO:0015920,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
lipopolysaccharide transport,GO:0015920,Parkinsonian Disorders,MESH:D020734,1,Lipopolysaccharides,0,
lipoprotein biosynthetic process,GO:0042158,"Parkinson Disease, Secondary",MESH:D010302,2,Amiodarone|Cimetidine,0,
lipoprotein biosynthetic process,GO:0042158,Parkinsonian Disorders,MESH:D020734,2,Amiodarone|Cadmium,0,
lipoprotein biosynthetic process,GO:0042158,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
lipoprotein lipid oxidation,GO:0034439,Parkinson Disease,MESH:D010300,1,Copper,0,
lipoprotein lipid oxidation,GO:0034439,Parkinsonian Disorders,MESH:D020734,1,Curcumin,0,
lipoprotein metabolic process,GO:0042157,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
lipoprotein metabolic process,GO:0042157,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
lipoprotein oxidation,GO:0042161,Parkinson Disease,MESH:D010300,2,Estradiol|Lipopolysaccharides,0,
lipoprotein oxidation,GO:0042161,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
lipoprotein oxidation,GO:0042161,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Resveratrol,0,
lipoxin A4 biosynthetic process,GO:2001303,Parkinson Disease,MESH:D010300,2,Aspirin|Naproxen,0,
lipoxygenase pathway,GO:0019372,Parkinsonian Disorders,MESH:D020734,1,Indomethacin,0,
liver development,GO:0001889,Parkinson Disease,MESH:D010300,2,Estradiol|Manganese,7,ALDH2|CP|HGF|IGF2R|INSR|NOS1|SOD2
liver development,GO:0001889,"Parkinson Disease, Secondary",MESH:D010302,2,Carbamazepine|Manganese,1,CNR2
liver development,GO:0001889,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Manganese,2,ALDH1A1|ALDH1A2
liver regeneration,GO:0097421,Parkinson Disease,MESH:D010300,1,Carbon Tetrachloride,6,HFE|HGF|HMOX1|IL6|INSR|TNF
liver regeneration,GO:0097421,"Parkinson Disease, Secondary",MESH:D010302,2,geraniol|Silymarin,1,SHH
liver regeneration,GO:0097421,Parkinsonian Disorders,MESH:D020734,2,geraniol|Silymarin,0,
lncRNA transcription,GO:0140742,Parkinson Disease,MESH:D010300,1,Paraquat,0,
lncRNA transcription,GO:0140742,"Parkinson Disease, Secondary",MESH:D010302,1,Paraquat,0,
lncRNA transcription,GO:0140742,Parkinsonian Disorders,MESH:D020734,1,Paraquat,0,
locomotion,GO:0040011,Parkinson Disease,MESH:D010300,9,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Amantadine|Amphetamine|Chlorpyrifos|Estradiol|Levodopa|Manganese|Oxidopamine|Paraquat",0,
locomotion,GO:0040011,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
locomotion,GO:0040011,"Parkinson Disease, Secondary",MESH:D010302,9,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Amantadine|Benzo(a)pyrene|Doxorubicin|Haloperidol|Levodopa|Manganese|Oxidopamine|Paraquat",0,
locomotion,GO:0040011,Parkinsonian Disorders,MESH:D020734,10,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|6-methyl-2-(phenylethynyl)pyridine|Amantadine|Amitriptyline|Donepezil|Haloperidol|Levodopa|Manganese|Oxidopamine|Paraquat",1,ATP1A3
locomotion involved in locomotory behavior,GO:0031987,Parkinson Disease,MESH:D010300,37,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Air Pollutants|Amphetamine|Apomorphine|Atrazine|Caffeine|Chlorpyrifos|Clozapine|Copper|Diazepam|Diazinon|Gabapentin|Hexachlorocyclohexane|istradefylline|Lead|Levodopa|Lipopolysaccharides|Lithium|Manganese|Methamphetamine|Methomyl|Minocycline|Oxidopamine|Paraquat|Particulate Matter|pendimethalin|Permethrin|Pioglitazone|Reserpine|Rivastigmine|Roflumilast|Rotenone|Smoke|Trichloroethylene|Vehicle Emissions|Zinc|Ziram",0,
locomotion involved in locomotory behavior,GO:0031987,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
locomotion involved in locomotory behavior,GO:0031987,"Parkinson Disease, Secondary",MESH:D010302,28,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|3-methyladenine|Apomorphine|Atrazine|Benzo(a)pyrene|Diazepam|Fluoxetine|Haloperidol|Levodopa|Lithium|Manganese|Methamphetamine|Minocycline|Nicotine|Nifedipine|Olanzapine|Oxidopamine|Paraquat|Pyridostigmine Bromide|Reserpine|Resveratrol|Risperidone|Rotenone|Sulpiride|Trichloroethylene|Valproic Acid|Venlafaxine Hydrochloride|Ziram",0,
locomotion involved in locomotory behavior,GO:0031987,Parkinsonian Disorders,MESH:D020734,28,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|3-iodotyrosine|Apomorphine|Cadmium|Clozapine|Curcumin|Docosahexaenoic Acids|Haloperidol|Indomethacin|istradefylline|Levodopa|Lipopolysaccharides|Manganese|manganese chloride|Olanzapine|Oxidopamine|Paraquat|Particulate Matter|Permethrin|Plant Extracts|Reserpine|Resveratrol|Rimonabant|Risperidone|Rivastigmine|Rotenone|SCH 23390|Valproic Acid",0,
locomotion involved in locomotory behavior,GO:0031987,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Lithium,0,
locomotor rhythm,GO:0045475,Parkinson Disease,MESH:D010300,0,,2,CNTNAP2|MTA1
locomotory behavior,GO:0007626,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
locomotory behavior,GO:0007626,Parkinson Disease,MESH:D010300,17,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Apomorphine|beta-N-methylamino-L-alanine|Diazepam|Dopamine|Eicosapentaenoic Acid|Lead|Manganese|Methamphetamine|Ozone|Paraquat|Particulate Matter|Probenecid|Reserpine|Rotenone|SK&F 82958|Testosterone",10,ATP13A2|CNTNAP2|DRD1|DRD2|PRKN|SLC18A2|SLC6A3|SOD1|SOD2|TH
locomotory behavior,GO:0007626,"Parkinson Disease, Secondary",MESH:D010302,12,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Apomorphine|Diazepam|Haloperidol|Manganese|Methamphetamine|Paraquat|Poly I-C|Reserpine|Resveratrol|Rotenone|Valproic Acid",3,ATP13A2|PRKN|SLC18A2
locomotory behavior,GO:0007626,Parkinsonian Disorders,MESH:D020734,18,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Apomorphine|Dopamine|Haloperidol|mancozeb|Manganese|manganese chloride|Paraquat|Particulate Matter|Probenecid|Quinpirole|Reserpine|Resveratrol|Rimonabant|Rotenone|SCH 23390|SK&F 82958|Valproic Acid",6,ATP13A2|ATP1A3|DRD2|PRKN|SLC18A2|TH
locomotory behavior,GO:0007626,"Parkinsonism-Dystonia, Infantile",MESH:C567730,0,,1,SLC6A3
locomotory exploration behavior,GO:0035641,Parkinson Disease,MESH:D010300,7,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Air Pollutants|Amantadine|Nitrates|Particulate Matter|Reserpine|Rotenone",1,LRRK2
locomotory exploration behavior,GO:0035641,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
locomotory exploration behavior,GO:0035641,"Parkinson Disease, Secondary",MESH:D010302,5,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Amantadine|Nicotine|Reserpine|Rotenone",0,
locomotory exploration behavior,GO:0035641,Parkinsonian Disorders,MESH:D020734,6,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Amantadine|Cadmium|Particulate Matter|Reserpine|Rotenone",1,LRRK2
long-chain fatty acid biosynthetic process,GO:0042759,Parkinson Disease,MESH:D010300,0,,2,CYP2D6|CYP2E1
long-chain fatty acid metabolic process,GO:0001676,Parkinson Disease,MESH:D010300,1,Eicosapentaenoic Acid,1,CYP2E1
long-term memory,GO:0007616,Parkinson Disease,MESH:D010300,2,Methamphetamine|Testosterone,2,DDC|DRD2
long-term memory,GO:0007616,"Parkinson Disease, Secondary",MESH:D010302,2,Methamphetamine|Methotrexate,0,
long-term memory,GO:0007616,Parkinsonian Disorders,MESH:D020734,0,,2,DDC|DRD2
long-term memory,GO:0007616,"PARKINSONISM WITH SPASTICITY, X-LINKED",OMIM:300911,0,,1,ATP6AP2
long-term synaptic depression,GO:0060292,Parkinson Disease,MESH:D010300,2,Amphetamine|Rotenone,1,DRD1
long-term synaptic depression,GO:0060292,"Parkinson Disease, Secondary",MESH:D010302,1,Rotenone,0,
long-term synaptic depression,GO:0060292,Parkinsonian Disorders,MESH:D020734,1,Rotenone,0,
long-term synaptic potentiation,GO:0060291,Parkinson Disease,MESH:D010300,3,Aluminum|Amphetamine|Rotenone,4,DRD1|GFAP|MIR181C|SNCA
long-term synaptic potentiation,GO:0060291,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
long-term synaptic potentiation,GO:0060291,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
long-term synaptic potentiation,GO:0060291,"Parkinson Disease, Secondary",MESH:D010302,3,Benzo(a)pyrene|Nicotine|Rotenone,1,SNCA
long-term synaptic potentiation,GO:0060291,Parkinsonian Disorders,MESH:D020734,2,Rimonabant|Rotenone,1,SNCA
long-term synaptic potentiation,GO:0060291,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
low-density lipoprotein particle clearance,GO:0034383,Parkinson Disease,MESH:D010300,0,,1,HMOX1
low-density lipoprotein particle clearance,GO:0034383,Parkinsonian Disorders,MESH:D020734,1,Curcumin,0,
low-density lipoprotein receptor particle metabolic process,GO:0032799,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
low-density lipoprotein receptor particle metabolic process,GO:0032799,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
L-phenylalanine biosynthetic process,GO:0009094,Parkinson Disease,MESH:D010300,2,1-Methyl-4-phenylpyridinium|Carbon Tetrachloride,0,
L-phenylalanine biosynthetic process,GO:0009094,Parkinsonian Disorders,MESH:D020734,1,1-Methyl-4-phenylpyridinium,0,
L-phenylalanine metabolic process,GO:0006558,Parkinson Disease,MESH:D010300,4,Air Pollutants|Endosulfan|Nitrogen Dioxide|Particulate Matter,0,
L-phenylalanine metabolic process,GO:0006558,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
L-pipecolic acid biosynthetic process,GO:0062034,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
L-proline betaine biosynthetic process,GO:0019503,Parkinson Disease,MESH:D010300,1,Polychlorinated Biphenyls,0,
L-proline biosynthetic process,GO:0055129,Parkinson Disease,MESH:D010300,1,1-Methyl-4-phenylpyridinium,0,
L-proline biosynthetic process,GO:0055129,Parkinsonian Disorders,MESH:D020734,1,1-Methyl-4-phenylpyridinium,0,
L-proline import across plasma membrane,GO:1904271,Parkinson Disease,MESH:D010300,0,,1,SLC38A2
L-serine biosynthetic process,GO:0006564,Parkinson Disease,MESH:D010300,2,1-Methyl-4-phenylpyridinium|Carbon Tetrachloride,0,
L-serine biosynthetic process,GO:0006564,Parkinsonian Disorders,MESH:D020734,1,1-Methyl-4-phenylpyridinium,0,
L-serine import across plasma membrane,GO:1903812,Parkinson Disease,MESH:D010300,0,,1,SLC38A2
L-serine metabolic process,GO:0006563,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
L-serine metabolic process,GO:0006563,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
L-serine transport,GO:0015825,Parkinson Disease,MESH:D010300,0,,1,SLC38A2
lung alveolus development,GO:0048286,Parkinson Disease,MESH:D010300,2,Air Pollutants|Particulate Matter,0,
lung alveolus development,GO:0048286,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
lung-associated mesenchyme development,GO:0060484,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
lung development,GO:0030324,Parkinson Disease,MESH:D010300,1,Particulate Matter,1,CP
lung development,GO:0030324,"PARKINSON DISEASE 18, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:614251,0,,1,EIF4G1
lung development,GO:0030324,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
lung development,GO:0030324,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,1,ALDH1A2
lung epithelium development,GO:0060428,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
lung goblet cell differentiation,GO:0060480,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
lung goblet cell differentiation,GO:0060480,Parkinsonian Disorders,MESH:D020734,2,Curcumin|Particulate Matter,0,
lung growth,GO:0060437,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
lung lobe morphogenesis,GO:0060463,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
lung morphogenesis,GO:0060425,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
luteinizing hormone secretion,GO:0032275,Parkinson Disease,MESH:D010300,1,Estradiol,0,
lymphocyte activation,GO:0046649,Parkinson Disease,MESH:D010300,5,Dopamine|Ketoconazole|Lipopolysaccharides|Pentoxifylline|Sirolimus,0,
lymphocyte activation,GO:0046649,"Parkinson Disease, Secondary",MESH:D010302,1,Ribavirin,0,
lymphocyte activation,GO:0046649,Parkinsonian Disorders,MESH:D020734,4,Cadmium|Dopamine|Ketoconazole|Lipopolysaccharides,0,
lymphocyte activation,GO:0046649,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
lymphocyte activation involved in immune response,GO:0002285,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
lymphocyte activation involved in immune response,GO:0002285,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
lymphocyte chemotaxis,GO:0048247,Parkinson Disease,MESH:D010300,4,Ozone|Paraquat|Particulate Matter|Vehicle Emissions,0,
lymphocyte chemotaxis,GO:0048247,"Parkinson Disease, Secondary",MESH:D010302,1,Paraquat,0,
lymphocyte chemotaxis,GO:0048247,Parkinsonian Disorders,MESH:D020734,3,Curcumin|Paraquat|Particulate Matter,0,
lymphocyte costimulation,GO:0031294,Parkinson Disease,MESH:D010300,0,,1,IL6
lymphocyte homeostasis,GO:0002260,Parkinson Disease,MESH:D010300,13,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Air Pollutants|Chlorpyrifos|Clozapine|Lipopolysaccharides|Lithium Carbonate|Ozone|Particulate Matter|Polychlorinated Biphenyls|Rotenone|Soot|Vehicle Emissions|Zinc",0,
lymphocyte homeostasis,GO:0002260,"Parkinson Disease, Secondary",MESH:D010302,3,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Lithium Carbonate|Rotenone",0,
lymphocyte homeostasis,GO:0002260,Parkinsonian Disorders,MESH:D020734,6,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Clozapine|Lipopolysaccharides|Particulate Matter|Plant Extracts|Rotenone",0,
lymphocyte mediated immunity,GO:0002449,Parkinson Disease,MESH:D010300,4,Hexachlorocyclohexane|Lead|mangiferin|Polychlorinated Biphenyls,0,
lymphocyte migration,GO:0072676,Parkinson Disease,MESH:D010300,9,Air Pollutants|Atrazine|Iron|Lipopolysaccharides|Ozone|Paraquat|Particulate Matter|Soot|Trichloroethylene,1,GBA1
lymphocyte migration,GO:0072676,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
lymphocyte migration,GO:0072676,"Parkinson Disease, Secondary",MESH:D010302,4,Amiodarone|Atrazine|Paraquat|Trichloroethylene,0,
lymphocyte migration,GO:0072676,Parkinsonian Disorders,MESH:D020734,5,Amiodarone|Lipopolysaccharides|Paraquat|Particulate Matter|taxifolin,1,GBA1
lymphocyte migration,GO:0072676,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Amiodarone|Isoproterenol,0,
lymphocyte proliferation,GO:0046651,Parkinson Disease,MESH:D010300,5,Air Pollutants|Lipopolysaccharides|Particulate Matter|Soot|Vehicle Emissions,0,
lymphocyte proliferation,GO:0046651,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Particulate Matter,0,
lymphoid progenitor cell differentiation,GO:0002320,"Parkinson Disease, Secondary",MESH:D010302,1,Cytarabine,1,SHH
lysine biosynthetic process,GO:0009085,Parkinson Disease,MESH:D010300,3,1-Methyl-4-phenylpyridinium|Endosulfan|Polychlorinated Biphenyls,0,
lysine biosynthetic process,GO:0009085,Parkinsonian Disorders,MESH:D020734,1,1-Methyl-4-phenylpyridinium,0,
lysine metabolic process,GO:0006553,Parkinson Disease,MESH:D010300,1,Endosulfan,0,
lysosomal lumen acidification,GO:0007042,Parkinson Disease,MESH:D010300,6,Copper|Manganese|Methamphetamine|Particulate Matter|Sirolimus|Vehicle Emissions,0,
lysosomal lumen acidification,GO:0007042,"Parkinson Disease, Secondary",MESH:D010302,4,Doxorubicin|Manganese|Methamphetamine|Trifluoperazine,0,
lysosomal lumen acidification,GO:0007042,Parkinsonian Disorders,MESH:D020734,5,Cadmium|Manganese|manganese chloride|Particulate Matter|Trifluoperazine,0,
lysosomal lumen acidification,GO:0007042,"PARKINSONISM WITH SPASTICITY, X-LINKED",OMIM:300911,0,,1,ATP6AP2
lysosomal lumen pH elevation,GO:0035752,Parkinson Disease,MESH:D010300,2,Paraquat|Rotenone,0,
lysosomal lumen pH elevation,GO:0035752,"Parkinson Disease, Secondary",MESH:D010302,2,Paraquat|Rotenone,0,
lysosomal lumen pH elevation,GO:0035752,Parkinsonian Disorders,MESH:D020734,4,Cadmium|Curcumin|Paraquat|Rotenone,0,
lysosomal membrane organization,GO:0097212,Parkinson Disease,MESH:D010300,2,Copper|Paraquat,0,
lysosomal membrane organization,GO:0097212,"Parkinson Disease, Secondary",MESH:D010302,2,Doxorubicin|Paraquat,0,
lysosomal membrane organization,GO:0097212,Parkinsonian Disorders,MESH:D020734,3,Cadmium|coenzyme Q10|Paraquat,0,
lysosomal protein catabolic process,GO:1905146,Parkinson Disease,MESH:D010300,1,Sirolimus,0,
lysosomal protein catabolic process,GO:1905146,"Parkinson Disease, Secondary",MESH:D010302,1,Amiodarone,0,
lysosomal protein catabolic process,GO:1905146,Parkinsonian Disorders,MESH:D020734,2,Amiodarone|Cadmium,0,
lysosomal protein catabolic process,GO:1905146,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
lysosomal transport,GO:0007041,Parkinson Disease,MESH:D010300,0,,3,ATP13A2|HSPA1A|IGF2R
lysosomal transport,GO:0007041,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,1,ATP13A2
lysosomal transport,GO:0007041,Parkinsonian Disorders,MESH:D020734,0,,1,ATP13A2
lysosome organization,GO:0007040,Parkinson Disease,MESH:D010300,8,1-Methyl-4-phenylpyridinium|Acrolein|Atrazine|Copper|Lipofuscin|Methamphetamine|Organophosphorus Compounds|Paraquat,3,GBA1|LRRK2|VPS35
lysosome organization,GO:0007040,PARKINSON DISEASE 17,OMIM:614203,0,,1,VPS35
lysosome organization,GO:0007040,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
lysosome organization,GO:0007040,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
lysosome organization,GO:0007040,"Parkinson Disease, Secondary",MESH:D010302,6,Amiodarone|Atrazine|Doxorubicin|Methamphetamine|Organophosphorus Compounds|Paraquat,0,
lysosome organization,GO:0007040,Parkinsonian Disorders,MESH:D020734,5,1-Methyl-4-phenylpyridinium|4-hydroxy-2-nonenal|Amiodarone|Paraquat|Plant Extracts,2,GBA1|LRRK2
lysosome organization,GO:0007040,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
macroautophagy,GO:0016236,Parkinson Disease,MESH:D010300,0,,3,HMOX1|PINK1|PRKN
macroautophagy,GO:0016236,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
macroautophagy,GO:0016236,"Parkinson Disease, Secondary",MESH:D010302,0,,1,PRKN
macroautophagy,GO:0016236,Parkinsonian Disorders,MESH:D020734,0,,2,PINK1|PRKN
macromolecule biosynthetic process,GO:0009059,"PARKINSON DISEASE 18, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:614251,0,,1,EIF4G1
macrophage activation,GO:0042116,Parkinson Disease,MESH:D010300,7,Carbon Disulfide|Carbon Tetrachloride|Lipopolysaccharides|Minocycline|Nitrites|Ozone|Particulate Matter,2,AIF1|FCER2
macrophage activation,GO:0042116,"Parkinson Disease, Secondary",MESH:D010302,3,Amiodarone|Minocycline|Valproic Acid,0,
macrophage activation,GO:0042116,Parkinsonian Disorders,MESH:D020734,9,Amiodarone|Cadmium|Carbon Disulfide|Curcumin|cypermethrin|Lipopolysaccharides|Particulate Matter|Procaine|Valproic Acid,0,
macrophage activation,GO:0042116,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
macrophage activation involved in immune response,GO:0002281,Parkinson Disease,MESH:D010300,4,Lipopolysaccharides|Ozone|Particulate Matter|Soot,1,TNF
macrophage activation involved in immune response,GO:0002281,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
macrophage activation involved in immune response,GO:0002281,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Particulate Matter,0,
macrophage chemotaxis,GO:0048246,Parkinsonian Disorders,MESH:D020734,1,Rimonabant,0,
macrophage colony-stimulating factor signaling pathway,GO:0038145,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
macrophage differentiation,GO:0030225,Parkinson Disease,MESH:D010300,3,Lipopolysaccharides|Particulate Matter|Vehicle Emissions,1,IL6
macrophage differentiation,GO:0030225,Parkinsonian Disorders,MESH:D020734,3,cypermethrin|Lipopolysaccharides|Particulate Matter,1,PARP1
macrophage homeostasis,GO:0061519,Parkinson Disease,MESH:D010300,4,Air Pollutants|Carbon Tetrachloride|Particulate Matter|Vehicle Emissions,0,
macrophage homeostasis,GO:0061519,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
macrophage migration,GO:1905517,Parkinson Disease,MESH:D010300,11,Air Pollutants|Carbon Tetrachloride|Herbicides|Hexachlorocyclohexane|Lipopolysaccharides|Ozone|Paraquat|Particulate Matter|Rivastigmine|Soot|Vehicle Emissions,0,
macrophage migration,GO:1905517,"Parkinson Disease, Secondary",MESH:D010302,4,Amiodarone|Methotrexate|Paraquat|Resveratrol,0,
macrophage migration,GO:1905517,Parkinsonian Disorders,MESH:D020734,8,Amiodarone|Cadmium|Curcumin|Lipopolysaccharides|Paraquat|Particulate Matter|Resveratrol|Rivastigmine,0,
macrophage migration,GO:1905517,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
macrophage proliferation,GO:0061517,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
macrophage proliferation,GO:0061517,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|manganese chloride,0,
magnesium ion homeostasis,GO:0010960,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
magnesium ion homeostasis,GO:0010960,Parkinson Disease,MESH:D010300,1,Atrazine,0,
magnesium ion homeostasis,GO:0010960,"Parkinson Disease, Secondary",MESH:D010302,1,Atrazine,0,
magnesium ion transmembrane transport,GO:1903830,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
magnesium ion transport,GO:0015693,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
maintenance of animal organ identity,GO:0048496,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
maintenance of blood-brain barrier,GO:0035633,Parkinson Disease,MESH:D010300,6,Lead|Lipopolysaccharides|Melatonin|Methamphetamine|Oxidopamine|Particulate Matter,1,IL6
maintenance of blood-brain barrier,GO:0035633,"Parkinson Disease, Secondary",MESH:D010302,5,Melatonin|Methamphetamine|Oxidopamine|Resveratrol|Verapamil,0,
maintenance of blood-brain barrier,GO:0035633,Parkinsonian Disorders,MESH:D020734,6,Lipopolysaccharides|Melatonin|Oxidopamine|Particulate Matter|Resveratrol|Verapamil,0,
maintenance of cell number,GO:0098727,Parkinson Disease,MESH:D010300,2,Atrazine|Lead,0,
maintenance of cell number,GO:0098727,"Parkinson Disease, Secondary",MESH:D010302,3,Atrazine|Poly I-C|Silymarin,0,
maintenance of cell number,GO:0098727,Parkinsonian Disorders,MESH:D020734,2,Plant Extracts|Silymarin,0,
maintenance of gastrointestinal epithelium,GO:0030277,Parkinsonian Disorders,MESH:D020734,1,Curcumin,0,
maintenance of lens transparency,GO:0036438,Parkinsonian Disorders,MESH:D020734,0,,1,ALDH1A1
maintenance of location,GO:0051235,Parkinson Disease,MESH:D010300,2,Particulate Matter|Vehicle Emissions,0,
maintenance of location,GO:0051235,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
maintenance of protein location in mitochondrion,GO:0072656,Parkinson Disease,MESH:D010300,1,Rotenone,1,PINK1
maintenance of protein location in mitochondrion,GO:0072656,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
maintenance of protein location in mitochondrion,GO:0072656,"Parkinson Disease, Secondary",MESH:D010302,3,geraniol|Rotenone|Silymarin,0,
maintenance of protein location in mitochondrion,GO:0072656,Parkinsonian Disorders,MESH:D020734,3,geraniol|Rotenone|Silymarin,1,PINK1
maintenance of protein location in nucleus,GO:0051457,Parkinson Disease,MESH:D010300,1,Sirolimus,0,
maintenance of protein location in nucleus,GO:0051457,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
maintenance of protein location in nucleus,GO:0051457,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
maintenance of synapse structure,GO:0099558,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
maintenance of synapse structure,GO:0099558,Parkinson Disease,MESH:D010300,3,beta-N-methylamino-L-alanine|Maneb|Paraquat,1,CNTNAP2
maintenance of synapse structure,GO:0099558,"Parkinson Disease, Secondary",MESH:D010302,2,Maneb|Paraquat,0,
maintenance of synapse structure,GO:0099558,Parkinsonian Disorders,MESH:D020734,2,Maneb|Paraquat,1,DCTN1
malate metabolic process,GO:0006108,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
malate metabolic process,GO:0006108,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
male anatomical structure morphogenesis,GO:0090598,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
male genitalia development,GO:0030539,Parkinson Disease,MESH:D010300,1,Pesticides,0,
male genitalia development,GO:0030539,"Parkinson Disease, Secondary",MESH:D010302,1,Pesticides,1,SHH
male genitalia morphogenesis,GO:0048808,Parkinson Disease,MESH:D010300,1,Atrazine,0,
male genitalia morphogenesis,GO:0048808,"Parkinson Disease, Secondary",MESH:D010302,1,Atrazine,1,SHH
male germ cell proliferation,GO:0002176,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
male germ cell proliferation,GO:0002176,"PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:613643,0,,1,UCHL1
male germ-line stem cell population maintenance,GO:0036098,Parkinson Disease,MESH:D010300,1,Testosterone,0,
male gonad development,GO:0008584,Parkinson Disease,MESH:D010300,7,Atrazine|Chlorpyrifos|Endosulfan|Estradiol|Lead|Pesticides|Pioglitazone,2,GDNF|INSR
male gonad development,GO:0008584,"Parkinson Disease, Secondary",MESH:D010302,3,Atrazine|Pesticides|Resveratrol,1,GDNF
male gonad development,GO:0008584,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Resveratrol,1,GDNF
male mating behavior,GO:0060179,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
male mating behavior,GO:0060179,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
male meiosis chromosome separation,GO:0051308,Parkinson Disease,MESH:D010300,1,Polychlorinated Biphenyls,0,
male meiosis I,GO:0007141,Parkinson Disease,MESH:D010300,1,Estradiol,0,
male meiotic nuclear division,GO:0007140,Parkinson Disease,MESH:D010300,1,Atrazine,0,
male meiotic nuclear division,GO:0007140,"Parkinson Disease, Secondary",MESH:D010302,1,Atrazine,0,
male sex determination,GO:0030238,Parkinson Disease,MESH:D010300,0,,2,IGF1R|INSR
male sex differentiation,GO:0046661,Parkinsonian Disorders,MESH:D020734,1,cypermethrin,0,
mammary duct terminal end bud growth,GO:0060763,Parkinson Disease,MESH:D010300,3,Endosulfan|Herbicides|Zinc,0,
mammary duct terminal end bud growth,GO:0060763,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
mammary duct terminal end bud growth,GO:0060763,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,0,
mammary gland alveolus development,GO:0060749,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|Endosulfan,0,
mammary gland development,GO:0030879,Parkinson Disease,MESH:D010300,2,Bromocriptine|Herbicides,1,IGF1R
mammary gland development,GO:0030879,"Parkinson Disease, Secondary",MESH:D010302,1,Olanzapine,0,
mammary gland development,GO:0030879,Parkinsonian Disorders,MESH:D020734,3,Aripiprazole|Bromocriptine|Olanzapine,1,PRL
mammary gland duct morphogenesis,GO:0060603,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|Estradiol,0,
mammary gland epithelial cell proliferation,GO:0033598,Parkinson Disease,MESH:D010300,1,Estradiol,0,
mammary gland epithelium development,GO:0061180,Parkinson Disease,MESH:D010300,1,Atrazine,0,
mammary gland epithelium development,GO:0061180,"Parkinson Disease, Secondary",MESH:D010302,1,Atrazine,0,
mammary gland involution,GO:0060056,Parkinson Disease,MESH:D010300,0,,1,CP
mammary stem cell proliferation,GO:0002174,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
manganese ion export across plasma membrane,GO:0140048,Parkinson Disease,MESH:D010300,1,Manganese,1,SLC30A10
manganese ion export across plasma membrane,GO:0140048,"Parkinson Disease, Secondary",MESH:D010302,1,Manganese,0,
manganese ion export across plasma membrane,GO:0140048,Parkinsonian Disorders,MESH:D020734,1,Manganese,1,SLC30A10
manganese ion homeostasis,GO:0055071,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
manganese ion homeostasis,GO:0055071,Parkinson Disease,MESH:D010300,1,Manganese,1,SLC30A10
manganese ion homeostasis,GO:0055071,"Parkinson Disease, Secondary",MESH:D010302,1,Manganese,0,
manganese ion homeostasis,GO:0055071,Parkinsonian Disorders,MESH:D020734,4,Cadmium|mancozeb|Manganese|manganese chloride,1,SLC30A10
manganese ion transmembrane transport,GO:0071421,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
manganese ion transmembrane transport,GO:0071421,Parkinson Disease,MESH:D010300,2,Iron|Manganese,1,TRPM2
manganese ion transmembrane transport,GO:0071421,"Parkinson Disease, Secondary",MESH:D010302,1,Manganese,0,
manganese ion transmembrane transport,GO:0071421,Parkinsonian Disorders,MESH:D020734,1,Manganese,0,
manganese ion transmembrane transport,GO:0071421,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Quinidine,0,
manganese ion transport,GO:0006828,Parkinson Disease,MESH:D010300,0,,2,SLC30A10|TRPM2
manganese ion transport,GO:0006828,Parkinsonian Disorders,MESH:D020734,0,,1,SLC30A10
mannosylation,GO:0097502,Parkinson Disease,MESH:D010300,2,Copper|Zinc,0,
mannosylation,GO:0097502,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Disulfiram,0,
MAPK cascade,GO:0000165,Parkinson Disease,MESH:D010300,11,Estradiol|Levodopa|Lipopolysaccharides|Minocycline|Paclitaxel|Pentoxifylline|Pioglitazone|Reactive Oxygen Species|ropinirole|Rotenone|Sirolimus,4,EDN1|IGF1R|LRRK2|MAP3K5
MAPK cascade,GO:0000165,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
MAPK cascade,GO:0000165,"PARKINSON DISEASE 8, AUTOSOMAL DOMINANT",OMIM:607060,0,,1,LRRK2
MAPK cascade,GO:0000165,"Parkinson Disease, Secondary",MESH:D010302,6,Levodopa|Minocycline|Nicotine|Paroxetine|Rotenone|Trifluoperazine,0,
MAPK cascade,GO:0000165,Parkinsonian Disorders,MESH:D020734,9,Curcumin|Levodopa|Lipopolysaccharides|Paroxetine|Plant Extracts|Rimonabant|ropinirole|Rotenone|Trifluoperazine,1,LRRK2
mast cell degranulation,GO:0043303,Parkinson Disease,MESH:D010300,2,Air Pollutants|Lipopolysaccharides,0,
mast cell degranulation,GO:0043303,"Parkinson Disease, Secondary",MESH:D010302,1,Chlorpromazine,0,
mast cell degranulation,GO:0043303,Parkinsonian Disorders,MESH:D020734,2,Chlorpromazine|Lipopolysaccharides,0,
mast cell homeostasis,GO:0033023,Parkinson Disease,MESH:D010300,1,Probenecid,0,
mast cell homeostasis,GO:0033023,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
mast cell homeostasis,GO:0033023,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Probenecid,0,
mast cell proliferation,GO:0070662,Parkinson Disease,MESH:D010300,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
mast cell proliferation,GO:0070662,"Parkinson Disease, Secondary",MESH:D010302,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
mast cell proliferation,GO:0070662,Parkinsonian Disorders,MESH:D020734,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
maternal behavior,GO:0042711,Parkinson Disease,MESH:D010300,4,"Fungicides, Industrial|Ozone|Particulate Matter|Vehicle Emissions",1,DRD1
maternal behavior,GO:0042711,Parkinsonian Disorders,MESH:D020734,2,cypermethrin|Particulate Matter,1,PRL
maternal placenta development,GO:0001893,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,0,
maternal placenta development,GO:0001893,Parkinsonian Disorders,MESH:D020734,2,cypermethrin|Valproic Acid,0,
maternal process involved in female pregnancy,GO:0060135,Parkinson Disease,MESH:D010300,1,Endosulfan,1,PARK7
maternal process involved in female pregnancy,GO:0060135,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
maternal process involved in female pregnancy,GO:0060135,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
maternal process involved in female pregnancy,GO:0060135,"Parkinson Disease, Secondary",MESH:D010302,1,Valproic Acid,1,RGS2
maternal process involved in female pregnancy,GO:0060135,Parkinsonian Disorders,MESH:D020734,1,Valproic Acid,1,PARK7
maternal process involved in parturition,GO:0060137,Parkinson Disease,MESH:D010300,0,,1,EDN1
mating behavior,GO:0007617,Parkinson Disease,MESH:D010300,0,,2,DRD1|TH
mating behavior,GO:0007617,Parkinsonian Disorders,MESH:D020734,0,,1,TH
"maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)",GO:0000462,Parkinson Disease,MESH:D010300,0,,1,RPS8
mature conventional dendritic cell differentiation,GO:0097029,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
mature conventional dendritic cell differentiation,GO:0097029,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Plant Extracts,0,
mechanoreceptor differentiation,GO:0042490,Parkinson Disease,MESH:D010300,0,,1,BDNF
mechanosensory behavior,GO:0007638,Parkinson Disease,MESH:D010300,1,Gabapentin,0,
mechanosensory behavior,GO:0007638,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
mechanosensory behavior,GO:0007638,Parkinsonian Disorders,MESH:D020734,0,,1,CAT-2
medium-term memory,GO:0072375,Parkinson Disease,MESH:D010300,0,,1,PINK1
medium-term memory,GO:0072375,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,0,,1,PINK1
medium-term memory,GO:0072375,Parkinsonian Disorders,MESH:D020734,0,,1,PINK1
megakaryocyte development,GO:0035855,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
meiosis I,GO:0007127,Parkinson Disease,MESH:D010300,1,Melatonin,0,
meiosis I,GO:0007127,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
meiosis I,GO:0007127,Parkinsonian Disorders,MESH:D020734,1,Melatonin,0,
meiosis I cell cycle process,GO:0061982,Parkinson Disease,MESH:D010300,1,Lipopolysaccharides,0,
meiosis I cell cycle process,GO:0061982,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
meiosis I cell cycle process,GO:0061982,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Resveratrol,0,
meiosis I cytokinesis,GO:0007110,Parkinson Disease,MESH:D010300,1,Melatonin,0,
meiosis I cytokinesis,GO:0007110,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
meiosis I cytokinesis,GO:0007110,Parkinsonian Disorders,MESH:D020734,1,Melatonin,0,
meiotic anaphase I,GO:0007133,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
meiotic cell cycle,GO:0051321,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
meiotic cell cycle,GO:0051321,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
meiotic cell cycle checkpoint signaling,GO:0033313,Parkinson Disease,MESH:D010300,1,Estradiol,0,
meiotic cell cycle process,GO:1903046,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
meiotic cell cycle process,GO:1903046,Parkinsonian Disorders,MESH:D020734,1,coenzyme Q10,0,
meiotic cell cycle process involved in oocyte maturation,GO:1903537,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,1,EDN1
meiotic cell cycle process involved in oocyte maturation,GO:1903537,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
meiotic chromosome separation,GO:0051307,Parkinson Disease,MESH:D010300,2,pendimethalin|Permethrin,0,
meiotic chromosome separation,GO:0051307,Parkinsonian Disorders,MESH:D020734,1,Permethrin,0,
meiotic DNA double-strand break formation,GO:0042138,Parkinson Disease,MESH:D010300,1,Estradiol,0,
meiotic DNA double-strand break processing,GO:0000706,Parkinson Disease,MESH:D010300,1,Permethrin,0,
meiotic DNA double-strand break processing,GO:0000706,Parkinsonian Disorders,MESH:D020734,1,Permethrin,0,
meiotic DNA repair synthesis,GO:0000711,Parkinsonian Disorders,MESH:D020734,1,coenzyme Q10,0,
meiotic metaphase II,GO:0007137,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
meiotic metaphase II,GO:0007137,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
meiotic metaphase plate congression,GO:0051311,Parkinson Disease,MESH:D010300,1,Melatonin,0,
meiotic metaphase plate congression,GO:0051311,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
meiotic metaphase plate congression,GO:0051311,Parkinsonian Disorders,MESH:D020734,1,Melatonin,0,
meiotic spindle assembly,GO:0090306,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|Methomyl,0,
meiotic spindle assembly checkpoint signaling,GO:0033316,"Parkinson Disease, Secondary",MESH:D010302,1,Doxorubicin,0,
meiotic spindle organization,GO:0000212,Parkinson Disease,MESH:D010300,4,Chlorpyrifos|Melatonin|Methomyl|Permethrin,0,
meiotic spindle organization,GO:0000212,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
meiotic spindle organization,GO:0000212,Parkinsonian Disorders,MESH:D020734,2,Melatonin|Permethrin,0,
meiotic telophase I,GO:0007134,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
melanin biosynthetic process,GO:0042438,Parkinson Disease,MESH:D010300,3,Copper|Particulate Matter|Zinc,0,
melanin biosynthetic process,GO:0042438,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
melanin biosynthetic process,GO:0042438,Parkinsonian Disorders,MESH:D020734,3,Particulate Matter|Plant Extracts|Resveratrol,0,
melanin metabolic process,GO:0006582,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
melanin metabolic process,GO:0006582,"Parkinson Disease, Secondary",MESH:D010302,1,Benzo(a)pyrene,0,
melanocyte differentiation,GO:0030318,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
melanosome assembly,GO:1903232,Parkinson Disease,MESH:D010300,0,,1,RAB32
melanosome organization,GO:0032438,Parkinson Disease,MESH:D010300,0,,1,RAB32
melanosome transport,GO:0032402,Parkinsonian Disorders,MESH:D020734,0,,1,DCTN1
melatonin biosynthetic process,GO:0030187,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
melatonin biosynthetic process,GO:0030187,Parkinson Disease,MESH:D010300,2,beta-N-methylamino-L-alanine|Melatonin,0,
melatonin biosynthetic process,GO:0030187,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
melatonin biosynthetic process,GO:0030187,Parkinsonian Disorders,MESH:D020734,1,Melatonin,0,
melatonin metabolic process,GO:0030186,Parkinson Disease,MESH:D010300,1,Melatonin,0,
melatonin metabolic process,GO:0030186,"Parkinson Disease, Secondary",MESH:D010302,1,Melatonin,0,
melatonin metabolic process,GO:0030186,Parkinsonian Disorders,MESH:D020734,1,Melatonin,0,
membrane bending,GO:0097753,Parkinson Disease,MESH:D010300,0,,1,RTNL1
membrane depolarization,GO:0051899,Parkinson Disease,MESH:D010300,11,4-phenylbutyric acid|Chlorpyrifos|Diazepam|Homocysteine|Lipopolysaccharides|Melatonin|Particulate Matter|Permethrin|Rotenone|Trichloroethylene|Vehicle Emissions,2,EDN1|PARK7
membrane depolarization,GO:0051899,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
membrane depolarization,GO:0051899,"Parkinson Disease, Secondary",MESH:D010302,5,Diazepam|Melatonin|Nicotine|Rotenone|Trichloroethylene,0,
membrane depolarization,GO:0051899,Parkinsonian Disorders,MESH:D020734,7,Cadmium|Diazoxide|Lipopolysaccharides|Melatonin|Particulate Matter|Permethrin|Rotenone,2,ATP1A3|PARK7
membrane disassembly,GO:0030397,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
membrane disassembly,GO:0030397,"Parkinson Disease, Secondary",MESH:D010302,1,3-methyladenine,0,
membrane disassembly,GO:0030397,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
membrane fusion,GO:0061025,Parkinson Disease,MESH:D010300,0,,1,DNM1L
membrane hyperpolarization,GO:0060081,Parkinson Disease,MESH:D010300,3,1-Methyl-4-phenylpyridinium|Diazepam|Ketoconazole,1,PARK7
membrane hyperpolarization,GO:0060081,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
membrane hyperpolarization,GO:0060081,"Parkinson Disease, Secondary",MESH:D010302,2,Diazepam|Resveratrol,0,
membrane hyperpolarization,GO:0060081,Parkinsonian Disorders,MESH:D020734,4,1-Methyl-4-phenylpyridinium|Ketoconazole|Resveratrol|Rimonabant,1,PARK7
membrane lipid catabolic process,GO:0046466,Parkinson Disease,MESH:D010300,50,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Acrolein|Air Pollutants|Aluminum|Apomorphine|Aspirin|Bromocriptine|Carbon Tetrachloride|Chlorpyrifos|Cinnarizine|Copper|Ditiocarb|Eicosapentaenoic Acid|Estradiol|Glutathione Disulfide|Herbicides|Hexachlorocyclohexane|Iron|Ketoconazole|lazabemide|Lead|Levodopa|Lipopolysaccharides|Lithium|Lithium Carbonate|Manganese|mangiferin|Melatonin|Naproxen|Nitric Oxide|Nitrogen Dioxide|Ozone|Paclitaxel|Paraquat|Particulate Matter|Pentoxifylline|Pioglitazone|Probenecid|Propranolol|Quetiapine Fumarate|Reactive Oxygen Species|Reserpine|ropinirole|Rotenone|Smoke|Testosterone|Vehicle Emissions|Water Pollutants, Chemical|Zinc",0,
membrane lipid catabolic process,GO:0046466,"Parkinson Disease 6, Autosomal Recessive Early-Onset",MESH:C565276,1,Levodopa,0,
membrane lipid catabolic process,GO:0046466,"Parkinson Disease, Secondary",MESH:D010302,34,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|3-methyladenine|Amiodarone|Amlodipine|Apomorphine|Benzo(a)pyrene|Carbon Monoxide|Chlorpromazine|Cinnarizine|Cytarabine|Ditiocarb|Doxorubicin|Fluoxetine|Fluphenazine|Haloperidol|Levodopa|Lithium|Lithium Carbonate|Manganese|Melatonin|Nicotine|Nifedipine|Octreotide|Olanzapine|Paraquat|Reserpine|Resveratrol|Risperidone|Rotenone|Silymarin|Thioridazine|thymoquinone|Valproic Acid|Verapamil",0,
membrane lipid catabolic process,GO:0046466,Parkinsonian Disorders,MESH:D020734,43,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|4-hydroxy-2-nonenal|Amiodarone|Amitriptyline|Amlodipine|Apomorphine|Bromocriptine|Cadmium|Cephaloridine|Chlorpromazine|coenzyme Q10|Creatine|Curcumin|Disulfiram|Docosahexaenoic Acids|Enkephalin, Leucine-2-Alanine|Haloperidol|Indomethacin|Ketoconazole|lazabemide|Levodopa|Lipopolysaccharides|Malondialdehyde|Manganese|Melatonin|Olanzapine|Paraquat|Particulate Matter|Plant Extracts|Plant Preparations|Probenecid|Quetiapine Fumarate|Reserpine|Resveratrol|Risperidone|ropinirole|Rotenone|sesamin|Silymarin|Thioridazine|Valproic Acid|Verapamil",0,
membrane lipid catabolic process,GO:0046466,Wolff-Parkinson-White Syndrome,MESH:D014927,5,Amiodarone|Isoproterenol|Lithium|Propranolol|Quinidine,0,
membrane organization,GO:0061024,Parkinson Disease,MESH:D010300,2,Particulate Matter|Rotenone,1,SNCA
membrane organization,GO:0061024,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
membrane organization,GO:0061024,"PARKINSON DISEASE 20, EARLY-ONSET",OMIM:615530,0,,1,SYNJ1
membrane organization,GO:0061024,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
membrane organization,GO:0061024,"Parkinson Disease, Secondary",MESH:D010302,3,Benzo(a)pyrene|Doxorubicin|Rotenone,1,SNCA
membrane organization,GO:0061024,Parkinsonian Disorders,MESH:D020734,3,Indomethacin|Particulate Matter|Rotenone,1,SNCA
membrane organization,GO:0061024,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
membrane raft organization,GO:0031579,"Parkinson Disease, Secondary",MESH:D010302,1,Nicotine,0,
memory,GO:0007613,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
memory,GO:0007613,Parkinson Disease,MESH:D010300,27,"4-phenylbutyric acid|6,7-dihydroxyflavone|Air Pollutants|Aluminum|Aspirin|Atrazine|Chlorpyrifos|Copper|Diazinon|Eicosapentaenoic Acid|Estradiol|Lead|Lipopolysaccharides|Lithium|Maneb|Manganese|mangiferin|Melatonin|Methamphetamine|Minocycline|Paraquat|Particulate Matter|Polychlorinated Biphenyls|Rivastigmine|Rotenone|Vehicle Emissions|Zinc",7,BDNF|DRD1|IGF2|INSR|MAPT|NGF|TH
memory,GO:0007613,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE",OMIM:612953,0,,1,PLA2G6
memory,GO:0007613,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
memory,GO:0007613,"Parkinson Disease, Secondary",MESH:D010302,14,Atrazine|Benzo(a)pyrene|Lithium|Maneb|Manganese|Melatonin|Methamphetamine|Minocycline|Nicotine|Paraquat|Poly I-C|Resveratrol|Risperidone|Rotenone,0,
memory,GO:0007613,Parkinsonian Disorders,MESH:D020734,19,Cadmium|coenzyme Q10|Docosahexaenoic Acids|Donepezil|ginsenoside Re|Lipopolysaccharides|Maneb|Manganese|manganese chloride|Melatonin|Muscimol|Paraquat|Particulate Matter|Plant Extracts|Resveratrol|Rimonabant|Risperidone|Rivastigmine|Rotenone,4,ATP1A3|MAPT|NGF|TH
memory,GO:0007613,Wolff-Parkinson-White Syndrome,MESH:D014927,2,Isoproterenol|Lithium,0,
memory T cell proliferation,GO:0061485,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
memory T cell proliferation,GO:0061485,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
menarche,GO:0042696,Parkinson Disease,MESH:D010300,1,Lead,0,
menarche,GO:0042696,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
menopause,GO:0042697,Parkinson Disease,MESH:D010300,2,Lead|Pesticides,0,
menopause,GO:0042697,"Parkinson Disease, Secondary",MESH:D010302,1,Pesticides,0,
menstrual cycle,GO:0044850,Parkinson Disease,MESH:D010300,1,Maneb,0,
menstrual cycle,GO:0044850,"Parkinson Disease, Secondary",MESH:D010302,1,Maneb,0,
menstrual cycle,GO:0044850,Parkinsonian Disorders,MESH:D020734,2,mancozeb|Maneb,0,
mesenchymal cell apoptotic process,GO:0097152,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
mesenchymal cell differentiation involved in kidney development,GO:0072161,Parkinson Disease,MESH:D010300,1,Lithium,0,
mesenchymal cell differentiation involved in kidney development,GO:0072161,"Parkinson Disease, Secondary",MESH:D010302,1,Lithium,0,
mesenchymal cell differentiation involved in kidney development,GO:0072161,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Lithium,0,
mesenchymal cell proliferation,GO:0010463,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
mesenchymal cell proliferation involved in lung development,GO:0060916,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
mesenchymal-epithelial cell signaling involved in prostate gland development,GO:0060739,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
mesenchymal smoothened signaling pathway involved in prostate gland development,GO:0060783,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
mesenchymal stem cell maintenance involved in metanephric nephron morphogenesis,GO:0072309,Parkinson Disease,MESH:D010300,1,Chlorpyrifos,0,
mesenchymal stem cell migration,GO:1905319,Parkinson Disease,MESH:D010300,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
mesenchymal stem cell migration,GO:1905319,"Parkinson Disease, Secondary",MESH:D010302,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
mesenchymal stem cell migration,GO:1905319,Parkinsonian Disorders,MESH:D020734,1,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine",0,
mesenchymal to epithelial transition,GO:0060231,Parkinson Disease,MESH:D010300,2,Atrazine|Rotenone,0,
mesenchymal to epithelial transition,GO:0060231,"Parkinson Disease, Secondary",MESH:D010302,2,Atrazine|Rotenone,0,
mesenchymal to epithelial transition,GO:0060231,Parkinsonian Disorders,MESH:D020734,1,Rotenone,0,
mesenchymal to epithelial transition involved in metanephros morphogenesis,GO:0003337,Parkinson Disease,MESH:D010300,0,,1,GDNF
mesenchymal to epithelial transition involved in metanephros morphogenesis,GO:0003337,"Parkinson Disease, Secondary",MESH:D010302,0,,1,GDNF
mesenchymal to epithelial transition involved in metanephros morphogenesis,GO:0003337,Parkinsonian Disorders,MESH:D020734,0,,1,GDNF
mesoderm development,GO:0007498,Parkinson Disease,MESH:D010300,0,,2,PRM|UP
metabolic process,GO:0008152,Parkinson Disease,MESH:D010300,10,"Chlorpyrifos|Eicosapentaenoic Acid|Estradiol|Fatty Acids|Glutathione Disulfide|Hydrocarbons, Chlorinated|Lead|Polychlorinated Biphenyls|Pyridoxine|Trichloroethylene",0,
metabolic process,GO:0008152,"Parkinson Disease, Secondary",MESH:D010302,6,"Benzo(a)pyrene|Doxorubicin|Hydrocarbons, Chlorinated|Pyridoxine|Resveratrol|Trichloroethylene",0,
metabolic process,GO:0008152,Parkinsonian Disorders,MESH:D020734,5,baicalin|Creatine|Docosahexaenoic Acids|Plant Extracts|Resveratrol,1,ATP1A3
metal ion homeostasis,GO:0055065,Parkinson Disease,MESH:D010300,6,Copper|Iron|Lead|Lithium|Manganese|Zinc,0,
metal ion homeostasis,GO:0055065,"Parkinson Disease, Secondary",MESH:D010302,2,Lithium|Manganese,0,
metal ion homeostasis,GO:0055065,Parkinsonian Disorders,MESH:D020734,2,Cadmium|Manganese,0,
metal ion homeostasis,GO:0055065,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Lithium,0,
metal ion transport,GO:0030001,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,0,,1,TRPM7
metal ion transport,GO:0030001,"Dystonia-Parkinsonism, Adult-Onset",MESH:C567844,0,,1,SLC39A14
metal ion transport,GO:0030001,Parkinson Disease,MESH:D010300,1,Lead,0,
metal ion transport,GO:0030001,Parkinsonian Disorders,MESH:D020734,1,Cadmium,0,
metamorphosis,GO:0007552,"Parkinson Disease, Secondary",MESH:D010302,1,Amiodarone,0,
metamorphosis,GO:0007552,Parkinsonian Disorders,MESH:D020734,1,Amiodarone,0,
metamorphosis,GO:0007552,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
metanephric collecting duct development,GO:0072205,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
metanephric mesenchymal cell proliferation involved in metanephros development,GO:0072136,"Parkinson Disease, Secondary",MESH:D010302,0,,1,SHH
metanephros development,GO:0001656,Parkinson Disease,MESH:D010300,0,,1,GDNF
metanephros development,GO:0001656,"Parkinson Disease, Secondary",MESH:D010302,0,,2,GDNF|SHH
metanephros development,GO:0001656,Parkinsonian Disorders,MESH:D020734,0,,1,GDNF
metaphase plate congression,GO:0051310,"Parkinson Disease, Secondary",MESH:D010302,1,Vincristine,0,
methanol biosynthetic process,GO:0046169,"Parkinson Disease, Secondary",MESH:D010302,1,Methotrexate,0,
methionine biosynthetic process,GO:0009086,Parkinson Disease,MESH:D010300,2,Carbon Tetrachloride|Endosulfan,1,MTHFR
methionine metabolic process,GO:0006555,Parkinson Disease,MESH:D010300,2,Homocysteine|Particulate Matter,1,MTHFR
methionine metabolic process,GO:0006555,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,1,CNR2
methionine metabolic process,GO:0006555,Parkinsonian Disorders,MESH:D020734,2,Particulate Matter|Resveratrol,0,
methotrexate transport,GO:0051958,Parkinson Disease,MESH:D010300,1,Probenecid,0,
methotrexate transport,GO:0051958,"Parkinson Disease, Secondary",MESH:D010302,3,Methotrexate|Resveratrol|Verapamil,0,
methotrexate transport,GO:0051958,Parkinsonian Disorders,MESH:D020734,3,Probenecid|Resveratrol|Verapamil,0,
methylation,GO:0032259,Parkinson Disease,MESH:D010300,4,Particulate Matter|Polychlorinated Biphenyls|Soot|Vehicle Emissions,0,
methylation,GO:0032259,Parkinsonian Disorders,MESH:D020734,2,Curcumin|Particulate Matter,0,
methylglyoxal catabolic process to lactate,GO:0061727,Parkinson Disease,MESH:D010300,0,,1,PARK7
methylglyoxal catabolic process to lactate,GO:0061727,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
methylglyoxal catabolic process to lactate,GO:0061727,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
methylglyoxal metabolic process,GO:0009438,Parkinson Disease,MESH:D010300,0,,1,PARK7
methylglyoxal metabolic process,GO:0009438,"Parkinson Disease 7, Autosomal Recessive Early-Onset",MESH:C565238,0,,1,PARK7
methylglyoxal metabolic process,GO:0009438,Parkinsonian Disorders,MESH:D020734,0,,1,PARK7
microglia development,GO:0014005,Parkinson Disease,MESH:D010300,2,Lipopolysaccharides|Particulate Matter,0,
microglia development,GO:0014005,Parkinsonian Disorders,MESH:D020734,2,Lipopolysaccharides|Particulate Matter,0,
microglia differentiation,GO:0014004,Parkinson Disease,MESH:D010300,1,Ozone,1,GBA1
microglia differentiation,GO:0014004,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
microglia differentiation,GO:0014004,Parkinsonian Disorders,MESH:D020734,0,,1,GBA1
microglial cell activation,GO:0001774,AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1,OMIM:105500,1,beta-N-methylamino-L-alanine,0,
microglial cell activation,GO:0001774,Parkinson Disease,MESH:D010300,26,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|Air Pollutants|Atrazine|beta-N-methylamino-L-alanine|Chlorpyrifos|Copper|Diazepam|Dopamine|Lead|Lipopolysaccharides|Maneb|Manganese|Methamphetamine|Minocycline|Oxidopamine|Paclitaxel|Paraquat|Particulate Matter|Permethrin|Probenecid|Reactive Oxygen Species|Roflumilast|Rotenone|Vehicle Emissions|Zinc",5,AIF1|MAPT|MIR181C|SNCA|TNF
microglial cell activation,GO:0001774,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
microglial cell activation,GO:0001774,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
microglial cell activation,GO:0001774,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
microglial cell activation,GO:0001774,"Parkinson Disease, Secondary",MESH:D010302,15,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Atrazine|Carbon Monoxide|Diazepam|Dichlorvos|Maneb|Manganese|Methamphetamine|Minocycline|Nicotine|Oxidopamine|Paraquat|Pyridostigmine Bromide|Resveratrol|Rotenone",1,SNCA
microglial cell activation,GO:0001774,Parkinsonian Disorders,MESH:D020734,16,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|1-Methyl-4-phenylpyridinium|baicalin|Dopamine|ginsenoside Re|Lipopolysaccharides|Maneb|Manganese|manganese chloride|Oxidopamine|Paraquat|Particulate Matter|Permethrin|Probenecid|Resveratrol|Rotenone",2,MAPT|SNCA
microglial cell migration,GO:1904124,Parkinson Disease,MESH:D010300,5,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Air Pollutants|Atrazine|Particulate Matter|Rotenone",0,
microglial cell migration,GO:1904124,"Parkinson Disease, Secondary",MESH:D010302,3,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Atrazine|Rotenone",0,
microglial cell migration,GO:1904124,Parkinsonian Disorders,MESH:D020734,3,"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|Particulate Matter|Rotenone",0,
microglial cell proliferation,GO:0061518,Parkinson Disease,MESH:D010300,8,1-Methyl-4-phenylpyridinium|Air Pollutants|Melatonin|Methamphetamine|Paraquat|Particulate Matter|Rotenone|Vehicle Emissions,1,GBA1
microglial cell proliferation,GO:0061518,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,GBA1
microglial cell proliferation,GO:0061518,"Parkinson Disease, Secondary",MESH:D010302,5,Melatonin|Methamphetamine|Paraquat|Rotenone|Valproic Acid,0,
microglial cell proliferation,GO:0061518,Parkinsonian Disorders,MESH:D020734,8,1-Methyl-4-phenylpyridinium|Donepezil|manganese chloride|Melatonin|Paraquat|Particulate Matter|Rotenone|Valproic Acid,1,GBA1
micronucleus organization,GO:0032125,Parkinson Disease,MESH:D010300,13,Air Pollutants|Caffeine|Endosulfan|Estradiol|Herbicides|Insecticides|Ozone|Particulate Matter|Pesticides|Propranolol|Rotenone|Smoke|Vehicle Emissions,0,
micronucleus organization,GO:0032125,"Parkinson Disease, Secondary",MESH:D010302,9,Benzo(a)pyrene|Carbamazepine|Doxorubicin|Nicotine|Oxcarbazepine|Pesticides|Rotenone|Verapamil|Vincristine,0,
micronucleus organization,GO:0032125,Parkinsonian Disorders,MESH:D020734,6,Cadmium|coenzyme Q10|Particulate Matter|Plant Extracts|Rotenone|Verapamil,0,
micronucleus organization,GO:0032125,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Propranolol,0,
microtubule anchoring at centrosome,GO:0034454,Parkinsonian Disorders,MESH:D020734,0,,1,DCTN1
microtubule-based process,GO:0007017,Parkinson Disease,MESH:D010300,0,,1,MAPT
microtubule-based process,GO:0007017,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
microtubule-based process,GO:0007017,Parkinsonian Disorders,MESH:D020734,0,,1,MAPT
microtubule bundle formation,GO:0001578,Parkinson Disease,MESH:D010300,1,Paclitaxel,1,MAP2
microtubule cytoskeleton organization,GO:0000226,Parkinson Disease,MESH:D010300,4,"2,4,5-Trichlorophenoxyacetic Acid|Paclitaxel|Particulate Matter|Reactive Oxygen Species",2,MAP2|MAPT
microtubule cytoskeleton organization,GO:0000226,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,2,ATXN3|MAPT
microtubule cytoskeleton organization,GO:0000226,"Parkinson Disease, Secondary",MESH:D010302,2,Valproic Acid|Vincristine,0,
microtubule cytoskeleton organization,GO:0000226,Parkinsonian Disorders,MESH:D020734,2,Particulate Matter|Valproic Acid,2,GAPDH|MAPT
microtubule polymerization,GO:0046785,Parkinson Disease,MESH:D010300,1,Paclitaxel,1,MAPT
microtubule polymerization,GO:0046785,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,MAPT
microtubule polymerization,GO:0046785,"Parkinson Disease, Secondary",MESH:D010302,1,Resveratrol,0,
microtubule polymerization,GO:0046785,Parkinsonian Disorders,MESH:D020734,1,Resveratrol,1,MAPT
microvillus organization,GO:0032528,Parkinson Disease,MESH:D010300,3,Air Pollutants|Particulate Matter|Zinc,1,CHP
microvillus organization,GO:0032528,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
micturition,GO:0060073,Parkinson Disease,MESH:D010300,2,Chlorpyrifos|Methamphetamine,0,
micturition,GO:0060073,"Parkinson Disease, Secondary",MESH:D010302,2,Methamphetamine|Methotrexate,0,
micturition,GO:0060073,Parkinsonian Disorders,MESH:D020734,1,Rimonabant,0,
midbrain development,GO:0030901,Parkinson Disease,MESH:D010300,0,,1,GDNF
midbrain development,GO:0030901,"Parkinson Disease, Secondary",MESH:D010302,0,,2,GDNF|SHH
midbrain development,GO:0030901,Parkinsonian Disorders,MESH:D020734,0,,1,GDNF
midbrain dopaminergic neuron differentiation,GO:1904948,Parkinson Disease,MESH:D010300,1,Methamphetamine,0,
midbrain dopaminergic neuron differentiation,GO:1904948,"PARKINSON DISEASE, LATE-ONSET",OMIM:168600,0,,1,NR4A2
midbrain dopaminergic neuron differentiation,GO:1904948,"Parkinson Disease, Secondary",MESH:D010302,1,Methamphetamine,0,
midbrain morphogenesis,GO:1904693,Parkinson Disease,MESH:D010300,1,Homocysteine,0,
middle ear morphogenesis,GO:0042474,Parkinson Disease,MESH:D010300,0,,1,EDN1
middle ear morphogenesis,GO:0042474,Parkinsonian Disorders,MESH:D020734,0,,1,PRKRA
midgut development,GO:0007494,Parkinsonian Disorders,MESH:D020734,0,,2,ALDH1A1|ALDH1A2
mineralocorticoid receptor signaling pathway,GO:0031959,Parkinson Disease,MESH:D010300,2,Atrazine|Permethrin,0,
mineralocorticoid receptor signaling pathway,GO:0031959,"Parkinson Disease, Secondary",MESH:D010302,1,Atrazine,0,
mineralocorticoid receptor signaling pathway,GO:0031959,Parkinsonian Disorders,MESH:D020734,2,cypermethrin|Permethrin,0,
miRNA-mediated gene silencing,GO:0035195,Parkinson Disease,MESH:D010300,0,,1,MIR181C
miRNA-mediated gene silencing by inhibition of translation,GO:0035278,Parkinson Disease,MESH:D010300,0,,1,MIR181C
miRNA-mediated gene silencing by inhibition of translation,GO:0035278,"PARKINSON DISEASE 18, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO",OMIM:614251,0,,1,EIF4G1
miRNA-mediated gene silencing by mRNA destabilization,GO:0035279,Parkinson Disease,MESH:D010300,0,,1,MIR181C
miRNA processing,GO:0035196,Parkinsonian Disorders,MESH:D020734,0,,1,PRKRA
miRNA transcription,GO:0061614,Parkinson Disease,MESH:D010300,3,Air Pollutants|Particulate Matter|Vehicle Emissions,0,
miRNA transcription,GO:0061614,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
miRNA transport,GO:1990428,Parkinson Disease,MESH:D010300,1,Particulate Matter,0,
miRNA transport,GO:1990428,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,0,
mitochondrial ATP synthesis coupled electron transport,GO:0042775,Parkinson Disease,MESH:D010300,5,entacapone|Lead|Pioglitazone|Rotenone|Tolcapone,1,SNCA
mitochondrial ATP synthesis coupled electron transport,GO:0042775,"PARKINSON DISEASE 1, AUTOSOMAL DOMINANT",OMIM:168601,0,,1,SNCA
mitochondrial ATP synthesis coupled electron transport,GO:0042775,"Parkinson Disease 4, Autosomal Dominant Lewy Body",MESH:C565324,0,,1,SNCA
mitochondrial ATP synthesis coupled electron transport,GO:0042775,"Parkinson Disease, Secondary",MESH:D010302,4,Amiodarone|Buspirone|Doxorubicin|Rotenone,1,SNCA
mitochondrial ATP synthesis coupled electron transport,GO:0042775,Parkinsonian Disorders,MESH:D020734,6,Amiodarone|Buspirone|Cadmium|entacapone|Rotenone|Zidovudine,1,SNCA
mitochondrial ATP synthesis coupled electron transport,GO:0042775,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Amiodarone,0,
mitochondrial calcium ion homeostasis,GO:0051560,Parkinson Disease,MESH:D010300,6,4-phenylbutyric acid|Chlorpyrifos|Homocysteine|Lead|Methamphetamine|Oxidopamine,0,
mitochondrial calcium ion homeostasis,GO:0051560,"Parkinson Disease, Secondary",MESH:D010302,3,Doxorubicin|Methamphetamine|Oxidopamine,0,
mitochondrial calcium ion homeostasis,GO:0051560,Parkinsonian Disorders,MESH:D020734,3,ginsenoside Re|Oxidopamine|Procaine,0,
mitochondrial calcium ion transmembrane transport,GO:0006851,Parkinsonian Disorders,MESH:D020734,1,Indomethacin,0,
mitochondrial cytochrome c oxidase assembly,GO:0033617,Parkinson Disease,MESH:D010300,2,Copper|Particulate Matter,0,
mitochondrial cytochrome c oxidase assembly,GO:0033617,Parkinsonian Disorders,MESH:D020734,2,oleuropein|Particulate Matter,0,
mitochondrial depolarization,GO:0051882,Parkinson Disease,MESH:D010300,19,1-Methyl-4-phenylpyridinium|4-phenylbutyric acid|Acrolein|Aspirin|Carbon Tetrachloride|Chlorpyrifos|Copper|Iron|Lead|Lipopolysaccharides|Manganese|mangiferin|Methamphetamine|Methomyl|Oxidopamine|Paraquat|Particulate Matter|Rotenone|Zinc,0,
mitochondrial depolarization,GO:0051882,"Parkinson Disease, Secondary",MESH:D010302,11,3-methyladenine|Doxorubicin|Manganese|Methamphetamine|Oxidopamine|Paraquat|Resveratrol|Risperidone|Rotenone|saxagliptin|Trifluoperazine,0,
mitochondrial depolarization,GO:0051882,Parkinsonian Disorders,MESH:D020734,12,1-Methyl-4-phenylpyridinium|Cadmium|coenzyme Q10|Lipopolysaccharides|Manganese|Oxidopamine|Paraquat|Particulate Matter|Resveratrol|Risperidone|Rotenone|Trifluoperazine,0,
mitochondrial depolarization,GO:0051882,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
mitochondrial DNA catabolic process,GO:0032043,Parkinson Disease,MESH:D010300,1,Carbon Tetrachloride,0,
mitochondrial DNA metabolic process,GO:0032042,Parkinson Disease,MESH:D010300,4,Air Pollutants|Lead|Nitrogen Dioxide|Particulate Matter,0,
mitochondrial DNA metabolic process,GO:0032042,Parkinsonian Disorders,MESH:D020734,1,Particulate Matter,1,PARP1
mitochondrial DNA repair,GO:0043504,Parkinsonian Disorders,MESH:D020734,0,,1,PARP1
mitochondrial DNA replication,GO:0006264,Parkinson Disease,MESH:D010300,11,1-Methyl-4-phenylpyridinium|Carbon Tetrachloride|Lead|Lipopolysaccharides|mangiferin|Melatonin|Oxidopamine|Ozone|Paraquat|Rotenone|Sirolimus,0,
mitochondrial DNA replication,GO:0006264,"Parkinson Disease, Secondary",MESH:D010302,7,Benzo(a)pyrene|Doxorubicin|Melatonin|Oxidopamine|Paraquat|Resveratrol|Rotenone,0,
mitochondrial DNA replication,GO:0006264,Parkinsonian Disorders,MESH:D020734,10,1-Methyl-4-phenylpyridinium|Cadmium|coenzyme Q10|Lipopolysaccharides|Melatonin|Oxidopamine|Paraquat|Resveratrol|Rotenone|Zidovudine,1,POLG
mitochondrial DNA replication,GO:0006264,Wolff-Parkinson-White Syndrome,MESH:D014927,1,Isoproterenol,0,
"mitochondrial electron transport, cytochrome c to oxygen",GO:0006123,Parkinson Disease,MESH:D010300,6,Copper|entacapone|Nitric Oxide|Pesticides|Rotenone|Tolcapone,0,
"mitochondrial electron transport, cytochrome c to oxygen",GO:0006123,"Parkinson Disease, Secondary",MESH:D010302,5,Benzo(a)pyrene|geraniol|Pesticides|Resveratrol|Rotenone,0,
"mitochondrial electron transport, cytochrome c to oxygen",GO:0006123,Parkinsonian Disorders,MESH:D020734,5,Curcumin|entacapone|geraniol|Resveratrol|Rotenone,0,
